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Abstract  
Opioid dependency remains a worldwide crisis and treatments aimed at abstinence 
and recovery are mainly ineffective with high relapse rates. There is mounting 
evidence that social deficits and emotional co-morbid impairments negatively 
impact recovery from opioid dependency following detoxification and constitute a 
motivational trigger to relapse.   
This work aimed to identify risk and protective factors for relapse to opioid 
misuse following the start of treatment. Given the emergence of preclinical and 
clinical data showing anti-addictive properties of neuropeptide oxytocin, a 
randomised double-blind placebo-controlled pilot trial was performed to investigate 
the efficacy of intranasal oxytocin in preventing relapse in post-detoxified opioid-
dependent individuals. This work also investigated the efficacy of intranasal 
oxytocin in reducing opioid craving, anxiety, depression, social anxiety and sleep 
disturbances while enhancing social cognition and quality of life in these individuals. 
The results described in this thesis show that inpatient psychosocial support 
was a protective factor against relapse, compared to a community centre treatment 
program.  Also, remaining in and completing a treatment program was protective 
against relapse.  The pilot trial did not complete due issues with the supply of 
oxytocin. Two participants were administered intranasal oxytocin over 2 treatment 
days, and showed reduced anxiety and social anxiety, improved sociability, 
improved mood, increased trustworthiness, decreased hostility and decreased 
subjective withdrawal symptoms with reduced sleep disturbances, compared to 
baseline. This thesis also provides a reflective analysis on the difficulties in 
recruiting and working with vulnerable participants as well as the challenges of 
setting up and running a clinical trial of an investigative medicinal product, within 
the NHS.  The work suggests some changes to be implemented for a successful 
clinical trial.   
Given these results and the evidence for anti-addiction and pro-social properties of 
oxytocin, future studies would direct attention to oxytocin-based treatment 
programs, looking to engage addicts in psychosocial treatment programmes. 
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Opioid addiction has devastating health and socio-economic consequences, and current 
pharmacotherapy is limited and often accompanied by side effects, thus novel treatment 
is warranted. Traditionally, the neurohypophyseal peptide oxytocin (OT) is known for its 
effects on mediating reward, social affiliation and bonding, stress and learning and 
memory. There is now strong evidence that OT is a possible candidate for the treatment 
of drug addiction and depression-addiction co-morbidities. This review summarizes and 
critically discusses the preclinical evidence surrounding the consequences of 
pharmacological manipulation of the oxytocinergic system on opioid addiction-related 
processes, as well as the effects of opioids on the OT system at different stages of the 
addiction cycle. The mechanisms underlying the effects of OT on opioid addiction, 
including OT’ interaction with the monoaminergic, glutamatergic, opioidergic systems and 
its effect on the amygdala, the hypothalamic–pituitary–adrenal axis and on memory 
consolidation of traumatic memories, are also reviewed. We also review clinical evidence 
on the effects of intranasal OT administration on opioid-dependent individuals and 
discuss the therapeutic potential along with the limitations that accompany OT-based 
pharmacotherapies. Review of these studies clearly indicates that the OT system is 
profoundly affected by opioid use and abstinence and points towards the OT system as an 
important target for developing pharmacotherapies for the treatment of opioid addiction 
and co-existing affective disorders, thereby preventing relapse. Therefore, there is a clear 
need for clinical studies assessing the efficacy of OT-based pharmacotherapies in opioid 
addiction. 
1 LINKED ARTICLES 
This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To 
view the other articles in this section visit 
http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc 
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1.1 Opioid addiction 
Opioid dependence is a chronic, relapsing brain disease characterised by aversive 
withdrawal symptoms, intense cravings triggered by environmental cues, the 
inability to control intake, social dysfunction and isolation (Maremmani et al., 
2011b, Schulteis et al., 2003, De Vries and Shippenberg, 2002, Koob and Volkow, 
2010). It has been estimated that between 24 and 34 million people consume 
opiates worldwide (United Nations Office on Drugs and Crime, 2016) and, 
regardless of the route of administration, opioid use continues to have a negative 
impact.  According to Center for Behavioral Health Statistics and Quality (2016) in 
2015, of the 20.5 million Americans aged 12 years and older with a substance use 
disorder, approximately 2.5 million individuals were found to misuse and abuse 
opioids.  Furthermore more than 20 000 overdose deaths in America were related 
to prescription pain relievers and over 12 000 overdose deaths related to heroin use 
in 2015 (Rudd, 2016).  In Europe, approximately 644 000 opioid users received 
treatment in the EU in 2014 and the occurrence of substance use and mental health 
disorders (comorbidity) continues to challenge treatment providers (European 
Monitoring Centre for Drugs and Drug Addiction, 2016).  Of the estimated 4 million 
people in the UK who use illicit drugs every year (cannabis being by far the most 
commonly used), almost 290,000 individuals were in contact with drug and alcohol 
services in 2015-16.   
Individuals that presented with a dependency on opiates made up the largest 
proportion of the total numbers of individuals in drug and alcohol treatment in 
2015-16 (149,807, 52%).   This is a decrease in the number since 2014-15 and a 
substantial reduction (12%) since a peak in 2009-10, when there were 170 032 
opiate clients in treatment (Public Health England, 2015). 
Opiate patients also had the lowest rate of successful exits from treatment in 
2015-16 at 28%, down from 30% in 2014-2015 and a peak of 37% in 2011-2012 
(Public Health England, 2015).  This lower success rate is reflective of a large 
proportion of opiate users now in treatment having a very entrenched drug use, 
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often with co-morbid illness including mental health disorders and also less likely to 
have access to personal and social resources that can aid recovery and abstinence, 
such as employment and stable housing . 
The number of opiate patients who died in treatment increased by 19% in 
2015-16 (1,428-1,693) with deaths as proportion of all opiate patients in treatment 
increasing from 0.9% to 1.1%.  The number of registered heroin deaths in 2014-15 
increased by 26% (953 to 1,201) and are now the highest on record.  The median 
age of opiate patients recorded as having died in 2015-16 was 44 years and 75% 
were male (Public Health England, 2015). 
 Opioid dependence has serious individual consequences as well as societal 
and economic consequences with increased healthcare costs through treatment 
and prevention services. According to the Health and Social Care Information Centre 
(HSCIC) (2016), the total prescription items dispensed for treating substance 
dependence amounted to over 4 million prescription items in 2014-15 with a total 
net ingredient cost of over £71 million. Treatments for opioid dependency; 
(methadone maintenance treatment (MMT), buprenorphine and naltrexone), alone 
amounted to over £29 million. 
 Crime related to drug use also amounts to 54% of the overall costs attributed 
to illicit drug use in the UK.  These crimes range from trafficking of drugs, 
possession, violent incidents as well as acquisitive crime (stealing).  According to the 
Home Office (2016),  between  April  2015  and  March  2016  approximately 250 
000 violent incidents in England and Wales were carried out by individuals under 
the influence of drugs.  They also report that over 26 000 offences were related to 
trafficking of drugs and over 116 000 offences were for possession of drugs. 
Furthermore, over half of all acquisitive crime is drug-related and the market value 
of stolen goods linked to drug use could range between £2-2.5 billion each year 
(Home Office, 2016). 
The economic and social costs of opioid addiction is also seen in decreased 
productivity due to unemployment with only 16-19% of addicts in paid work , 12-
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19% of addicts reporting acute housing problems and rising numbers of opiate 
related deaths  (Public Health England, 2015).    
Age is also a factor in the negative consequences of heroin addiction, as users 
presenting for treatment are often older. Many opiate patients entering treatment 
with a median age of 39 years; 73% male (109,366) and 27% female (40,441) (Public 
Health England, 2015), have been using heroin since 1980/1990.  This population 
are often in poor health, with a range of vulnerabilities associated with long-term 
drug use such as lung disease and hepatitis as well as HIV infection in injecting drug 
users.  This makes these users particularly vulnerable and requiring a wide range of 
support, including social care.  This puts extra pressure on the health services as 
they attempt to treat these individuals with very complex needs.  
Figures also show that over 57% of adults in treatment were either parents or 
have children living with them (Public Health England, 2015) putting extra pressure 
on social care services. Families affected by parental substance misuse often have a 
number of complex needs.  As well as drug and/or alcohol dependency, they 
experience problems relating to poor mental health, housing, unemployment, poor 
education and domestic violence, which can cause severe and lasting problems.  
The costs of addressing these can be considerable and involve a number of services 
including housing, education, antisocial behaviour law enforcement and children’s 
services as well as the criminal justice and health systems.  These services and the 
cost of a ‘troubled family’ has been estimated to cost the government in excess of 
£75 000 per year per family (Department for Communities and Local Government., 
2013). 
1.2 Addiction: Pathology and Neurobiology Cycle 
 Definition and Diagnostic Criteria 1.2.1
 The distinction between substance abuse and substance dependence as per 
American Psychiatric Association (2000 (DSM-IV-TR)) had been criticized for several 
reasons; (i) the diagnosis of substance abuse is poorly reproducible compared to 
that of substance dependence (Hasin and Beseler, 2009), (ii) substance abuse is  
considered a predecessor of substance dependence, which has been refuted by 
several prospective studies (Schuckit et al., 2001, Schuckit et al., 2008, Grant et al., 
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2001) which found that abuse of substances did not consistently progress to 
dependence, (iii) the presence of ‘orphan’ patients who fulfil neither of the criteria 
for substance abuse or dependence (Lynskey and Agrawal, 2007, Martin et al., 
2008, Pollock and Martin, 1999).  The American Psychiatric Association (2013 (DSM-
5)) has taken these criticisms into account and has merged substance abuse and 
substance dependence into a single disorder entitled as ‘Substance Use Disorder’ 
(SUD), measured on a continuum from mild to severe (see DSM-5).  This revision 
minimizes the importance of tolerance and withdrawal but includes drug craving 
into the list of criteria, defined as a strong desire for the substance. Drug craving, a 
concept not listed in the previous DSM-IV-TR criteria, is now documented in 
humans via imaging studies as significant increase in cerebral blood flow and 
dopamine release in certain brain structures in response to cues associated with the 
substance (Childress et al., 1999, Volkow et al., 2006). The DSM-5 (2013) SUD 
criteria have mainly remained the same as previous DSM-IV substance abuse and 
dependence criteria, although now it is presented in a single list, with two 
exceptions; the DSM-IV criterion of recurrent substance-related legal problems was 
deleted and the new criterion, craving or a strong desire to urge to use a substance, 
has been added.  A further change included setting the threshold of the number of 
criteria that must be met for a diagnosis at two or more of the following criteria:  
 Recurrent substance use resulting in a failure to fulfil major role obligations 
at work, school, or home. 
 Recurrent substance use in situations in which it is physically hazardous 
 Continued substance use despite having persistent or recurrent social or 
interpersonal problems caused or exacerbated by the effects of the 
substance. 
 Tolerance, as defined by either of the following: 
o A need for markedly increased amounts of the substance to 
achieve intoxication or desired effect. 
o Markedly diminished effect with continued use of the same 
amount of the substance. 
 Withdrawal, as manifested by either of the following: 
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The characteristic withdrawal for the substance. 
The same (or closely related) substance is taken to relieve or avoid 
withdrawal symptoms. 
 The substance is often taken in larger amounts or over a longer period than 
was intended. 
 There is a persistent desire or unsuccessful efforts to cut down or control 
substance use. 
 A great deal of time is spent in activities necessary to obtain the substance, 
use the substance, or recover from its effects. 
 Important social, occupational, or recreational activities are given up or 
reduced because of substance use. 
 The substance is continued despite knowledge of having a persistent or 
recurrent physical or psychological problem that is likely to have been 
caused or exacerbated by the substance. 
 
As with most addictions, opioid dependence is characterised by a cluster of 
cognitive, behavioural and physiological features.  The World Health Organisation 
(1992) identifies opioid abuse and dependence as the presence of three or more of 
the following features : 
 A strong desire or sense of compulsion to take opioids 
 Difficulties in controlling opioid use 
 A physiological withdrawal state 
 Tolerance 
 Progressive neglect of alternative pleasures or interests because of opioid 
use 
 Persisting with opioid use, despite clear evidence of overtly harmful 
consequences. 
 The Addiction Cycle 1.2.2
Addiction is characterised as a cycle of neurochemical and psychological 
changes that brings about a shift from the occasional impulsive use of a drug to the 
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compulsive use and dependence of a drug (see Koob and Le Moal, 2008); also see 
Figure 1.1.   
Only a proportion of drug users become “addicted”, as defined by the loss of 
control and compulsive use and, depending on the drug, by the development of 
tolerance and withdrawal.  Tolerance and withdrawal reflect the physical 
dependence to a substance; tolerance is seen where, following repeated use of a 
drug, the body adapts, requiring an escalation of the dose to achieve the same 
initial effects (see Koob and Le Moal, 2001). Withdrawal is seen as the eliciting of 
drug-specific physical or mental symptoms at cessation of the drug.  Physical 
dependence, or reliance, can occur with the chronic use of many drugs, including 
prescription drugs even when used as prescribed.  As such, physical dependence in 
and of itself does not constitute addiction, but it often accompanies addiction. 
Drug addiction has aspects of impulse control disorders and compulsive 
disorders as the individual moves from occasional use to dependence (see Figure 
1.1).  Impulse control disorders are seen by an increasing sense of arousal before 
committing an impulsive act followed by pleasure, gratification or relief at the time 
of committing the act and is largely associated with positive reinforcement.  In 
contrast, compulsive disorders are associated with anxiety and stress felt before 
committing a compulsive repetitive behaviour. Relief from the anxiety and stress is 
achieved by performing the compulsive behaviour and so largely associated with 
negative reinforcement, automaticity and ultimately relapse.  
As an individual moves from impulsive use to compulsive use, so the 
motivation for behaviour shifts, moving from positive reinforcement to negative 
reinforcement and automaticity (Koob and Volkow, 2010) 
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Figure 1.1: The drug addiction cycle.  
Upon administration, drugs of abuse induce euphoric effects that positively reinforce the user 
to repeat drug use. Following repeated administration tolerance develops, meaning that 
increased amount of a drug is needed to induce the initial pleasurable effects. Acute positive 
reinforcement is gradually replaced with negative reinforcement to prevent the emergence of 
negative withdrawal symptoms following drug cessation. The acute impulsive use of the drug 
becomes compulsive use. Even after long-term abstinence individuals are still vulnerable to 
relapse and re-administration of the drug, with approximately 70% of opioid dependent 
individuals relapsing following abstinence.  Modified from (Le Moal and Koob, 2007a). 
 
Impulsivity and compulsivity underlie the stages of the addiction cycle; (1) 
binge/intoxication, (2) withdrawal/negative affect and (3) 
preoccupation/anticipation, outlined by Koob and Volkow (2010) (Figure 1.2).  This 
cycle is initially dominated by impulsivity and the activation of the mesolimbic 
dopaminergic (DAergic) reward pathway. Drug use is rewarding, inducing a 
pleasurable affect and driving the administration of the drug, creating positive 
reinforcement and escalated drug use. Following repeated drug use and the 
development of tolerance, the cycle moves into a negative effect and the 
experience of withdrawal symptoms, which range from mild to severe.  There is a 
shift from a pleasurable effect driving the self-administration of drugs;  positive 
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reinforcement, to a situation where drug administration is driven by a compulsion 
or need to self-medicate in order to reduce or avoid the withdrawal symptoms; 
negative reinforcement (see Figure 1.1). These withdrawal include short-lived 
physical symptoms such as irritability, sweating hot flashes, flu-like symptoms and 
changes to appetite as well as protracted emotional/psychological symptoms such 
as anxiety, depression and social withdrawal. Opioid withdrawal symptoms also 
include nausea, muscle cramping, agitation and cravings. (For further details 
regarding the emotional and psychological consequences of opioid withdrawal, see 
chapter 1.3.1).   Finally preoccupation and anticipation of drug use, modulated by 
the prefrontal cortex and basolateral amygdala, leads to relapse and reinstatement 
to drug-seeking where the user cycles back to the binge/intoxication stage.  As this 
cycle becomes more intense, the individual finds themselves in the pathological 
state of addiction (Koob and Le Moal, 2001).  
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Figure 1.2: The three stages of addiction cycle.  
Acute administration of a drug of abuse which involves the activation of the mesolimbic DAergic 
pathway, reflecting the binge/intoxication component of the addiction cycle. Repeated 
administration of the drug brings about a shift towards the dorsal striatum and tolerance. The 
withdrawal/negative affect stage and cessation of drug use is reflected by the activation of the 
brain stress systems, such as corticotrophin releasing factor (CRF) within the extended 
amygdala. Reinstatement to drug-seeking following abstinence is associated with the 
preoccupation/anticipation component of the cycle which is primarily modulated by the 
prefrontal cortex (PFC) and basolateral amygdala (BLA). Modified from Koob and Volkow (2010) 
and (Koob and Le Moal, 2001). 
 
 Neurobiology of addiction 1.2.3
 Brain regions involved in the transition from non-dependence to drug 1.2.3.1
dependent state. 
As a disorder of the brain, understanding of the neurobiological processes 
underlying the progression from initial drug use to compulsive drug use and 
subsequent relapse is essential not only to shed light on the effects of drug abuse 
on the brain but also to develop novel and more effective pharmacotherapy to treat 
this devastating disorder.  The following section will focus on the neurobiology of 
drug addiction and the effects of substance abuse on these regions. 
Binge/ 
Intoxication 
Mesolimbic DAergic pathway 
 
Withdrawal / 
negative affect 
Extended Amygdala 
 
Preoccupation 
/Anticipation 
Prefrontal Cortex, Basolateral Amygdala 
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All drugs of abuse will, to varying extents and depending on the type of drug 
and individual differences, affect some key regions and interacting circuits in the 
brain (see Figure 1.3). 
These anatomical regions comprise of the prefrontal cortex (PFC), an area of 
the frontal cortex which plays a vital role in higher-order functions of conscious 
thought, judgment and decision making.  The PFC is important in rational, sound 
decisions and assists in overriding impulsive decisions, thus preventing the need to 
act upon sudden urges without considering the potential consequences. As such, 
the PFC is described as the brain’s “brakes” to certain stimulus such as drug use. 
High-order functions are also carried out by the anterior cingulate cortex (ACC) 
which plays an active role in reward anticipation, decision-making, impulse control 
and emotion. These two regions, PFC and ACC, form part of a circuit which assesses 
the salience or value of rewards in the decision to use drugs and well as inhibit the 
impulse to use drugs. Changes to the PFC and ACC, though repetitive drug use 
results in an inclination to act impulsively without considering the potential 
consequences, a behaviour which falls within the DSM-5 criteria of classification of 
addiction.  
The ventral tegmental area (VTA) is located in the midbrain and is the origin 
of DAergic cell bodies which, along with the PFC circuit, make up the 
mesocorticolimbic dopamine system.  Dopamine (DA), acting as a neurotransmitter 
in the brain, plays a major role in reward-motivated behaviour; as such the VTA is 
widely implicated in the drug and natural reward circuity of the brain, serving 
functions in motivation, cognition as well as addiction.  DAergic neurons project 
from VTA to nucleus accumbens (NAcc), forming part of the mesolimbic reward 
pathway (Qi et al., 2016).  The NAcc comprises two sub regions; core and shell with 
neuron subpopulations within each region, and is responsible for different cognitive 
functions. DA signalling and release within the core is consistent with learning 
through reward prediction error as well as spatial short-term memory for goal-
directed behaviour (Di Chiara et al., 2004) while the shell is consistent with 
motivation-based learning such as incentive salience (Saddoris et al., 2015). As a 
whole, the NAcc plays a significant role in aversion, motivation, reward, and 
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reinforcement learning.  The NAcc sends axonal DA projections to the ventral 
pallidum (VP), and together the VTA, NAcc and VP form the mesolimbic reward 
circuit.   
The encoding and reactivation of memories, including those memories of drug 
use, are found within the hippocampus (HIPP) and amygdala (AMY) (Goodman and 
Packard, 2016).  The HIP is involved in context-dependent conditioning and context-
related processes; place memories of drug use. It is also a key structure in stress-
related physiological responses.  The AMY processes emotional aspects of the 
memories, including those of drug use and is also strongly affected by acute 
stressors.  As such, both the HIP and AMY are vulnerable to stress and as a 
consequence play a strong role in drug seeking behaviour and drug abuse relapse 
following a stress response and/or cue induced relapse.  For in-depth review of the 
neurobiology of addiction the reader is referred to the review by Baler and Volkow 
(2006).  
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Figure 1.3. Brain regions and circuits involved in addiction 
Four interacting circuits involved in addiction. The rewarding dopamine circuit, (green), 
passes from the ventral tegmental area (VTA) to the nucleus accumbens (NAcc) and flows 
through the ventral pallidum (VP). The encoding and reactivation of memories of drug use 
are found within the hippocampus (HIPP) and amygdala (AMY) (red).  Cognitive control is 
managed by the prefrontal cortex (PFC) and anterior cingulate gyrus (ACG) (purple) and 
orbito-frontal cortex (OFC), (blue), assesses the salience or value of rewards in the decision 
to use drugs (Modified from Baler and Volkow, 2006) 
 
As stated, the above interacting regions and circuits combine to form the 
mesocorticolimbic DAergic system, comprising two ascending pathways originating 
from the cell bodies of the VTA.  The mesolimbic DAergic pathway, as a component 
of the medial forebrain bundles (MFB), comprises DAergic projections from VTA to 
NAcc, passing through the hypothalamus (Hyp).  This is the main reward pathway, 
going on to innervate the HIP and AMY and lateral septum (LS).  The mesocortical 
DAergic pathway projects from the VTA and the NAcc and innervates the areas of 
prefrontal cortex (PFC) and orbitofrontal cortex (OFC) mediating emotional and 
motivation responses, reactivity to conditioned cues, planning and judgement in 
responding to the reward.   The PFC and ACG, responsible for cognitive control, rely 
on a balance of Gamma-Aminobutryric Acid (GABA) and glutamate interactions, 
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exerting a “top-down” control on the motivation and pleasure areas.  The OFC 
assesses the salience or value of rewards and the decision to use or engage in the 
rewarding behaviour or substance. Normally the PFC, ACG and OFC are in balance, 
with the OFC having the final “say” in behavioural control, i.e. “NO-GO” for drug use 
(see Figure 1.4; Normal brain).  
In an addicted brain this control is compromised due to repeated drug use 
and development of tolerance.  The pathway from the PFC and ACG to the OFC is 
suppressed and the drive to use drugs becomes disinhibited with impulsive and 
compulsive behaviour, resulting in a “GO”.  As well as a suppression of the pathway 
to the OFC, the connections between NAcc and OFC become strengthened, as well 
as connections between NAcc and PFC and between NAcc and HIP/AMY. With the 
strengthening of these connections, and underpinned by drug related memories 
and stress-induced drives, the result is a “GO” response, and a subsequent use of 
drugs of abuse (see Figure 1.4; Addicted brain).  
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Figure 1.4: Differences in neuronal pathway activation between normal and addicted brain  
The figure above shows the four interacting brain circuits and the pathways involved in an addicted 
brain compared to a normal brain. The reward circuit (green) comprises the dopamine pathway from 
the ventral tegmental area to the nucleus accumbens (NAcc,), which then outflows through the ventral 
pallidum (VP). This pathway has a role in responding to and directing behaviour towards rewards.  The 
red areas regulate the encoding and reactivation of memories of drug use. These comprise the 
hippocampus (HIPP), responsible for place memories of drug use and the amygdala (AMY) for the 
emotional aspects of these memories.  The purple areas of the prefrontal cortex (PFC) and anterior 
cingulate gyrus (ACG) are responsible for cognitive control and rely on a balance of GABA and glutamate 
interactions.  This region, in the normal brain, will exert “top-down” control on the motivation and 
pleasure areas. The orbito-frontal cortex (OFC) assesses the salience of rewards and the decision to use 
drugs.  Normally these are in balance as indicated by the arrows, with the OFC having the final “say” in 
behavioural control, i.e. “NO-GO” for drug use (A: Normal Brain).  
In addiction the balance is disrupted; the compulsion to use drugs becomes more powerful and drug 
cues and memories become more dominant.  This dysregulated and strengthening of connectivity is 
reflected in the size of the arrows as the “top-down” mechanisms become weaker and the drive to use 
drugs cannot be restrained.  This results in a “GO”, take drugs response (B: Addicted Brain). 
 (Modified from Baler & Volkow, 2006).  
 
A 
A 
B 
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 Neurobiological alterations underlying the transition from non-1.2.3.2
dependence to dependence. 
 
The role of mesolimbic DAergic system in the positive reinforcing effects of drugs of 
abuse. 
Our understanding of the rewarding and reinforcing effects of drugs and 
subsequent dependant, addictive behaviour can be traced to early work on the 
identification of the mesolimbic DAergic reward system in the brain, with the 
discovery of electrical brain stimulation reward or intracranial self-stimulation by 
Olds and Milner (1954).  Olds (1956) went onto propose “pleasure centres” in the 
hypothalamus and related brain regions and Phillips and Fibiger (1978) later 
proposed the existence of a DAergic system responsible for the rewarding effects of 
electric brain stimulation. 
The mesolimbic DAergic pathway, as the main reward pathway is key to 
addictive behaviours (see Nestler, 2005).  DA has a well-validated role in the 
addiction process as all known drugs of abuse cause DA release in the NAcc, 
preferentially in the NAcc shell region, and also more broadly throughout the 
mesolimbic DA pathway (Tanda et al., 1997, Di Chiara and Imperato, 1988); 
although the mechanism of action of each drug differs.  For example cocaine and 
amphetamine act directly on the DAergic neurons at NAcc to release DA, whereas 
opioids act on the GABA-nergic inter-neurons in the VTA, leading to disinhibition of 
DAergic neurons projecting to the NAcc, resulting in an increase of DA release 
(Pierce and Kumaresan, 2006).    
Drugs, when administered acutely, will initially decrease DA reward thresholds 
resulting in increased reward and euphoria; a sense of “liking” (Berridge et al., 
2009) and the activation of the DA system has multiple roles in drug abuse.  For 
example, DA is also seen to give incentive salience to stimuli in the environment, to 
promote performance of goal directed behaviour and has an enabling function as 
well as the activation of reward in general (Berridge et al., 2009).   
Other neurotransmitters also act on the mesolimbic reward pathway, playing 
a role in dependence and addiction. Serotonin (5-HT) is responsible for function of 
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mood, impulsivity, anxiety, sleep and cognition, and virtually all known drugs of 
abuse  have acute effects on the extracellular 5-HT activity.  For example, unlimited 
access to cocaine increased 5-HT levels, as well as DA levels, to approximately 340% 
of base line in the NAcc and VP of rats (Parsons et al., 1995).   
Endogenous opioid peptides, endorphins and dynorphin, responsible for the 
function of and response to pain, as well as relevant mood, also act on the DAergic 
reward pathway by interacting with receptors kappa (κ), mu (μ), delta (δ). The 
physiological responses to activation of the opioid receptors are varied, for example 
the activation of the μ receptor will result in analgesia, sleepiness, euphoria, 
reduced awareness and respiratory depression (Borg, 2003). Opioids, such as 
heroin, morphine, co-codomine, fentynl and methadone induce their reinforcing 
and dependence effect by activating the μ opioid receptors. As such, the μ receptor 
activation is highly reinforcing psychologically and also dependence inducing. 
Activation of κ  receptors will, like μ receptor, produce analgesia, however unlike 
the μ receptor, κ activation is associated with dysphoria rather than euphoria and 
aversion rather than reinforcement and as such is involved in the “dark side” of 
addiction (De Vries and Shippenberg, 2002, Koob, 2010). The δ receptors mediate 
the emotional aspects of opioid addiction (De Vries and Shippenberg, 2002).  The μ 
opioid receptor is the prototype receptor for morphine addiction and for an 
extensive review on the role of the endogenous opioid system see Le Merrer et al. 
(2009).   
The role of the mesolimbic DAergic pathway in the positive reinforcing and 
initial effects of drug of abuse was confirmed by microdialysis studies which show 
that extracellular DA concentrations in the NAcc are increased during self-
administration of drugs (Pettit and Justice, 1989) and self-administration of drugs of 
abuse is attenuated upon administration of DA receptor antagonists (Rassnick et al., 
1992). 
With chronic use of drugs of abuse, there is a change in neurological 
responses and functioning. It has been hypothesised that the ‘switch’ from 
voluntary, social drug use to habitual and compulsive drug use is through a 
transition at the neural level from ventral to dorsal striatum control, mediated by its 
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DAergic connections (Everitt et al., 2008). The NAcc (ventral striatum) is 
predominantly involved in the acute reinforcing effects of drugs, while in contrast, 
the dorsal striatum (caudate putamen, CPU) appears to be recruited during the 
development of compulsive drug-seeking (Everitt et al., 2008).   
 As the behaviour transitions away from the initial voluntary stages of drug 
taking and positive reinforcement there is an increase in reward thresholds, with 
the development of tolerance and a decrease in the acute reward experience 
(Paterson et al., 2000). These findings indicate a shift in the activity of the 
neurotransmitters and the systems that are implicated in the positive reinforcing 
effects of drugs, a “within-system” change  (Koob and Le Moal, 1997).  
The role of DAergic system in drug dependence. 
DAergic neurotransmission is not only implicated in the rewarding and 
positive reinforcing effects of drugs of abuse, DA is also seen to be involved in the 
effects of drug withdrawal.  Acute withdrawal leads to suppression of reward 
pathways and DAergic transmission and a possible mechanism underlying drug 
craving (Weiss et al., 1996, Shen, 2003) (see Figure 1.5). Specifically, DA levels 
within the NAcc are found to be reduced following opiate withdrawal in rats 
(Druhan et al., 2000), leading to reward suppression. As well as a DA effect, central 
5-HT neurotransmission participates in the negative symptoms expressed in 
individuals following withdrawal from opioids, contributing to the emotional 
negative reinforcement of substance abuse.   Zhang et al. (2016) demonstrated that 
the activation of serotonin receptors in the VTA, NAcc and locus coerleus (LC) 
suppressed withdrawal symptoms in morphine-dependent mice, suggesting a hypo-
serotonergic state in a dependent brain.  Also when access to drugs of abuse such 
as cocaine is stopped after prolonged self-administration, there are emotional 
withdrawal symptoms characterized by dysphoria, anhedonia, depression and 
anxiety, behaviours which correlate with serotonergic and DAergic dysfunction 
(Parsons et al., 1996), further supporting the role of serotonin in dependence.  
These depressive and anxiety-like behaviours are also seen following morphine 
abstinence (Zanos et al., 2014). The emotional impairment and negative withdrawal 
affect following chronic use of drugs of abuse also involves additional systems other 
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that the ones involved in the rewarding positive reinforcement of addictive 
substances; a “between-system” change (Koob and Le Moal, 1997). 
The role of stress pathways in dependence 
The transition from voluntary use to dependence and addiction leads to the 
marked activation and recruitment of two interacting systems; the hypothalamic-
pituitary-adrenal (HPA)-axis and extra-hypothalamic brain regions and stress 
systems (i.e. CRF, NA, dynorphin, vasopressin and orexin) (see Figure 1.5).   
Stress and the stress systems which comprise the HPA axis, play a key role in 
the development of, and maintenance of dependence on drugs of abuse. The 
activation of the HPA system is characterized by the release of adrenal steroids 
glucocorticoids, triggered by adrenocorticotropic hormone (ACTH) from the 
pituitary gland. The release of ACTH is controlled by the release of hypothalamic 
corticotropic releasing factor (CRF) into the pituitary portal system and is also finely 
tuned via negative feedback from circulating glucocorticoids that act on 
glucocorticoid receptors in brain. 
Most drugs of abuse have an effect on the HPA axis.  For instance cocaine 
and stimulants will activate the HPA axis, while opioids suppress this system. With 
dependence of drugs, the HPA system becomes hypersensitive and hyperactive, 
increasing stress reactivity and relapse vulnerability and following withdrawal all 
drugs activate the HPA system, with elevated hypothalamic production of CRF 
(Buckingham, 1982, Rivier et al., 1984), increased stress response and increased risk 
of relapse. 
CRF is also located outside of the HPA axis with CRF receptors widely 
distributed within stress-responsive brain regions, which include PFC, central 
nucleus of amygdala (CeAmy), extended AMY, medial septum, HIPP and thalamus 
(Van Pett et al., 2000).  Zorrilla et al. (2014) point out that CRF systems have a 
prominent role in driving addiction via actions in these stress-responsive brain 
regions producing anxiety-like behaviour, reward deficits, excessive, compulsive-like 
drug self-administration and stress-induced reinstatement of drug seeking.  Logrip 
et al. (2011) discuss the role of the AMY CRF system in craving and emotional 
withdrawal symptoms and in their review Zorrilla et al. (2014) suggest that CRF 
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neuron activation in the PFC may also contribute to the loss of control which is 
characteristic of compulsive addictive behaviour, as a shift from impulsive 
rewarding behaviour to compulsive behaviour is driven by negative reinforcement.  
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Figure 1.5.  Neurocircuitry associated with the positive reinforcing effects of drugs of abuse and the 
negative reinforcement during dependence, demonstrating the transition from non-dependent to 
dependent drug-taking state. 
 
(A) Main elements of the reward circuit, dopamine and opioid peptide neurons, which interact at both 
VTA and NACC.  These are activated during initial drug use and the early binge/intoxication stage of 
the addiction cycle. At this stage behaviour is driven by positive reinforcement and reward, as 
indicated by the large arrows and there is no dependency at this stage.  
(B) The main elements of the stress circuit include CRF and noradrenergic neurons (NE) converge on γ-
aminobutyric acid (GABA) interneurons in the central nucleus of the amygdala.  These are activated 
during the development of dependence and are driven by negative reinforcement, as indicated by 
large arrows.  As the dependence and addiction develops, there is suppression of positive 
reinforcement and reward pathways, as indicated by the small arrows.   
       (Modified from Wee & Koob (2010) 
 
 
Withdrawal from drugs also increase the release of noradrenaline (NA) in 
the Bed Nucleus of the Stria Terminalis (BNST) within the extended AMY.  The BNST 
is important in a range of behaviours such as the stress response, fear and social 
behaviours and as such plays a role in the regulation of anxiety disorders, social 
dysfunction and psychological trauma (See Lebow and Chen, 2016 for a review on 
the role of the BNST in psychiatric disorders).  It is these disorders which contribute 
to the negative reinforcement which underpins continued drug seeking and relapse.   
As such, suppression of reward systems and recruitment of brain stress 
systems (as illustrated in Figure 1.5) are hypothesised to maintain hedonic stability 
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in an allostatic state, as opposed to a homeostatic state, leading to an increase in 
allostatic load and negative reinforcement. This negative stress affect underpins the 
vulnerability for development of and dependence of drugs of abuse and the risk of 
relapse (Breese et al., 2005).  
The reader is directed to reviews by Koob (2008; 2009; 2010) for further and 
in- depth information on the role of the brain stress systems in addiction. 
 Neurobiology of opioid dependence 1.2.3.3
With regards to opioid dependence specifically, the initial reinforcing 
properties of these drugs utilises the reward mesolimbic DAergic circuitry as 
described above, as well as additional sites of interaction (Koob and Bloom, 1988).  
The opiate system also includes the AMY, as well as the locus coeruleus (LC) and 
periaqueductal gray (PG) (Thompson, 2000).  These regions, following chronic use of 
opiates, contribute to the negative emotional state produced by dependence and a 
drive to drug-seeking through negative reinforcement mechanisms.   
Opioids induce hedonic effects by binding to, and activating the μ receptor, 
located in presynaptic GABA-nergic interneurons in the VTA terminals, inhibiting the 
release of neurotransmitter GABA (Vaughan et al., 1997). As a consequence of 
inhibiting GABA following opioid administration, opiates disinhibit the adjacent 
DAergic neurons in the VTA and enhance DA release in the NAcc (Di Chiara and 
Imperato, 1988, Johnson and North, 1992).  As such, by inhibiting GABAergic 
interneurons, opioids are also able to alter excitatory glutamate transmission 
adding to the pleasurable feelings of euphoria that heroin users report 
experiencing. As such, the acute effect of opioid creates reward and reinforcement.  
With chronic use of opiates, like all drugs of abuse, there is a change in 
neurological responses and functioning and an increase in reward thresholds. As 
such there is the development of tolerance, a decrease in the acute reward 
experience and increase in withdrawal symptoms (Paterson et al., 2000) and so a 
transition to dependence and addiction.  
The LC is responsible for some of the most distressing physical opioid 
withdrawal symptoms and is a major noradrenaline (NA)-containing region.  It has 
been identified as a site at which opiates and stress interact, most often resulting in 
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a negative effect (Van Bockstaele et al., 2010).  Acute opiate use causes the 
inhibition of LC neuronal firing rates and results in drowsiness, slowed respiration 
and low blood pressure, behaviours indicative of opioid intoxication (see Kosten and 
George, 2002  review).  As with dependence on drugs of abuse, chronic use of 
opiates leads to tolerance towards this inhibitory effect followed by the inability to 
inhibit LC neurons. Withdrawal from chronic opiate use increases neuronal activity 
in the LC of rats, triggering jitters, anxiety, muscle cramps, and diarrhea which 
contribute to the physical symptoms experienced by opioid dependent individuals 
undergoing withdrawal (Rasmussen et al., 1990). At an intracellular level, repeated 
opiate administration mimics the effects of chronic stress, sensitizing the LC-NE 
system to stress and contributing to the vulnerability to opiate abuse or stress 
related relapse following abstinence.  
 The cessation of opiate use induces changes in the mesolimbic DAergic 
neurons and in other neurotransmitters which are implicated in the acute 
rewarding and reinforcing effects of drugs, and as such increase vulnerability to 
relapse through emotional and physical withdrawal symptoms. For example, the 
decreased DAergic and reduced 5-HT neurotransmission in the NAcc may underlie 
the emotional impairments of anhedonia and dysphoria experienced during opiate 
withdrawal (Janiri et al., 2005) and decreased GABAergic and increased 
glutamatergic transmission and sensitization within the mesolimbic DA system is 
also involved in the negative effect upon cessation. 
Harris and Aston-Jones (1994) found that dopamine D2 antagonists induce 
affective signs of withdrawal in morphine-dependent mice while receptor agonists 
attenuate these, demonstrating the suppression of the mechanisms involved in the 
aversive effects of opiate withdrawal and, at least in part, the disruption of the 
same circuits implicated in drug reward are also responsible for the negative affect 
at cessation of opioid use.  Also, repeated opiate use alters the activity of the NAcc 
neurons, which are the primary target of DA neurons. These output neurons which 
contain GABA, dynorphin and enkephalin as well as substance P project to the VP 
and VTA and alterations in these output neurons contribute to the aversive 
consequences of opiate withdrawal (De Vries and Shippenberg, 2002) 
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(For more detail on opioid withdrawal and the emotional-mental health 
consequences, see section 1.3.2) 
Overall the chronic use of opioids and dependence induces 
neuroadaptations which result in a negative affect and emotional impairments 
following withdrawal, leading to a co-morbid disorder, poor treatment prognosis 
and increased vulnerability to relapse.  As the work in this thesis focuses on these 
factors we will concentrate our introduction on opioid addiction and mental health 
co-morbidity 
1.3 Opioid Addiction-Mental Health Co-morbidity 
 Comorbidity is the presence of two (or more) pathologies in the same 
individual in a given period of time, without the need of such pathologies occurring 
simultaneously (Valderas et al., 2009).  Dual diagnosis of pathologies is frequent in 
psychiatry (Compton et al., 2005, Cerdá et al., 2008) and research and consideration 
of comorbidity has important implications. For one, it allows for the development of 
new working hypotheses regarding common neurobiological mechanisms involved 
in different psychiatric and psychological disorders and also allows for the 
development of more appropriate treatments, targeting the comorbidity rather 
than each disorder individually.  Further consideration of comorbidity allows for 
better understanding of complex disorders as seen in opioid abusers and those 
seeking abstinence and so allows for the development of more targeted and 
appropriate treatments and better ways to prevent relapse in these individuals, 
especially following treatment and detoxification.  
 Prevalence and impact of opioid addiction-mental health co-morbidities. 1.3.1
 Hospital admissions for drug-related mental health disorders remains high 
(Health and Social Care Information Centre (HSCIC), 2016), with individuals treated 
at speciality mental health clinical settings more likely to have comorbid substance 
use disorders (SUDs) than not. 
The negative prognosis of a dual diagnosis of poor mental health and SUD is 
related not only to its high prevalence but also its difficulty in managing and 
treating multiple disorders, with poor outcomes for those individuals affected.  The 
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2017 Drug Strategy Report (HM Government, 2017), report that these individuals 
are often unable to access the care they need and are at high risk of dying by 
suicide.  Between 2004 and 2014, 33% of patients in mental health treatment who 
died by suicide had a history of drug misuse, but only 7% were in contact with drug 
treatment services.    In comparison to those with a single disorder, individuals 
with comorbid mental disorders-SUD show higher psychopathological severity 
(Langas et al., 2012) and increased rates of risky behaviour, which can lead to 
infection with diseases such as HIV/AIDS and hepatitis C (Khalsa et al., 2008), 
psychosocial impairments and criminal behaviour (Greenberg and Rosenheck, 2014, 
Krausz et al., 2013).  Taking into account the burden on health and legal systems, 
psychiatric comorbidity among individuals with SUDs leads to higher costs for 
society as well as a high burden to the individual (DeLorenze et al., 2014). 
While the temporal sequence of opioid addiction-mental health disorders is 
still unclear, certain mental health disorders are frequently presented co-morbidly 
with opioid addiction; namely depression (Rounsaville et al., 1982a), anxiety 
disorders (Fatseas et al., 2010) and sleep disorders (Mahfoud et al., 2009). These 
are chronic, relapsing disorders which contribute to the difficulty in treating SUDs.  
Drugs of abuse, including heroin also have a profound effect on social behaviour, 
both acutely and in the long-term, and social deficits contribute to the development 
of dependence and addiction to drugs of abuse, adding to the complexity of 
treatments needed for this debilitating disorder.  
 Social deficits  1.3.1.1
 Addictive drugs affect social behaviour, from sociability driven by the 
intoxicating effects of the drug to the depressed, anxious and socially withdrawn 
state frequently observed in chronic heroin users.  
The initial motivation to consume drugs of most types is inextricably linked to 
the social context.  Examples are the widespread use of alcohol as 'social lubricant', 
particularly in individuals with low self-esteem and anxiety (Monahan and Lannutti, 
2000) as well as the popular use of 'party and social drugs' such as 3,4-
methylenedioxymethamphetamine (MDMA) (Ecstasy) for their prosocial and pro-
sexual effects (see Kamilar-Britt and Bedi, 2015 for a review) and drug initiation in 
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adolescence as a result of 'peer influence' (Bauman and Ennett, 1996).  As such, 
social drug-taking and acute positive reinforcement is one likely cause of SUD, as 
the initial drug use escalates and leads to compulsive abusive behaviour (Koob & Le 
Moal, 2006) (see Chapter 1.2.2).  However, as drug use escalates the consequences 
can lead to social breakdown and social deficits, which may underpin the co-morbid 
mental and emotional impairments seen in heroin addicts.   
For the purposes of this thesis, social deficits refer to poor interpersonal 
behaviour, poor social perception and deficits in social and cognitive functioning.   
Social functioning and social support plays a significant role in addiction, in 
particular during treatment and prevention of relapse following abstinence (see 
section 2.1.3).  
Competent social skills are based upon good social perception and the ability 
to form impressions of and make inferences about other people. This is achieved 
through an understanding of others feelings and emotions by interpreting 
information from physical appearance, verbal and nonverbal communication.  Social 
deficits and in particular, deficits in social perception can cause failures to recognise 
and accurately interpret social signals, leading to misunderstandings and negative 
interaction.  As such, poor social skills and poor social understanding can result in an 
individual finding social situations unnatural, stressful and anxiety provoking. 
Rather than embracing social interaction and relationships, those with social deficits 
avoid these situations, and so find themselves isolated.  
Studies have found that opioid use leads to social deficits and problems with 
sociability as well as social perception, seen in problems with the accuracy and 
speed of recognition of facial expressions, which are important for social 
perception. Kornreich et al. (2003b) found that detoxified opiate addicts as well as 
those under methadone maintenance treatment demonstrated impaired decoding 
of emotional facial expression compared to controls. Darke et al. (2012) reported 
that opioid maintenance patients exhibited poorer performance in executive 
function, processing speed, verbal and non-verbal learning relative to ex-opioid 
users and controls. Furthermore research by McDonald et al., (2013a) compared 
emotional perception and social inference in opioid maintenance patients with 
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abstinent ex-users and controls and found that opioid users had significant 
difficulties reading the emotional state of others and also had difficulty 
understanding conversations that were slightly ambiguous.  The researchers noted 
that these kinds of difficulties translate into significant interpersonal problems, with 
misunderstanding of everyday interactions and misreading mood and intentions of 
others.   
One challenge is untangling the genetic, environmental, pharmacological and 
neural determinants, such as acquired brain damage through a drug overdose or 
traumatic brain injury, which all lead to social deficits, and while this is important it 
is beyond the scope of this thesis. 
 Co-morbid Depression 1.3.1.2
 Depression is a highly prevalent world-wide psychiatric disorder with a 
lifetime risk close to 20% and is associated with high levels of morbidity and 
mortality (Kessler et al., 2005).  Depressed patients are at higher risk of serious 
physical health problems such as coronary artery disease and diabetes and 
worsening of the prognosis of other medical conditions (Knol et al., 2006, Evans et 
al., 2005). Depression is also a long term, relapsing condition and three quarters of 
patients experience more than one episode of depression (Hollon et al., 2006). 
Major depression is characterised by a persistent and pervasive low mood that is 
accompanied by a loss of interest or pleasure in normally enjoyable activities along 
with other physical and somatic symptoms. Psychomotor retardation is common in 
patients with major depression, with visible slowing of physical reactions 
(Buyukdura et al., 2011) and cognitive abnormalities associated with emotional 
information processing for example attention bias towards negative emotional cues 
and enhanced memory for negative emotional material (Koster et al., 2005).  
 The DSM-5 (American Psychiatric Association, 2013) core criterion symptoms 
applied to diagnose major depression disorder (MDD)  have not changed from DSM-
IV (American Psychiatric Association, 2000), which are: 
A. Five (or more) of the following symptoms have been present during the 
same 2-week period and represent a change from previous functioning; at 
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least one of the symptoms is either (1) depressed mood or (2) loss of 
interest or pleasure. 
1) Depressed mood most of the day, nearly every day, as indicated by either 
subject report, or observation by others 
2) Markedly diminished interest or pleasure in all, or almost all, activities most 
of the day, nearly every day (as indicated by either subjective account or 
observation made by others) 
3) Significant weight loss when not dieting or weight gain, or decrease or 
increase in appetite nearly every day 
4) Insomnia or hypersomnia nearly every day 
5) Psychomotor retardation or agitation nearly every day (observable by 
others, not merely subjective feelings of restlessness or being slowed down) 
6) Fatigue or loss of energy nearly every day 
7) Feeling of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-approach or guilt about being 
sick) 
8) Diminished ability to think or concentrate, or indecisiveness, nearly every 
day (either by subjective account or as observed by others) 
9) Recurrent thoughts of death (not just fear of dying), recurrent suicidal 
ideation without a specific plan, or a suicide attempt or a specific plan for 
committing suicide 
B. The symptoms do not meet criteria for a Mixed Episode. 
C. The symptoms cause clinically significant distress, or impairment in social, 
occupational, or other important areas of functioning. 
D. The symptoms are not due to the direct physiological effects of a substance 
or a general medication 
E. The symptoms are not better accounted for by bereavement, i.e., after the 
loss of a loved one, the symptoms persist for longer than 2 months or are 
characterized by functional impairment, morbid preoccupation with 
worthlessness, suicidal ideation, psychotic symptoms, or psychomotor 
retardation. 
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 Although recovery rate from a depressive episode increases progressively, 
even in the absence of treatment, major depression is still considered a chronic 
disorder, with 4-10% of people in England experiencing depression at least once in 
their lifetime and mixed depression and anxiety is classed as the most common 
mental disorder in Britain (National Institute for Health and Care Excellence (NICE), 
2014).   
Depression-SUD as a comorbidity show prevalence rates ranging from 12% to 
80% (Torrens et al., 2011), depending on the characteristics of the sample (e.g. 
clinical versus non-clinical sample and diagnostic criteria used).  Opioid addicts 
contribute to these co-morbid prevalence rates and studies report that the lifetime 
prevalence of major depression is approximately 30-50% in post-dependent 
individuals undergoing maintenance therapy (Peles et al., 2007, Nunes et al., 1998).  
Comorbid depression- SUD is a major issue in psychiatry as it is accompanied by 
compounded symptoms, longer illness duration, higher health services utilisation 
and higher relapse rates (Brooner et al., 1997, Kosten et al., 1986) as well as 
impaired quality of life (Astals et al., 2009).   Depression is more likely to be the 
primary disorder within depression-SUD comorbidity although drug induced 
depression is widespread (Maremmani et al., 2011a).  This makes treatment and 
abstinence from opioid abuse challenging as it is difficult to separate the two. 
Research shows that people affected by major depression show a higher 
vulnerability to developing a SUD and that people with SUD have a greater risk of 
developing major depression during their life, compared to the general population 
(Maremmani et al., 2011a).  Research also indicates that comorbid depression-SUD 
is more frequent in females (Torrens et al. 2011b). Sordo et al. (2012) supports this 
finding in research on 561 heroin users in a cross-sectional survey measuring 
depression.  The prevalence of depression was 22.3% among this group, with 
females rating statistically higher than males (35.2% female; 17.3% male).  The 
etiology of the comorbid disorder may, however, differ depending on the temporal 
course of its development. Depression followed by drug abuse may differ 
neurologically compared to drug abuse followed by depression.  It is possible that 
drugs are used in attempt to self-medicate the depressive state whereas early 
51 
 
exposure to drugs of abuse might lead to neurobiological changes that increase the 
risk of depression (Volkow, 2004). While various neurobiological mechanisms are 
hypothesised to contribute to the cause of these dual disorders, depression and 
SUDs are both associated with alterations in some of the same hormonal and 
neurotransmitter systems including dysfunction of the HPA axis and abnormal 
activity of CRF response, 5-HT neurotransmission and NA neurotransmission on 
(Brady and Sinha, 2005). Depression and SUD neurobiological correlates also share 
changes in the limbic and PFC structures including the HIPP and AMY   (Markou et 
al., 1998, Palazidou, 2012).  As such, depression-opioid SUD comorbidity, linked by 
some shared neurobiology results in a clinical phenotype that is relapsing, often 
severe and more difficult to treat than addiction or depression alone. The challenge 
in treating this co-morbidity is a treatment that addresses both of these disorders 
simultaneously with a focus on preventing relapse in both of the disorders. For a 
discussion on opioid withdrawal and co-morbid depression, please see section 
1.3.2. 
 Co-morbid Anxiety Disorders 1.3.1.3
 Anxiety is an emotion characterised by feelings of tension, worried thoughts 
and somatic changes. Like fear, which is an appropriate cognitive and emotional 
response to a perceived threat, anxiety is common in everyday life and part of 
normal behaviour and of value as a defence mechanism in raising awareness and 
responding to novel situations. Nonetheless, it can cause dysfunctional and 
pathological behaviour. To be diagnosed as a psychological disorder, the fear and 
anxiety are found to be excessive or out of proportion to the actual threat posed, 
persistent and associated with impairments in social, occupational, or other 
important areas of functioning (American Psychiatric Association, 2013; DSM-5). 
 The DSM-5 lists a number of anxiety disorders (generalized anxiety disorder 
(GAD), specific phobia, social anxiety disorder (SAD), separation anxiety disorder, 
agoraphobia, panic disorder and selective mutism) and each disorder differs by 
symptom. However as a group, anxiety disorders are a prevalent mental health 
condition, with worldwide lifetime estimates in the range of 6–12% (Kessler et al., 
2009).   
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Although categorical diagnostic criteria are used clinically (DSM-5), anxiety is a 
dimensional construct, and the distinction between what is normal and abnormal 
rests on clinical judgments of severity, frequency of occurrence, persistence over 
time, as well as degree of distress and impairment in functioning.  Anxiety disorders 
are also highly co-morbid with each other, with people often presenting with more 
than one type of anxiety disorder, sharing common dimensions such as acute fear, 
anticipatory anxiety, or sustained threat response. 
Anxiety disorders are also highly correlated with MDD, with shared 
association of poor neuropsychological performance in attention with reduced PFC 
activity (Bishop, 2009, Vasterling et al., 1998), and reduced memory (Dalgleish and 
Watts, 1990).  The comorbidity anxiety-depression have a high degree of 
interconnectivity between neurotransmitter and neuropeptide-containing circuits 
and, as such, are characterised by neuroendocrine, neurotransmitter and 
neuroanatomical disruptions, which complicates identifying the most relevant 
disorder to treat first.   This is further challenged by the high risk and prevalence of 
SUDs in these individuals.  In a study of large sample of more than 40 000 
individuals mood disorders such as depression and anxiety disorders were all 
positively associated and statistically significant (Conway et al., 2006) with comorbid 
anxiety increasing the risk of illicit drug use.  This contributes to the challenge of 
differential diagnosis and treatment.   
Like depression, the neurobiological mechanisms that contribute to anxiety-
SUD comorbidity are alterations in some of the shared brain structures as well as 
neuroendocrine and neurotransmitter pathways. The limbic system, and 
predominantly the AMY, striatum and insula, play a large role in the response to 
fear and threat as well as formation and retrieval of emotional and fear-related 
memories. Studies of these areas report hyperactivity as well as structural 
abnormalities, for example abnormalities in AMY volume have been reported in 
those experiencing GAD (Schienle et al., 2011). The HIPP also contributes to the 
formation and retrieval of emotional and fear-related memories as well as drug-
context associations. Anxiety is also associated with the dysfunction of the HPA axis 
and abnormal activity of CRF response (as outlined in section 1.2.3.). 
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These shared neurobiological mechanisms create a vulnerability to using 
drugs of abuse or lead to neuroadaptations that manifest as an anxiety disorder. A 
study of 5,877 adults found that anxiety disorders, specifically generalised anxiety 
disorder (GAD) is most often associated with misuse of substances (Bolton and 
Sareen, 2006).  Comorbid GAD-SUDs was associated with an accelerated 
progression from first use of substance to the onset of dependence (Sartor et al., 
2007)  and the presence of comorbid SUDs was also been shown to significantly 
decrease the likelihood of recovery from GAD (Bruce et al., 2005) and increased 
relapse. 
 Research by Martins et al. (2012) provided information on the longitudinal 
associations between opioid disorder and anxiety disorder by collecting data 
approximately 3 years apart. Data drawn from face-to-face surveys of over 34 000 
adult participants found that the use of opioids was associated with anxiety 
disorders such as GAD. The authors explored the direction of the association of this 
co-morbidity in order to ascertain whether to support a precipitation hypothesis; 
that opioid use leads to anxiety disorders or whether to support a self-medication 
hypothesis; that anxiety leads to opioid use.  The authors support a “self-
medication” model, suggesting that individuals with anxiety disorders use opioids in 
order relieve their symptoms of anxiety. This model receives support from 
preclinical research demonstrating the anxiolytic properties of opioids (Berrendero 
and Maldonado, 2002). The “precipitation” however receives support from the 
DSM-5 (2013) which provides a diagnoses of substance-induced mood anxiety 
disorders; suggesting that    behavioural and neural plasticity through excessive 
opioid use could lead to anxiety disorders which may drive the need to abuse opioid 
or relapse as a means of “self-medication”.   
 Social anxiety disorder (SAD) has been recognised by clinicians as co-morbid 
with opioid dependency and prevalent in those seeking treatment, as reported by 
Grenyer et al. (1992).  SAD scores were obtained from a randomly selected files of 
159 opioid users presenting for treatment from opioid abuse. Approximately one-
quarter of the sample reported anxiety considered psychologically and socially 
dysfunctional.  
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It is not difficult to conclude that perhaps the treatment of anxiety-opioid SUD 
comorbidity should address both disorders, addressing the shared neurobiology 
mechanism. If it is the case that vulnerable individuals abuse substances such as 
opioids as a form of self-medication the focus should be on providing an 
appropriate alternative treatment. For a discussion on opioid withdrawal and co-
morbid anxiety, please see section 1.2.3. 
 Co-morbid Sleep Disorders 1.3.1.4
Sleep is a naturally recurring condition of mind and body, characterised by a 
change in consciousness, repressed sensory activity, restriction of all voluntary 
muscles and reduced interactions with surroundings. It is distinguished from 
wakefulness by a decreased ability to react to stimuli, but is more easily reversed 
than a state of being comatose. Normal sleep occurs in cycles in which the body 
alternates between two highly distinct conditions known as rapid eye movement 
(REM) and non-REM, each with its own unique characteristics including variations in 
brain wave patterns, eye movements and muscle tone. This structural organisation 
of normal sleep is known as sleep architecture.  Our 24 hour sleep-wake cycle is 
regulated by circadian rhythms controlled by an internal circadian clock, a dense 
cluster of neurons in the suprachiasmatic nucleus (SCN) within the brain, referred to 
as the circadian pacemaker.    
Sleep disturbance and poor sleep quality is common; 63.1% of people 
surveyed in 2016 UK Sleep Survey reported that they were unhappy with the 
amount of sleep they get, with women 14.6% more likely than men to report 
inadequate sleep.   The DSM-5 (2013) classifies clinical sleep disturbances as Sleep-
Wake disorders with the (International Classification of Sleep Disorders (ICSD-3)) 
reporting over 80 different types and range of sleep.   
Physiological, behavioural, psychological and environmental factors all affect 
sleep architecture, which may present as sleep disorders; for example insomnia and 
hypersomnia. 
Hypersomnia, with a lifetime prevalence of 8% (Breslau et al., 1996), relates to 
excessive sleepiness and inability to remain awake during the day, and is associated 
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with psychiatric disorders of depression and anxiety as well as agitation, poor 
cognitive ability and poor memory function (Breslau et al., 1996). 
 Insomnia, which presents as problems with falling asleep or staying asleep, 
despite adequate opportunity and circumstance to sleep, is a common yet serious 
sleep disorder.  It often coincides with stressful events and increased insomnia is 
associated with the development of psychiatric disorders; depression, anxiety and 
also maladaptive coping skills such as substance abuse.  
Impaired sleep quality is also one of the diagnostic markers in patients 
suffering from mental health disorders, in particular MDD and/or anxiety disorders. 
Compared with normal controls, sleep continuity of depressed individuals is often 
impaired, with increased wakefulness and reduced sleep efficiency.  Sleep onset 
latency is significantly increased and total sleep time is reduced.  REM latency is 
shortened and duration of first REM sleep is increased (see Wilson and 
Argyropoulos, 2005).  
Co-morbid insomnia-depression-anxiety is frequent in the general population;   
Ohayon and Roth (2003) interviewed approximately 15 000 individuals focusing on 
sleep disorders, psychiatric disorders and psychiatric history.  They found that 28% 
of participants with insomnia had a clinical co-morbid diagnosis of 
depression/anxiety. The researchers report that in most cases insomnia appeared 
before depression (>40%) or the same time (>22%) while anxiety was found to 
present before insomnia (34%) or at the same time (>38%). This co-morbidity and 
direction of association is supported by  Johnson et al. (2006) concluding that a 
sleep disorder and disrupted sleep is likely to lead to depression while increased 
anxiety leads to disrupted sleep and sleep disorders such as insomnia.  
SUD is also linked to disturbed sleep, in a bidirectional mode, in that 
substance use may directly cause sleep disturbances, and difficulty in sleeping may 
be a risk factor for relapse to substance use, particularly self-medication.  The DSM-
5 (2013) includes substance- or medication-induced sleep disorders as a category of 
Sleep Disorders and prevalence of sleep disorders in this population are high. 
Mahfoud et al. (2009) report that 40% of participants who rate a score indicative of 
poor sleep quality are opiate dependent.   
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While all drugs affect sleep architecture, the impact differs depending on the 
type of drug. Stimulants such as cocaine use will supress REM sleep and decrease 
total sleep time with increased wakefulness (Watson et al., 1992) and 
amphetamine-type stimulants increased sleep latency, decreased total sleep time 
and sleep efficiency and supressed REM sleep  (Herrmann et al., 2017, Schierenbeck 
et al., 2008). Cannabis and cannabinoids have contrasting effects on sleep 
depending on the class or type of cannabinoid. They can cause a slight residual  
sedation and may decrease sleep latency but could possibly improve REM sleep 
disorders and excessive daytime sleepiness (Babson et al., 2017). Cannabinoids may 
reduce nightmares associated with high anxiety and post-traumatic stress disorder 
(PTSD) and improve sleep in patients with chronic pain (Babson et al., 2017). 
Depressants for example benzodiazepines, alcohol and opiates such as heroin 
initially produce soporific effects, including increased daytime sleepiness and 
reduced sleep latency, but will also impact on the progression into slow wave sleep 
with disruptions and abrupt transitions from quiet awake or sleeping conditions into 
the awake state, due to withdrawal effects (Howe et al., 1981). As such, the use of 
opioids leads to hypersomnia and the inability to stay awake or alert, which 
presents as a sedated effect and an identifiable trait of heroin abuse. Paradoxically 
another disruption of sleep patterns due to the use of heroin often results in a 
sleepless condition known as “morphine insomnia” that reduces the total sleep 
hours due to the abrupt transition into an awake state due to withdrawal effect  
(Howe et al., 1981).   
Dimsdale et al. (2007) investigated the effects of opioids on sleep in healthy 
adults. 42 healthy participants were monitored with polysomnography after a 
bedtime dose of placebo, morphine or methadone on 3 different nights, in a double 
blind multiple cross-over study. Both opioid drugs significantly reduced deep sleep 
and increased stage 2 sleep, concluding that single doses of opioid can significantly 
affect sleep, reducing slow wave sleep.   
  This disrupted sleep activity is mirrored in heroin addicts following drug use.  
Kay et al. (1981) investigated the effect of heroin on human sleep, focusing on the 
increased stage 2 sleep, and decreased stage 3 sleep; namely a “morphine-like 
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insomnia”. Seven abstinent opiate addicts participated in weekly sleep studies with 
a double blind crossover design and randomised trial. Kay et al (1981) reported that 
heroin was found to be about twice as potent as morphine in producing insomnia. 
The researchers reported that heroin caused an increase in wakefulness, drowsiness 
episodes, muscle tension and shifts in sleep-waking patterns and overall produced a 
decrease in total sleep and sleep efficiency.  
 
 
 Emotional-mental health consequences of opioid withdrawal. 1.3.2
 Several factors contribute to interrupt drug abstinence.  External factors, such 
as life stress events and drug-associated contexts (Koob and Volkow, 2010), are 
well-studied determinants which lead to relapse following withdrawal and 
abstinence. Another key factor, which is less understood, is the alteration of 
emotional homeostasis which becomes clear following cessation of drug use. 
Abstinence, notably from opiate addiction, is characterised by withdrawal 
symptoms which range from mild to severe. Early withdrawal symptoms usually 
start within 6-12 hours for short-acting opiates such as heroin and within 30 hours 
for longer-acting opioid drugs such as methadone (National Institute on Drug Abuse 
(NIDA). 2017).These include muscle aches, trouble falling and staying asleep, 
anxiety and agitation.  Late withdrawal symptoms peak within 72 hours and include 
nausea, vomiting, low mood and drug cravings (National Institute on Drug Abuse 
(NIDA). 2017).  Opiate withdrawal and detoxification usually last a week to 10 days 
and typically end after two weeks, especially when a medical professional oversees 
and assists in the process. However, the chronic abuse of prescription opioids or 
opiates can also lead to post-acute withdrawal symptoms (PAWS) and protracted 
withdrawal symptoms which can persist for over a year (National Institute on Drug 
Abuse (NIDA). 2017). These are largely psychological and mood-related and 
comparable to clinical symptoms of anxiety and depression (Goeldner et al., 2011, 
Zanos et al., 2014). Furthermore, these are also associated with lower social 
competence, social deficits and sleep disturbances (Bakken et al., 2007, Mahfoud et 
al., 2009, McGregor et al., 2008b) and together increase the risk of relapse. 
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 As discussed earlier, both depression and anxiety are comorbid opioid abuse 
disorders (see section 1.3.1.2 and 1.3.1.3).  They are relapsing disorders with some 
shared neurobiology and common dysfunction of hormonal and neurotransmitter 
systems.  Together these complex comorbidities contribute to the protracted 
withdrawal symptoms and emotional impairments following chronic opioid abuse, 
and as such implicated in the relapse of drug use following a period of abstinence.  
 Goeldner et al. (2011) investigated emotional alterations and changes in the 
serotonergic (depression) system in mice undergoing withdrawal by using a chronic, 
intermittent escalating morphine (versus saline) regime, followed by abstinence.  
This mimics opioid detoxification and abstinence in heroin dependent individuals. 
Naloxone-precipitated withdrawal symptoms, indicating physical dependency, were 
measurable two hours after last morphine injection and these withdrawal 
symptoms decreased as abstinence increased, illustrating the short lived nature of 
the physical opioid withdrawal symptoms and also how physical dependence 
attenuates as abstinence unfolds.  In contrast, emotional withdrawal symptoms 
presented themselves as abstinence continued.  The researchers also reported that 
the social interactions of morphine treated mice decreased over time; they showed 
less social interaction after a 4-week abstinence period compared to 1 week 
abstinence.  The researchers also evaluated despair behaviour, an indication of 
depression, by measuring immobility time during a tail suspension test (TST).  Like 
social deficits, increased immobility was only measurable after 4 weeks compared 
to 1 week.  Altogether, impaired social interactions and despair (depression) 
behaviour was enhanced after a prolonged abstinence period, mimicking protracted 
withdrawal symptoms seen in abstinent opioid addicts.   
Investigating the shared neuroanatomy and activity of neurotransmitters, 
Goeldner et al. (2011) reported major morphine-induced alterations of serotonergic 
activity in both limbic areas and brainstem. The initial chronic morphine treatment 
increased 5-HT activity in the PFC, CeA and hippocampus but not in the dorsal raphe 
nucleus (DRN), the main serotonergic brain nucleus. However high turnover rates 
were maintained in the DRN throughout the abstinent condition.  The results show 
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that opioid use followed by abstinence causes alterations of serotonergic activity 
which evolves over time. 
 Further evidence that 5-HT systems are directly involved in emotional 
protracted withdrawal symptoms are seen in studies of anti-depressants.  Research 
has found that administration of 5-HT reputake inhibitors prevented the emergence 
of low sociability in heroin-abstinent animals (Lutz et al., 2014, Goeldner et al., 
2011).  
 Like Goeldner et al. (2011), Zanos et al. (2014) also found that chronic 
administration of morphine and a 7-day withdrawal regime resulted in depressive-
like behaviour and social withdrawal, in mice, as well as increased anxiety following 
chronic withdrawal.  
Sleep disorders through neurobiological changes in the sleep behaviours and 
sleep architecture of individuals following acute heroin abstinence have been 
demonstrated by Howe et al (1980, 1981).  Howe et al (1980) recorded behavioural 
characteristics and electroencephalogram (EEG) data on a 24 hour day basis for 5 to 
7 consecutive days following withdrawal from heroin. They concluded that heroin 
withdrawal produces a differential action upon CNS structures for the different 
states of sleep, waking and relating behaviours, with a marked disruption of the 
mechanisms responsible for the maintenance of normal sleep-wake cycle.  
Research on sleep disorders, as a consequence of opioid withdrawal, have 
focused on the stress response and in particular corticotropin-releasing factor (CRF) 
as one of the key underlying mechanisms (Nemeroff 1999).  This is important 
because, in addition to its role as the main regulator of the hypothalamic pituitary 
adrenal (HPA) axis, studies have found that CNS exposure to CRF disrupts sleep 
(Opp, 1995, Wellman et al., 2015) and sleep architecture (Ehlers et al., 1986, Opp et 
al., 1989). 
Altogether the literature highlights the ‘incubation period’ of depression and 
anxiety as well as social withdrawal, social deficits and sleep disturbances following 
cessation of opioid use. It would also suggest that when looking to treat opioid 
60 
 
addition, these disorders should be part of the focus, in particular when looking to 
prevent relapse. 
 Treating opioid addiction and mental health disorders  1.3.3
Until recent years opioid addiction treatment focused on harm reduction 
rather than abstinence as a goal, but the evidence makes clear that abstinence and 
recovery is an effective treatment option and this is now the way forward in 
treating opioid dependency.  As with all health, public health and social care in the 
UK, mental health disorders, including addiction treatment, follow NICE (2009) 
guidelines.  These are evidence-based recommendations seeking to prevent and 
manage specific conditions.    
 Pharmacological management and treatment of opioid addiction 1.3.4
 
Treating opioid dependence comprises a set of pharmacological interventions 
aimed at:  
 Reducing or ceasing opioid use 
 Preventing future harms associated with opioid use 
 Improving quality of life and well-being of the opioid-dependent individual.  
NICE (2009) recommendations, for all patients who are opioid dependent and have 
expressed an informed choice to become abstinent, should offer detoxification as a 
readily available and effective treatment option. While opioid dependence has a 
number of detoxification treatment agents available, none as yet are curative. The 
treatments do, however, work to diminish withdrawal symptoms and block opioid 
effects due to lapses back to drug use and thereby maintain abstinence.  The 
current and most effective withdrawal methods are the use of methadone or 
buprenorphine, which act as substitute or opioid replacement treatments (ORT), 
and are also used effectively in a tapering-off treatment regime until the patient 
reaches abstinence. Naltrexone as well as the use of α2-adrenergic agonists, to 
ameliorate withdrawal symptoms, are also common treatments.   
Methadone is a partial μ-opioid receptor (MOPr) agonist and is prescribed as 
a maintenance therapy for those with opioid addiction and also for use during 
detoxification from opioid use, with slow withdrawal increments until the patient is 
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detoxified.  Methadone Maintenance Treatment (MMT) is the most widely available 
pharmacotherapy for opioid addiction, and under medical supervision has been 
found to be an effective and safe treatment. It is important as a treatment through 
its high systemic bioavailability when administered orally (>90%) (Nilsson et al., 
1982) and its long half-life; approximately 24 hours in an opioid-tolerant individual 
(Grissinger, 2011). 
 Methadone is rapidly absorbed orally with a delayed onset of action, 
detectable in plasma at 30 minutes with peak levels at 2-4 hours and sustained 
levels maintained over 24 hours (Kling et al., 2000).   Due to slow metabolism and 
release into the blood, methadone levels remain relatively constant, ensuring its 
suitability as a treatment for opioid addiction and is effective as an oral, once-a-day 
treatment.  
 Methadone has low tolerance and low risk of abuse and reward due to its 
slow onset and offset, in contrast to heroin.  (Heroin has a rapid onset of action and 
is short-acting in effects and a quick onset of withdrawal syndrome.)  As an agonist 
for μ opioid receptors, methadone, which blocks the euphoric effect following 
heroin use, is found to reduce heroin self-administration (Donny et al., 2005).  As 
such, MMT as a long term treatment offers positive outcomes for most opioid 
addicts, and many individuals who aim for complete opioid withdrawal, 
detoxification and abstinence, a tapering methadone withdrawal regime manages 
to achieve this.   
 While methadone is effective in reducing heroin use, as well as reducing  
medical co-morbidities such as Hepatitis C infection, also reducing HIV risky 
behaviour and drug associated criminal behaviour  (Marsch, 1998), as a treatment, 
however, methadone is not without negative side effects.  Methadone users report 
lightheadedness, dizziness, anorexia, nausea and vomiting as well as dry mouth and 
sweating and methadone toxicity is also a risk with increased drowsiness and 
hypertension (Wolff, 2002). 
 Methadone fatalities are not uncommon with the number of deaths involving 
methadone doubling from 202 deaths to over 400 deaths between year 2000 - 2014  
(Public Health England, 2015). Most deaths involving methadone result from 
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respiratory depression and are more likely to occur when the drug is used in 
combination with other drugs, including opiates and/or alcohol (Modesto-Lowe et 
al., 2010, Hartel et al., 1995).  The use of benzodiazepines, which are commonly 
prescribed with methadone for the treatment of drug dependence, like alcohol, 
depress the respiratory system, and when combined with methadone, they 
augment these effects of the drug, increasing the risk of death. (Modesto-Lowe et 
al., 2010). 
 Cravings, a recent inclusion in the DSM-5 (2013), may play a role in the 
continued use of opiates despite being in MMT. The effect of methadone on 
cravings is controversial; some report that methadone reduces heroin craving while 
other studies report the opposite (Greenwald, 2002, Shi et al., 2007, Curran et al., 
1999). 
 Cravings can be triggered by environmental factors and heroin related cues 
(Langleben et al., 2008) but may also be due to positive reinforcement and an 
increased desire to use heroin due to its euphoric effect.  It is also possible that 
opioid cravings are due to negative reinforcement and the desire to use heroin to 
alleviate emotional protracted withdrawal symptoms. Yin et al. (2015) surveyed a 
total of 1301 MMT patients and found that prevalence rates for protracted 
withdrawal symptoms depression and anxiety, both of which are co-morbid and 
linked with withdrawal from chronic opioid use, were higher than the national 
average for both disorders.  As such, MMT, while effective at reducing physical 
withdrawal symptoms following heroin withdrawal, is less effective at preventing 
emotional and psychological impairments and protracted withdrawal symptoms 
such as depression, anxiety and cravings.   
Buprenorphine is a long acting partial MOPr and nociceptin receptor agonist 
and KOPr antagonist.  Like methadone, buprenorphine is prescribed for the relief of 
opioid withdrawal symptoms and cravings for 24 hours or longer,  but with less 
euphoric effects than methadone (see Lintzeris et al., 2009) and as such 
buprenorphine has a much lower risk of overdose than methadone and is preferred 
as a treatment for high risk patients.  Like methadone, buprenorphine is used as an 
ORT, as well as a flexible and tapering detoxifying treatment.  
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Studies have compared buprenorphine with methadone as a treatment for 
opioid withdrawal and detoxification.  Connock et al. (2007) found that both a 
flexible dose regime of MMT and buprenorphine maintenance treatment (BMT) 
were effective and cost efficient compared to no drug as a treatment.  MMT, 
however, was better at maintaining individuals in treatment compared to BMT, and 
therefore associated with slightly higher health gain and lower costs, although this 
needs to be balanced with the possible risk of higher mortality of MMT due to 
overdose.  Mattick et al. (2014) found BMT effective in the treatment of heroin 
dependence, compared to placebo-trials.  However, compared to MMT, 
buprenorphine retains fewer people within treatment when doses are flexibly 
delivered and at low fixed doses.  If fixed medium or high doses are used, BMT and 
MMT are no different in their effectiveness; equal retention in treatment and equal 
suppression of illicit opioid use.  The authors point out that fixed doses are rarely 
used in clinical practice so the results from studies on flexible tapering doses are 
more relevant to patient outcomes.  
Additionally, the safety of buprenorphine when administered along with other 
sedative substances such as alcohol is still unclear and at high doses, could be fatal 
(see Lintzeris et al., 2009).  
MMT, assisted with an α2-
 adrenergic receptor agonist (for example 
lofexidine) is another option to assist with withdrawal and abstinence. α2-
adrenergic agonists produce effects within both central and peripheral nervous 
systems and are able to attenuate stress-induced reinstatement of drug seeking, 
thereby reducing  acute physical withdrawal symptoms (Shaham et al., 2000) as well 
as preventing cue induced drug reinstatement (Smith and Aston-Jones, 2011).   
Gowing et al. (2009) assessed the effectiveness of interventions involving the use of 
α2-adrenergic agonists compared with placebo and other treatments during the 
acute phase of opioid withdrawal and found that α2-adrenergic agonists were 
significantly more effective than placebo for the management of withdrawal from 
heroin or methadone.  
 Naltrexone, an opioid receptor antagonist is another treatment used in opioid 
dependence.  Naltexone can be administered orally or as a subcutaneous  implant, 
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which has shown to be more effective compared to oral use, with reduced cravings 
in heroin users (Hulse, 2010) or poly-drug addicts (Tiihonen et al., 2012).  
Naltrexone has shown to block the effects induced by heroin, at doses as high as 
500mg of heroin (Brewer, 2002) further adding to its efficacy.    
 Methadone and buprenorphine in treating comorbid opioid addiction-1.3.4.1
mental disorders 
Opioid substitution therapies methadone and buprenorphine, while effective at 
treating opioid dependence, have also been shown to favourably alter several brain 
neurotransmitters important to mood regulation, thus offering a possible treatment 
effect for comorbid addiction-mental health disorders, depression and anxiety 
(Emrich et al., 1982, Dean et al., 2004).   
Traditionally individuals presenting with depression and anxiety disorders benefit 
from the following pharmacologic agents and mechanisms:  
(a) serotonin re-uptake inhibitors SSRIs which increase serotonin; (b) serotonin and 
noradrenaline reuptake inhibitors (SNRIs) which increase serotonin and noradreline; 
(c) monoamine oxidase inhibitors (MOAOIs) which increase serotonin, dopamine, 
and catecholamines; noradrenaline and adrenaline; (d) tricyclic antidepressants 
(TCAs)  which increase catecholamines noradrenaline and adrenaline; (e) opioids 
which decrease circulating cortisol. 
Methadone possesses antidepressant capabilities and animal studies have 
shown both methadone and morphine are able to raise brain serotonin levels by 
inhibiting serotonin re-uptake and increasing extracellular serotonin levels (Ciofalo, 
1974).  Methadone has also been shown to have MAOI properties, inhibiting brain 
MAO by 20% to 60% in the hippocampus, caudate, hypothalamus, and cerebral 
cortex of rodents, brain regions important for mood regulation (VanderWende and 
Spoerlein, 1979). Elevated cortisol levels, which contribute to depression and 
anxiety disorders, are reduced upon administration of methadone, demonstrating 
an antidepressant and anxiolytic effect (Judd et al., 1982, Gold et al., 1980) and 
animal studies have also shown that methadone is able to act as a TCA, blocking re-
uptake of catecholamines and suggesting an “anti-depressant action” (de Montis et 
al., 1982). 
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These results, however, are based on either animal research or on non-addict 
population and therefore may not be applicable to this population.  Furthermore 
Rounsaville et al. (1982b) report that patients with clinical depression do not 
experience improved mood on completion of ORT, and any improvement was not 
the result of an opioid agonist-antidepressant effect.  
The literature on antidepressant treatment in ORT patients is sparse and the 
findings mixed.  Kosten et al. (2004) report a poor outcome following the treatment 
of depressed opioid-dependent patients using a combination of TCA-buprenorphine 
and recommended against using this combination, although Nunes et al. (1998) 
showed, in a placebo-controlled trial, an improvement in depression in MMT 
patients treated with TCA.   
While a few studies have reported success with SSRIs in depressed 
methadone patients (Carpenter et al., 2004, Hamilton et al., 2000), generally the 
results are negative as to successful treatment in this population (Petrakis et al., 
1998). For example, Pani et al. (2010) report, in a meta-analysis, that there is little 
evidence to support the use of antidepressants for the treatment of depression 
among patients treated with opioid agonists. This finding was replicated in a second 
meta-analysis by Pedrelli et al. (2011) who found that there was no significant 
difference between antidepressants or placebo for patients with MDD or dysthymia 
undergoing MMT. Treatment is further complicated due to low rates of compliance, 
with only 55% of patients undergoing dual treatment complying with ORT-
antidepressant treatment regime (Hassan et al., 2017).   
Treating anxiety-opioid addiction co-morbidity has added challenges due to its 
multiple potential causal pathways which result in an anxiolytic and/or anxiogentic 
state; i.e. the anxiety disorder could be substance-induced, in that anxiety 
symptoms are caused by the effects of the substance intoxication or caused by the 
withdrawal of substance use (McHugh, 2015) It is also possible that an anxiety 
disorder is a consequence of the opioid use in that substances are used to manage 
feelings of anxiety, i.e. self-medication.  It is also possible that the two are 
independent disorders that co-occur either by chance or common risk factors 
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further challenging a treatment plan. As such, almost half of patients undergoing 
maintenance therapy also present with an anxiety disorder. 
SSRIs and TCAs are considered the first-line pharmacological treatment for 
anxiety disorders (Ravindran and Stein, 2010) and as such are often prescribed for 
patients while undergoing ORT, however the efficacy of this treatment regime 
remains mixed (see Donovan et al., 2010 for a review). 
Withdrawing and detoxifying patients are also offered benzodiazepines as a 
short term adjunct treatment for anxiety (Mark et al., 2009). Short-acting 
benzodiazepines, however, are at risk of both abuse and toxicity problems and 
when used with ORT, benzodiazepines significantly increase severe respiratory 
depression and risk of death through overdose (Borron et al., 2002, Kintz, 2002, 
Boyd et al., 2003), although Bleich et al. (2002) report the successful use of long-
acting benzodiazepine, clonazepam, for maintenance treatment of anxiety disorders 
in methadone patients with a history of benzodiazepine abuse.  
In general, studies are mixed with respect to whether and which dual 
treatment for comorbid opioid addiction-mental health disorders is effective. It also 
appears that treating one disorder does not typically lead to improvements in the 
other and that when only a single disorder is treated, the psychological and 
emotional impairments persist, increasing the risk of relapse following abstinence. 
Considering the above literature, there is still a lack of consensus regarding the 
most appropriate pharmacotherapy strategy to successfully adopt.  Historically 
people with co-occurring mental health and substance dependence have typically 
fallen between parallel service systems; substance abuse-dependence services and 
mental health disorder services.  Today the care of individuals with co-morbidity 
disorders is focused on a more comprehensive and integrated approach. In the case 
of opioid detoxification treatment and prevention of relapse, psychological 
therapies are needed to be part of the treatment plan in order to address the 
compulsions as well as psychological, emotional protracted withdrawal symptoms 
which all contribute significantly to the risk of relapse following detoxification and 
abstinence. 
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 Treating sleep disorders 1.3.4.2
 Impaired sleep quality is one of the diagnostic markers in patients suffering 
from mental health disorders, in particular MDD and/or anxiety disorders and, as 
discussed in section 1.3.1.4,  poor sleep quality is also prevalent among these 
individuals as well as those who are opiate dependent (Mahfoud et al., 2009, Howe 
et al., 1980, Kay et al., 1981). 
 Since the 1970s benzodiazepines are frequently used for the treatment of 
insomnia and sleep disorders and studies have found that benzodiazepines are 
effective as a treatment (Mitler et al., 1984). 
 All benzodiazepines can result in respiratory depression and there is an 
increased risk of overdose and death when used alongside treatments for opioid 
addiction, such methadone maintenance treatment (Borron et al., 2002).  Also, like 
any medication or substance used to induce sleep, benzodiazepines can also result 
in a dependence on that medication to induce sleep.  
 Cognitive Behavioural Therapy (CBT), a psycho-social approach to treatment, 
is proving to be a safe and effective means of managing chronic insomnia and its 
effects as well as other comorbid opioid addiction-mental health disorders (Brooks 
and Wallen, 2014). NICE (2009) recommends regular visits to a CBT clinician, 
completion of sleep assessments and homework, to allow for ways to change the 
sleep habits.  Also available via the internet where the patient participants in an 
interactive CBT programme. This talking therapy addresses the cognitive factors 
associated with insomnia such as intrusive thoughts, worry and other negative 
emotions and helps establish a healthy sleep pattern. In light of the co-morbidity of 
sleep disorders/depression/anxiety (Ohayon and Roth, 2003), this type of treatment 
is able to address all these facets effectively. Castronovo et al. (2017) found that 
CBT was able to reduce insomnia as well as depression scores observed in sleep 
clinic patients completing a 7 session CBT treatment plan.  de Bruin et al. (2015) 
found that CBT was effective for insomnia amongst adolescents using an online 
internet CBT programme or  face to face group therapy.  
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 Psycho-social therapy in treating opioid dependence and comorbid 1.3.5
mental health disorders 
 
Formal psychosocial interventions for opioid dependency have not been 
widely used in UK drugs services, however evidence reviewed by NICE (2009) shows 
that increased use of psychosocial interventions can bring real benefits and provide 
an important adjunct to detoxification, promote recovery and prevent relapse.  
The recommended psychosocial intervention as the primary adjunct to 
detoxification treatment, is contingency management (CM). CM is based on the 
principles of behavioural and operant conditioning in that behaviour which is 
followed by positive consequences is more likely to be repeated (Schultz, 2015). 
This intervention aims to promote abstinence from opioid use and reduce drug 
misuse, for example, illicit drug use by people receiving MMT (Shoptaw et al., 2002, 
Stitzer et al., 1986).  It also aims to prevent or reduce polydrug-abuse such as use of 
benzodiazepines while receiving MMT (Stitzer et al., 1992, Dolan et al., 1985) and 
promoting adherence to interventions that can improve physical health outcomes, 
for example, attendance to hepatitis C testing services (Petry 2006). CM incentives 
have included vouchers (exchangeable for goods such as food), cash rewards (of 
low monetary value), prizes (including cash and goods) and clinic privileges (such as 
non-supervised consumption) and studies have found that CM is effective as an 
intervention to reduce or abstain from drug use and as such an appropriate 
treatment adjunct to detoxification.  Studies have also found that CM is effective 
when treating comorbid opioid addiction-emotional disorders, with improved 
symptoms of depression and anxiety among patients with opioid use disorders 
(Gruber et al., 2000, Petry et al., 2013).  
However, the use of CM in drug misuse services presents challenges. Many 
NHS staff are not trained in the technique and so this intervention is not effectively 
delivered during detoxification, or staff only use some components of the treatment 
plan. As such, NICE (2009) guidelines recommend that drug services ensure that CM 
training is delivered to staff and the intervention programme is introduced into the 
NHS drug services, in phased implementation stages, however this is not without 
substantial costs and many NHS trusts have not been able to start the processes. 
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Also the cost of incentives as well as the cost and need for frequent urine 
monitoring is a disadvantage to the sustainability of CM in clinical practice. 
Furthermore, the effects of positive reinforcement tend to weaken after the 
contingencies are no longer enforced and not all substance abusers respond to CM, 
so there is a need to address these individual differences in response to CM 
approaches and consider alternative treatments plans to ensure abstinence 
following detoxification.   
Cognitive Behavioural Therapy (CBT) as a treatment is recommended 
following abstinence or stabilisation, and can be used to treat co-morbid 
depression-anxiety, if appropriate, with a focus on relapse prevention.  CBT 
comprises a relapse prevention (RP) component. The defining features of CBT-RP 
treatment includes understanding the cause of the drug use and realistic 
consequences of the abuse, helping the individual learn to recognise situations and 
triggers where they are vulnerable to drug use, how to avoid these triggers and how 
to use taught behaviours and cognitive strategies to cope with situations where 
triggers are unavoidable and as such avoid relapse (Martlatt and Gordon, 1985).  
Extensive research has shown support for CBT-RP in treating alcohol use 
disorders (see Miller and Wilbourne, 2002 for a review) and cocaine abuse (Maude-
Griffin et al., 1998), however research on the efficacy of CBT when focusing on 
opioid dependence is sparse and research has mixed results.  Fiellin et al. (2013) 
found no significant differences in self-reported frequency of opioid use when 
comparing physician management of buprenorphine maintenance treatment (BMT) 
or BMT with CBT.  Kakko et al. (2003), however, reported 1 year retention in 
treatment in heroin addicts in BMT plus CBT-RP compared to placebo plus CBT-RP. 
Pan et al. (2015) report that CBT was effective in reducing opiate use and improving 
employment and decreasing stress levels for opiate-dependent patients in MMT 
(Zhuang et al., 2014).  In light of this, NICE guidelines recommend that CBT is used 
as a relapse prevention intervention and should not be offered routinely to those 
undertaking opioid detoxification or maintenance treatment and that CBT is only 
considered for those who have achieved abstinence or are stabilised on opioid 
maintenance treatment.  With regards to co-morbid depression and anxiety or 
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sleep disorders, NICE (2009) guidelines point to the CBT-RP programme to include 
treating these co-morbid disorders. The full and detailed guidance for the treatment 
of depression and anxiety is beyond the scope of this thesis, but in summary those 
individuals seeking treatment for severe depression can expect 16-20 sessions of 
CBT over a period of 3-4 month. If an individual is presenting with co-morbid 
anxiety, they can expect to receive treatment for anxiety alongside the depression 
treatment, within the same time frame.  
CBT is a very effective and reliable, first-line approach for treatment of adult 
depression (Cuijpers et al., 2013), is effective for anxiety disorders (Hofmann and 
Smits, 2008), compared to pill placebo conditions and also effective in treating 
anxiety related sleep disorders such as insomnia.  The therapy does, however, 
require motivation on the part of the patient as well as insight into their behaviours 
and thoughts and how they relate to drug use and this might prove to be very 
challenging to some opioid dependent individuals.  
 
NICE (2009) recommend that those who are in limited contact with NHS 
services, for example those who are under primary care settings such as a GP 
service, are offered brief motivational interventions in these settings.  These 
interventions comprise one or two sessions of 10-45 minutes duration to provide 
non-judgmental feedback aimed at increasing motivation to change behaviour. This 
is challenging for GP services as due to lack of trained staff or time pressures on the 
GPs themselves.  NICE (2009) recommend that patients seeking treatment for 
opioid abuse are routinely provided information about self-help group programmes, 
for example Narcotics Anonymous (N-ANON) services.   
Specific recovery pathways such as 12-step programmes (TSP) and mutual-
help organisations, Narcotics Anonymous (N-ANON) and Alcoholics Anonymous (A-
ANON), are common recovery options offered to individuals with substance use 
disorders.  These programmes, often relied upon as an aftercare resource following 
detoxification, provide support, practical help and care for group members who 
share a common substance abuse and addiction disorder.  Kelly et al. (2014) 
compared  N-ANON and A-ANON outcomes and found little difference with respect 
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to group participation and at no greater risk of dropout or diminished recovery 
should drug addicts attend A-ANON  instead of N-ANON. 
 Research literature has shown that patients remain abstinent following 
treatment; Kaskutas (2009) report two studies with a positive effect for A-ANON 
and Gossop et al. (2008) found abstinence from opiates was increased in the 
patients who attended N-ANON/A-ANON.  Moreover the more frequent N-
ANON/A-ANON attendance, the more likely to remain abstinent from opiates, 
compared to non-attenders and to infrequent (less than weekly) attenders.  
Ronel et al. (2011) investigated using a TSP in MMT for heroin-addicted 
individuals in recovery. The researchers found that the TSP helped to create group 
coherence and a sense of belonging and helped to meet the needs of this 
population undergoing treatment. They concluded that the TSP was able to produce 
a sense of self-efficacy and stimulated motivation for change. Montgomery et al. 
(1995) also found support for TSP in treating addiction, however the researchers 
point out that it was the extent of involvement, engagement or active participation 
the TSP which was associated with favourable outcomes after treatment, rather 
than coerced attendance alone.    
Furthermore, TSP are also able to reduce health care costs, with reductions in 
inpatient days and mental health costs in individuals undergoing treatment for 
addiction (Mundt et al., 2012).  
 When considering TSP for individuals with comorbid addiction-mental health 
disorders, the outcome is mixed.  Bogenschutz et al. (2006) report that, except for 
psychotic disorder, co-morbid individuals attended and benefited from TSP 
programmes, at rates comparable to non-co-morbid individuals. Both attendance 
and active involvement in TSP also predicted higher subsequent rates of abstinence 
in those with co-morbid disorders (Bergman et al., 2014).  However, Kelly et al. 
(2003) found that SUD-depression comorbid individuals did not significantly benefit 
from the programmes and continued to suffer from significant levels of depression.  
The researchers report that the patients who continued to suffer from depression 
were less socially involved in the TSP over time, compared to the non-co-morbid 
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individuals and suggest that dual-diagnosis-specific self-help groups may be a better 
fit for these patients. 
 The challenge faced by many individuals seeking to reinforce their treatment 
and recovery is comorbid anxiety and difficulty experienced when participating in 
group settings such as TSP.  As discussed earlier, SAD is commonly seen in those 
seeking treatment from substance abuse and (Book et al., 2009) report that 
regardless of treatment setting (inpatient or outpatient), one out of four individuals 
are likely to present with comorbid SAD. The core feature of SAD is fear of scrutiny 
in social situations, such as participating in STP, which are characterised by public 
speaking at meetings.  Given their fear of social interactions and social 
performance, as well as social deficits (as discussed earlier), it follows that socially 
anxious opioid abusers find these TSP challenging and therefore benefit less from 
the treatment.  Timko et al. (2013), however, found those individuals who attended 
at least one meeting had positive outcomes and those with more social anxiety 
benefited more from participation with the group.   
While these self-help groups N-ANON and A-ANON provide on-going, long 
term support from others who have had similar experiences, the social anxiety 
surrounding attending group treatment as well as the religious nature of the 12 step 
approach is seen as a deterrent and some individuals also find difficulty integrating 
the programme principles or 12 steps into their treatment of addiction. Due to the 
anonymous principles of these TSP, findings on attendance to these meetings is 
unclear, however it is expected that many detoxified opioid dependent individuals 
do not benefit from the supportive programmes and remain at risk to relapse 
following treatment. 
In summary, pharmacological treatments for opioid addiction, as the principal 
treatment for opioid addiction, are found to be effective, with a focus on managing 
the physical withdrawal symptoms.  Treatment of the co-morbid emotional 
impairments and protracted withdrawal symptoms however appear to fall short of 
this pharmacological efficacy and are risk factors to relapse. Likewise, treatment of 
emotional impairments alone are unlikely to reduce substance abuse or ensure 
sustained abstinence. Psychosocial treatment programmes such as CM, CBT or self-
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help programmes; N-ANON and A-ANON, offer some promise, however these are 
not without problems. In particular the psychosocial and self-help treatments 
require more than attendance and the literature points out that social interaction, 
motivation and active participation are more likely to ensure success.  This in itself 
is challenging, considering the high instances of co-morbid disorders; depression, 
SAD and social withdrawal observed in opioid withdrawn individuals and discussed 
earlier.  This highlights the need to acquire an intervention treatment that 
addresses issues and ensures these individuals continue in treatment and remain 
abstinent. 
1.4 Oxytocin Neuropeptide  
Oxytocin (OT), a CNS peptide, was discovered by Sir Henry Dale, in 1906, who 
found extracts from the human posterior pituitary gland contracted the uterus of a 
pregnant cat (Dale, 1906).  He coined the name OT from the Greek words ωκνξ, 
τoκoxξ, meaning “swift birth”, and was jointly awarded the Nobel Prize in 1936 for 
his pioneering work on chemical transmission of nerve impulses.  OT was sequenced 
in 1984 and was the first peptide hormone to be chemically synthesized by Vincent 
du Vigneaud in 1953, who was awarded the Nobel Prize in 1955 for this work (Du 
Vigneaud, 1956).  
 As an abundant neuropeptide, OT is best known in mammalian species for the 
characteristic peripheral and reproductive effects that it promotes, including 
uterine contractions during parturition and milk ejection during lactation. There is 
also compelling evidence that OT acts in the brain to promote a variety of vital 
adaptive responses including maternal behaviour, monogamous pair-bonds, sexual 
arousal and orgasm, peer to peer social interaction, social memory and anxiety 
reduction (Neumann, 2007 for a review). As such, OT has also received a lot of 
attention for its potential to positively influence prosocial behaviour in both males 
and females and with its anxiolytic and antidepressant properties, its therapeutic 
potential (Striepens et al., 2011, Churchland and Winkielman, 2012). 
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 Oxytocin system structure and neurobiology.  1.4.1
Oxytocin (OT) is a nine amino-acid CNS peptide (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-
Gly), primarily synthesised in the magnocellular neurosecretory cells of the 
supraoptic (SON) and paraventricular (PVN) nuclei of the Hyp (Figure 1.6).  It is 
transported in the neurons to the posterior pituitary gland where it is stored in 
large dense core vesicles (LDCVs) and released into the bloodstream to exert 
peripheral effects (Morris and Pow, 1991).   
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OT is also synthesised in the smaller parvocellular neurons of the PVN which, 
via volume transmission, innervate several extrahypothalamic regions in the central 
nervous system (CNS) (olfactory nuclei, nucleus accumbens (NACC), the amygdala 
(AMY), bed nucleus of the stria termnalis (BNST)), as well as brain stem (nucleus 
tractus solitarii and locus coeruleus) and spinal cord (intermediolateral cell column 
and dorsal horn) (Loup et al., 1989, Landgraf and Neumann, 2004b) (see Fig 1.6).  
OT exerts several central effects by binding to OT receptors (OTR) in these brain 
regions (Meyer-Lindenberg et al., 2011, Fuxe et al., 2012).  The binding of OT to 
receptors results in behaviours which range from appetite control, autonomic 
regulation, antinociception (Loup et al., 1991), social/sexual behaviours (Kendrick, 
2004), attenuation of the stress response through the reduction of CRF (Jurek et al., 
2015) as well reduced anxiety-like and depressive-like behaviours (Zanos et al., 
2014, Goeldner et al., 2011). The OT-ergic circuit, projecting from the PVN also 
innervates the VTA and the DAergic neurons which project to the NAcc.  The 
activation of this mesolimbic reward pathway has prosexual and prosocial effect 
and is also implicated in addictive behaviour (McGregor et al., 2008b).  
Furthermore, due to its prosocial, antidepressant and anxiolytic properties as well 
as its role in stress and addictive behaviours, OT offers treatment potential in 
various psychiatric disorders including anxiety, depression, sleep disorders and 
addiction and disorders characterised by social interaction deficits such as autism 
(Carter, 1998b) and schizophrenia (Heinrichs and Gaab, 2007).  
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Figure 1.6: Prominent oxytocinergic projections in the brain of rodents.  
Oxytocin (OT) is primarily synthesised in the magnocellular neurosecretory cells in the 
supraoptic (SON) and paraventricular (PVN) nuclei; it is then transported to the posterior 
pituitary gland where it is stored in vesicles and is released into the bloodstream to exert its 
peripheral effects. Moreover, OT is also synthesised in the parvocellular neurons of the 
PVN, which innervate several extrahypothalamic regions in the CNS, including the olfactory 
nuclei, the nucleus accumbens, the amygdala, bed nucleus of the stria termnalis, and also 
to the brainstem and spinal cord, to exert its local effects 
(  magnocellular neurons;       parvocellular neurons)  
 
Abbreviations:  Acb, nucleus accumbens; Amy, amygdala; BNST, bed nucleus of stria 
terminalis; CgCx, cingulate cortex; CPu, caudate-putamen; DR, dorsal raphe nucleus; FCx, 
frontal cortex; LS, lateral septum; NL, neural lobe of the pituitary; OB, olfactory bulb; PAG, 
Periaqueductal gray; PVN, paraventricular hypothalamic nucleus; Sol, Solitary tract nucleus; 
SC, spinal cord; SON, supraoptic hypothalamic nucleus; Th, thalamus; Tu, olfactory tubercle; 
VDB, vertical limb of the diagonal band of Broca. Figure founded on Baskerville and 
Douglas, (2010) , Fuxe et al., (2012), Meyer-Lindenberg et al., (2011) 
 
The OTR belongs to the G- protein coupled receptor superfamily and is widely 
distributed throughout the peripheral and central nervous system (although there 
are species differences in this distribution).For more detail on OTR distribution in 
the human brain, see Table 1.1. 
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Table 1.1. Distribution of oxytocin receptors in the human brain.  
Brain Regions  
Olfactory system  
Anterior olfactory nucleus N/R 
Olfactory tubercle N/R 
Islands of Calleja + 
Piriform cortex N/R 
Entorhinal/perirhinal area - 
Cortical areas  
Peduncular cortex +/- 
Insular and Cingulate cortex N/R 
Frontal and Temporal cortex - 
Taenia tecta N/R 
Ventral limb of the Diagonal band of Broca + 
Basal nucleus of Meynert + + + 
Basal ganglia  
Caudate putamen - 
Ventral pallidum + + 
Glopus pallidus + + 
Nucleus Accumbens - 
Limbic system  
Lateral septum + + + 
Bed nucleus of stria terminalis - 
Amygdaloid-hippocampal area - 
CA1 and  CA3 region of Hippocampus N/R 
Central and  Medial amygdaloid nucleus - 
Basolateral amygdaloid nucleus - 
Parasubiculum and presubiculum - 
Dorsal and Ventral subiculum - 
Thalamus and hypothalamus  
Anteroventral thalamic nucleus - 
Paraventricular thalamic nucleus + 
Ventromedial hypothalamic nucleus - 
Anterior medial preoptic area + + 
Supraoptic nucleus - 
Paraventricular nucleus - 
Medial tuberal nucleus + 
Posterior hypothalamic area + + 
Supramammillary nucleus - 
Lateral mammillary nucleus + + 
Medial mammillary nucleus + 
Brain stem  
Substantia nigra + + + 
Ventral and dorsal tegmental area - 
Central gray + 
Dorsal raphe nucleus + 
Reticular nuclei - 
Medial vestibular nucleus - 
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Hypoglossus nucleus + + 
Nucleus of the solitary tract + + + 
Dorsal motor nucleus of the vagus nerve + 
Inferior olive nucleus +/- 
Substantia gelatinosa of trigeminal nucleus + + + 
 
OT receptor binding levels in the human brain.  The data has been derived from Gimpl and 
Fahrenholz (2001), Klein et al. (1995), Loup et al. (1989), Loup et al. (1991), Russell and Brunton 
(2009). 
 
+, low binding; ++, moderate binding; +++, high binding; +/- at the detection limit; -, not detectable; 
N/R, not reported 
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 Oxytocin and the blood-brain barrier 1.4.2
 Evidence suggests that central and peripheral OT are independently 
regulated, with a protective blood-brain barrier (BBB) ensuring that numerous drugs 
and endogenous chemicals are unable to easily enter the brain. As such, OT a large, 
non-steroid and water soluble peptide is carried freely within the blood circulation, 
however has limited ability to cross the BBB and gain access to the CNS; ~0.1% of 
systemic OT enters the brain (Jones and Robinson, 1982). With OT potential to 
positively influence social behaviour and potential efficacy in treating disorders 
characterised by social interaction deficits such as autism (Carter, 1998b), 
schizophrenia (Heinrichs and Gaab, 2007)  and addiction, CNS OT remains of high 
interest.  
Endogenous, peripheral OT concentrations are known to fluctuate in the 
presence of social stimuli (Churchland, Winkielman, 2012).  The assumption is that 
the stimulus causes OT release in the brain, which then directly modifies the activity 
of socially-relevant brain circuitry.  This was demonstrated by Barraza and Zak 
(2009) with an increase in plasma levels of OT after the viewing of an emotional 
video scene as well as an empathetic response and high levels of generosity 
towards strangers in social interaction, suggesting a release of central OT. The 
relation between social stimuli and elevated plasma levels of OT is probably due to 
a reaction in the autonomic nervous system (Porges, 1998).  The viscera, especially 
the heart and the gut, is likely to respond to the stimuli and contribute to OT plasma 
level.  More significantly visceral signals are picked up by the afferent branches of 
the vagus nerve resulting in the registration of emotional signals in the brain and 
release of OT in the brain (McEwen, 2004). However, OT has a short plasma half-life 
of 3-5 minutes so OT’s prolonged effects remain unclear (Uvnas-Moberg, 1998). 
With ongoing interest in OT and its active role within socially-relevant brain 
circuitry, the question of BBB penetration provides a challenge.  There is some 
evidence suggesting that the OT peptide might cross the BBB.   Peripheral injections 
of OT can mirror some effects seen after central administration of OT. For example 
in Mongolian gerbils, affiliation between monogamous females and their partners 
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was significantly increased following subcutaneous injections of OT (Razzoli et al., 
2003).  A study into the effects of OT on social cognition in autism found that 
intravenous OT (pitocin) facilitated the processing and retention of social 
information in adults diagnosed with autism or Asperger’s disorder (Hollander, 
2006).  In a previous study Hollander et al. (2003) found that OT intravenous 
administration reduced repetitive behaviours in adults with autism or autism 
spectrum disorders and concluded that OT reduces anxiety and AMY reactivity 
which autistic individuals experience when faced with social situations.  Another 
possible mechanism by which systemically administered OT may affect the CNS is 
via the formation of active fragments that may have the capability to cross the BBB. 
Fragments of OT have been found to cross the BBB and regulate several memory 
processes (Burbach et al., 1983).   
The restriction that the BBB places on the delivery of psychopharmacological 
agents to the CNS has also led to research for alternative routes for the delivery of 
drug treatments to the brain mechanisms (Pardridge, 2005).   
One such route, proving to show potential, is intranasal administration (Born 
et al., 2002). Direct nose-to-brain transport after intranasal deposit and absorption 
from the mucosal epithelium provides a non-invasive means for peptides to 
circumvent the BBB and gaining access directly to the brain or via the cerebrospinal 
fluid, gaining access to central nervous receptors.  In comparison with other 
administration routes, intranasal administration may offer ease of use, reduced 
systemic exposure, faster drug onset, increased compliance and this route hopes to 
result in similar effects that are produced by peripherally delivered drugs. There is 
some evidence to suggest that OT is able access the CNS via this route. Intranasal 
administration of the structurally related neuropeptide, vasopressin, has shown to 
result in a rise in neuropeptide content in human cerebrospinal fluid (CSF) within 10 
min (Born et al., 2002).  Increased OT concentrations in human plasma (Gossen et 
al., 2012) and saliva (Weisman et al., 2012) have been found after intranasal 
application and Neumann et al. (2013) demonstrated increased OT levels in the 
extracellular fluid of brain regions, AMY and dorsal HIPP following intranasal 
administration of OT in rats and mice.   The rise in central OT following intranasal 
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administration was also paralleled by increased OT concentrations in plasma.  Wang 
et al. (2013) found that intranasal OT was able to relieve a human headache in a 
dose-dependent manner, the OT concentration in both plasma and cerebrospinal 
fluid (CSF) increased significantly in relation to pain level and there was a positive 
relationship between plasma and central OT concentration.  However, transmucosal 
nasal drug delivery is not without its challenges and there is on-going debate on the 
route(s) intranasal administered OT uses to access the CNS as well as the quantity 
required to ensure significant effects (Leng and Ludwig, 2016).  
1.5 Oxytocin and Emotions  
There is an increasing number of animal and human studies demonstrating 
that OT, via its actions on the OTRs in the brain, is involved in the regulation of a 
wide variety of CNS behaviours. These include sexual behaviour; learning and 
memory as well as emotional and stress-related behaviours of depression and 
anxiety. (Zanos et al., 2017). OT has also been hypothesised to play a role in 
addiction (see section 1.6), (furthermore see Neumann, 2008, McGregor et al., 
2008b, Zanos et al., 2014, Gimpl and Fahrenholz, 2001, Kovacs et al., 1998). 
This thesis concentrates on the role of OT in modulating the emotional 
impairments following protracted withdrawal which may be implicated in relapse in 
detoxified opioid dependent individuals. These include social behaviours, anxiety 
disorders, depression and sleep disturbances.  As such the introduction will 
concentrate on the role of OT in those behaviours alone.  The reader is directed to 
reviews on the central effects of OT by Gimpl and Fahrenholz (2001) and Wojciak et 
al. (2012) for further information.  
 Oxytocin and social behaviours 1.5.1
Social inclusion and social support are important for psychological and physiological 
health benefits (Berkman et al.,1992, Brummett et al., 2001).  Social interaction and 
support are associated with decreased susceptibility to disease and lower 
cardiovascular reactivity (Kamarck et al., 1990), as well as enhanced immune 
function (Jemmott et al., 1988, Glaser & Kiecolt-Glaser, 2005).  
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 Positive psychological health outcomes through social interaction include 
lower rates of depression and anxiety (Fuller-Iglesias, 2015) as well as reduced 
addictive behaviours (Groh et al., 2007, Hser, 2007).  
 Baumeister and Tice (1990) reviewed multiple sources and concluded that 
one major cause of anxiety is exclusion from social groups and the threat or actual 
breaking of social bonds is associated with a deeply rooted and innate form of 
distress and fear.  Cohen and Wills (1985b) point out that perceived availability 
and/or the presence of social support is able to moderate the relationship between 
anxiety/stress and stress-induced psychopathology, thereby increasing resilience to 
negative outcomes.  
To successfully establish and maintain social relationships, individuals need to 
have competent social skills, demonstrating sensitive and appropriate responses to 
others.   Animal and human studies indicate that OT has a facilitatory role in a 
number of social-enhancing behaviours.  For example; after its central release, OT 
promotes important aspects of social behaviour which include social preference 
(Lukas et al., 2011), pair bonding in monogamous species (Carter et al., 1992, 
Carter, 1998a) as well as social cognition (Bielsky and Young, 2004).  Studies have 
confirmed these pro-social effects of OT after administration in healthy participants 
as well as patients with emotional and social dysfunctions, in particular in the 
regulation of autism spectrum disorders which are characterised by abnormalities in 
social behaviour and social cognition (Andari et al., 2010, Dai et al., 2012, Hollander, 
2006, Hollander et al., 2003).   
Intranasal OT administration in humans has shown to affect many aspects of 
sociability ranging from social perception, increased gazing toward the eye region 
(Guastella and MacLeod, 2012, Gamer et al., 2010) and improved recognition of 
emotional facial expression (Domes et al., 2007a, Savaskan et al., 2008).  Intranasal 
OT is also involved in complex social behaviours such as trust, (Savaskan et al., 
2008) social-risk taking (Kosfeld et al., 2005a), co-operation and empathy (Ditzen et 
al., 2009, Hurlemann et al., 2010).  Intranasal OT also increased the ability infer the 
mental and emotional states of others from subtle facial cues, specifically the 
recognition of happy facial expressions (Marsh et al., 2010).    
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As a whole, these findings support the hypothesis for OT to be the “social” 
molecule enhancing several social behaviours in humans and animals. The findings 
also allude to the impact that dysregulated or deficient OT could have on social 
functioning.  
 Oxytocin and Emotional Impairments 1.5.2
 As a key effector of social behaviour, OT is of particular interest when 
investigating behaviours that are associated with social withdrawal, in particular 
anxiety and stress, depression and sleep disorders. See Cochran et al. (2013) for a 
review on the possible involvement of OT in the pathophysiology of 
neuropsychiatric disorders that impact social functioning and which are beyond the 
scope of this thesis. 
 Anxiety and stress response 1.5.2.1
 A large body of evidence has illustrated the anxiolytic effects of OT with both 
peripheral and central administration OT reducing both hormonal stress-response 
of the HPA axis and anxiety levels (Neumann 2002).  For instance, chronic infusion 
of synthetic OT into the lateral ventricles of female rats was seen to reduce the 
corticosterone response to psychogenic stress and reduced anxiety-related 
behaviour (Windle et al., 1997).  Direct OT administration to the AMY of rats was 
shown to decrease activation in this region and to attenuate amygdala-brain stem 
communication, which are known to play a role in the autonomic and behavioural 
components of anxiety and fear (Kirsch et al., 2005).  Also intracerebroventricular 
administration of OT attenuated the high-anxiety levels of rats selectively bred for 
high-anxiety behaviour while infusion of an OT antagonist increased the anxiety 
levels of rats with low-anxiety behaviour (Slattery and Neumann, 2010), suggesting 
an anxiolytic effect of OT. Neuroimaging studies have shown that intranasal OT 
administration diminished stressed induced AMY hyperactivity in humans (Domes 
et al., 2007a) and also decreased functioning between the AMY and brainstem in 
response to negative emotional stimuli (Kirsch et al., 2005).   
One of the underlying mechanisms behind these anxiety-stress regulatory 
findings appears to be that OT has direct and indirect inhibitory effects on the AMY, 
which contains large numbers of OT receptors.  In addition, Samolinski et al. (2007) 
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found, through the use of functional magnetic resonance imaging (fMRI), intranasal 
OT increased connectivity between the AMY and rostral medial frontal cortex 
(rmFC). The rmFC is a critical region for social cognition and emotion regulation and 
so further contributes to our understanding of the neural mechanisms by which OT 
modulates social and cognitive behaviours 
As well as an anxiolytic role though its regulation of AMY activity, OT is also 
implicated in the suppression of the stress response via an HPA axis mediated 
mechanism.  Lactating women, with high levels of OT, are found to have lower 
cortisol and ACTH in response to a physical exercise stressor compared to non-
breastfeeding women (Altemus et al., 1995).  An increase in plasma OT was found 
after exposure to a stressor of uncontrollable noise (Sanders et al., 1990) and  
Marazziti et al. (2006) found a positive correlation between plasma OT levels and 
stress levels in that the higher an individual scored on a stress test, the higher their 
OT levels in plasma.  Taylor et al. (2009) found elevated plasma OT levels in females 
in stressful relationships and Jong et al (2015) found increased salivary 
concentrations of OT in response to running, a natural stressor, and a social stress-
induced test.   
These studies point to OT as part of the stress response circuitry, in that OT 
suppresses CRF release from the hypothalamus. Cohen et al. (2010) showed OT, 
microfused into the hippocampus following exposure to stress, was able to 
significantly reduce stress response behaviour of male rats. The administration of 
OT was seen to initially cause a sharp increase in corticosterone levels followed by a 
decline (compared to a control group in which corticosterone levels remained 
raised).  As such, the presence of OT enabled a more effective HPA axis response to 
stress, in two seemingly opposite effects.  Initially the elevated OT levels increased 
corticosterone secretion from the adrenal cortex followed by HPA axis negative 
feedback and modulated stress response, allowing for the re-establishment of 
homeostasis (see Figure 1.7) 
Moreover, the researchers also found that stress exposure was able to 
induce elevated levels of OT in the plasma (peripheral) as well as centrally and so it 
would appear that there is a coupling of peripheral and central OT release in 
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response to stress.  These findings are supported Neumann (2002), who also 
reported that in response to stressors, OT is released not only peripherally, but also 
centrally. 
In addition to the relationship between OT and the HPA axis, elevated 
endogenous OT signalling in specific brain regions enhances prosocial behaviours.  
Smith and Wang (2014) demonstrated the relationship between OT and social 
interaction in the response to stress.  Using prairie voles, the authors report that 
following restraint stress, females allowed to recover with their male partners, 
demonstrated reduced anxiety-like behaviour and had reduced corticosterone 
levels while the OT levels in the PVN remained high.  
Cohen et al. (2014) argued that, as well as a peripheral release, stress 
triggers a central release of OT, encouraging social approach and support as a 
coping strategy, which in turn will facilitate OT signalling.  In addition, OT release 
after social exposure appears to enable a more effective hypothalamic-pituitary-
adrenal axis response to stress, possibly acting both to trigger and to regulate the 
initial sharp peak in the activity of the hypothalamic-pituitary-adrenal (HPA) axis 
and the subsequent feedback downregulation that terminates the neuroendocrine 
stress response through negative feedback  (see Figure 1.7).   
 This recurrent association between OT release, attenuated stress response 
and the subsequent expression of social behaviours may explain the long-term 
benefits of social contact and social support found in human studies (particularly in 
light of the short half-life of OT, which is minutes only).  For example, Heinrichs et 
al. (2003) reported that during and following a stress task, those participants who 
had received intranasal OT and had social support from a friend during the task 
showed significantly supressed cortisol levels and decreased anxiety.   
 Thus, social support and social interaction act as a buffer, and as such 
moderate the relationship between stress and stress related behaviour.  Due to the 
role in both pro-social behaviour and regulation of stress, OT may be responsible for 
mediating this relationship.  
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 Considering the increase in anxiety and stress response associated with 
withdrawal and detoxification from drugs of abuse and that CRF antagonists are 
seen to block these impairments as well as drug-seeking behaviour in rodent 
models (Rodriguez de Fonseca et al., 1997, Heilig and Koob, 2007) and factoring in 
that OT shows inhibitory effects on HPA axis and prosocial anxiolytic properties  
(Uvnas-Moberg, 1998, Windle et al., 2004a) it could be argued that OT is an 
appropriate treatment reducing the withdrawal symptoms and risk of relapse 
following abstinence, in particular the use of an OT-based pharmacotherapy to 
preferably jump-start the AMY to attenuate the emotional distress, including 
anxiety, and activate stress-coping mechanisms.  
 Furthermore OT is believed to play an important role in shifting salience to 
social, affiliative processes, both by increasing the salience of rewarding stimuli 
and/or by reducing stress, allowing for attention to social bonding (Baskerville and 
Douglas, 2010). This is relevant to addiction and treatment for SUDs, where the 
salience of drug stimuli often overshadows the motivation for social interaction and 
affiliation, and where stress may trigger drug seeking and relapse (Sinha, 2008).   
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Figure 1.7: Oxytocin-mediated stress coping strategy 
Stress exposure stimulates oxytocin (OT) release which encourages social approach and 
support as a coping strategy.  Positive support, contact and interactions are associated with 
OT release, which further promotes social-approach behaviours (A). In addition, OT release 
after social exposure enables a hypothalamic-pituitary-adrenal axis response to stress, 
acting both to trigger and to regulate the initial sharp peak in the activity of the 
hypothalamic-pituitary-adrenal (HPA) axis and the subsequent feedback downregulation 
that terminates the neuroendocrine stress response through negative feedback (B)  
 ACTH: adrenocorticotropic hormone;  CRH: corticotropin-releasing hormone. 
(Adapted from Cohen et al., 2014) 
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 Depression 1.5.2.2
 As outlined in section 1.5.2.1. above, OT plays an moderating role in the stress 
response through its association with CRF, the HPA axis as well as the AMY.  Studies 
also support the association between the CRF system, stress, anxiety and mood 
disorder, depression (for a review, see Binder and Nemeroff, 2010).   Administration 
of a 5-HT receptor agonist to healthy individuals increased plasma OT levels (Lee et 
al., 2003), and studies investigating the OT levels of those suffering major 
depressive disorder (MDD) have also shown a connection between depression and 
OT. For example, Frasch et al. (1995) found an 86% reduction of plasma OT in 
patients with MDD, compared to controls.  Differences were more pronounced in 
older patients, who tended to have lower plasma oxytocin levels than younger 
patients (Zetzsche et al., 1996). Anderberg and Uvnås-Moberg (2000) found a 
negative correlation between plasma OT levels and scores for depression and 
anxiety and they also report a positive correlation between OT levels and scores of 
happiness. Gender differences are also reported in studies, with lower plasma OT in 
depressed female patients compared to males (Ozsoy et al., 2009, Anderberg and 
Uvnås-Moberg, 2000).  Finally, post-mortem studies have found neuropathological 
differences in OT-related functioning in patients with depression. Purba et al. (1996) 
report an increase of 23% of OT-producing neurons within PVN of depressed 
patients compared to controls and Meynen et al. (2007) report increased  OT mRNA 
within PVA of depressed patients.  
It is interesting to note the while the periphery OT levels were seen to be 
reduced for those individuals with depression, this is not the case for CNS OT levels.  
This is an indication of the complexity of OT and its complicated role in mental 
disorders.  
 Treating depression has also been found to have mixed effects OT levels.  
Studies of plasma levels following electroconvulsive therapy (ECT) treatment for 
depression found OT levels to be 9-fold higher than baseline (Smith et al., 1990, 
Smith et al., 1994) while Ozsoy et al. (2009) found that antidepressant treatments 
had no effect on OT levels.   
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 One mechanism for the role of OT in the pathophysiology and treatment of 
depression is via its interactions with the serotonergic system.  Animal studies 
found that 5-HT injections potentiated the regular OT bursts that occur within the 
paraventricular hypothalamic nucleus (PVN) in response to suckling stimulus (Moos 
and Richard, 1983). Yoshida et al. (2009) suggest that the anxiolytic action of OT is 
mediated via OT-induced 5-HT receptor activation within the raphe nuclei, where all 
serotonergic neurons project from.  As such OT might regulate serotonin release 
and exert antidepressant effects via direct activation of OT receptors expressed in 
serotonergic neurons. Also serotonergic terminals, originating from the dorsal and 
median raphe nuclei were shown to project to the PVN magnocellular neurons 
(Sawchenko et al., 1983),  where they possibly regulate OT release via an interaction 
with the 5-HT receptors (Jorgensen et al., 2003, Ho et al., 2007).    
  
 Sleep disorders 1.5.2.3
 Human and animal studies have demonstrated the role of stress response and 
CRF on sleep disorders with dysregulated sleep architecture.  Research has also 
pointed to the modulating effect OT has on the HPA axis and stress response. As 
such, OT has been investigated in sleep-wake behaviour. In a study by Lancel et al. 
(2003) intracerebroventricular (icv) low dose of OT, higher dose of OT and an OT 
receptor antagonist was administered into male rats.  Compared to placebo, the OT 
antagonist increased wakefulness at the expense of all sleep states, suggesting that 
endogenous OT promotes sleep. However, acute icv infusion of OT delayed sleep 
onset, which resulted in a reduction of non-REM and REM sleep as well as high 
frequency activity in the EEG within non-REM sleep and the researchers concluded 
that icv OT induces a state of arousal and a stress response.  Based on their findings 
Lancel et al. (2003) argued that OT has a dual mechanism of action with sleep-wake 
behaviour.  Under stress-free conditions endogenous OT may promote sleep, as per 
their OT antagonist condition.  Conversely, under stress conditions the high levels of 
OT is accompanied by behavioural arousal and, possibly via an excitatory action on 
the CRF system, increased vigilance.   
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1.6 Oxytocin and Addiction  
 Oxytocin (OT), as a neuropeptide, is found to modulate the processes 
associated with addiction and drug dependency, i.e reward, tolerance, associative 
learning, memory and stress responses as well as the behaviours and emotional 
impairments presenting co-morbidly with addiction. These co-morbid impairments 
include social deficits, anxiety and depression and are implicated in relapse to drug 
seeking following a period of abstinence. 
As discussed previously, the mesolimbic DA reward system plays a critical role 
in the incentive motivational processes underlying the response to natural 
rewarding stimuli as well as addictive drugs and also drug-related cues.  A critical 
interaction between OT and this brain reward system has been seen in rodent 
studies where OT infused into the VTA or PVN increased mesolimbic DA activity as 
well as sexual motivation (Melis et al. 2007) and an OT-DA relationship in rewarding 
pair bonding has been confirmed (Lim et al. 2006). Interest in the involvement of 
the oxytocinergic system in drug addiction initially came from findings that the brain 
systems involved in drug reward interact with systems involved in natural rewards 
such as sexual behaviour and social bonding and that the pro-social properties of 
some drugs of abuse induce stimulation of the oxytocinergic system (Dumont et al., 
2009).  As such there might be an overlap between the neural circuits which 
underpin social bonding and drug reward mesolimbic DA system (Young et al., 
2011).   
 Studies have indicated that OT has both a prosocial and antisocial role in 
addiction. Morley and McGregor (2000) showed that low doses of MDMA, which 
are seen to activate OT-containing neurons in the SON and PVA of the 
hypothalamus and increase plasma OT levels in rats (Thompson et al., 2007), had 
powerful prosocial effects in rats and increased social interaction.  The researchers 
point out, however, that this effect is short lived and is followed by a much longer 
lasting ‘antisocial’ state.  This was seen in deficits in social behaviour, increased 
anxiety, poor memory and reduced coping responses to acute stress.  These effects 
are also seen in human MDMA users where anxiety and depressive disorders are 
over-represented as well as the impairment of processing of social cues.     
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MDMA is not the only drug that leads to lasting social deficits.  These 
behaviours are also seen following exposure to methamphetamine (Clemens et al., 
2004),  cannabinoids (O'Shea et al., 2006), NMDA antagonists ketamine (Koros et 
al., 2007) and opioids are also implicated in social deficits and social withdrawal 
behaviours.  
Importantly however, social deficits caused by repeated exposure to 
phencyclidine (PCP) is seen to be reversed by intra-amygdala administration of OT 
and Zanos et al. (2014) showed that administration of OT analogue, carbetocin, was 
able to reverse social deficits in morphine withdrawn mice. These findings suggest 
that long-term adaptations in brain OT systems plays a critical role in social deficits 
due to drug exposure and highlights OT as a potential pharmacotherapy in treating 
drug induced social deficits. This is important in light of the role of sociability in 
preventing relapse to drug seeking behaviour and, moreover, sociability and social 
interaction underpins addiction treatment programmes such as Narcotics 
Anonymous.  
As well as targeting social deficits, OT is also able to prevent drug withdrawal-
induced emotional impairments.  Zanos et al. (2014) found that carbetocin was able 
to prevent morphine withdrawal symptoms of depression and anxiety in mice and 
human research and clinical trials have highlighted OT potential to help prevent 
stress related withdrawal symptoms.  Pedersen et al. (2013b) reported that 
following an intranasal OT treatment regime, patients undergoing alcohol 
detoxification had significantly fewer alcohol withdrawal symptoms. As heavy 
alcohol drinking is associated with dysregulation of HPA-axis and increased anxiety 
and craving during abstinence (Sinha et al., 2011), the researchers concluded that 
OT was able to block alcohol withdrawal in human patients due to its action on the 
HPA-axis.  McRae-Clark et al. (2013) found that intranasal OT was able to reduce 
craving and anxiety in marijuana-dependent individuals following a stress task and  
Flanagan et al. (2015) found that intranasal OT was able to attenuate social stress 
reactivity among individuals who were cocaine dependent.   
Overall OT is seen to ameliorate physical and behavioural effects associated 
with drug dependency and withdrawal.  Brain oxytocin is seen to increase 
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sociability, trust, mood and coping with stress while reducing drug associated 
aggression and irritation as well as anxiety (Kirsch et al., 2005, Kosfeld et al., 2005a, 
Domes et al., 2007b, Slattery and Neumann, 2008).  In that OT provides pro-social, 
anxiolytic and antidepressant effects, it is perhaps not surprising that this 
neuropeptide should be potentially therapeutic and as such a target for the 
treatment of addiction, in particular opioid addiction.  As the focus of this thesis is 
on opioid addiction, the role of OT in other substance abuse will not be discussed 
and will focus on the involvement of OT in opioid addiction based on clinical and 
preclinical studies.  
 The oxytocinergic system and opioid addiction 1.6.1
The effects of opioid addiction on the oxytocinergic system and the effect of OT 
treatment in modulating addiction-related behaviours are summarised in Tables 1.2 
and 1.3 respectively. 
 Effects of acute opioid administration on oxytocin system. 1.6.1.1
Early studies have shown an interaction between the oxytocinergic system 
and acute reinforcing effects of morphine (see Table 1.2 for detailed summary of 
the effects of opioid drugs on the oxytocinergic system).  Acute morphine 
administration was shown to decrease hypothalamic OT release in female rodents 
(Clarke et al., 1979, Haldar and Sawyer, 1978).  Pumford et al. (1991) also found that 
the spontaneous activity of oxytocin in the supraoptic nucleus was significantly 
inhibited with a reduction to less than 50% of the initial firing rate, following i.c.v. 
injection of morphine in virgin female rats.  The effects were also completely 
reversed by intravenous injection of naloxone, indicating that the suppressive 
effects of OT is via by μ receptor mediated mechanism.  This was supported by 
Bicknell et al. (1988) who found that concentrations of OT in plasma, measured by 
radioimmunoassay in sample of femoral arterial blood, increased 6 minutes after 
administration of naloxone in morphine treated lactating rats. 
Conversely Kovacs et al. (1987a) observed increased OT immunoreactvity in extra-
hypothalamic limbic areas of the male mouse brain, including hippocampus, 
amygdala and basal forebrain, following acute morphine treatment.  
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This does suggest either differential effects of acute opioid administration on OT 
neurotransmission in different areas of the brain or a sex-dependent regulation of 
the oxytocinergic system following acute administration of opioids.  
 Effects of chronic opioid administration on oxytocin system 1.6.1.2
Chronic administration of morphine (see Table 1.2) induced a significant decrease in 
OT immunoreactivity in the hippocampus, decreased OT within the SON and 
hypothalamus as well as reduced brain OT synthesis and plasma OT levels (Kovacs 
et al., 1987a, Laorden et al., 1997, You et al., 2000, Zanos et al., 2014). This general 
down-regulation of the oxytocinergic system following chronic opioid 
administration, in different brain regions, may be a result of several neuroadaptive 
changes in the oxytocinergic system caused by chronic exposure to opioids.  Zanos 
et al. (2014) also found a marked increase in OT receptor binding within the 
olfactory nuclei and AMY of chronically morphine treated mice, suggesting a 
neuroadaptive and compensatory mechanism to counteract the decreased 
oxytocinergic signalling in the brain.  Naloxone precipitated withdrawal, as a model 
of acute withdrawal, caused an increase in CSF and plasma OT levels and an 
increase in firing rate of OT neurons within the SON (Bicknell et al., 1988, Coombes 
et al., 1991).  The withdrawal also increased messenger RNA (mRNA) levels in the 
PVN and median eminence and increased OT levels in the mediolateral septum.  
Naloxone precipitated withdrawal had no effect on OT levels in the dorsal Hip or in 
the nucleus of tractus solitaries (Laorden et al., 1998, Russell et al., 1992).  
Spontaneous withdrawal was seen to cause an increase in OTR levels in the 
olfactory nuclei, medial septum, lateral septum, piriform cortex and AMY and a 
decrease in OT plasma levels (Zanos et al., 2014).  
 In summary; acute and chronic long term withdrawal induces central 
oxytocinergic deficits. There is evidence, at least with respect to opioid abstinence, 
that this oxytocinergic deficit may underlie the emotional impairments experienced 
by long term opioid abstinent individuals and administration of the oxytocin 
analogue carbetocin was shown to reverse these emotional impairments (Zanos et 
al 2014).  Although, in humans, higher levels of OT was seen in plasma of heroin 
individuals undergoing detoxification, with higher withdrawal stress levels 
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associated with higher plasma OT levels (Nikolaou et al., 2017), highlighting the 
complexity of this hormone in response to withdrawal from opioids; there is a lack 
of correlation between a peripheral response and a central response to stress 
related withdrawal from opioids.   
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Table 1.2: The acute and chronic effects of opioids on the endogenous oxytocinergic system.  
 
Treatment Addiction 
phase 
Administration paradigm Animal Model Effect on Oxytocin Reference 
 
Morphine 
 
 
 
 
Acute 
4μg, intraventricular Lactating Wistar rats ↓ hypothalamic OT release (Clarke et al., 1979) 
10 mg/kg, s.c. Swiss Webster mice between 
the 11
th
 and 22
nd
 day of 
lactation 
↓ OT release during suckling (Haldar and Sawyer et al. 1978) 
5 mg/kg, s.c. Male CFLP mice (25±5 g) 
housed in groups 
↑ OT immunoreactivity in Hipp,  
 Amy and basal forebrain 
(Kovacs et al. 1987a) 
5 mg/kg, i.v. Virgin Sprague-Dawley female 
rats (~270 g) 
↓ spontaneous activity of SON 
 OT neurons 
↓ plasma OT levels 
 
(Pumford et al., 1991) 
0.1-1.5 μg/μl, i.c.v. Virgin Sprague-Dawley female 
rats (~300 g) 
↓ spontaneous activity of SON 
 OT neurons 
(Pumford et al., 1991) 
 
 
 
 
Chronic 
Morphine pellet (37.5 mg 
morphine. HCl), s.c. 
Male CFLP mice (25±5 g), 
housed in groups 
↔ OT immunoreactivity in Amy 
 and basal forebrain 
(Kovacs et al. 1987a) 
Osmotic mini-pump (75 mg), 
s.c., 
1 on day 0, 2 on day 2 and 3 
on day 4. On day 8 
morphine.HCl (30 mg/kg.i.p.) 
Male Sprague-Dawley rats 
(230-270 g) housed in groups 
↓ OT immunoreactivity in the 
 Hipp, SON, ME and ARC 
↓ OT peptide levels in SON and 
 ME 
↔ OT peptide levels in PVN 
(Laorden et al., 1998, Laorden et al., 
1997) 
Osmotic mini-pump, s.c., 
10μg/h/40hrs then 
20μg/h/40hrs and then 50 
μg/h/40hrs 
Lactating, primiparous 
Sprague-Dawley female rats 
(2-4 days post-partum) 
↔ plasma OT levels 
 
(Bicknell et al. 1988) 
Osmotic mini-pump, s.c., 
10μg/h/40hrs then 
20μg/h/40hrs and then 50 
μg/h/40hrs 
Virgin Sprague-Dawley female 
rats (~270 g) 
↔ firing rate of active non-
 phasic OT neurons 
(Pumford et al., 1991) 
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20-100 mg/kg/day, for 7 
days, i.p. morphine.HCl   
Male C57BL/6J mice (20-25 g), 
housed individually 
↑ OT levels in the olfactory 
 nuclei, PirCx and Amy 
↓ hypothalamic OT levels 
(Zanos et al., 2014) 
 
 
Naloxone -
Precipitated 
withdrawal 
Morphine: osmotic mini-
pump, s.c., 10μg/h/40hrs 
then 20μg/h/40hrs and then 
50μg/h/40hrs 
Naloxone: 
5 mg/kg, i.v. 
Lactating, primiparous 
Sprague-Dawley female rats 
↑ plasma OT levels; 
↑ firing rate of OT neurons 
 (SON)  
(Bicknell et al. 1988) 
Morphine sulphate (20-40 
mg/kg) x 5 days, i.c.v (1 
μl/hr) 
Naloxone: 
5mg/kg, i.v. 
Virgin Sprague-Dawley female 
rats (243-287 g) housed 
individually 
↑ plasma OT levels; 
↑ OT levels in CSF 
 
(Coombes et al. 1991) 
Osmotic mini-pump (75 mg), 
s.c., 1 on day 0, 2 on day 2, 3 
on day 4.  
Naloxone.HCl        1 mg/kg, 
s.c. (on day 7) 
Male Sprague-Dawley rats 
(200-210 g) housed in groups 
↑ OT mRNA levels in the ME 
 and PVN 
(Laorden et al., 1998) 
Morphine: osmotic mini-
pump, s.c., 10μg/h/40hrs, 
then 20μg/h/40hrs, then 
50μg/h/40hrs 
Naloxone:  
5 mg/kg, i.v. 
Virgin Sprague-Dawley female 
rats (~250 g) housed 
individually 
↑ plasma OT levels 
↑ OT peptide levels in the 
 mediolateral septum 
↔ OT levels in the dorsal Hip 
↔ OT levels in the nucleus of 
 tractus solitarius 
(Russell et al., 1992) 
Morphine: osmotic mini-
pump, s.c., 10μg/h/40hrs, 
then 20μg/h/40hrs, then 
50μg/h/40hrs 
Naloxone:  
5 mg/kg, i.v. 
Virgin Sprague-Dawley female 
rats housed individually 
↑ OT SON neuron post-spike 
 excitability in morphine-
 dependent rats and to a 
 lesser extend in 
morphine- naïve rats 
(Brown et al., 2005) 
 
Spontaneous 
20-100 mg/kg/day, for 7 
days, i.p. morphine.HCl   
Male C57BL/6J mice (20-25 g), 
housed individually 
↑ OTR levels in the olfactory 
 nuclei, MS, VDB, LS, PirCx 
(Zanos et al., 2014) 
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withdrawal Withdrawal: 7 days in home 
cage without injections 
 and Amy 
 
A detailed summary of the effects of opioid drugs on the endogenous oxytocinergic system upon acute administration, chronic administration, as well as acute and chronic 
withdrawal. ↑ increase; ↓ decrease; ↔ no effect. Abbreviations: Amy, amygdala; ARC, arcuate nucleus; BNST, bed nucleus of the stria terminalis; CSF, cerebrospinal fluid; 
HCl, hydrogen chloride; Hipp, hippocampus; Hyp, hypothalamus; i.p., intraperitoneal; i.v., intravenous; LS, lateral septum; ME, median eminence; MPOA, medial preoptic area; 
mRNA, messenger RNA; MS, medial septum; SON; supraoptic nucleus of the Hyp; OT, oxytocin; OTR, oxytocin receptors; PirCx, piriform cortex; PPD1, post-partum day 1; PPD2, 
post-partum day 2;PVN, paraventricular nucleus of the Hyp; s.c., subcutaneous; VDB, ventral limb of the diagonal band of Broca; VMH, ventromedial Hyp; VTA, ventral 
tegmental area. 
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 Effects of oxytocin on opioid addiction related behaviour  1.6.1.3
Although OT shows potential as a treatment for drug addiction, central 
administration of OT has failed prevent the acquisition of morphine-conditioning in 
rats and it even increased the expression of morphine place-preference when it was 
administered prior to the post-conditioning test in a conditioned place preference 
study (Moaddab et al., 2015). In line with these findings, Van Ree and De Wied 
(1977a) showed that peripherally administered OT slightly facilitated heroin self-
administration in rats. These paradoxical effects might be related to the direct 
actions of OT stimulation on the dopaminergic system.  The fact that activation of 
the central OT receptors directly increased striatal DAergic content (Georgiou et al 
2015) and OT facilitates the effects of DA (Insel, 2003) which is directly involved in 
the reinforcing properties of the drugs of abuse (Volkow et al, 2006) suggests that 
OT might promote opioid self-administration by augmenting the hedonic effects of 
morphine.   Lintas et al. (2011) found, like morphine, OT administration increased 
the firing rate of accumbal neurons, indicating a possible addictive effect of 
morphine and OT on the hyper-excitability of the mesolimbic DAergic neurons.  
While these results are paradoxical in findings, Peters et al. (2014) showed dose-
dependent differential effects of chronic central administration on anxiety and 
stress related behaviours and OT receptor binding in different brain regions, 
highlighting the importance of choosing the correct dose for OT to exert its 
beneficial effects.   
 OT has, however, been found to modulate opioid tolerance and regulate 
opioid withdrawal and, as discussed earlier, also modulate the emotional 
impairments implicated in the protracted opioid withdrawal symptoms, and as such 
offer the potential for pharmacotherapy for comorbid mood and substance abuse, 
and thereby reduce the risk of relapse following detoxification treatment.   
1.6.1.3.1 Effects of oxytocin on opioid tolerance 
 OT has been shown to modulate short-term and long-term opioid tolerance. 
In particular, both peripheral and central OT administration dose-dependently 
attenuated the development of analgesic morphine and heroin tolerance in 
rodents, and a single OT injection also blocked the expression of heroin tolerance 
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following repeated heroin administration (Kovacs et al., 1998, Kovács et al., 1984, 
Kovacs et al., 1985b, Kovacs et al., 1987a). These results strongly suggest that OT 
can rapidly modulate both the early development, as well as the expression of an 
already developed opioid tolerance, which might also explain the effects of oxytocin 
in preventing heroin self-administration (Ibragimov et al., 1987). Importantly, OT 
treatment reduced heroin self-administration in heroin-tolerant (Kovacs et al., 
1985a), but not in non-tolerant rats (Kovacs et al., 1998), but it inhibited the 
development of tolerance to morphine-induced hyper-locomotion in mice (Kovacs 
and Telegdy, 1987), which might indicate differential effect of OT on the adaptive 
versus acute opioid tolerance processes. Importantly, the lateral septum was shown 
to mediate the inhibitory effect of OT on heroin self-administration since direct 
microinjection of OT within this brain region abolished heroin self-administration in 
heroin-tolerant rats (Ibragimov and Kovacs, 1987).   
1.6.1.3.2 Effects of oxytocin on opioid withdrawal/relapse 
 The first evidence for a role of OT on the regulation of opioid withdrawal 
came from Kovacs et al., (1985c) who showed that peripheral OT administration 
decreases naloxone-precipitated morphine withdrawal symptoms in rodents. In line 
with these findings, Georgiou et al. (2015) and Zanos et al. (2014) found that the 
administration of administration of OT analogue carbetocin, was able to prevent 
morphine withdrawal-induced emotional impairments, including depression, 
anxiety and social deficits, as well as stress- and priming-induced reinstatement of 
morphine conditioned preference in mice.  As discussed earlier, oxytocin is also able 
to modulate the protracted withdrawal symptoms of anxiety, depression and sleep 
disorders in humans, which often presented co-morbidly with opioid withdrawal.   
 In summary, these findings demonstrate the ability of OT to reduce the 
physical and emotional withdrawal symptoms of opioid abstinence, suggesting a 
promising pharmacotherapy for comorbid mood impairments substance use 
disorders as well as relapse prevention.  Thus warranting a clinical investigation of 
opioid abuse and abstinence of those undergoing detox.  
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Table 1.3 The effects of oxytocin or oxytocin-based drug administration on the behavioural effects of opioids in rodents. 
Addictive 
substance 
Administration paradigm Animal model 
Oxytocin administration 
paradigm 
Effect of OT Reference 
Morphine Morphine tolerance: 
37.5 mg morphine.HCl pellet, 
s.c./48 hours 
Male CFLP mice 
(25±5g) housed in 
groups 
Oxytocin: 50 μg and 100 
μg/ animal, s.c. (2 hours 
prior to morphine pellet 
implantation) 
↓development of 
tolerance 
(Kovacs et al., 1985c) 
Morphine tolerance: 
30 mg/kg morphine.HCl, s.c. 
and 5 hours later 5 mg/kg 
morphine.HCl, s.c. 
Male albino inbred 
mice (25±5g) 
housed in groups 
Oxytocin: 1 μg i.c.v. or 
intra-CPu (1 hr prior the 
tolerance-inducing dose 
of morphine) 
↔ development 
of tolerance 
(Sarnyai et al., 1988) 
Morphine tolerance: 
30 mg/kg morphine.HCl, s.c. 
and 5 hours later 5 mg/kg 
morphine.HCl, s.c. 
Male albino inbred 
mice (25±5g) 
housed in groups 
Oxytocin: 1 μg 
microinjection into: 
posterior olfactory 
nucleus, CeA, ventral 
hipoccampus (1 hr prior 
the tolerance-inducing 
dose of morphine) 
↓ development of 
tolerance 
(Sarnyai et al., 1988) 
Morphine tolerance: 
60 mg/kg morphine.HCl, s.c. 
and 5 hours later 1 mg/kg 
morphine.HCl, s.c. 
Male CFLP mice 
(25±5g) housed in 
groups 
Oxytocin: 0.002 mg/kg, 
s.c. (1 hr prior the 
tolerance-inducing dose 
of morphine) 
↓ development of 
tolerance 
(Kovacs et al., 1987b) 
Morphine tolerance: 
100 mg/kg morphine.HCl, s.c. 
and 5 hours later 1 mg/kg 
morphine. HCl, s.c. 
Male CFLP mice  
(25±5 g) housed in 
groups 
Oxytocin: 0.002 mg/kg, 
s.c. (1 hr prior the 
tolerance-inducing dose 
of morphine) 
↓ development of 
tolerance 
(Kovacs et al., 1987b) 
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Morphine tolerance: 
37.5 mg morphine.HCl pellet, 
s.c./48 hours 
then, morphine.HCl (5 mg/kg, 
s.c.) 
Male CFLP mice, 
housed in groups 
Oxytocin: 50 μg, s.c. ↓ development of 
tolerance 
(Kovacs et al., 1984) 
Morphine tolerance: 
37.5 mg/ morphine.HCl pellet, 
s.c./48 hours 
then, morphine.HCl (5 mg/kg, 
s.c.) 
Male CFLP mice, 
housed in groups 
Oxytocin: 0.005 or 0.5 
μg/1μl, i.c.v. 
↓ development of 
tolerance 
(Kovacs et al., 1984) 
Morphine tolerance: 
37.5 mg morphine.HCl pellet, 
s.c./48 hours 
then, morphine.HCl (5 mg/kg, 
s.c.) 
Male CFLP mice, 
housed in groups 
Oxytocin: 0.5 ng/1μl, into 
the dorsal Hip or the Acb 
↓ development of 
tolerance 
(Kovacs et al., 1984) 
Morphine tolerance: 
37.5 mg morphine.HCl pellet, 
s.c./48 hours 
then, morphine.HCl (5 mg/kg, 
s.c.) 
Male CFLP mice, 
housed in groups 
Oxytocin: 0.5 ng/1μl, into 
the CPu, VTA or external 
cortical surface 
↔ development 
of tolerance 
(Kovacs et al., 1984) 
Morphine-induced 
conditioned-place 
preference: 
Acquisition: 3 conditioning 
days (morphine. HCl, 5 
mg/kg/day, s.c.) 
Male Wistar rats 
(250-300 g), 
housed in groups 
Oxytocin: 0.2 μg, i.c.v., 5 
min prior to each 
conditioning session 
(both prior to morphine 
and prior to saline 
injections) 
↔ acquisition of 
morphine CPP 
(Moaddab et al., 
2015) 
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Morphine-induced 
conditioned-place 
preference: 
Expression: 3 conditioning 
days (morphine. HCl, 5 
mg/kg/day, s.c.) 
Male Wistar rats 
(250-300 g), 
housed in groups 
Oxytocin: 0.2 μg, i.c.v., 5 
min prior to the post-
conditioning session 
↑ expression of 
morphine CPP 
(Moaddab et al., 
2015) 
Physical signs following 
precipitated withdrawal: 
Day 1: 2 x 20 mg/kg, i.p.  
Days 2-4: 2 x 40 mg/kg 
(morning and afternoon 
injections) 
Naloxone: 4 mg/kg, i.p. (1 
hour after the morning 
morphine injection daily) 
Female Wistar rats 
(130-150 g) 
housed individually 
Oxytocin: 1.0 μg/animal, 
s.c. (1 hour prior to each 
morphine injection daily) 
↑ physical 
dependence 
(decreased body 
weight) 
(van Ree and de Wied, 
1976) 
Naloxone-precipitated 
withdrawal: 
37.5 mg morphine.HCl pellet, 
s.c./48 hours 
Naloxone: 1 mg/kg, i.p. 
Male CFLP mice, 
housed in groups 
Oxytocin: 50 μg, s.c. ↑ latency of 
naloxone-
precipitated 
withdrawal 
(Kovacs et al., 1984) 
Naloxone-precipitated 
withdrawal: 
37.5 mg morphine.HCl pellet, 
s.c./48 hours 
Naloxone: 1 mg/kg, i.p. 
Male CFLP mice, 
housed in groups 
Oxytocin: 0.005 or 0.5 
μg/1μl, i.c.v. 
↑ latency of 
naloxone-
precipitated 
withdrawal 
(Kovacs et al., 1984) 
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Naloxone-precipitated 
withdrawal: 
37.5mg morphine.HCl pellet, 
s.c./48 hours 
Naloxone: 1mg/kg, i.p. 
Male CFLP mice, 
housed in groups 
Oxytocin: 0.5 ng/1μl, into 
the dorsal Hip or the 
mesolimbic Acb 
↑ latency of 
naloxone-
precipitated 
withdrawal 
(Kovacs et al., 1984) 
Naloxone-precipitated 
withdrawal: 
37.5 mg morphine.HCl pellet, 
s.c./48 hours 
Naloxone: 1 mg/kg, i.p. 
Male CFLP mice, 
housed in groups 
Oxytocin: 0.5 ng/1μl, into 
the CPu, VTA or external 
cortical surface 
↔ latency of 
naloxone-
precipitated 
withdrawal 
(Kovacs et al., 1984) 
Naloxone-precipitated 
withdrawal: 
37.5mg morphine.HCl pellet, 
s.c./72 hours 
Naloxone: 1 mg/kg, i.p. 
Male CFLP mice  
(25±5 g) housed in 
groups 
Oxytocin: 50 μg and 100 
μg/ animal, s.c. (2 hours 
prior to morphine pellet 
implantation) 
↓ withdrawal 
symptoms 
(Kovacs et al., 1985c) 
Spontaneous withdrawal: 
20-100 mg/kg/day, for 7 days, 
i.p. morphine.HCl   
Withdrawal: 7 days in home 
cage without injections 
Male C57BL/6J 
mice (20-25 g), 
housed individually 
Carbetocin: 6.4 mg/kg, 
i.p. (15 min prior to FST, 
EPM/ 5 min prior to 3-CB 
test/  
↓ withdrawal-
induced 
depressive-, 
anxiety-like 
behaviours, 
sociability deficits 
(Zanos et al., 2014) 
Stress-induced 
reinstatement: 
10 mg/kg, s.c., for 4 
conditioning days 
(morphine.HCl in the 
afternoon) 
Male C57BL/6J 
mice (20-25 g), 
housed individually 
Carbetocin: 6.4 mg/kg, 
i.p. (5 min prior to swim 
stressor for 
reinstatement) 
↓ stress-induced 
reinstatement of 
morphine place 
preference 
(Zanos et al., 2014) 
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Stress: forced-swim stress (6-
min total) 
Priming-induced 
reinstatement: 
10 mg/kg, s.c., for 4 
conditioning days 
(morphine.HCl in the 
afternoon) 
Priming: 2 mg/kg, i.p. 
(morphine.HCl) 
Male C57BL/6J 
mice (20-25 g), 
housed individually 
Carbetocin: 6.4 mg/kg, 
i.p. (5 min prior to 
morphine priming 
injection) 
↓ morphine-
primed induced 
reinstatement of 
morphine place 
preference 
(Georgiou et al., 2015) 
Heroin Self-administration: 
5 days of fixed ratio schedule 
of reinformcement: 0.25 ml of 
heroin solution (0.125 
mg/ml/infusion), i.v.; 
experimenter delivered two 
initial heroin injections by 
pressing the lever 
Male Wistar rats 
(200-230 g) 
housed individually 
Oxytocin: 1.0 μg/animal, 
s.c. (1 hour prior to 
experimentation daily) 
↑ self-
administration 
(slightly) 
(Van Ree and De 
Wied, 1977b) 
Escalating-dose injections: 
0.05 mg/kg s.c., 2 x daily/4 
days + 0.4 mg/kg, s.c., 2 x 
daily/3 days 
Followed by 
Self-administration: 
7 days of progressive ratio 
Male Wistar rats 
(200-220 g) 
housed individually 
Oxytocin: 1.0 μg/animal, 
s.c. (1 hour prior to self-
administration session on 
the day 7) 
↓ self-
administration 
(Kovacs and Van Ree, 
1985) 
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schedule of reinformcement: 
0.25 ml of heroin solution 
(0.125 mg/ml/infusion), i.v. 
 Development of heroin 
tolerance (escalating-dose): 
2 x daily i.p. injections (100, 
200, 400, 800, 800, 800 μg/kg) 
Self-administration: 
On day 7 of heroin injections, 
rats were placed in self-
administration chambers; 
fixed-ratio reinforcement: 50 
μl of heroin solution (0.4 g/l) – 
flow rate 5 μl/sec; schedule 
terminated upon stable level 
of responding for 3 
consecutive days (usually 7-8 
days)  
Male Sprague-
Dawley  rats (250 ± 
30 g) housed 
individually 
Oxytocin: intra-accumbal  
or injections directly into 
the ventral hippocampus; 
2 ng; treatment block of 
saline/OT/saline/OT 1.0 
μg/animal, s.c. (1 hour 
prior to self-
administration session 
daily) 
↓ self-
administration 
(Ibragimov et al., 
1987) 
A detailed summary on the effects of oxytocin or oxytocin-based drugs administration on the behavioural effects of opioids in rodents. ↑ increase; ↓ decrease; ↔ no effect.  
Abbreviations: Acb, nucleus accumbens; CeA, central amygdala; CPP, conditioned place preference; CPu, caudate-putamen; HCl, hydrogen chloride; Hipp, hippocampus; s.c., 
subcutaneous;  i.c.v., intracerebroventricular; i.p., intraperitoneal; i.v., intravenous; MAP, methamphetamine; mPFC, medial prefrontal cortex; OT, oxytocin; STh, subthalamic 
nucleus; Tu, olfactory tubercle; VTA, ventral tegmental area. 
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 Mechanisms underlying oxytocin and opioid addiction 1.6.2
 The mechanism/s by which OT exerts its effect on drug-related behaviours are 
complex and not fully understood.  Evidence has, however, found that OT interacts 
with the mechanisms which are implicated in addiction; the DA system, NA and 5-
HT system, the glutamate system, the AMY and the HPA axis. These systems are 
also implicated in the co-morbid mental health impairments presented in opioid 
dependent individuals undergoing withdrawal and detoxification. 
 Interactions with the monoaminergic system: Dopamine 1.6.3
 The mesolimbic DA system has a long history of research with focus on the 
incentive motivational processes underlying the response to natural rewarding 
stimuli as well as addictive drugs and drug-related cues.  The interaction between 
OT and the mesolimbic DA system has also been explored through studies of sexual 
and social behaviour. There are common DA- and OT- related brain areas involved 
in pair bonding and sexual behaviours which include NAcc, VTA, SON, PVN, Amy and 
MPOA; regions which are also known to modulate several reward and addiction 
processes (Skuse and Gallagher, 2009).  
 Oxytocinergic projections from the PVN to the VTA innervate the 
mesocorticolimbic DAergic neurons which project to the NAcc (see Fig 1.5) and this 
circuit has a rewarding pro-sexual effect.   Melis et al. (2007) who found that OT 
infused into the caudal VTA or PVN caused penile erections, increased sexual 
motivation and increased mesolimbic DA activity.  OT is also released during 
ejaculation, which is associated with VTA activation in human subjects (Holstege et 
al., 2003) and Carmichael et al. (1987) found that sexual self-stimulation increased 
plasma OT levels in male and female humans.  OT also appears to be responsible for 
the reduced anxiety that is typical of the post-orgasmic state (Waldherr and 
Neumann, 2007).   
 The OT-DA relationship in rewarding pair bonding was also demonstrated 
through the use of antagonists.  Lim and Young (2006) were able to show that DA or 
OT antagonists injected into the NAcc blocked pair bonding and partner preference.   
The interaction effects between DA-ergic and OT (as well as AVP) systems are also 
abolished by an oxytocin receptor antagonist injected into the VTA as well as  
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 DA receptor antagonists injected into either the NAcc shell or into the PVN of 
the hypothalamus, highlighting a neural circuit in which dopamine and oxytocin 
influence motivation/rewarding behaviours (Melis et al., 2007).   
 DA turnover, modulated by OT and OTRs, have also been shown to 
functionally interact with D2 receptors in the NAcc, giving experimental support 
that D2R-OTR interactions in the NAcc play a significant part in oxytocin-induced 
social and emotional behaviours (Romero-Fernandez et al., 2012).   
 The striatum, involved in reward-related/motivational learning and a key site 
for neural adaptations that underlie addictive processes, also contain OT receptors 
in addition to DA receptors, with an oxytocinergic and DAergic interaction in 
reward-related behaviours.  Georgiou et al. (2015) showed that administration of 
the oxytocin analogue carbetocin increases DA turnover in the striatum, which was 
also associated with the ability of OT to prevent both priming- and stress-induced 
reinstatement to opioid place preference. 
 Interactions with the monoaminergic system: Noradrenaline 1.6.3.1
 There is some evidence for an interaction between the oxytocinergic and NA-
ergic systems. Onaka et al. (2003) investigated the role of dendritic OT release in 
regulating presynaptic NA release within the hypothalamus and found enhanced NA 
release in the SON of the hypothalamus, which activated hypothalamic OT neurons. 
The effect of oxytocin was also blocked by an oxytocin receptor antagonist.  The 
researchers concluded that dendritic oxytocin facilitates activation of OT neurons 
through, at least in part, noradrenaline release.   
 Georgiou et al. (2015) also showed that the prevention of morphine primed-
reinstatement of opioid seeking behaviour following the administration of CBT is 
directly associated the ability of OT to suppress striatal NA turnover. 
 Interactions with the monoaminergic system: 5-HT 1.6.3.2
 Research into the involvement of the serotonergic system in the mechanisms 
underlying the effects of OT on opioid addiction-related behaviours is ongoing, yet 
studies have found an interaction between the serotonergic and the oxytocinergic 
systems. For example, administration of a 5-HT receptor agonist to healthy 
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individuals increased plasma OT levels (Lee et al., 2003), and studies investigating 
the OT levels of those suffering major depressive disorder (MDD) have found a 
reduced levels of plasma OT. For example, as discussed earlier, Frasch et al. (1995) 
found an 86% reduction of plasma OT in patients with MDD, compared to controls.  
Differences were more pronounced in older patients, who tended to have lower 
plasma oxytocin levels than younger patients (Zetzsche et al., 1996).   
 Interactions with the glutamatergic system 1.6.3.3
 Glutamate is implicated in addiction through its role in memory formation. As 
opiate addiction develops, the addict becomes conditioned, through learning, to 
engage in addictive behaviours and these behaviours can be triggered by opiate 
associated cues and memories during abstinence, eliciting a withdrawal syndrome 
characterised by acute elevations in cortisol.  This would result in relapse, see 
Peters and De Vries (2012) for a review on the glutamate mechanisms underlying 
opiate memories.  
Also, through the attenuation of the AMY response and dampening of the 
stress-induced activation of the HPA axis, (see review by Benz et al 2010), and 
discussed in more detail below, there is some evidence that OT facilitates the 
extinction of memories associated with anxiety and fear. Therefore it is possible 
that OT, as a treatment, interacts with the glutamatergic system and controls drug 
seeking through the extinction of negative or traumatic memories, which may be 
triggers to relapse.   
 Role of the amygdala 1.6.3.4
 Intranasal OT has been shown to decrease anxiety by reducing AMY reactivity 
in response to threat  (Kirsch et al., 2005, Domes et al., 2007a, Baumgartner et al., 
2008, Labuschagne et al., 2010).  As there is high comorbidity between drug 
addiction and anxiety disorders, it is plausible that OT may act within this precise 
brain network to induce its restorative effect on recovering emotional impairment 
in drug-dependent individuals.  Research has shown that chronic administration of 
morphine (Zanos et al., 2014) as well as other drugs of abuse; cocaine (Georgiou et 
al., 2015, Georgiou et al., 2016), methamphetamine (Zanos et al., 2014, Georgiou et 
al., 2016), and nicotine (Zanos et al., 2015), induces an upregulation of the OT 
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receptor binding in the amygdala of mice, indicating a possible common 
neuroadaptation of the oxytocinergic system in response to drugs of abuse.  While 
the exact mechanisms underlying these neuroadaptations need further 
investigation, it is likely that these changes within the OT receptor system in the 
amygdala are involved in the emotional impairments often presented co-morbid 
with drug addiction. 
 Hypothalamic-pituitary-adrenal- (HPA) axis activity 1.6.3.5
 As addressed earlier, there is evidence to show that OT plays a regulatory role 
within the stress response, through action on the HPA axis (see Fig 1.7). Specifically 
i.c.v. administration of OT decreased stress-induced corticosterone release in rats 
and intra-PVN administration of an OT receptor antagonist increased basal 
adrenocorticotropic hormone (ACTH) levels, while it reduced ACTH release in 
response to a forced swim stress in male rats.  These findings indicate a possible 
tonic inhibition of the HPA axis by OT and an enhancing action under stress 
conditions.  
An association between intranasal administration of OT and a reduced stress 
response has also been seen in human studies  (Heinrichs et al., 2003b, Ditzen et al., 
2009).   As such, OT may play a role in attenuating stress induced withdrawal 
symptoms following opioid withdrawal.  
 Extinction of traumatic memories 1.6.3.6
 As discussed previously, and although not tested in the context of drug 
addiction, there is evidence to suggest that OT facilitates extinction of memories 
associated with fear.  This could be through various routes.  For instance, 
intracerebroventricular infusion of OT prior to fear conditioning does not appear to 
have any effect on fear learning; however, later fear extinction is facilitated by OT, 
while OT receptor antagonists administration impairs extinction learning and 
retrieval (Toth et al., 2012).  OT infusions into the central nucleus of the amygdala 
reduces fear expression by inhibiting excitatory output to fear-eliciting brain stem 
structures (Viviani et al., 2011)  suggesting another possible mechanism for OT on 
extinction.  Another possible mechanism might be OT-dampening of the stress-
induced activation of the HPA axis (see review by Benz et al 2010). Therefore, it is 
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possible that OT may be able to alleviate the affective emotional consequences of 
drug addiction and prevent relapse by interfering with the consolidation of fear 
memories, making these memories weaker and more susceptible to extinction.  
 Interaction with endogenous opioid system 1.6.3.7
 Opioid peptide regulation of the OT system has been suggested to at least 
partly underlie the effects of opioid drugs on the OT system.  See section 1.6.1 for 
further discussion and research.  These studies indicate possible interactions 
between the opioid and oxytocinergic systems.   Recently demonstrated, with the 
use of receptor auto radiographic binding in μ receptor knockout mice, the 
presence of brain region specific interactions between the μ  receptor and OT 
receptor systems, which may be involved in the effects of OT on the modulation of 
opioid associated behaviours and in particular the emotional withdrawal symptoms 
following cessation of drug use.  
1.7 Therapeutic potential of oxytocin in the treatment of opioid 
dependence-mental health co-morbidity 
 In light of the literature reviewed above, OT has an important role in 
mediating several opioid addiction-related behavioural and neurochemical 
processes.  As such, OT can be considered a promising target for the treatment of 
opioid dependence and the emotional impairments which present themselves co-
morbidly upon withdrawal from opioid uses.  Moreover, by attenuating these co-
morbid emotional impairments, OT may play a key role in preventing relapse 
following opioid detoxification and abstinence.  One important factor that 
distinguishes OT from currently available medications is that it does not show abuse 
or addiction potential.  Evidence suggests that patients treated with OT could not 
discriminate between placebo or the actual drug (MacDonald et al., 2011).   
 Another unique property of OT that is important for the treatment of opioid 
addiction and/or comorbid mood disorders is related to its prosocial effects 
(Churchland and Winkielman, 2012).  Prolonged use of drugs of abuse result sin 
disintegration of social lives of drug addicts and may lead to social isolation and 
poor decision making in their social domain, at the expense of compulsive pre-
occupation with the drug and its related cues (Volkow et al., 2011).  Impaired social 
111 
 
behaviours have been linked with the propensity of addicts to relapse after long 
term abstinence.  Therefore, considering the therapeutic effects of social support 
groups (e.g. Alcoholic Anonymous, Narcotics Anonymous) and the benefits of social 
reintegration in keeping addicts abstinent from drug use (McGregor and Bowen, 
2012b), the pro-social effects of OT may suggest its use as an adjunct to 
psychotherapy as a novel effective “psycho-biological therapy’ for prevention of 
relapse to drug seeking.  In support of this, OT and social support have been shown 
to interact and exert a stress-buffering effect (Heinrichs et al., 2003b).  Moreover, in 
light of the potential benefit that OT has in interfering with the consolidation of fear 
memories, making these memories weaker and more susceptible to extinction 
(Toth et al., 2012), OT may further aid in the psychological treatment to assist in 
preventing relapse to drug use. Finally there is clinical evidence for a beneficial role 
of OT in the treatment of other disorders characterized by social, emotional and 
cognitive impairment including autistic spectrum disorders (Carter, 2007) and 
schizophrenia (Heinrichs and Gaab, 2007), as well as a substance use disorders 
including alcohol (Sinha et al., 2011, Pedersen, 2017), marijuana (McRae-Clark et al., 
2013) and cocaine (Flanagan et al., 2015).  As opioid addiction, and more 
specifically, withdrawal and abstinence is associated with negative social and 
emotional impairments, it is plausible that OT may act on the brain networks 
implicated in these withdrawal symptoms, inducing a restorative effect and 
preventing relapse following detoxification from opioid use.  
1.8 Aims and Hypotheses  
 Overall the aims of this thesis is to assess the sociodemographic factors 
associated with 30 day relapse in an opioid dependent population admitted at NHS 
Surrey and Borders Partnership Trust (SABP) for opioid withdrawal and 
detoxification treatment. The thesis also aims to assess the efficacy of oxytocin as a 
novel treatment to prevent relapse and reduce co-morbid emotional impairments 
implicated in relapse to opioid use, following a withdrawal and detoxification 
treatment.   
The aims and hypotheses of each chapter are provided below.  
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Chapter 2 of this thesis assesses the presence and association between specific 
sociodemographic parameters, in an attempt to identify risk and/or protection 
factors associated with relapse of opioid use within 30 days following the start of a 
withdrawal and detoxification treatment programme.  
This is a retrospective case study, using archived and active clinical charts and 
files of patients, in order to assess the sociodemographic factors associated with 
relapse in an opioid dependent population admitted at NHS Surrey and Borders 
Partnership Trust (SABP) for detoxification treatment, between 2013 and 2015.    
10 parameters plus gender were explored within this study. These were past 
criminal behaviour, present criminal behaviour at time of admission to treatment, 
support through a significant relationship other than family, family support, past 
employment, present employment, mental health status, treatment type, 
completion of the treatment, age of first substance use (excluding alcohol) as well 
as data relating to relapse within 30 days from the start of treatment 
 The hypothesis for this study is that there is an association between the 
sociodemographic factors and relapse within 30 days from the start of a treatment 
programme.    
 Chapter 3 of this thesis aims to investigate the efficacy of intranasal oxytocin 
in preventing relapse in detoxified opioid dependent individuals. This is a double 
blind randomised placebo controlled pilot trial.   
 The first objective will be to investigate the efficacy of intranasal oxytocin in 
retaining post-detoxified opioid dependent individuals in an inpatient rehabilitation 
programme and prevent relapse to opioid use.   
 The hypothesis will be that post detoxified opioid dependent individuals 
exposed to two week, twice daily, intranasal oxytocin will have decreased 
rates of relapse and higher retention rates in an inpatient rehabilitation 
programme compared to individuals exposed to a placebo control  
 The second objective will be to investigate the efficacy of intranasal oxytocin 
in reducing opioid craving, anxiety, depression, social anxiety, sleep disturbances 
and enhancing social cognition as well as improving quality of life in post-detoxified 
opioid dependent individuals in an inpatient rehabilitation programme.  Anxiety, 
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depression, social anxiety, social cognition and quality of life will be measured 
through psychological assessments at 4 time points; baseline, day 2, day 14 and day 
30.  Opioid cravings will be measured every day until day 30.  Sleep disturbances will 
be measured every day though psychological assessments until day 30 as well as the 
use of actigraphy recordings until day 14.  
 The hypothesis will be that post detoxified opioid dependent individuals 
exposed to two week, twice daily, intranasal oxytocin will have reduced 
opioid cravings compared to individuals exposed to a placebo control. 
 The hypothesis will be that post detoxified opioid dependent individuals 
exposed to two week, twice daily, intranasal oxytocin will have reduced 
anxiety compared to individuals exposed to a placebo control. 
 The hypothesis will be that post detoxified opioid dependent individuals 
exposed to two week, twice daily, intranasal oxytocin will have reduced 
depression compared to individuals exposed to a placebo control. 
 The hypothesis will be that post detoxified opioid dependent individuals 
exposed to two week, twice daily, intranasal oxytocin will have reduced 
social anxiety compared to individuals exposed to a placebo control. 
 The hypothesis will be that post detoxified opioid dependent individuals 
exposed to two week, twice daily, intranasal oxytocin will have reduced 
sleep disturbances compared to individuals exposed to a placebo control. 
 The hypothesis will be that post detoxified opioid dependent individuals 
exposed to two week, twice daily, intranasal oxytocin will have enhanced 
social cognition compared to individuals exposed to a placebo control. 
 The hypothesis will be that post detoxified opioid dependent individuals 
exposed to two week, twice daily, intranasal oxytocin will have enhanced 
quality of life compared to individuals exposed to a placebo control 
The aim of chapter 4 is to reflect on the process of carrying out a double blind 
randomised placebo controlled clinical pilot trial within an NHS inpatient 
detoxification and treatment centre.  A further aim is to reflect on using vulnerable 
detoxified opioid dependent adults as participants for a double blind randomised 
placebo controlled clinical pilot trial.  
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2 CHAPTER 2 
 
 
AN ASSESSMENT OF RISK AND PROTECTIVE FACTORS OF 
RELAPSE IN AN OPIOID DEPENDENT POPULATION 
ADMITTED AT NHS SURREY AND BORDERS PARTNERSHIP 
TRUST BETWEEN 2013-2015: a retrospective study  
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2.1 Introduction 
As discussed previously, opioid dependence remains a worldwide, chronic co-
morbid mental health disorder. For the UK alone, of those individuals seeking 
treatment for substance misuse, over 50% are opioid dependent.  Furthermore 
opioid dependent individuals have the lowest rate of successful exits from 
treatment and in 2016, 54% of all drug related deaths involved an opiate.  
Also with the increasing opioid epidemic and substantial overdose deaths 
related to opioid abuse in the USA, as well as steady increase of prescribed opioid 
drugs in England between 2010 and 2014, there is growing concern, worldwide, 
about the serious individual consequences as well as societal and economic 
consequences of opioid dependency 
Accordingly there is ongoing interest in the understanding of contributing 
factors underlying dependency as well as relapse rates following detoxification, 
ways to prevent relapse as well as alternative treatment options for long term 
abstinence from drug use. 
Studies focused on relapse have identified certain sociodemographic and 
environmental risk and protective factors that may be implicated in relapse 
vulnerability to drug use in drug dependent individuals (including opioid dependent) 
undergoing detoxification treatment.  
 These factors include the type of treatment the individual engages in, the 
treatment setting and support offered within the setting, engaging in and 
completing of treatment, social and emotional support, criminal behaviour, 
employment history, mental illness and age of first substance abuse.   
 Treatment Setting/Treatment Type and relapse prevention. 2.1.1
 Detoxification and treatments vary and individuals looking to cease their 
abuse of substances can undergo treatment in different settings, namely; 
outpatient community programmes, inpatient detoxification, residential 
detoxification and detoxification within the prison services.  Each has different 
treatment retention rates, different successful detoxification rates and varied 
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successful long term abstinence (NICE, 2016).   In 2016 NICE published guidelines 
for community health and social care services which provide care for those with 
coexisting severe mental illness and substance misuse disorders. 
Aside from those detained under prison services, individuals looking to 
undertake opioid detoxification are routinely, and as first line, offered a community-
based programme, with an anticipated duration of 12 weeks for opioid withdrawal 
and detoxification (NICE, 2007). 
Community-based programmes are multidisciplinary services, delivered by an 
addiction psychiatrist or an addiction specialist and staffed by professionals with a 
range of disciplines including medicine, nursing, psychology and social work, all 
experienced in working with substance misuse patients. Within these programmes, 
opioid dependent individuals undergo a period of outpatient stabilisation through 
pharmacological treatment, usually methadone or buprenorphine (NICE, 2007) and 
when appropriate, proceed with detoxification with the long term aim to remain 
abstinent.  This is coordinated by a specialist or primary practitioner, with weekly 
appointments by the patient for observations and prescriptions.  The community 
programmes also provide adjunct psychosocial interventions (as per NICE., 2007 
guidelines) during the stabilisation and maintenance phases of detoxification, of 
which some of these interventions are mandatory. Psychosocial interventions are 
provided on a one-to-one basis as well as through self-help group work with 
services such as Narcotics Anonymous.  The interventions are cognitive behavioural 
in nature with contingency management, incentives and relapse prevention 
strategies.  All service users are offered continued support and monitoring for at 
least a period of 6 months following detoxification, designed to maintain abstinence 
maintenance (NICE, 2007) .   
One such community team is the NHS Surrey and Borders Partnership 
Foundation Trust (SABP) who provide a range of services which include community 
drug and alcohol services for adults in Surrey, named i-Access, as well as an 
inpatient residential detoxification treatment programme at Windmill House, St 
Peters Hospital.  
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 i-Access, as a community drug and alcohol service, comprises a multi-
disciplinary team of staff which provide detoxification and  stabilisation through 
pharmacological treatment.  The staff also provide advice and information, one-to-
one key-working sessions and group work to support those individuals looking to 
recover and remain abstinent from drugs and alcohol.  
Opioid dependent individuals who do not benefit from formal community-
based outpatient detoxification and support groups will be considered for 
residential or inpatient treatment as per NICE (2007) guidelines.   
Residential detoxification requires patients to live within a secure residential 
treatment facility or home, where they will receive care and a treatment plan in a 
structured environment, 24 hours a day.  Residential treatment is offered to those 
individuals who have significant comorbid physical or mental health problems, who 
require concurrent detoxification from opioids and benzodiazepines or sequential 
detoxification from opioids and alcohol (National Institute for Health and Care 
Excellence (NICE). 2007).  It is also offered to those who have less severe levels of 
opioid dependence, for example, for those early in their drug-using career, or those 
who would benefit significantly from a residential rehabilitation programme to 
withdraw and detoxify from a methadone or buprenorphine maintenance regime 
(NICE, 2007).   NHS Surrey and Borders Partnership Trust, Windmill House, offer a 
residential detoxification service for this purpose.  
Inpatient, rather than residential detoxification is normally only considered 
for people who require a high level of medical and/or nursing support because of 
significant and severe comorbid physical or mental health problems or for those 
who need concurrent detoxification from alcohol or other drugs that require a high 
level of medical and nursing expertise and typically this is carried out in a hospital 
setting (NICE, 2007).  
There are advantages and disadvantages in using residential/inpatient 
treatment compared to outpatient treatment.  Inpatient and residential treatment 
are substantially more expensive than community outpatient treatment, with drug 
services reported to cost the NHS almost £170 000 per bed, per year for 
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inpatient/residential treatment.  Community services cost the NHS almost £60 000 
per patient, per year (Department of Health., 2015).  In addition to that, there are 
significant  prescription costs for treating substance dependence, which during 
2014-15 reached over £71 million in England and Wales alone (Health and Social 
Care Information Centre (HSCIC), 2016).   
Nonetheless, residential and inpatient treatment have several benefits.  A 
hospital setting or residential care has a high level of medical supervision and safety 
for those patients who require physical or psychiatric monitoring or treatment and 
medical professionals are able to assist with medically dangerous withdrawal 
symptoms.  This type of treatment can help interrupt the cycle of drug use as it also 
separates the user from the people and places associated with substances use, 
thereby removing triggers and/or cues which may cause cravings and/or relapse 
(Shaham et al., 2003).  Most inpatient treatment units offer structured therapeutic 
or psychological treatment programmes as well as medical treatments and so offer 
the patient extra support and tools to prevent relapse and manage their abstinence.  
This treatment plan will allow detoxification to be safely completed at a much 
quicker rate than outpatient/community treatment plans (National Institute for 
Health and Care Excellence (NICE). 2007).   However the protectiveness of an 
inpatient/residential unit is often a disadvantage.  The patient is separated from an 
environment where they may be exposed to drugs and so they are vulnerable to the 
risk of relapse once exposed to stressors and cues in their everyday life (Breese et 
al., 2005, Koob, 2008).   Inpatients are also separated from families and social 
support, work and their daily activities and, for some, this could produce an extra 
level of stress (Cohen and Wills, 1985a) and some patients also feel stress and 
anxiety due to the stigmatisation or prejudice of undergoing inpatient or residential  
treatment for a disorder such as addiction (Corrigan and Watson, 2002). 
On the other hand, patients undergoing outpatient detoxification treatment 
are exposed to extra financial stressors as they are usually expected to travel to a 
hospital or other treatment facility for medical appointments, usually with a 
community practitioner or physician who will monitor their progress, offer support 
as well as provide a prescription for treatment medication. These patients are also 
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expected to attend one-to-one therapy or group therapy, which would involve extra 
travel, usually at their own cost.  Further costs include travel to a pharmacy to fill 
the prescription and in most cases, administer the medication on site. As such, 
detoxification in an outpatient setting requires the patient to cope with every day, 
sometimes stressful situations as well as encounters with people or places related 
to drug use and as such, are at increased risk of relapse (Hyman et al., 2007).   
Compared with residential inpatients, patients in outpatient treatment programmes 
do, however retain greater freedom, are able to continue to work and maintain 
day-to-day activities with fewer disruptions. 
Relapse to drug use, however, remains high for both inpatient and outpatient 
treatment. Day and Strang (2011b) carried out a randomised control trial comparing  
treatment type and relapse rates in detoxified opioid dependent individuals.  68 
opioid patients receiving treatment were randomly assigned to either a 3 week 
inpatient setting (n=35) or a 3 week outpatient setting (n=33). Both groups received 
the same treatment medications, although inpatients received extra support from 
daily nurse visits and occupational therapy as well as psychoeducation regarding 
addiction and relapse prevention, which the outpatients did not receive.  The 
outcome measure was being opioid-free at detoxification completion.  The results 
were a 70% relapse rate during detoxification across both groups, although more 
inpatients completed and were drug free at 1 month and 6 month follow up.  At 1 
month follow up 13 patients were drug free of which 8 were inpatients and 5 were 
outpatients.  At a 6 month follow up 11 patients were drug free of which 8 were 
inpatients and 3 were outpatients.  These results show that inpatient treatment 
programmes are superior in their treatment outcomes compared to outpatient 
treatment programmes and as such, suggests that inpatient treatment is a better 
option when looking for effective detoxification and long term abstinence from 
opioid use.  
Hakansson and Hallen (2014) find support for these results in their research 
aimed to assess predictors of dropout and relapse to opioid use during opioid 
detoxification.  They demonstrated that patients with only an outpatient post-
detoxification plan were at significantly higher risk of relapse and concluded that 
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the type of post detoxification planning was associated with dropout and relapse. 
The researchers point out that a structured inpatient treatment plan with an 
appropriate post detoxification plan, within a residential or institution treatment, is 
likely to reduce dropout and relapse.  
Acute inpatient detoxification treatment followed by outpatient aftercare is 
also less successful in maintaining abstinence.  Chutuape et al. (2001a) found a 70% 
relapse rate for inpatient detoxification following an acute 3-day withdrawal 
treatment, with almost 36% of patients reporting daily heroin use at follow up and 
Davison et al. (2006) also found that only 22% of patients successfully engaged in an 
outpatient programme and maintained abstinence, following an acute 
detoxification  treatment.  
The results of the above mentioned studies, investigating different types of 
treatment settings and treatment types, highlight the difficulty for opioid addicts in 
remaining abstinent following detoxification, with long term abstinence seen only in 
a minority of cases. These studies also show that a long-term inpatient/residential 
treatment programme, with medical assistance and psychosocial support, is more 
effective in ensuring that the patient remains abstinent for longer.  
 Completion of detoxification treatment and relapse prevention.  2.1.2
 Gossop et al. (2002) investigated factors associated with relapse to heroin use 
following a residential treatment programme.  The researchers found that 
abstinence from illicit opiates following treatment fell in line with other research in 
this area; less than 40% remained drug free within the first month.  One treatment 
variable associated with relapse was treatment completion.  Patients who 
completed their treatment programme were twice as likely to be abstinent at 
follow up interviews approximately 3 months after treatment compared to those 
who failed to complete their treatment programme.  
Aron and Daily (1976) found that addicts who complete treatment, compared 
to “drop-outs”, not only had lower relapse rates and were substance free for longer, 
they also had lower unemployment and arrest rates. Ravndal and Vaglum (1998), 
also pointed out that while treatment completion was associated with rates of 
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relapse, successful treatment was largely related to positive social functioning.  
Social functioning is an individual’s ability to interact with their environment and 
fulfil their role within such environments which includes work, social activities and 
relationships with partners and family (Bosc, 2000).   Social functioning and social 
skills are encouraged and developed through psychotherapy and psycho-social 
support as part of a treatment plan to prevent relapse and remain abstinent 
following treatment (NICE 2017 guidelines).  Stark (1992), argues that even short 
bouts of psychotherapy can have a positive outcome.  He comments that while it 
seems obvious, it cannot be assumed that “drop-outs” have poorer outcomes than 
those who complete treatment.  This is especially true if individuals receive 
psychotherapy support alongside their treatment. The benefits of psychotherapy is 
proportionally greater in the early sessions of treatment and those who attend as 
little as three sessions of therapy while in treatment are seen to have approximately 
the same improvement rate as those who complete a course of therapy, which is on 
average 12 sessions  (Orlinsky and Howard, 1986, Harnett et al., 2010). 
 Simpson et al. (1997) also investigated the factors that impact retention in 
drug abuse treatment, measured through attendance of individual counselling 
sessions and group counselling session.  They found that pre-treatment motivation 
and willingness to engage in treatment were significant predictors of treatment 
retention.  Ball et al. (2006) support these predictors, reporting that reasons for 
dropout of drug abuse treatment were found to be related to lost motivation or no 
hope for change.   
 In conclusion, the above studies and their results show that motivation and 
willingness to engage and complete treatment is likely to ensure that the individual 
is exposed to enough psychosocial support and therapy, designed to promote 
abstinence and prevent relapse.   
 Social and Emotional support as a protective factor 2.1.3
 As well as psychosocial support through therapy, as discussed above, another 
factor associated with successful treatment outcomes is social support.  Dobkin et 
al. (2002) investigated treatment retention and compared outpatients with high and 
low social support during their treatment.  They found that psychological distress 
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was higher among patients with low support and that outpatients with low support 
reported higher severity of substance abuse at 6 months and the drop out of 
treatment was also higher in this group of patients.  
Social support is both the structure of an individual's social life, for example 
family or group membership, as well as the function that the structure serves, for 
example providing emotional support (see Cohen et al., 1985 for review). Research 
into the role of social support in health maintenance (see reviews by Cohen, 1988; 
Berkman et al., 2000; Uchino, 2004) show that people with supportive spouses, 
friends and family members, who provide psychological and material resources, are 
healthier physiologically and psychologically compared to those with fewer 
supportive social contacts (Berkman et al., 2000, Brummett et al., 2001).  Social 
support leads to decreased susceptibility to disease and lower cardiovascular 
reactivity (Kamarck et al., 1990) and enhanced immune function (Jemmott and 
Magloire, 1988, Kiecolt-Glaser et al., 1984) as well as lower rates of depression and 
anxiety (Fuller-Iglesias, 2015).   
Furthermore, social groups with supportive relationships have a greater 
chance of retention of abstinence from drug use (Zywiak et al., 2002, Macdonald, 
1987) and reduced substance use behaviours (Groh et al., 2007) compared to 
socially isolated individuals.  Hser (2007) found that individuals with greater social 
network of support reported higher levels of recovery and abstinence from heroin 
use compared to individuals who did not have wide social/support network.  They 
also had lower levels of psychological problems such as suicidal thoughts and 
negative emotional state, better general health and less bodily pain compared to 
non-recovered group. 
Social support can influence health outcomes and prevent negative stress-
related behaviour through two distinct but not necessarily independent pathways.   
One pathway involves behavioural processes such as adhering to medical regimes 
and avoiding risky health behaviours and situations likely to lead to relapse.   Cohen 
and Wills (1985) point out that social support and social interaction can act as a 
buffer between a stressful event and a negative reaction by encouraging self-
efficacy and offering a solution to the problem and as such this pathway also 
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involves psychological processes that are linked to emotions, moods, appraisals and 
feelings of control. 
 The second pathway is a physiological response to social support in 
preventing stress-related behaviour, in that social support as well as exposure to 
stress induces elevated levels of oxytocin, peripherally as well as centrally 
(Neumann, 2002).   This anxiolytic neuropeptide attenuates the stress response by 
regulating the activity of the hypothalamic-pituitary-adrenal (HPA) axis (Cohen et al. 
2014) (See Figure 1.7).  As such, social support is able to moderate the relationship 
between stress and stress related behaviours and promote abstinent behaviours by 
preventing negative stress-related behaviour such as drug-seeking and 
reinstatement (Koob and Kreek, 2007, Koob, 2008).   
 Detoxification and rehabilitation methods and models used in recovery from 
substance abuse recognise the importance of social support and its attenuating 
effect in stress and negative stress response within addiction.  Improving healthy 
social networks plays an integral role in Alcoholics Anonymous (A-NON) and 
Narcotics Anonymous (N-ANON) as well as other self-help recovery groups and 
social interaction underpins cognitive behavioural therapies, an essential part of 
substance abuse treatment (McHugh et al., 2010, NICE, 2007).  
 Mental Health-Addiction co-morbidity as a risk factor for relapse.  2.1.4
 Comorbidity, the presence of two (or more) pathologies including mental 
health disorders, in the same individual in a given period of time, is frequent in 
psychiatry (Compton et al., 2005, Cerdá et al., 2008).  Co-occurring mental illness 
depression and/or anxiety is also seen in those seeking treatment for opioid 
addiction (Rounsaville et al., 1982a, Fatseas et al., 2010), and sleep disorders are 
found to also be common in those seeking detoxification from opioids (Mahfoud et 
al., 2009). As discussed in section 1.3, opioids induce long-lasting alterations to the 
nervous system and some of these changes are responsible for the physical 
dependence that causes the aversive withdrawal syndrome common in dependent 
individuals, as opioid levels decline. Such drug-induced changes include a hyper 
responsiveness to stress, increased anxiety and a reduced response to pleasure with 
depressive symptoms. 
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Research findings on the treatment outcomes in those with addiction-mental 
illness co-morbidity is mixed. Collins et al. (1985) report that negative emotional 
states, such as anger, anxiety, depression, frustration and boredom are associated 
with the highest rates of relapse.  Kosten et al. (1986) found no significant 
relationship between depression and relapse to opioid use, however Bradizza et al. 
(2006) point out that there are too few studies conducted on opioid-addicted, 
depressed individuals to draw any true conclusions.  
The pathological effects of substance misuse may increase the risk of the 
mental disorder, or vice versa; for instance mood disorders may cause individuals to 
relapse to drugs in order to cope with their negative affective states.  As such, more 
research is needed to identify the true risk factors, particularly when looking for 
ways to prevent relapse (Quello et al., 2005).  
 Gender and drug relapse 2.1.5
 Worldwide, males are more likely than females to use almost all types of 
drugs, including alcohol and cannabis, and across most age groups, men have higher 
rates of dependence on drugs of abuse compared to women (Degenhardt et al., 
2008) although this male-female gap is closing, with the number of females using 
and abusing prescription and illegal drugs on the rise (Rudd, 2016). 
 Drug use reporting in England during 2016/17 found there was no percentage 
differences between boys and girls aged 11-15 years old using any drug (both 15%), 
after which the level of drug use remained higher for males than females; 11.5% of 
males aged 16-59 years old reported taking any drug compared to 5.5% of females 
aged 16-59 years old (Home Office, 2017). 
 Females tend to increase their rate of consumption of abusive drugs more 
rapidly than males do and enter into treatment earlier in their drug-taking career 
than males (Brady and Randall, 1999, Hernandez-Avila et al., 2004), although males 
tend to make up a larger percentage of those undergoing treatment. Fewer females 
also presented for opiate treatment compared to males; 27% females compared to 
73% males (Home Office, 2017). 
As such, research on substance misuse and treatment outcomes have 
traditionally focused on the “typical” patient, i.e. male. Fewer studies have included 
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females with a focus on gender differences in treatment outcomes.  Walitzer and 
Dearing (2006) reviewed 13 substance abuse outcome studies, of which only 5 
tested gender differences.  4 studies reported no gender differences in outcomes 
and 1 study reported that men had superior outcomes compared to females. The 
researchers also report that for women, marriage and marital stress are risk factors 
to relapse and that men and women make use of different coping strategies and 
support systems, so it is plausible that men and women respond differently to 
treatment, which is likely to impact on treatment outcomes and relapse rates.  
Fiorentine et al. (1997) interviewed 330 individuals (55% female) undergoing 
an outpatient drug treatment programme.  They found that women attended more 
group counselling sessions per month compared to men and women were less likely 
to relapse to drug use compared to men.  The researchers concluded that, despite 
that the women in their sample had more psychological risk factors associated with 
relapse; emotional distress and depression, the lower relapse rate was attributed to 
greater group therapy attendance and social support.  
Hitschfeld et al. (2015), however, found that compared to males, females are 
more susceptible to cravings,  find it more difficult to cease using drugs of abuse, 
including alcohol use and find it difficult to remain abstinent (Rubonis et al., 1994); 
all key phases of the addiction cycle (Koob and Volkow, 2010).  
 Age as a factor in addiction and relapse 2.1.6
 Historically research on the characteristics and risk factors of adult substance 
dependence and relapse has mostly disregarded the role of age as a predictor to 
relapse following treatment. 
Certainly, drug use at an early age has been found to be an important 
predictor of the development of substance use disorder later.  The majority of 
individuals with a substance use disorder started using drugs before age 18 and had 
developed their disorder by age 20.  Also, the likelihood of developing a substance 
use disorder is greatest for those who started to use drugs in their early teens, 
before age 18 (Dennis et al., 2002). 
 McCabe et al. (2007) supports this argument, examining the associations 
between the early onset of non-medical use of prescription drugs, including opioids, 
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and the development of prescription drug abuse and dependence. They found that 
a higher percentage of individuals who began using prescription drugs non-
medically at or before 13 years of age were more likely to abuse prescription drugs 
and become dependent compared to those who began using at or after 21 years. 
However, relapse and the circumstances surrounding early drug use and 
relapse have mostly gone unattended.  Anderson et al. (2007) examined the risk 
and protective factors of substance use treatment outcomes in adolescents 
(M=15.9 years old, SD=1.3) in order to predict relapse vulnerability.  At one year 
follow up, researchers found that 65% of the participants had relapsed.  They report 
that mental illness diagnosis (depression, anxiety and bipolar depression), was a 
significant risk factor to relapse as well as negative peer group influence.  They 
concluded that entering treatment without a mental illness diagnosis and with 
social support from a peer network that was largely abstinent from substance use 
was protective from relapse as this cohort was associated with abstinence one year 
later. 
With reports of over 16% of young adults, aged between 16 to 19 years, 
reporting taking drugs in 2015-16 (Home Office, 2017) and considering the above 
research, that early onset is likely to develop into dependence and seeking 
treatment as a consequence, a better understanding of the role of age and 
investigations into age specific treatment plans to prevent relapse, is warranted. 
 Employment Status and drug relapse 2.1.7
 UK records show that drug dependence is lowest for those in employment 
(Office for National Statistics, 2016) and research has confirmed a correlation 
between employment status and substance abuse/disorders;  Henkel (2011) reports 
that unemployed individuals are more likely to abuse substances and have a drug 
disorder.  Also problematic substance use increases the likelihood of unemployment 
and decreases the chance of securing employment.  The research also found that 
unemployment increases the risk of relapse after treatment. 
Gallie et al. (2003) report that unemployment increases the risk of social 
isolation and increases the risk of poverty, which in turn makes it more difficult for 
people to return to work.  Moreover, these factors are likely to increase stress, 
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which has been found to create vulnerability to abuse substances and increase the 
risk of relapse (Sinha, 2008).  
Furthermore Linn et al. (1985) found that unemployment had a negative 
effect on mental and physical health, with increased symptoms of somatization, 
depression and anxiety in unemployed individuals, disorders associated with 
substance abuse (Rounsaville et al., 1982a, Fatseas et al., 2010). The researchers 
point out the protective effects of social support through family and friends in that 
those with social support displayed higher levels of self- esteem and better coping.  
It would appear that unemployment is a risk factor to substance abuse and 
relapse (and vice versa) and this bi-directional relationship may be due to the 
stressors of social isolation, poverty and mental impairments while the protective 
factors of high self-esteem through social support is able to protect an individual 
from these negative consequences. Certainly, as discussed earlier, the positive 
effects of social support in buffering stress is discussed by Cohen and Wills (1985a) 
and social support is seen to promote abstinence from drug use (Zywiak et al., 2002, 
Macdonald, 1987) and reduced substance use behaviours (Groh et al., 2007) 
compared to socially isolated individuals. 
 Criminal behaviour and relapse 2.1.8
 There is a close relationship between addiction and crime.  Drug abusers, 
including opiate users, commit crimes such as shoplifting and burglary, to pay for 
their drugs, amounting to a market value of stolen goods linked to drug use of 
between £2-2.5 billion each year.  Also many criminals are under the influence of 
drugs and/or alcohol while committing crimes, with approximately 250 000 violent 
incidents in England and Wales carried out by individuals under the influence of 
drugs and alcohol (Home Office, 2016).  As such, drug offences alone account for 
the second highest proportion of prisoners at the end of 2016, not including 
robbery and theft offences or criminal damage and arson (Allen and Watson, 2017) 
A high proportion of individuals enter prisons with drug and alcohol problems 
with lifetime prevalence rates highest for cannabis (71%), followed by powder 
cocaine (45%), crack cocaine (43%), ecstasy (42%), amphetamines (41%) and heroin 
(40%).  National treatment data showed that over half of prisoners report they used 
128 
 
illicit drugs or medication in the two months before going to prison and, between 
April and September 2014, 25% of all new entrants into prisons in England began 
treatment for substance misuse (including alcohol) within three weeks of their 
arrival (HM Inspectorate of Prisons., 2015). 
Also a substantial number of prisoners continue to misuse drugs and 
medications while in prison. The most commonly misused medications in prison are 
those that have a depressant effect on the nervous system, reflecting a desire to 
blunt emotions, relieve boredom and create a decreased awareness of 
surroundings.  As such there is a preference for, and increase in dependency on 
depressants such as heroin and cannabis over stimulants such as cocaine, crack 
cocaine and ecstasy, with buprenorphine as a common drug of misuse in prison 
(Bullock, 2003).   
Binswanger et al. (2012) pointed out that prisoners are at risk of relapsing into 
drug use following release from prison, and an increased risk of drug-related death 
following overdose. Those prisoners who successfully withdraw from opiates in 
prison and then return to the same drug-related social circumstances on their 
release, are at a higher risk of relapse.   
 Binswanger et al. (2012) followed up and interviewed former prison inmates 
following release from prison which included 29 who had relapsed within two 
months following release. They found that relapse had occurred in the context of 
poor social support and isolation, medical and mental health co-morbidity including 
depression and anxiety and poor economic resources with limited medical and 
mental health treatment.  The former inmates reported that they had experienced 
exposure and cues to drugs within their living environments and intentional 
overdose was considered a way to escape from their situational stressors described 
above, while accidental overdose was seen to be related to decreased tolerance.  
Protective factors against relapse included a structured drug treatment programme, 
spirituality/religion, community based resources such as self-help groups and 
support through family.  
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2.2 Aims and Hypotheses 
 The aim of this study is to assess the presence and strength of association 
between specific sociodemographic parameters, in an attempt to identify risk 
and/or protection factors associated with relapse to opioid use following the start 
of a withdrawal and detoxification treatment programme. 
In light of the research discussed above, this research aims to investigate the 
association between treatment setting and type, completing a residential treatment 
programme, social and emotional support through a relationship, family support, 
criminal behaviour, employment status, mental illness, age of first illicit substance 
use and their association with relapse within 30 days from the start of treatment.   
The research will also assess the interrelationship between all these 
sociodemographic factors for further insight into the roles of these factors in an 
opioid dependent population.  
 There is limited previous research evaluating the role of potential risk factors 
to relapse and to our knowledge, this is the first comprehensive investigation of 
these ten factors and their role in treatment outcomes in the same population. To 
our knowledge, this is also the first comprehensive study of risk and protective 
factors within this NHS Trust, which services Surrey and surrounding areas. Surrey is 
a wealthy county with the highest GDP per capita of any English county, a large 
percentage of schools, both state and private and a population of 1.1 million 
people.  According to 2011 Census data, Surrey is also less diverse compared to 
other counties; 84% of Surrey population were classified as White: British, over 60% 
were classified as religion: Christian and only 4.7% of households contain a lone 
parent with dependent children. These data differ from other counties within 
England (see 2011 Census for more information).  Also Surrey and surrounding 
areas are amongst the lowest regions to report drug misuse deaths; 39% drug 
misuse deaths reported in Surrey compared to 77% drug misuse deaths reported in 
North East England. These data make this population and their sociodemographic 
unique and this study may offer insight into the role of these sociodemographic 
factors in opioid dependency. 
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NHS SABP Trust provides mental health services for the whole of Surrey and 
Borders population and treatment for substance misuse falls within this service.  
The NHS is world leading in offering free treatment for addiction, and is the primary 
treatment facility for almost all opioid misusers in the UK, offering assessment and 
recovery for people who abuse these substances as well as providing support for 
families and carers of substance misusers.    
With almost 150 000 NHS users presenting with dependency on opiates in 
2015-16 and the low rates of successful exits from opioid treatment in 2015-16, as 
well as the high societal and economic consequences to these costs, research into 
identifying risk and protective factors in sustaining abstinence from opioid abuse 
remains ongoing.   
Also with the increasing opioid abuse epidemic currently being experienced in 
USA developing into a “public health crises”, there is the potential risk for UK to 
follow suit. Certainly, the number of opioid-related deaths is rising in England, 
Wales and Scotland as well as the number of people taking prescription pain killers.  
Prescriptions of addictive medication has increased over the past 5 years and in 
2015-16, 7.5% of adults aged 16-59 years had taken a prescription-only analgesic 
that was not prescribed to them.   
In conclusion, with the large number of opioid dependent individuals seeking 
treatment and the risk of this number increasing, along with low treatment 
outcomes and the increasing number of deaths of these individuals, there remains 
the need for opioid addicts to safely withdraw and detoxify from opioids and 
abstain from use long term.  As such an investigation into the risk and protective 
factors in treatment outcomes is justified and the results will help in this. 
The hypotheses for this study is that  
(a) There is a significant association between sociodemographic factors; 
treatment setting and type, completing a residential treatment programme, 
social and emotional support, criminal behaviour, employment status, 
mental illness, age of first illicit substance use  and relapse within 30 days 
from the start of a treatment programme. 
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(b) There is a significant association between these sociodemographic 
parameters; treatment setting and type, completing a residential treatment 
programme, relationship status, family support, criminal behaviour, 
employment status, mental illness and age of first illicit substance use, 
within this population.      
2.3 Materials and Methods 
 Design 2.3.1
This is a retrospective case study aiming to assess the factors associated with 
relapse in an opioid dependent population admitted at NHS Surrey and Borders 
Partnership Trust (SABP) for detoxification treatment.  Archived and active clinical 
charts and files of patients enrolled in clinical treatment between 2013 and 2015, 
for opioid withdrawal and detoxification, were reviewed to assess the risk and 
protective factors associated with relapse within 30 days of enrolling into 
treatment.  As the study was deemed to be retrospective it did not require patient 
consent.   
 Participants 2.3.2
This study sample comprised 90 participants, 63 males and 27 females, ages ranged 
from 20 – 55 years.  The participants were all NHS SABP Trust, i-Access, service 
users who were undergoing detoxification from opioid use, between January 2013 
and January 2015.  These service users had either undergone detoxification through 
a community-based treatment programme or through a residential treatment 
programme. 
 Procedure 2.3.3
All data was generated from archived or active NHS SABP Trust clinical charts and 
patient files, which were made available to the researcher.  Patient file notes 
include self- reported past or current criminal behaviour, mental health history, any 
family or social support/relationship, employment history and age of first drug use, 
as well as doctor and patient key worker notes, which noted any relapse 
information.   
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10 parameters plus gender were explored within this study. These included 
past criminal behaviour, present criminal behaviour at time of admission to 
treatment, employment status, mental health status,  the treatment, age of first 
substance use (excluding alcohol) as well as data relating to relapse within 30 days 
from the start of treatment. (See Table 2.1 for a list of the variables analysed, 
together with their respective definitions).  All variable factors were recorded as 
“Yes” or “No”, creating categorical data suitable for Pearson’s Correlation and Chi 
Square statistical testing. 
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Table 2.1:  Risk and Protective Factors associated with relapse to opioid use within 
30 days of detoxification treatment. 
  
FACTOR IDENTIFICATION OF THE FACTOR FROM PATIENT FILE NOTES 
Past crime  Any reference to past crime, arrest and criminal record, including outstanding 
sentencing. 
Present crime  Any acknowledgement of carrying out criminal behaviour at time of admittance 
to treatment. 
Relationship 
support  
If patient considered themselves to be in a relationship:  married, living with a 
partner or significant person.  
Family 
support 
If patient considered their family to support them in their decision to undergo 
treatment.  This was separate to being in a relationship / social support.  
Current 
Employment 
If patient considered themselves in current employment; paid or volunteer at 
time of admittance to treatment.  
Past 
Employment 
If patient referred to having had past employment; paid or volunteer. 
Mentally Ill If medical records indicate mental illness, including doctor reference letter and 
prescription for medication for psychological illness.   
Residential 
Treatment  
If patient file contains a signed contract and admittance agreement to Windmill 
House between 2013 and 2015.  Patients undertook a residential withdrawal and 
detoxification programme as well as a psycho-social therapy programme. 
Completion of 
Treatment 
If the patient file contains confirmation that between 2013 and 2015 the patient 
enrolled onto a withdrawal and detoxification treatment programme, started and 
completed the programme as per physician instruction and without any lapse, 
relapse or re-start. 
Relapse within 
30 days from 
the start of 
the 
detoxification 
programme 
 
 
As indicated by file notes.  
Adolescent < 
19 years Drug 
Start Age 
 (Range: 7-46 
years) 
As indicated by file notes. Patients either had first experience of drugs at 19 years 
or younger (adolescent) or older than 19 years.  Drug at start date included any 
illicit drug including cannabis but not alcohol.  
Risk and protective sociodemographic factors with respective descriptions, as extracted from files 
of patients who underwent withdrawal and detoxification at NHS SABP between 2013 and 2015.    
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2.4 Data Analysis 
Descriptive analysis was performed on all demographic and potential risk/ 
protective factors. All variable factors were treated as a binary variable and 
categorised as “yes” or “no”.  See Table 2.2 for all data presented proportionately; 
indicating whether the factor was present [yes] or absent [no] in patient file notes.   
Pearson Chi Square analysis was carried out to determine any significant 
associations between relapse within 30 days from the start of treatment and the 
potential risk/protective sociodemographic factors extracted.  The level of 
significance was set at p-value <0.05  
Pearson Correlation analysis was carried out on all the factors to determine 
any significant relationship between all the risk and protective sociodemographic 
factors identified, which would warrant further analysis.  The level of significance 
was set at p-value <0.05 (two tailed).  
Further analysis of the significant sociodemographic correlations was carried 
out using Pearson Chi-square analysis.  The level of significance was set at p-value 
<0.05.  
Fisher’s exact approach was used for post-hoc analysis of the chi-squared test. 
Fisher’s exact test is an appropriate and accurate test when the expected numbers 
are small and the total sample size is less than 1000 (McDonald, 2014). 
Phi analysis was used to determine the effect size of the significant 
associations and odds ratio was used to determine the risk.  All analysis was carried 
out using SPSS vs 22 (IBM, 2012).  
2.5 Results 
Clinical charts and patient files were reviewed retrospectively in order to 
assess risk and protective factors associated with relapse within 30 days from the 
start of clinical treatment for opioid withdrawal and detoxification.  Ninety patients 
(m=63; f=27) were enrolled for opioid addiction treatment between 2013-2015, at 
NHS SABP Trust. Data of all factors extracted, including the number and percentage 
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of patients where each factor was present [yes] or absent [no] is tabulated in Table 
2.2. The number and percentages of missing data is included. 
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Table 2.2: Demographics of patients within each factor (n=90) 
FACTOR PATIENT (n=90) RECORDED DATA 
 YES NO UNKNOWN 
Relapse within 30 
days from start of 
treatment 
Total=47  
(52%) 
Male=28 
Female=19 
Total=22 
(24%) 
Male=16 
Female=6 
Total=21 
(23%) 
Male=19 
Female=2 
 
Past crime  
Total = 69 
(77%) 
Male = 51 
Female = 18 
Total=21 
(23%) 
Male = 12 
Female = 9 
Total=0 
(0%) 
 
 
Present crime  
Total=18  
(21%) 
Male=16 
Female=2 
Total=69 
(79%) 
Male=45 
Female=24 
Total=3 
(3.3%) 
Male=2 
Female=1 
 
Relationship support Total=17 
(19%) 
Male=10 
Female=7 
Total=69 
(77%) 
Male=50 
Female=19 
Total=4 
(4%) 
Male=3 
Female=1 
Family support Total=39 
(43%) 
Male=27 
Female=12 
 
Total=47  
(52%) 
Male=33 
Female=14 
Total=4 
(4%) 
Male=3 
Female=1 
 
Current Employment Total=14 
(16%) 
Male=11 
Female=3 
Total=72  
(80%) 
Male=48 
Female=24 
Total=4 
(4%) 
Male=4 
Female=0 
Past Employment Total=26  
(28%) 
Male=33 
Female=20 
Total=53 
(59%) 
Male=19 
Female=7 
Total=11 
(12%) 
Male=11 
Female=0 
Mentally Ill Total=52 
(58%) 
Male=33 
Female=19 
Total=37  
(41%) 
Male=29 
Female=8 
Total=1 
(1%) 
Male=1 
Female=0 
Residential 
Treatment 
Programme between 
2013-2015 
Total=35 
(39%) 
Male=26 
Female=9 
 
Total=53 
(59%) 
Male=37 
Female=16 
Total=2 
(2%) 
Male=0 
Female=2 
 
Completion of 
Treatment started 
between 2013-2015 
Total=33 
(37%) 
Male=23 
Female=10 
Total=56 
(62%) 
Male=40 
Female=16 
Total=1 
(1%) 
Male=0 
Female=1 
Adolescent < 19 
years Drug Start Age 
 (Range: 7-46 yrs) 
Mean Age: 18 yrs 
Mode Age: 13,14 yrs 
Total=53 
(59%) 
Male=37 
Female=16 
Total=30 
(33%) 
Male=19 
Female=11 
Total=7 
(8%) 
Male=7 
Female=0 
Sociodemographics showing the number, (as well as percentage) and males and females 
categorised within each factor.  Any missing or unknown data is also included. 
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In short, the results were that 47 patients (52%) (m=28; f=19) relapsed within 
30 days from the start of treatment while 22 (24%) (m=16; f=6) had not relapsed 
within 30 days from the start of treatment. Missing data for this factor totalled 21 
(23%) (m=19; f=2) (see Table 2.2).   
In terms of risk and protective factors associated with relapse within 30 days 
the following was detected: 
 Association between Residential Treatment and 30 Day Relapse  2.5.1
In the 67 cases for whom the data with regards to relapse within 30 days and 
residential treatment were complete, a significant association was detected, 
X2 (1) = 4.382, p<0.05. Ф= 0.256. OR= 3.11, CI= 1.05-9.19. 
More patients relapsed within 30 days than did not relapse within 30 days (46 
(69%) vs 21 (31%)).  Of the cases which were classed as not being admitted into 
residential treatment, 28 (80%) had relapsed within 30 days from the start of 
treatment, while from those who were admitted into residential treatment, 18 
(56%) relapsed within 30 days from the start of treatment (see Table 2.3). 
  For this data the OR = 3.11; the odds of relapsing within 30 days for those 
who were not admitted into residential treatment are over 3 times the odds of 
relapsing within 30 days for those who are admitted into residential treatment.  
  Association between Completing Treatment and 30 Day Relapse 2.5.2
In the 68 cases for whom the data were complete with regards to relapse 
within 30 days and treatment completion, there was a significant association;  
X2 (1) = 21.591, p< 0.01. Ф= 0.56. OR=15.73, CI= 4.31- 57.35.  
Of the 27 cases classed as having completed their treatment programme, 17 
(63%) did not relapse within 30 days, while 37 (90%) of the cases who failed to 
complete their treatment programme did relapse within 30 days (see Table 2.3). 
For this data the OR=15.73. The odds of relapsing within 30 days for those 
who did not complete the treatment programme are over 15 times the odds of 
relapsing within 30 days for those who did complete the treatment programme. 
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No other factors were found to be significantly associated with relapse within 
30 days from the start of treatment.  See Table 2.3 for associations between all 
factors and relapse within 30 days, which includes proportional data in each 
association as well as any missing, unknown data for the association and 
significance levels. 
 
Table 2.3. Associations extracted between sociodemographic factors and relapse within 
30 days from start of treatment 
 
Factor Relapse within 30 days 
from start of treatment 
Total Missing data  Significance 
    P<0.05  
 Yes  No     
Gender      
    Male 28 (64%) 16 (37%) 44   
    Female 19 (76%)   6 (24%) 25   
Total 47 (52%) 22 (24%) 69 21 (23%) ns 
      
Residential Treatment 
Programme 
     
    Yes 18 (56%) 14 (44%) 32   
    No 28 (80%)   7 (20%) 35   
Total 46 (69%) 21 (31%) 67 23 (26%) p<0.05 
      
Completed Treatment 
programme 
     
    Yes 10 (37%) 17 (63%) 27   
    No 37 (90%)   4 (10%) 41   
Total 47 (69%) 21 (31%) 68 22 (24%) p<0.01 
      
Past Crime      
    Yes 37 (67%) 18 (33%) 55   
    No 10 (71%)   4 (29%) 14   
Total 47 (68%) 22 (32%) 69 21 (23%) ns 
      
Present Crime      
    Yes 9 (69%)   4 (31%) 13   
    No 36 (68%) 17 (32%) 53   
Total    66 24 (27%) ns 
      
Current Relationship       
    Yes 9 (60%)   6 (40%) 15   
    No 38 (72%) 15 (28%) 53   
 47 (69%) 21(30%) 68 22 (24%) ns 
Current Employment      
    Yes 7 (64%)   4 (36%) 11   
    No 39 (70%) 17 (30%) 56   
Total    23 (26%) ns 
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Past Employment      
    Yes 27 (63%) 16 (37%) 43   
    No 15 (75%)   5 (25%) 20   
Total    27 (30%) ns 
      
Pre-Adolescent Start      
    Yes 29 (69%) 13 (31%) 42   
    No 18 (78%)   5 (22%) 23   
Total    25 (28%) ns 
      
Mental Illness      
    Yes 30 (71%) 12 (29%) 42   
    No 17 (63%) 10 (37%) 27   
Total    21 (23%) ns 
      
Family Support      
   Yes 17 (63%) 10 (37%) 27   
   Not 28 (70%) 12 (30%) 40   
Total 45 (67%) 22 (33%) 67 23 (26%) ns 
 
Proportionate data of the sociodemographic factors associated with relapse within 30 days from start of 
treatment.  Data was extracted from files of patients who underwent withdrawal and detoxification at NHS 
SABP between 2013 and 2015 and all factors were included in the analysis.  Significant as well as non-
significant factors are included in the table, showing the number, as well as percentages for each 
association.   Any missing or unknown data is also included.  
Abbreviation: ns=no significant association. 
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Pearson correlation analysis of all potential risk and protective 
sociodemographic factors is seen in Table 2.4.  This analysis found further significant 
correlations between completion of treatment programme and relationship status 
(r=.325, p<0.05), past employment and family support (r=.240, p<0.05), positive 
mental illness diagnosis and current criminal behaviour at time of admission 
(r=.214, p<0.05) and starting substance use (excluding alcohol) pre-adolescence and 
attending the residential treatment programme (r=.220, p<0.05).  Chi square testing 
was carried out on these correlations, for further analysis. 
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Table 2.4.  Co-efficient table of significant correlations between sociodemographic factors extracted from 90 opioid dependent individuals undergoing detoxification 
treatment between 2013-2015 at NHS SABP Trust.   
 Gender Past Crime 
Present 
Crime 
Relationship 
Status 
Family 
Support 
Current 
Employment 
Past 
Employment 
Mental 
Illness 
Pre Adoles 
Start 
Completed 
Treatment 
Programme 
Residential 
treatment 
Programme 
Relapsed 
in 30 days 
Gender Pearson Correlation  .155 .209 .159 .011 .095 .107 .160 .066 .018 .049 .128 
Sig. (2-tailed)  .145 .052 .143 .923 .386 .347 .134 .551 .864 .653 .296 
N  90 87 86 86 86 79 89 83 89 88 69 
Past Crime Pearson Correlation   .089 .013 .114 .069 .098 .039 .139 .121 .164 .036 
Sig. (2-tailed)   .411 .908 .294 .529 .390 .715 .210 .258 .128 .770 
N   87 86 86 86 79 89 83 89 88 69 
Present Crime Pearson Correlation    .135 .006 .156 .070 .214* .174 -.165 -.169 .011 
Sig. (2-tailed)    .224 .954 .157 .545 .048 .123 .126 .121 .929 
N    83 84 84 77 86 80 87 86 66 
Relationship Status Pearson Correlation     .033 .075 .009 .022 .061 .325** .007 .105 
Sig. (2-tailed)     .772 .499 .937 .842 .592 .002 .948 .394 
N     82 83 76 85 80 85 84 68 
Family Support Pearson Correlation      .175 .240* .071 .007 .015 .051 .073 
Sig. (2-tailed)      .116 .038 .519 .954 .888 .644 .554 
N      82 75 85 80 85 85 67 
Current Employment Pearson Correlation       .135 .037 .098 .179 -.098 .048 
Sig. (2-tailed)       .243 .738 .386 .102 .375 .700 
N       77 85 80 85 84 67 
Past Employment Pearson Correlation        .165 .086 .187 .004 .121 
Sig. (2-tailed)        .148 .466 .101 .975 .347 
N        78 74 78 77 63 
Mental Illness Pearson Correlation         .053 -.089 .100 -.089 
Sig. (2-tailed)         .636 .409 .355 .469 
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N         82 88 87 69 
 
  
Gender Past Crime 
Present 
Crime 
Relationship 
Status 
Family 
Support 
Current 
Employment 
Past 
Employment 
Mental 
Illness 
Pre Adoles 
Start 
Completed 
Treatment 
Programme 
Residential 
Treatment 
Programme 
Relapsed 
in 30 days 
Pre Adolescent 
Start 
Pearson Correlation          .013 .220* .098 
Sig. (2-tailed)          .908 .049 .435 
N          82 81 65 
Completed Treatment  
Programme 
Pearson Correlation           .110 .563** 
Sig. (2-tailed)           .309 .000 
N           88 68 
Residential Treatment  
Programme 
Pearson Correlation            .256* 
Sig. (2-tailed)            .037 
N            67 
Correlation coefficient data extracted from 90 opioid dependent individuals undergoing detoxification at NHS SABP Trust, between 2013-2015. The data represents the correlation coefficient, significance and the 
number of cases represented in the correlation.  Shaded boxes indicate significant correlations.  
N= Number of cases in the correlation. 
*= Correlation is significant at the p<0.05 level (2 tailed). 
**= Correlation is significant at the p<0.01 level (2 tailed).  
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 Association between Relationship Status and Completion of Treatment 2.5.3
In the 85 cases for whom data was complete with regards completing the 
treatment and relationship status, there was a significant association between 
these two factors;  
X2 (1) = 8.987, p<0.05, Ф= 0.325. OR= 5.05, CI= 1.66-15.40.  
More patients failed to complete their treatment programme compared to 
those who did complete their treatment programme (54 vs 31).  Of the 54 patients 
that failed to complete the treatment programme, 48 (89%) were not in a 
relationship and classed themselves as single.  Of the 31 cases that completed the 
treatment programme, 12 (39%) were in a relationship (see Table 2.5). 
For this data the OR = 5.05.  The odds of not completing the treatment 
programme for those who are not in a relationship are 5 times the odds of not 
completing the programme and being in a relationship.   
Table 2.5.  Association between relationship status and completion of treatment 
programme 
 Relationship Status  
  In a 
relationship 
Not In a 
relationship 
Total 
Completion of 
Treatment  
Yes 12 (39%) 19 (61%) 31 
No 6 (11%) 48 (89%) 54 
Total  18  67  85 
Proportion of patients who completed the treatment programme, categorised by relationship 
status.  Data was extracted from files of patients who carried out withdrawal and detoxification at 
NHS SABP between 2013 and 2015. 
 
 
 Association between Family Support and Past Employment  2.5.4
In the 75 cases for whom the data were complete there was a significant 
association between family support and past employment; 
 X2 (1) = 4.20, p< 0.05, Ф= .240, OR= 3.0, CI= 1.03- 8.76. 
More patients were in past employment prior to engaging in treatment 
compared to those who had no history of past employment (52 vs 23).  Of the 52 
patients classified as having been in past employment prior to engaging in 
treatment, 27 (52%) were classified as having family support.  17 (74%) of patients 
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who had no family support had also not been in previous employment prior to 
engaging in treatment (see Table 2.6). 
 The OR for this data = 3.  The odds of being in past employment for those 
with family support are 3 times the odds of being in past employment with no 
family support.  
 
Table 2.6: Association between family support and previous employment status.  
 Family Support  
  No Yes Total 
Past Employment  No 17 (74%) 6 (26%) 23 
Yes 25 (48%) 27 (52%) 52 
 Total  42  33 75 
Proportion of patients who were in past employment prior to entering into a treatment 
programme, categorised by family support.  Data was extracted from files of patients who carried 
out withdrawal and detoxification at NHS SABP between 2013 and 2015 
 
 
  Association between Mental Illness and Current Crime Conviction 2.5.5
 
In the 86 cases for whom the data was complete, there was a significant 
association between mental illness and current criminal behaviour at time of 
treatment admission; X2 (1) = 3.931, p< 0.05. Ф= .214. OR= 2.88, CI= .99- 8.40. 
More patients had a diagnosis of mental health illness at the time of 
treatment admission (51 vs 35).  Of the 51 cases of a confirmed mental illness 
diagnosis at time of admission onto a treatment programme, 7 (14%) had a current 
crime conviction (Table 2.7).  Of the 35 who had no mental illness diagnosis at the 
time of treatment admission, 11 (31%) had current criminal behaviour at time of 
treatment admission.   For this data the OR = 2.9. The odds of not having current 
criminal behaviour for those with mental health illness at time of admission are 
over 2 times the odds of having a current crime conviction and mental illness at 
time of admission onto a treatment programme.  
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Table 2.7:  Association between mental illness and current crime conviction at 
time of treatment programme. 
 
 Mental Health Illness  
  No Yes Total 
Current Crime  Yes 11 (31%) 7 (14%) 18 
No 24 (69%) 44 (86%) 68 
 Total  35  51 86 
Proportion of patients with a current crime conviction at time of treatment , categorised by 
patients with mental health illness.  Data was extracted from files of patients who carried out 
withdrawal and detoxification at NHS SABP between 2013 and 2015 
 
 
 Association between Start Age and Residential Treatment  2.5.6
 In the 81 cases for whom the data was complete, there was a significant 
association between starting to use drugs (not alcohol) pre-adolescence (early 
starters) and enrolling into a residential treatment programme; 
  X2 (1) = 3.909, p< 0.05. Ф= .220. OR= 1.84, CI= .95- 3.54. 
Overall more patients were early starters compared to starting after the age 
of 19 years (51 vs 30).  The early starters were also almost 50/50 split as to whether 
they engaged in a residential treatment programme (51%) or engaged in 
community outpatient treatment programme (49%).  
Overall of those who underwent detoxification in a residential treatment 
programme (33 in total), more early starters (25 (49%)) engaged in this treatment 
programme compared to post adolescence starters (8 (27%)), who engaged in 
community treatment (see Table 2.8). 
For this data the OR = 1.84. The odds of engaging in a residential treatment 
programme for those who started using drugs (not alcohol) pre-adolescence are 
almost 2 times the odds of engaging in residential treatment programme for those 
who started to use drugs post-adolescence.  
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Table 2.8:  Association between start age and residential treatment programme. 
 Residential Treatment  
  No Yes Total 
Pre-adolescent 
start age (<19yrs) 
Yes 26 (51%) 25 (49%) 51 
No 22 (73%) 8 (27%) 30 
 Total  48  33 81 
Proportion of patients who engaged in a residential treatment programme, categorised by 
patients who started opioid use pre-adolescence (<19yrs).  Data was extracted from files of 
patients who carried out withdrawal and detoxification at NHS SABP between 2013 and 2015 
 
2.6 Discussion 
This research sought to assess the risk and protective sociodemographic 
factors of relapse within 30 days in opioid dependent individuals undergoing 
detoxification treatment within the NHS Surrey and Borders Partnership Trust. The 
study also considered the interrelationship of these sociodemographic factors, 
which comprised the setting and type of treatment, entering and completing a 
residential treatment programme, social and emotional support received while 
undergoing treatment, family support while undergoing treatment, criminal 
behaviour, employment status, mental illness, age of first illicit substance use.  
To our knowledge, this is the first comprehensive investigation of these 
sociodemographic factors and their role in treatment outcomes within NHS Surrey 
and Borders Partnership Trust.   
Overall just over half of patients relapsed within 30 days from the start of 
treatment compared to the 24% who did not relapse within 30 days (52% vs 24%).  
Wider research on opioid addiction and treatment report higher relapse rates than 
those in our research; closer to 70% (Chutuape et al., 2001a, Day and Strang, 
2011a).  Based on this difference, it would appear that there are sociodemographic 
protective factors in preventing relapse within our research population. It should be 
noted that, for this study, not all the relapse data was available and some of the 
clinic file notes were not clear as to precise relapse dates, resulting in a percentage 
of missing data totalling 23%.  As such, the number of relapsed patients could differ, 
but this does not detract from the need for better understanding of the protective 
and risk factors on relapse to opioid use.  
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With reference to the primary hypothesis, the study found that there was  a 
significant association between relapse within 30 days of start of treatment and two 
sociodemographic factors; the type of treatment plan and completing the 
treatment. With reference to the secondary hypothesis, the study found significant 
associations between mental illness and crime, completing treatment and being in a 
relationship, family support and past employment and also inpatient treatment plan 
and pre-adolescent substance abuse. 
The type of treatment plan was significantly associated with 30 day relapse.  
18 (56%) patients who underwent a residential treatment programme relapsed 
within 30 days compared to 28 (80%) patients who underwent a community 
treatment programme.  Also the odds of 30 day relapse if in community treatment 
were 3 times the odds of 30 days relapse if undergoing detoxification in a 
residential treatment facility.  This suggests that a residential treatment 
programme, such as that provided by Windmill House, NHS SABP Trust, protects 
patients against relapse more than an outpatient community treatment 
programme.    
Windmill House (WMH) as a 24 hour residential unit with full time medical 
and support staff.  This inpatient residential treatment centre allows for individuals 
to undertake a withdrawal and detoxification treatment programme, with 
professional who ensure their regime and medication is safely adhered to and 
withdrawal symptoms are minimised, thereby protecting against the risk of relapse.  
WMH also provides a structured programme of supportive counselling and therapy 
work, through individual face to face therapies and reward-driven group work with 
some of the components of contingency management (CM) interventions.   
Patients are also required to attend regular, onsite Narcotics Anonymous 
meetings as well as relapse prevention, solution focused group work.  Group 
therapies and 12-step recovery meetings such as Narcotics Anonymous not only 
provide relapse prevention education and strategies, they also provide social, 
emotional and peer support (see appendix 1 for more information on WMH).  Such 
support has been found to promote abstinence from drug use (Hser, 2007, 
Macdonald, 1987) and can intervene between the stress and negative reactions 
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experienced during withdrawal and detoxification (Koob and Volkow, 2010). Also, 
social support may offer further protection by promoting the perceived ability to 
cope with stressors (Cohen and Wills, 1985a) and thus increase self-efficacy, the 
belief in personal ability to succeed in specific situations, and as such reduce the 
likelihood of relapse. WMH residential treatment programme is also structured so 
that patients remain on-site or under close observation on day excursions, ensuring 
that patients are not exposed to triggers and cues which may cause craving and 
relapse (Shaham et al., 2003), thereby assisting with relapse prevention and 
maintenance of abstinence.   
Our results reflect previous research findings which compare inpatient and 
outpatient opioid treatment; inpatient, residential treatment programmes, which 
are comprehensive, structured and supportive, are more effective than outpatient 
treatment programmes in ensuring longer abstinence from opioid relapse (Day and 
Strang, 2011a). The results also support the findings that social groups with 
supportive relationships, such as those provided in the therapy groups at WMH, 
have greater chance of retention of abstinence from drug use (Zywiak et al., 2002, 
Macdonald, 1987) and reduced substance use behaviours (Groh et al., 2007) 
compared to individuals who are socially isolated. In all, it appears that a residential 
treatment programme is a protective factor in preventing relapse to opioid use 
within 30 days. 
Our research also found that patients who did not complete their treatment 
programme were 15 times at risk of relapse within 30 days compared to patients 
who did complete their programme.  On the whole, more patients failed to 
complete treatment than complete treatment, which falls in line with wider 
research findings, however for those that did complete treatment, 63% of that 
cohort, regardless of whether they engaged in residential or outpatient treatment, 
were still abstinent after 30 days.   This is in line with earlier research (Gossop et al., 
2002, Aron and Daily, 1976) who investigated factors associated with relapse to 
heroin use after treatment and found that patients who spent longer in treatment 
and completed treatment were twice as likely to remain abstinent after treatment.  
As pointed out by Ravndal and Vaglum (1998), successful treatment is related to 
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positive social functioning and positive social skills.  The treatment programmes 
provided by NHS SABP Trust, both residential and community outpatient, as well as 
providing a medical detoxification, encourage patients to form relationships and 
friendships with other patients, who, through shared experiences, provide social 
and emotional support. WMH residential treatment programme is also structured in 
such a way that patients engage in a number of recreational activities and games, 
promoting positive social functioning and social skills.  Activities focused on 
integrating back into society and the workforce, such as CV writing and job 
interview preparation, also form part of the WMH treatment programme.  These 
structured activities provide motivation and positive outlook for the future, thereby 
protecting the patient from relapse, as motivation and hope for change are seen to 
be significant predictors of treatment retention and drug abstinence (Ball et al., 
2006). 
Furthermore, by completing the treatment programme, patients are able to 
gain the full benefit of the relapse prevention strategies learned during therapy. For 
example, during their time at WMH patients are made aware of triggers and cues to 
substance use and the appropriate protective strategies are put in place to prevent 
relapse.  Patients who fail to complete their treatment programme are at more risk 
and vulnerable to relapse without these protective strategies. 
In our study, relationship status was found to be a significant factor related to 
completing treatment. At the time of enrolling onto a treatment programme 67 
(79%) of patients were rated as single when entering into treatment and 89% of 
these single individuals failed to complete their treatment programme. This 
suggests that being single when undertaking an opioid treatment programme is a 
risk factor, contributing to the failure to complete the treatment programme.   
 However, not all those in a relationship completed their treatment 
programme in that 11% failed to complete, suggesting not all relationships are a 
protective factor against failing to complete treatment. It may be that it is the type 
of relationship which is important. Long-term, positive and committed relationships 
often provide the primary form of social support for many individuals and this type 
of support  has been found to reduce psychological distress as well as reduce 
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treatment drop-out rates in substance dependent individuals (Dobkin et al., 2002).  
Bachman (1997) supported these findings, showing that marriage, or engagement 
to be married, is associated with a significant reduction in substance abuse and also, 
compared to single or divorced, being in a satisfying relationship was found to have 
a primary effect of abstinence from drug use. Heinz et al. (2009) investigated the 
interaction between being married and heroin use over time.  The results were that 
being in a close and personal relationship/marriage predicted a greater decrease in 
heroin use, relative to being single or cohabitating.  They also found that the quality 
of the relationship affected substance use outcomes and concluded that while 
positive relationships predicted a decrease in substance misuse, in the absence of a 
loving close and personal relationship, being separated actually predicted a more 
favourable outcome over time.   
While not all these studies focus on treatment retention and completion, they 
do show that supportive relationships are protective against substance misuse and 
increased marital satisfaction and close supportive relationships may be a 
protective factor to relapse while a relationship which is absent from such support 
might be a risk factor to better treatment retention and reduced relapse.   
Unfortunately substance abuse is more often related to divorce or separation 
of couples (Lex, 1994) and/or remaining unmarried (Kaestner, 1997) and this is 
reflected in the large percentage of single patients enrolling into the detoxifying 
treatment programme reflected in our study; 67 (79%).  Poor, or lack of 
relationships and substance abuse is bi-directional in causality and there are a 
number of reasons for this, which include stress or a negative life event.  Also, as 
the use of drugs such as heroin escalates, the consequences can lead to social 
deficits and poor interpersonal behaviour, including the failure to interpret social 
and emotional signals (Kornreich et al., 2003b, McDonald et al., 2013), all of which 
underpin the social skills required to form significant, close and personal 
relationships. This suggests that those individuals who abuse heroin fail to secure or 
maintain long term, meaningful relationships and would explain the large number 
of single individuals entering treatment in our study.  
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Based on the above mentioned research, as well as the findings from our 
study, we could conclude that through improved sociability and social skills opioid 
dependent individuals are more likely to form close and supportive relationships, 
which in turn will ensure opioid dependency treatment is completed.  This is 
important as we were also able so show that those who completed their treatment 
programme were less likely to relapse.  As such, further research into the role of 
sociability and social impairments in relapse to opioid use is warranted. 
The benefits of social and emotional support are further evidenced in our 
findings that family support was associated with previous employment. Overall, 
prior to entering treatment, more patients had been in past employment than had 
not been in past employment (52 vs 23). Of the patients who confirmed they were 
in past employment, 27 (52%) noted that they were supported by their family while 
they underwent treatment. 
As stated earlier, family support represents both a structural as well as 
functional social support in that structural support offers supportive resources such 
as family or group membership while functional support represents the function 
that the structure provides, such as emotional support (Beattie, 2001, Cohen and 
Wills, 1985a). Both structural and functional support through family is likely to 
encourage positive coping strategies, the development of social skills and provide 
the opportunity for individuals to function on a daily basis and meet the needs of 
society, such as engaging in employment.   
Based on these findings, family support could be considered a protective 
factor for those who are attempting to engage in society post-treatment for opioid 
dependency and may protect against vulnerability to relapse.  
Our findings offer some support for this argument as 74% of patients who 
were unemployed prior to entering treatment had no family support. Henkel (2011) 
pointed out unemployed individuals are more likely to use illicit prescription drugs, 
have drug disorders and problematic substance use, which in turn decreases the 
chance of securing employment.  Being unemployed is also likely to reduce an 
individual’s support network as they become isolated and also increases their 
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exposure to stressors through financial pressures and as such contributes to the risk 
of relapse.  
These findings highlight the protective factor of engaging in employment as 
soon as possible following treatment and the importance of family support in 
ensuring this. Family support could be promoted through family therapy when 
committing to a drug treatment programme. Bernal et al. (1992) investigated the 
effects of family therapy with methadone maintenance patients and their family 
members.  They found that family therapy was effective in reducing drug abuse as 
well as improving family support.  
Moreover family therapy is particularly effective in treating drug abuse during 
the adolescence stage (Liddle et al., 2001) and this is important in the context of our 
study. Our data showed that 63% of patients started drug use (excluding alcohol) 
before 19 years of age (early starters). It may be that engaging in family therapy at 
pre-adolescence stage could prevent serious long term dependency.   
For our study, early starters were more likely to engage in residential 
treatment programme compared to those who started drug use (excluding alcohol) 
later in their lives.  One explanation for the difference in treatment programme 
intake is outlined by NICE guidelines (2007), which stipulate that residential 
detoxification is to be offered to those individuals who do not benefit from formal 
community-based outpatient detoxification.  It may be that this cohort of early 
starters, had previously not benefited from community-based treatment and 
perhaps, with repeated relapses, a residential treatment programme was offered. 
 NICE (2007) also recommend that residential detoxification is also offered to 
those individuals who have significant comorbid physical or mental health 
problems.  While this study did not find a significant association between mental 
illness and drug start age, overall almost 60% of the patients were diagnosed with 
mental illness at enrolment into treatment.  The percentage of our patients 
diagnosed with mental illness is a true representation of the increasing prevalence 
of co-morbid substance use disorders and mental illness. Research has found that 
certain mental health disorders are common to opioid addiction, namely depression 
(Rounsaville et al., 1982a) with prevalence rates for comorbid depression-substance 
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use disorders ranging from 12% to 80% (Torrens et al., 2011), anxiety disorders 
(Fatseas et al., 2010, Bolton and Sareen, 2006) and sleep disorders (Mahfoud et al., 
2009).  It is possible that over time, with persistent drug use, alterations to the 
nervous system and increased protracted withdrawal symptoms, a large number of 
the early starters suffered from mental illness and as such benefited from engaging 
in a residential treatment programme. Quello et al. (2005) argue that treating co-
occurring mental illness and substance abuse may reduce cravings and substance 
misuse and thereby enhance a patient’s overall outcomes.  As such, treatment 
should maximize the use of psychotherapeutic interventions in order to prevent 
relapse, which is reflected in our study, which found that engaging in a residential 
treatment programme and completing treatment resulted in extended abstinence.   
There appeared to be an association between a mental illness diagnosis and relapse 
within 30 days in 30 (71%) cases (see Table 2.7), although this was not significant.  It 
should be noted that for this association there was also missing data in 21 (23%) 
cases.  It may be that with more and completed data, a stronger and significant 
association between mental illness and relapse would be identified.  
Our study found a significant association between a positive diagnosis of 
mental illness and current crime conviction at the time of enrolling onto a 
treatment programme with 44 (64%) of patients meeting this association.  Overall in 
this association, only 18 (21%) patients had a current crime conviction at time of 
enrolling onto a treatment programme and 51 (60%) of patients had diagnosed 
mental illness.   The odds of no current criminal conviction for those with mental 
health illness at time of admission are over 2 times the odds of having a crime 
conviction and mental illness at time of admission onto a treatment programme. 
Given the wider research findings of the prevalence of drug related 
convictions, one would expect the number of patients for this factor in our study to 
be higher than 18 (21%). Drug dependency and crime have been found to be 
positively correlated and the Home Office (2016), report  approximately 400 000 
crime and drug-related incidents in 2015-16.  However, most individuals who end 
up in custody for drug related crimes undergo a prison sentence and engage in 
detoxification treatment within the prison system and do not enroll into a 
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residential treatment programme, such as that offered by NHS SABP Trust.  In 2015-
16 approximately 56,000 adults within prison settings sought out drug and alcohol 
treatment and 48% of those presented with problematic use of opiates (Public 
Health England, 2015).   Therefore, the patients with a current crime conviction are 
less likely to be enrolling into a residential treatment and be represented in my 
data, as they are more likely to be undergoing a prison sentence.  A closer look at 
my data show that past criminal behaviour was noted by 69 patients (77%) and this 
falls closer in line with the high prevalence of substance abuse related criminal 
behaviour (Home Office, 2016).  
Retrospective investigations, such as this research, often relies on data 
collected from patient case files and notes completed by doctors and care staff. The 
researcher therefore relies on reliable note-taking by all parties as well as the 
honesty of the patient themselves. Furthermore, recording data relies on the 
objectivity of the researcher, as they need to decide which information would be 
considered a reliable factor, as patient files do not always share standardised formal 
note-taking. This is challenging and there is always the risk of non-standardised 
data, researcher bias and unreliable data.  
As such it is always better to avoid a type 1 error and not include some data. 
This was especially evident when collecting data for the factor "relapse within 30 
days", as this information was mostly provided by the patient themselves following 
contact with their therapist.  Due to the nature of substance abuse, which often 
leads to patient memory impairment and distorted cognitive function, much of the 
data provided in patient notes needed to be viewed as possibly unreliable and when 
unclear the data were captured as "unknown" or "missing". As such our results may 
not be true reflection of the role of sociodemographic factors in patient relapse.  
Hassan (2005) point out ways to overcome some of these issues; using 
standardised data collection protocols and standardised instruments would ensure 
that not only is the correct data identified, missing data is likely to be avoided.  
Using two researchers to collect data would ensure that there is increased reliability 
or alternatively by blinding the individual collecting data to the study hypothesis 
and specific factors being studied is likely to reduce bias.  
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 Overall this study has helped identify the sociodemographic risk and 
protective factors of relapse in opioid dependent individuals and well as significant 
interrelationships between these factors.  Social and emotional support through a 
supportive residential treatment programme, a positive relationship or supportive 
family is likely to ensure that the individual engages in and completes a 
detoxification programme and remains abstinent following treatment.  Likewise 
social and emotional impairments, including a mental illness diagnosis are risk 
factors to relapse to drug use.  
These findings point to further research within these areas and an 
investigation into the role of social and emotional impairments in relapse in as well 
their role in possible treatment to prevent this relapse.  As my findings were only 
associations and correlations, they do fall short on a causal explanation, and so 
point to an investigation which is experimental in design in order to determine any 
valid effects.  Research on oxytocin has found that this “social” peptide not only 
promotes social interaction and relationships (Ditzen et al., 2009) but also 
attenuates stress and emotional impairments associated with withdrawal from 
morphine in mice (Zanos et al., 2014).  In light of our findings in this study, as well as 
preclinical and clinical research in oxytocin, it seems that this neuropeptide may 
offer a novel pharmacotherapy in preventing relapse by promoting the protective 
factors identified in our study.   
 In order to determine the potential efficacy of a novel pharmacotherapy such 
as oxytocin in preventing relapse, a pilot randomised double blind placebo 
controlled clinical trial would need to be carried out on detoxified opioid dependent 
individuals.  NHS SABP Trust, Windmill House, presents such an opportunity. The 
lower rates of relapse of those undertaking treatment at Windmill House show that 
it is a structured and supportive environment, both psychosocially as well as 
medically, for those undertaking detoxification treatment. By carrying out a pilot 
clinical trial within WMH on detoxified opioid dependent individuals and focusing 
on the social and emotional impairments implicated in research, we might move 
forward on the much needed treatment to prevent relapse within this population.  
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3      CHAPTER 3 
 
A DOUBLE BLIND PLACEBO CONTROLLED PILOT TRIAL OF 
THE EFFICACY OF OXYTOCIN IN TREATING DETOXIFIED 
OPIOID DEPENDENT INDIVIDUALS 
158 
 
 
3.1 Introduction 
Relapse to drug use is a key characteristic of addiction and studies on opioid 
dependency consistently report a relapse rate of 70%, following a period of 
abstinence.  In some cases the period of abstinence could be as little as a day or two 
and only around 40% of clients maintain abstinence 1 month post detoxification   
(Broers et al., 2000b, Chutuape et al., 2001b).  Reasons for relapse varies from study 
to study, although there are common factors.  As discussed previously, Bradley et 
al. (1989), for example, interviewed relapsed opiate users following in-patient 
detoxification, in order to examine their renewed opiate use. At a six month follow-
up after detoxification, approximately 70% of participants had relapsed and 
following interviews with the participants, the researchers were able to identify 
factors that were associated with relapse.  The associated factors were negative 
mood states and cognitions, external influences and social pressure, the experience 
of withdrawal symptoms and the experience of leaving the clinic.  Almost all cases 
of relapsed participants reported negative mood states following detoxification and 
described these as low mood, anxiety, boredom, loneliness and anger as well as 
negative cognitions and thought processes. The external influences reported by the 
participants were events and situations which were associated with triggers or cues 
and social pressure was seen through direct or indirect offer of drugs.  The reported 
withdrawal symptoms were mainly insomnia followed by cravings and a strong 
desire or preoccupation with opiates.  The relapsed cases described leaving the 
detoxification clinic as feelings of loss or the removal of support. The researchers 
also identified priming as a risk factor as relapse was seen to follow the use of 
another substance such as alcohol, in particular following social pressure. The 
researchers, Bradley et al. (1989), concluded that interventions and treatments 
aimed at reducing the rate of relapse following opioid detoxification, should 
prioritise these risk factors, in particular negative cognitions and thoughts of using 
drugs as well protracted emotional withdrawal symptoms, such as depression,  
anxiety and loneliness, followed by physical withdrawal symptoms.   
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Opioid dependent individuals undergoing detoxification report persistent 
emotional withdrawal symptoms, (Jaffe, 1990, Martin and Jasinski, 1969, Nunes et 
al., 2004, Peles et al., 2007) which serve as a motivational trigger to re-administer 
the drug and relapse (Le Moal and Koob, 2007b). These symptoms are associated 
with emotional distress and dysphoria such as anxiety, irritability, stress, depression 
and anhedonia may persist for months in recovering opioid dependent individuals.  
In addition, adverse social consequences of opiate use and withdrawal has been 
recognised. Studies have found that withdrawal from opioids leads to reduced 
sociability as well as increased depressive and anxiety related behaviour (Zanos et 
al., 2014).   
As opioid substitution pharmacotherapy, benzodiazepine based anxiolytics 
and antidepressants have limited benefit in term of relapse prevention or can 
induce dependence in their own right, there is a need to develop more effective, 
safer treatment of emotional opioid withdrawal symptoms and relapse prevention. 
 The neuropeptide oxytocin is emerging as a potential candidate.  Oxytocin 
(OT) is a neurohypophysial hormone which is produced by the hypothalamus and 
stored and secreted by the posterior pituitary gland. As discussed earlier, the brain 
OT system comprises projections from hypothalamic OT neurons to several brain 
regions and there is a wide distribution of OT receptors throughout the brain. OT 
has important peripheral effects and is best known for its role in the hormonal 
regulation of reproductive functions, such as birth, lactation and sex (Neumann and 
Landgraf, 2012).  OT also acts as a neuromodulator in the brain and the OT system is 
heavily involved in many aspects of social behaviour (Landgraf and Neumann, 
2004a, Neumann and Landgraf, 2012) as well as the regulation of stress, anxiety and 
fear.  As such, the last two decades have witnessed a surge in research investigating 
the application of oxytocin as a method of enhancing psychological function in 
humans. Research involving healthy adults has linked intranasal oxytocin with a 
range of effects such as reducing levels of social anxiety (Heinrichs et al., 2003a), 
and increasing levels of trust (Kosfeld et al., 2005b), gaze into the eyes (Guastella et 
al., 2008), and accurate emotional processing (Di Simplicio et al., 2009). The vast 
majority of studies investigating oxytocin and social behaviour in humans has 
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utilised nasal delivery as the administration method (Macdonald and Macdonald, 
2010). This has triggered a growing number of clinical trials investigating the 
efficacy of intranasal OT in treating psychiatric conditions characterised by 
symptoms associated with increased anxiety and social withdrawal, such as autism 
and schizophrenia (Carter, 2007, Heinrichs and Gaab, 2007).   
Oxytocin (OT) has also been shown to decrease social anxiety in autistic 
individuals (Anagnostou et al., 2012), fragile X syndrome individuals (Hall et al., 
2012a), and healthy people (Di Simplicio et al., 2009) when administered 
intranasally. In addition, oxytocin has been shown to reduce depression scores 
(Baumgartner et al., 2008, Di Simplicio et al., 2009) and improve social cognition 
and quality of life in autistic spectrum disorder individuals (Anagnostou et al., 2012) 
and block alcohol craving and withdrawal (including mood, anxiety) in alcohol 
dependent individuals undergoing detoxification with lorazepam (Pedersen et al., 
2013b). Oxytocin is also known to modulate neural circuitry for social cognition and 
fear in humans (Kirsch et al., 2005) and it has been suggested to be effective for the 
treatment of psychiatric conditions characterised by symptoms associated with 
increased anxiety and social withdrawal (Carter, 2007, Heinrichs and Gaab, 2007).  
OT is currently being investigated as a potential treatment of social deficits and 
paranoia in schizophrenia and autism.  
With respect to addiction and as discussed earlier, there is emerging evidence 
supporting the involvement of OT in the modulation of the effects of a number of 
drugs of abuse (for reviews see Broadbear et al., 2011, McGregor and Bowen, 
2012a, McGregor et al., 2008a, Sarnyai, 2011, Bowen and Neumann, 2017). With 
respect to opioids, an inhibitory effect of OT has been demonstrated on morphine 
tolerance, on the physical symptoms of naloxone-precipitated morphine withdrawal 
(Kovacs et al., 1985c, Kovacs et al., 1984) and on heroin self-administration (Kovacs 
and Van Ree, 1985) in rodents. It has also been shown that the central oxytocinergic 
system is dysregulated in mice undergoing protracted opioid abstinence (Zanos et 
al., 2014). Mice have been found to experience profound emotional impairment 
(anxiety, depression and lack of social preference) following prolonged morphine 
withdrawal and this can be reversed by acute administration of the oxytocin 
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analogue carbetocin.  Carbetocin also prevents stress-induced reinstatement of 
morphine seeking behaviour in mice undergoing extinction from morphine 
conditioned place preference. Zanos et al. (2014) suggest that the profound 
dysregulation of the oxytocinergic system may be a possible mechanism linking 
anxiety, depression and hypohedonia, in particular lack of social interest and social 
withdrawal.  These emotional impairments as well as heightened stress responsivity 
often present with opioid withdrawal and can persist for months and even years 
into abstinence.  They are also a risk factor for relapse to drug use. 
 Chronic drug abuse-or drug withdrawal-induced changes in the endogenous 
OT system, including alterations in OT release and OTR binding, are likely involved in 
these aspects of protracted withdrawal (Zanos et al., 2014, You et al., 2000, 
Georgiou et al., 2016, Baracz et al., 2016).  One of the mechanisms by which 
oxytocin or its analogues can exert its beneficial effect is through the modulation of 
hypothalamic-pituitary-adrenal (HPA) axis. As outlined in section 1.5.2.1 (and 
described in Figure 1.7), OT has the potential to prevent the stress related 
symptoms due to its action on the HPA.  Furthermore, OT supresses amygdala 
activity (Domes et al., 2007a) and functioning between the amygdala and brainstem 
in response to negative emotional stimuli (Kirsch et al., 2005).  
Therefore OT has the potential to modulate the processes implicated in the 
emotional impairments associated with drug withdrawal by attenuating depression 
and/or anxiety, stress related symptoms and social withdrawal often seen in those 
seeking treatment for opioid addiction (Rounsaville et al., 1982a, Fatseas et al., 
2010).  
Given the anxiolytic, antidepressant and social enhancing effects of OT in 
humans following administration of intranasal spray (Baumgartner et al., 2008, 
Kirsch et al., 2005, Di Simplicio et al., 2009), or in animal models when administered 
centrally or peripherally (Dabrowska et al., 2011, Windle et al., 2004b), the 
oxytocinergic system may be potential target for the development of novel 
treatments for opioid withdrawal-related emotional impairment and relapse 
prevention.  
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This study was a translational, phase II Clinical Trial of an Investigative 
Medicinal Product (CTIMP), aiming to provide important pilot data on the efficacy of 
oxytocin (Syntocinon) in reducing protracted withdrawal symptoms and in 
preventing relapse in opioid dependent individuals undergoing detoxification. It 
sought to provide important information about the variability in response to 
treatment and to determine participant numbers required for adequate statistical 
power essential in a comparative long study.  Should the treatment prove effective, 
it would lead to a phase III trial, involving larger groups of patients and form the 
basis for the development of novel pharmacotherapy for the treatment of the 
negative emotional consequences of opioid addiction and relapse prevention, which 
will have a major health and socioeconomic impact.  
For full commentary and review of pilot studies see Thabane et al. (2010), but 
in short a pilot project or study is defined as an experimental, exploratory, test, 
preliminary, trial or “try out” investigation.  The National Institute for Health 
Research (NIHR) (2015) identify pilot studies as a smaller version of the main study, 
used to test whether the components of the main study can all work together. They 
point out that pilot trials focus on the processes of the main study ensuring that 
recruitment, randomisation, treatment and follow-up assessments all run smoothly 
and, as such, pilot trials resemble the main study in many ways, including assessing 
the primary outcomes.  For updated commentary on the importance of phased 
CTIMPs and research within the NHS, see the review released by The Academy of 
Medical Sciences (2011). 
3.2 Study Aims and Objectives 
This pilot study aimed to investigate in the efficacy of a medicinal product and 
as such was defined as a Clinical Trial of an Investigational Medicinal Product 
(CTIMP), as defined by the Medicines for Human Use (Clinical Trials) Regulations 
2004.  
The purpose of this pilot CTIMP is to test whether intranasal administration of 
the neuropeptide oxytocin is effective in assisting post-detoxification opioid 
dependent individuals to maintain abstinence from opioid use.  Also to determine 
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its efficacy in increasing retention rates in the post detoxification 4 week residential 
rehabilitation / relapse prevention programme, Windmill House, NHS Surrey and 
Borders Partnership Trust and also in lowering their craving for opioids; decreasing 
their anxiety (including social anxiety) and improving mood, social cognition and 
quality of life.   
 
 Objectives 3.2.1
Primary Objective 
The primary objective will be to investigate the efficacy of oxytocin in 
retaining post detoxification opioid dependent individuals in inpatient residential 
rehabilitation programme and prevent relapse to opioid use. 
Secondary Objective 
The secondary objective will be to investigate the efficacy of oxytocin in 
reducing opioid craving, anxiety, depression, social anxiety, sleep disturbances and 
in enhancing social cognition, quality of life in post-detoxification opioid dependent 
individuals. 
 Hypotheses 3.2.2
We hypothesise that: 
a) Post detoxification opioid dependent individuals exposed to intranasal 
oxytocin (Syntocinon) will have decreased rates of relapse and higher 
retention rates in inpatient residential rehabilitation programme compared 
to individuals exposed to placebo control. 
b) Intranasal oxytocin (Syntocinon) will reduce opioid craving, anxiety, 
depression, social anxiety, sleep disturbances (e.g. sleep efficiency, 
nocturnal awakenings, sleep duration) in post detoxification opioid 
dependent individuals compared to individuals exposed to placebo control. 
c) Intranasal oxytocin (Syntocinon) will have a positive effect on social 
cognition, quality of life in post-detoxification opioid dependent individuals 
compared to individuals exposed to placebo control. 
164 
 
 
 Study Endpoints 3.2.3
Primary Endpoint  
Retention rates in residential rehabilitation programme at approximately 2 
weeks from the first dose of Syntocinon/placebo treatment.  Rates of subjects 
relapsing to drug use (e.g. urine positives for opioid/illicit drug metabolites, self-
reporting) at specific time points from the first dose of Syntocinon/placebo 
administration (e.g. approximately 2 and 6 weeks).   
Secondary Endpoints 
Measures of withdrawal symptoms severity, opioid craving, anxiety, 
depression, social anxiety, social cognition, sleep disturbances at the start 
(treatment day 2) and the end (treatment day 14) of the 2 week 
placebo/Syntocinon treatment period and 1 month after the end of the last dose of 
placebo/Syntocinon treatment. Measures of quality of life (wellbeing) at baseline 
and 1 month after the last dose of placebo/Syntocinon treatment. Activity/sleep 
profile before (i.e. from screening), during and after placebo/Syntocinon treatment 
(up to 1 month after the end of the treatment will be acquired). 
 Rationale for study endpoints 3.2.4
The treatment of opiate dependence presents many challenges; detoxification 
can be achieved for the majority of dependent individuals, however, maintenance 
of abstinence is more difficult as dependent individuals relapse.  Relapse to opiate 
use frequently leads to premature exit from treatment either during the 
detoxification process or shortly afterwards. The most commonly used measure of 
successful treatment is the length of abstinence achieved post-treatment. There are 
multiple studies in the literature using retention in rehabilitation treatment and 
drug use (lapse/relapse) as primary endpoints to study efficacy of pharmacotherapy 
in heroin dependent individuals. As the majority of the opioid dependent individuals 
relapse within 1 month of detoxification (Broers et al., 2000b, Chutuape et al., 
2001b), we decided to study retention in the post-detoxification rehabilitation 
programme (2 weeks from baseline) and maintenance of abstinence up to 4 weeks 
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following treatment with placebo/Syntocinon.  Moreover, rates of relapse as 
measured by urine screen and/or self-report is a very common method to quantify 
efficacy of a treatment in preventing relapse. Both these measurements will give a 
good preliminary indication on the efficacy of Syntocinon on relapse prevention.  
The secondary endpoints were chosen in order to measure emotional and 
other consequences of opioid abstinence such as opioid craving, anxiety, 
depression, social anxiety, and reduction in social cognition, poor quality of life and 
sleep disturbances which we hypothesize to be modulated by Syntocinon/oxytocin.  
As quality of life has also become an important indicator in health care evaluation 
and is low in drug dependent individuals (DeMaeyer et al., 2010), we decided to use 
it as an endpoint for testing the efficacy of Syntocinon, but only 4 weeks post 
placebo/Syntocinon treatment. The environment in the rehabilitation unit is 
considered rather safe and protected. As a result, we did not decide to assess the 
effect of Syntocinon on quality of life during treatment in the rehabilitation unit.  
The timeline of the endpoints (i.e. at the start [treatment day 2], the end of the 2 
week oxytocin/placebo treatment period-treatment [day14] and 1 month after the 
last dose of Syntocinon/placebo administration) was chosen in order to investigate 
the acute and chronic effect of Syntocinon on those secondary parameters and 
whether this effect is persistent after the end of the treatment.   
 Rationale for doses 3.2.5
The route of administration dosage and regime proposed was entirely driven 
by literature where identical or similar protocols of Syntocinon (Oxytocin) 
administration were used in pilot and adequately powered clinical studies in healthy 
volunteers as well as patients suffering from autistic spectrum disorder, 
schizophrenia and fragile X syndrome  (Guastella and MacLeod, 2012, Heinrichs et 
al., 2003b, Hollander, 2006, Ditzen et al., 2009, Tachibana et al., 2013a, Hall et al., 
2012b). 
Intranasal route of administration was selected over intravenous as it is much 
less invasive, would be inappropriate for this population, can be easily self-
administered by the subject with minimum or no supervision and it is believed to 
reach (or stimulate) the brain more readily to induce its central effects. The dose of 
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6 insufflations (24 IU of oxytocin total), given twice daily (9-11 am and 16.00-18.00 
pm), has been repeatedly used in studies in the literature in healthy volunteers and 
patients (Guastella and MacLeod, 2012, Heinrichs et al., 2003b, Hollander, 2006, 
Ditzen et al., 2009, Tachibana et al., 2013a, Hall et al., 2012b, Feifel et al., 2010). 
This treatment regime has shown to be safe, as no or very minor adverse 
effects have been reported.  Long term administration (weeks-months) of a similar 
regime of Syntocinon administration in patients suffering from autistic spectrum 
disorder and schizophrenia showed no adverse effects (Tachibana et al., 2013b). On 
the contrary, the dose regiment of Syntocinon proposed in this study has shown 
repeatedly to exhibit positive effect in reducing anxiety, depression and/or 
enhancing social anxiety in patients suffering from autistic spectrum disorder, 
schizophrenia and fragile X syndrome and in withdrawn alcoholics (Andari et al., 
2010, Pedersen et al., 2013a). 
We decided to stick with the doses of Syntocinon used in the literature as (1) 
no adverse or side effects have been reported (MacDonald et al., 2011) (2) 
beneficial effects have been reported as described above and (3) a recent study 
conducted in early adolescent boys with autism spectrum disorders who were 
administered long term nasal oxytocin showed promising results with excellent 
compliance and no side effects (Tachibana et al., 2013b). We decided to be cautious 
and not to increase the dose of oxytocin as there is no substantial literature 
reporting its effect (positive or negative). Given that special warnings for prolonged 
use of excessive doses of i.v. oxytocin together with large volumes of fluid has been 
known to cause water intoxication with hyponatraemia (Mayer-Hubner, 1996), we 
decided to stay on the safe side.  In addition recent data in rats showed that higher 
doses of oxytocin can increase rather than decrease anxiety possibly due to its 
effect on vasopressin receptors at that concentration (Peters et al., 2014). 
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3.3 Materials and methods 
 Ethics and Governance 3.3.1
The pilot CTIMP application was registered on the European Clinical Trials 
Database (EudraCT) on 5 November 2014 and assigned EudraCT No:2014-002708-
26; https://www.clinicaltrialsregister.eu/ctr-search. 
Application was made to Medicines and Healthcare Products Regulatory 
Agency (MHRA) on 1 August 2014. This application received notice of non-
acceptance and right to amend (see Appendix 2).  Three further amendments were 
approved with the final amendment granted on 28 June 2017  
Ethical approval was received from NHS Health Research Authority, London 
Bridge Research Ethics Committee on 23 May 2017; REC reference: 14/LO/1495, 
Amendment No 4 (Appendix 3). 
Ethical approval was received from University of Surrey Ethics Committee on 
11 July 2014 
 Participants 3.3.2
 
30 (n=15 for each condition) opioid dependent individuals were sought for the 
whole study.  112 patients were admitted to Windmill House (WMH) for withdrawal 
and detoxification between September 2016 and September 2017. 77 were 
admitted for an alcohol detoxification and 36 were admitted for opioid treatment. 
18 took part in a drug stabilisation regime and discharged.  18 took part in 
withdrawal and detoxification and 4 week detoxification and relapse prevention 
programme.  
Nine opioid patients were pre-screened (see Table 3.1 for demographics of 
patients).  Three males (age: m=40 SD= 6.65) and six females (age: m=40, SD=5.3).  
Four patients consented and were screened; one male (age:48) and three females 
(age: m=38 SD=7.04).  Two patients were admitted onto the trial, one male (age:48) 
and one female (age 33).  Nil patients completed the trial (See Figure 3.1).  
 Inclusion criteria  3.3.2.1
All participants were aged between 18 and 65 years and had a primary 
diagnosis of opioid dependence according to DSM-5 criteria.  No females were 
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pregnant or lactating and all participants were willing and able to give informed 
consent and had an understanding of English.  All participants had completed an 
opiate withdrawal treatment regime at WMH and remained opiate free before the 
start of the study. All participants, following withdrawal, agreed to continue with 
the inpatient four week programme at WMH.  
 Exclusion criteria  3.3.2.2
Exclusion criteria meant that no participants had severe psychosis, bipolar 
affective disorder I, severe depression with suicidal ideation and intention, brain 
trauma or other severe neurological disorders. Also participants were not taking 
anxiolytics, antipsychotics, sedatives, prostaglandins, certain inhalation anaesthetics 
or opioids for pain management post opiate detoxification. No participants had a 
history of severe kidney disease, or cardiovascular disease (heart disease, heart 
attacks, high blood pressure, heart surgery), and had no history of nasal bleeding.  
Finally participants were questioned on their water intake due to a slight risk of 
hyponatremia due to the anti-diuretic properties of OT. Regular or habitual 
overconsumption of more than 1 litre of water per hour excluded participants.  
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Figure 3.1:  Flowchart of patient admissions to Windmill House and enrolment 
  onto  the trial between September 2016 and September 2017.  
 
 
N = 18 
Withdrawal Detoxification and 
4 week residential treatment   
N = 18 
Drug Stabilisation regime 
and discharged 
N= 112 
Admitted to WMH for 
withdrawal and detoxification 
N = 36 
Admitted for opioid treatment 
N = 76 
Admitted for alcohol 
detoxification and withdrawal 
N= 4 
Consented and screened 
N = 9 
Pre-screened for suitability 
 
N= 2 
Enrolled onto trial 
N= 0 
Completed the trial 
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Table 3.1 Demographics of patients who completed withdrawal and detoxification and pre-screened for admission onto the pilot CTIMP 
Gender Age at 
admission to 
WMH 
No of 
previous 
detoxification
s 
Comments on 
substance 
abuse history 
WMH 
Treatment 
plan 
Polyuse at 
admission to 
WMH 
Health at 
admission 
Consented 
Enrolled onto 
trial 
Completed 
Trial 
Reason for non-
completion/leavin
g WMH 
F 32 Not stated History of 
heroin and 
crack cocaine 
abuse 
Buprenorphine 
Detox  
Not Stated No diagnosis of 
mental illness. 
Complaints of 
numbness in 
hands and feet 
and headaches 
Consented : Yes 
Enrolled : Yes 
Completed: No 
Self-discharged to 
A&E. 
Returned home. 
F 43 Not stated History of 
alcohol abuse 
Buprenorphine 
Detox 
Alcohol Diabetes 1 Consented : No 
Enrolled : No 
Completed : No 
Self-discharge 
M 34 Numerous 
attempts.  
None at WMH 
(verbally 
confirmed).  
Has undergone 
heroin detox 
before 
Previous heroin 
Previous crack 
Previous 
cannabis 
Previous ecstasy 
and speed 
Previous 
ketamine and 
methadrone. 
Buprenorphine 
Detox 
None Previous 
depression.  No 
diagnosis at 
admission 
Consented : No 
Enrolled : No 
Completed : No 
Completed 
treatment and 
programme 
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F 51 1 alcohol detox 
at WMH 
(verbally 
confirmed)  
Alcohol  Buprenorphine 
Detox 
Benzodiazepine 
(prescription) 
Depression.  On 
antidepressants 
Consented : No 
Enrolled : No 
Completed : No 
Completed 
treatment and 
programme 
M 46 Not stated Previous 
cannabis 
Previous crack 
cocaine 
Previous heroin  
Previous 
methadone 
Buprenorphine 
Detox 
Heroin on top of 
buprenorphine 
Anxiety. 
Previous suicide 
attempt 
Consented : No 
Enrolled : No 
Completed : No  
Discharged. 
Breach of contract.  
Positive drug test 
M 48 5 Previous 
detox. 
2 WMH 
1 st Georges 
2 elsewhere 
(unknown) 
Methadone 
Cannabis 
Heroin 
Crack cocaine 
Methadone 
Detox. 
 
None None Consented : Yes 
Enrolled : Yes 
Completed : No 
Discharged. Breach 
of contract. Rule 
breaking 
F 42 Not stated Crack cocaine 
Alcohol 
Heroin 
Buprenorphine 
Detox 
Cocaine 
Opiate 
Benzodiazapine 
Buprenorphine 
None Consented : Yes 
Enrolled : No 
Completed: No  
 
Discharged. Breach 
of contract  
Positive drug test 
(cocaine) 
F 39 Not stated Heroin Methadone 
Detox 
None None Consented : Yes 
Enrolled : No 
Completed: No  
 
Delay to enrolment 
due to Diazepam 
script. 
IMP expired 
Completed 
treatment and 
programme 
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F 33 Not stated Not stated Methadone 
Detox 
Not stated None Consented : No 
 
Self Discharge 
 
Demographics of 9 patients pre-screened for enrolment onto the study between July 2016 and September 2017.  Patients who consented and enrolled onto the trial are 
shaded. Information obtained from admission records and NHS patient files. 
Upon admittance to WMH patients undergo withdrawal and detoxification treatment.  Once detoxification treatment is completed patients are approached about their 
willingness to enrol onto the pilot trial.  Patients are pre-screened in order to determine inclusion and exclusion criteria and if suitable, patients are provided an 
information sheet and consent form to sign and given the opportunity to enrol onto the pilot CTIMP.   
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 Setting 3.3.3
The pilot CTIMP comprised of two main sites; the trial site, where the spray 
treatment and assessments took place and the pharmacy site where the medicinal 
products were handled. 
The pilot CTIMP trial site was at Windmill House, Surrey and Borders 
Partnership Trust, St Peters Hospital, Chertsey, Surrey. All participants were 
admitted to Windmill House (WMH), a residential drug and alcohol treatment 
centre to undertake a 2 week (approximately) opioid withdrawal and detoxification 
treatment regime followed by a 4 week structured detoxification relapse prevention 
therapy programme. (See appendix 1 for more information on WMH).  
Only once patients had completed their withdrawal and detoxification regime 
and had engaged in the relapse prevention and therapy programme, were they 
enrolled onto the pilot trial.  Patients remained living at WMH throughout their 
time on the programme and during the trial.   
Administration of the investigative medicinal product (oxytocin/placebo) was 
performed in the clinic room at WMH.  This is a secure, temperature monitored 
room used for medical assessments and clinical observations as well as dispensing 
of medications.  Only clinical staff have access to this secure room and patients are 
scheduled for appointments with clinical staff. As well as storage for general 
medicinal use, such as first aid, the room also has a secure and temperature 
monitored fridge for storage of medicines and each patient is allocated a locked 
“medicine box” for storage of their personal prescription medicines and any other 
clinical products such as contraceptive medicines.  Patients are not permitted to 
have any clinical or medicinal products on the ward, except those used for bodily 
cleansing, and those are subject to regular checks.  
The pilot CTIMP assessment tests and questionnaires were carried out in a 
separate, safe and confidential interview room within WMH and comprised 
comfortable seating and a table. 
All handling and dispensing of the CTIMP medicinal products; OT nasal spray 
or placebo nasal spray, was carried out by NHS Surrey and Borders Partnership 
Trust pharmacy, situated at Farnham Road, Guildford.  WMH only has facility to 
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store dispensed prescription medicinal products and does not have the licence or 
infrastructure to import or handle investigative medicinal products.  The pharmacy 
is exempt under MHRA Regulation 37, which allows for hospitals and health centres 
to perform activities for CTIMPs, without the need to hold a Manufactures 
Importers Authorisation (MIA(IMP)) licence. This meant that the pharmacy could be 
included as a clinical site for the pilot CTIMP and received permission from the 
MHRA for this purpose. They could receive the IMP from the wholesalers, store and 
dispense it as required by the researchers for the pilot CTIMP.  As the CTIMP was 
double blinded and placebo controlled, the IMP required decanting into bottles 
which matched placebo bottles, then randomised and relabelled to retain 
anonymity. This process was carried out by Good Clinical Practice (GCP) certified 
pharmacy staff and monitored by University of Surrey Clinical Research centre, who 
ensured the study remained blinded until the end date and all trial processes within 
the pharmacy met with GCP requirements.  Within the pharmacy there was a room 
which was dedicated to handle trial medications.  This room included a temperature 
monitored fridge for storing both the IMP and placebo.  There was a secure 
cupboard which held empty bottles, screw on pumps, actuators, and lids and a 
secure space to carry out this work.  All communications between WMH and 
pharmacy are done by fax. (For details of the pharmacy procedure, please see 
Pharmacy Standardised Operating Procedures, Appendix 4)  
 Materials and Measures 3.3.4
The materials used within this pilot CTIMP comprised of (1) paperwork 
required to enrol a patient onto the trial and monitor the participant, (2) the 
assessments and questionnaires used to determine any treatment effect and (3) the 
trial medicinal products; intranasal oxytocin (syntocinon) (IMP) and intranasal 
placebo (saline).  Copies of materials, outlined below, are found in the appendix, 
including the research protocol. 
Participants who were interested in taking part in the pilot CTIMP were 
provided with a participant information sheet, which included a consent form, for 
their consideration while they underwent withdrawal and detoxification (appendix 
5).  They were also pre-screened to determine if they met inclusion and exclusion 
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criteria and were assigned a pre-screening number from the screening and 
randomisation log (appendix 6). Following completion of their withdrawal and 
detoxification regime, patients who were interested in taking part in the trial 
provided a signed consent form and they were fully screened [visit 1] (see appendix 
7 for a screening workbook).  A randomisation number was requested from the 
pharmacy and added to the screening and randomisation log.  Stickers were placed 
on the patient files to notify all staff that the patient was undertaking a clinical trial 
(appendix 8). Once the trial had commenced a workbook (appendix 9 for a section 
of the workbook) was used throughout the study.  This recorded any research 
procedures carried out with the patients, as per the protocol, and was completed at 
each visit to the treatment room. All procedures carried out with patients was done 
in accordance with the study procedures manual (appendix 10). 
Actigraphy was carried out throughout the trial and all participants were 
required to wear the same actigraph, light and activity monitor (Actiwatch L (AWL) 
Cambridge Neurotechnology Ltd, Cambridge, UK) 24 hours a day, for the duration of 
the study, including night time.  This unit records any movement during the 
recording period and the output displays this movement in hourly intervals.  Any 
stillness or inactivity may be an indication of rest or possible sleep.  
Participants were also required to self- assess their sleep, mood and 
sociability as well as withdrawal symptoms daily, throughout the duration of the 
trial.  As such, they completed a sleep diary every morning (appendix 11) and a self-
assessment mood and sociability state scale (SA) (appendix 12) and subjective 
opiate withdrawal symptom (SOWS) questionnaire (appendix 13).  These were 
completed every afternoon intranasal spray (between 16h00 – 18h00).    
To determine the effects on emotional impairments, participants completed 
further psychological assessments between 16h00-18h00, 50 minutes after 
intranasal spray at visit 2 [baseline], visit 4[day2], visit 5 [day 14] and visit 6 [post 
treatment visit; 30-35 days after discharge from WMH] (see fig 3.2 for a timeline).  
These psychological assessments comprised the Hamilton Anxiety Rating Scale 
(HAM-A) (appendix 14), Hamilton Depression Rating Scale (HAM-D) (appendix 15), 
Leeds sleep evaluation questionnaire (LSEQ) (appendix 16), Liebowitz Social Anxiety 
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Scale (LSA) (appendix 17), Reading the Mind in the Eyes (RtM) (appendix 18), The 
WHOQOL-BREF instrument (appendix 19). 
Details of the above questionnaires and actigraphy can be found below.  
 
 Self-assessment of mood and sociability state (SA)  3.3.4.1
 The self-assessment of mood and sociability state (SA) is a Likert scale and 
comprised 6 questions related to mood and sociability and 3 questions related to 
withdrawal symptoms (see appendix 12).  This scale was to be completed every day 
between 16h00 – 18h00). 
o Question 1 rates the state of mind: a score above 35 would indicate  
  feelings associated with anxiety. 
o Question 2 rates mood: a score above 25 would indicate low mood and 
  feelings of depression. 
o Question 3 rates trustworthiness of others in your life: A score below 5 
  indicates increased trustworthiness of others. 
o Question 4 rates hostility: a score below 5 indicates no feelings of 
hostility 
o Question 5 rates feelings of socialising: a score of 5 or above would  
   indicate feeling very antisocial. 
o Question 6 rates feelings of participating in groups: a score of 5 or above 
  would indicate feeling very uncomfortable about participating in 
  small group activities.  
o Feelings of withdrawal : a score of 15 or above indicated withdrawal  
  symptoms.  
 
 Subjective Opioid Withdrawal Scale (SOWS) 3.3.4.2
 The Subjective Opioid Withdrawal Scale (SOWS) is a self-administered scale 
for grading opioid withdrawal symptoms and has demonstrated to be a valid and 
reliable indicator of the severity of the opiate withdrawal syndrome, over a wide 
range of common signs and symptoms (Handelsman et al., 1987, Tompkins et al., 
2014) (see appendix 13). The questionnaire contains 15 symptoms related to 
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intensity which the patient rates on a scale of 0 (not at all) to 4 (extremely).  Scores 
are totaled and a score of 15 indicates little opioid withdrawal symptoms, a score of 
30 indicates moderate opioid withdrawal symptoms and a score of 60 indicates 
extreme opioid withdrawal symptoms. 
 Hamiltons Rating Scale for Anxiety  (HAM-A)  3.3.4.3
Hamilton Anxiety Rating Scale (HAM-A) (Hamilton, 1959), is a 14-item clinical 
interview measure of somatic and psychic anxiety symptoms. Patients are rated 
with a score between 0-4 for each question  (see appendix 14).  Scores are totalled 
and a total score would be in the range of 0-56.  A score of 17 or less indicates mild 
anxiety.  A score from 18-24 indicates mild to moderate anxiety and a score of 25 
and above indicates severe anxiety.  This questionnaire has been found to have high 
inter-rater and test-retest reliability and a valid measure of anxiety disorders (Shear 
et al., 2001).  This scale was completed  
 Hamiltons Rating Scale for Depression (HAM-D) 3.3.4.4
Hamilton Rating Scale for Depression (HAM-D) (Hamilton, 1960) is a 21 item 
clinical interview measure of depression, and also an indication of recovery (see 
appendix 15).  Patients are rated with a score of 0-2 or 0-4 per question.  Scores are 
totaled and an overall score of 0-7 is considered to be normal. Scores 8-13 = mild 
depression, 14-18 = moderate depression, 19–22= severe depression. > 23= Very 
severe depression.  The questionnaire has been found to be a reliable and valid self-
report measure of the severity of depression (Reynolds and Kobak, 1995) and 
validity included content, criterion, construct, and clinical efficacy. 
 Leeds Sleep Evaluation Questionnaire  (LSEQ) 3.3.4.5
Leeds sleep evaluation questionnaire (LSEQ) (Parrott and Hindmarch, 1980) is 
a standardized self-reporting instrument comprising ten 80mm visual analogue 
scales that measure the ease of getting to sleep (GTS), quality of sleep (QOS), ease 
of awakening from sleep (AFS) and alertness and behaviour following wakefulness 
(BFW) (see appendix 16). The questionnaire is used to monitor subjectively 
perceived sleep changes during psychopharmacological investigations. Scores are 
totalled and compared to determine any improvement in sleep behaviour.  Tarrasch 
et al. (2003) evaluated the LSEQ  and found the questionnaire had reliability, 
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construct validity and internal consistency and the participants found it was easier 
to evaluate their sleep visually than answering questions. 
 Liebowitz Social Anxiety Scale (LSA) 3.3.4.6
Liebowitz Social Anxiety Scale (LSA) (Liebowitz, 1987) is a short questionnaire 
developed to assist in the diagnosis of social anxiety disorder (see appendix 17). The 
scale is comprised of 24 items divided into 2 subscales, 13 measure performance 
anxiety and 11 measure the response social situations. The 24 items are first rated 
on a Likert Scale from 0 to 3 on fear (anxiety) felt during the situations, and the 
same items are rated 0-3 regarding avoidance of the situation. Adding and 
combining the total scores for the Fear and Avoidance sections provides an overall 
score with a maximum of 144 points.  Scores and anxiety are divided by 4 cut-off 
points.  Scores up to 30 considers social anxiety disorder (SAD) to be unlikely. Scores 
up to 60 is an indication that SAD is probable. Scores between 60 and 90 indicate 
that SAD is very probable. Scores higher than 90 indicate that SAD is highly 
probable.  Heimberg et al. (1999) investigated the reliability, validity and treatment 
sensitivity of the LSAS using a sample of 382 patients and found the scale had 
internal consistency. The convergent validity was supported through significant 
correlations with other commonly-used measures of social anxiety and avoidance. 
 “Reading the Mind in the Eyes” Questionnaire (RtM) 3.3.4.7
Reading the Mind in the Eyes (RtM) (Baron-Cohen et al., 2001) questionnaire 
consists of 36 (plus 1 practice) grey-scale pictures of the area around the eyes (see 
appendix 18).  Each photo is surrounded by four mental state terms, for example 
jealous, panicked, arrogant and hateful.  The participant is instructed to choose the 
word that best describes what the person in the photo is thinking.  The 
questionnaire is designed to measure a person’s Theory of Mind; the ability to 
attribute mental states to another person and an indication of social intelligence 
and social perception (Baron-Cohen et al., 2001).  Responses are marked as correct 
or incorrect and the scores are totalled. The average score, and an indication of 
average Theory of Mind, is 26. RtM studies have confirmed its validity with internal 
consistency and test-retest stability and applicable cross-culturally (Vellante et al., 
2013). 
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 World Health Organisation questionnaire Quality of Life revised (WHOQOL) 3.3.4.8
The WHOQOL-BREF instrument, a shorter version of the original instrument, 
comprises 26 items, which measures an individual’s perception of their physical 
health, psychological health, social relationships, and their environment (see 
appendix 19). The WHOQOL-BREF is used in research studies or clinical trials as a 
measure of an improvement in quality of life following an intervention.  The 
questionnaire has been found to be a useful tool for measuring overall quality of life 
among opioid substitution therapy patients (Feelemyer et al., 2014).  The scores are 
totalled and used as a comparison to determine any improvement to subjective 
quality of life. 
 Actigraphy 3.3.4.9
Actigraphy is a non-invasive method of monitoring human rest/activity cycles.  
A small actigraph, designed to be worn on the wrist like a watch, continually records 
movements of the user.  They are useful for determining sleep patterns, sleep/wake 
behaviour and circadian rhythms. The unit can be worn for several weeks and the 
data is later read to a computer and analysed, and as such can monitor sleep 
disorders common in substance abuse, such as insomnia, excessive sleepiness and 
restless leg syndrome. (Sadeh, 2011) confirm the validity and reliability of using 
actigraphy to monitor activity-based sleep-wake behaviour, however the researcher 
recommends using complementary assessment methods whenever possible.  In this 
trial participants were also required to complete the Leeds Sleep Evaluation 
Questionnaire (see appendix 16) as well complete a Sleep Diary on a daily basis (see 
appendix 11) to ensure validity of the actigraphy data. 
 Medicinal Products : Syntocinon (oxytocin) (IMP) and Placebo 3.3.4.10
The intranasal oxytocin spray (Syntocinon Spray) was the Investigative 
Medicinal Product (IMP).  The IMP comprised 40 IU/ml, 5 ml and was produced by 
Novartis in Switzerland (Swiss Medic Admissions number 25644).  The IMP was 
imported by Mawdsley-Brooks & Co Ltd, Quest Park, Silk Road, Off Wheatley Road, 
Doncaster, DN2 4LT, verified and certified through a Qualified Person (QP) and 
released to the NHS Pharmacy, Farnham Road, Guildford.  Mawdsley-Brooks & Co 
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Ltd hold Manufacturing and Importers Authorisation MIA [authorisation number 
741] for such required activities.  
The placebo control was normal saline (5ml Sodium Chloride 0.9% for 
Injection) manufactured by Mini-Plasco brand from B Braun.  This was standard NHS 
pharmacy stock and readily available. 
The dispensing and labelling of the IMP and placebo into intransal spray 
bottles and assembly with the pump and actuator was done by Surrey and Borders 
Partnership NHS Foundation Trust Pharmacy, under the instructions given by Surrey 
CRC, to ensure blinding of the study.  6 insufflations (24 IU Oxytocin total or 
placebo) were given twice daily (between 9h00-11h00 am and 16h00-18h00 pm) for 
up to 14 days, self-administered. The labelling had been approved by the MHRA 
(see appendix 20) and the spray bottles, pump and atcuators met with GCP and 
MHRA requirements. 
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Figure 3.2    Timeline of Trial from admission into Windmill House to end of Trial.  
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 Procedure 3.3.5
The trial procedure comprised participant screening, baseline measures, 14 
intranasal spray treatment days, a post study safety assessment and a post 
treatment assessment approximately 30 days after discharge from WMH (see Fig 
3.3 for a timeline) 
During this period there were 6 visits where participant assessments were 
completed;  
Visit 1 was a screening assessment 
Visit 2 was baseline psychological assessments as outlined above (section 
3.3.4) 
Visit 3 was day 1 of intranasal spray treatment (oxytocin / placebo) 
Visit 4 was day 2 of intranasal treatment and psychological assessments  
Visit 5 was day 14 of intranasal treatment and psychological assessments  
Visit 6 was post treatment psychological assessments and carried out 
approximately 30 days after discharge. 
The procedure, as per research protocol (appendix 21), is outlined in detail below; 
 As an overview; opioid dependent individuals were referred to Windmill 
House for a methadone or buprenorphine withdrawal and detoxification regime, 
which usually takes up to two weeks.  Once detoxified and no longer taking part in a 
methadone or buprenorphine detox regime, patients then undertake a four week 
week structured detoxification relapse prevention therapy programme, and remain 
living at WMH. It is during this period that patients are invited to enroll onto the 14 
day pilot CTRIMP, following consent and screening.  
 Prior to enrolment onto pilot CTIMP 3.3.5.1
 Upon admittance to WMH for withdrawal and detoxification, patients 
underwent standard NHS medical assessments and clinical tests which include 
drug/alcohol testing.  Patient records were updated with blood pressure readings, 
heart rate and body temperature.  These readings were recorded in patient files 
every morning.  Records also confirmed height and weight.  Clinical testing 
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urinalysis was carried out to screen for any infections including kidney disease, liver 
problems or diabetes.  Urinalysis was also used to screen for drugs or alcohol. 
Females were tested for pregnancy, if appropriate.  Patient records were also 
updated with any mental health disorders and any medications, such as 
antidepressants, anxiolytics or antipsychotic medications.  All these records were 
made available to the Principal Investigator (PI) and researcher of the pilot trial as a 
pre-screening assessment for suitability to undertake the pilot trial upon 
completion of their withdrawal and detoxification regime. 
 Patients newly admitted to WMH were informed about the pilot trial and 
given a participant information sheet to read.  Advertising regarding the CTIMP was 
available on notice boards in WMH and the researcher and PI were available for 
questions during their two week detoxification regime. 
 Screening (Visit 1) 3.3.5.2
Upon completion of their detoxification regime, patients were then enrolled 
onto a four week rehabilitation and relapse prevention programme. Pre-screened 
opioid dependent individuals were approached about their willingness to enrol onto 
the pilot trial. Willing patients were required to re-read the participant information 
sheet, given the opportunity to ask any questions and required to sign the consent 
form.  The consent form was held on the patient file and a copy was given to the 
patient.  The PI and researcher assessed the medical notes to ensure the participant 
was medically sound and met with the study inclusion and exclusion criteria (see 
section 3.3.2.1 & 3.3.2.2.).  Patients who were deemed suitable for the trial were 
then allocated a randomisation number received from NHS pharmacy, as per 
pharmacy SOP.  The screening workbook was completed and signed by the PI.  The 
researcher completed the stickers and attached to patient file highlighting that the 
patient was undergoing a clinical trial and providing contact details in the event of 
serious adverse event (SAE).  The patient was given an actigraphy unit (watch), with 
instructions and asked to start wearing the device immediately.  The patient was 
invited to attend the baseline visit and an appointment was arranged.  A 
prescription requesting nasal spray was completed by the PI and a delivery schedule 
was completed by the researcher. These were faxed to pharmacy for dispensing 
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according to their randomisation list and delivery was arranged on the pharmacy-
hospital delivery run. All staff at WMH were notified both verbally and via the 
patient information board that the patient was taking part in the CTIMP. 
 Baseline (Visit 2)  3.3.5.3
This visit took place not longer than two days following completion of 
detoxification. The participant arrived at the clinic room for the appointment with 
the researcher, between 09h00-11h00.   
The medical status, adverse events, prior and/or concomitant medications 
were reviewed and vital signs were noted from patient clinic notes, which had been 
completed by the physician that morning, prior to the appointment.  The actigraphy 
watch was checked for comfort and functioning. This process happened at every 
appointment, throughout the trial  
The researcher outlined the procedure of completing the Sleep Diary every 
morning throughout the trial and asked the participant to complete the Sleep Diary 
questionnaire. Completing the Sleep Diary happened at every morning appointment, 
between 09h00-11h00, throughout the trial.   
The participant was asked to return to the clinic or investigation/resources 
room for further baseline measurements between 16h00-18h00.  
Between 16h00 and 18h00 the participant arrived for the second appoint and 
the researcher outlined the procedure of completing the Self-Assessment (SA) and 
Subjective Opiate Withdrawal Symptoms (SOWS) and asked the participant to 
complete the questionnaires. Completing the SA and SOWS happened at every 
afternoon appointment, between 16h00-18h00, 50 minutes after treatment, 
throughout the trial.  
Approximately 50 minutes later the participant completed the psychological 
assessments. These were HAM-D, HAM-A, LSEQ, LSA, RtM and WHOQOL, as 
described in section 3.2.3.  
The workbook was completed and signed by the researcher and quality 
checked by a staff member who was certified as per good clinical practice (GCP). 
This happened at each visit.  
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 Treatment day 1 (Visit 3) 3.3.5.4
This visit took place not longer than three days from completion of 
detoxification.  The participant arrived at the clinic room between 09h00-11h00 for 
their first intranasal treatment.  The intranasal spray bottle was removed from the 
locked patient’s medicine box by a WMH clinical staff member (this happened at 
every appointment) and the researcher instructed the participant in the correct 
intranasal self-administration technique and observed the administration. The 
participant handed the bottle back to the researcher and the nasal component was 
wiped clean and the bottle was securely placed within the patient medicines box, 
(this happened at every appointment). The participant was asked to return to the 
clinic room between 16h00-18h00 for the second appointment. This concluded the 
visit and the workbook was completed and signed by the researcher and quality 
checked and signed by site staff.   
The participant returned to the clinic room between 16h00-18h00 for the 
second nasal spray dosage of the day.  Any adverse events were noted since the 
previous spray administration. The intranasal spray bottle removed from the locked 
patient’s medicine box and the researcher observed the administration. The 
participant handed the bottle back to the researcher and the nasal component was 
wiped clean and the bottle was securely placed within the patient medicines box.  
The workbook was completed and signed by the researcher and quality checked 
and signed by the attending site staff.   
50 minutes later the participant returned to the resources/interview room 
and completed the Self-Assessment and Subjective Opiate Withdrawal Symptoms 
(SOWS).  The researcher completed the treatment workbook and signed it.  
 Treatment day 2 (Visit 4) 3.3.5.5
The procedure for treatment day 2 was a repeat of treatment day 1, with a 
morning visit and an afternoon visit to the clinic room for administration of nasal 
spray.   
50 minutes after the afternoon visit the participant returned to the 
resources/interview room and as well as completing the Self-Assessment (SA) and 
Subjective Opiate Withdrawal Symptoms (SOWS), completed the psychological 
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assessments during this visit.  These were HAM-D, HAM-A, LSEQ, LSA, RtM as 
described in section 3.2.3. Participants did not complete the World Health 
Organisation Quality of Life Questionnaire  
 Treatment days 3-13 3.3.5.6
The procedure for treatment days 3-13 were the same as the procedure for 
treatment day 1, with two visits to the clinic room for administration of nasal spray. 
The sleep diary was completed at the morning visit.  SA and SOWS was completed 
50 minutes after the afternoon nasal administration. 
 Treatment day 14 (Visit 5)  3.3.5.7
The procedure for day 14 was a repeat of treatment day 2, with two visits to the 
treatment room for administration of nasal spray.  The sleep diary was completed 
at the morning visit.  SA and SOWS as well as the psychological assessments; HAM-
D, HAM-A, LSEQ, LSA, RtM and WHOQOL, as described in section 3.2.3, were 
completed 50 minutes after the afternoon administration.  
Participants also handed over the actigraphy unit (watch) and any outstanding 
paperwork.  
 No participants reached this stage of the trial.   
 
 Post study safety assessment  3.3.5.8
 A safety assessment was required for each participant following last intranasal 
treatment and/or prior to being released from WMH.  This formed part of the 
workbook and participants were invited to an appointment in the 
resources/interview room.  The medical status, adverse events, prior and/or 
concomitant medications were reviewed and vital signs were noted from patient 
clinic notes, which had been completed by the physician prior to the appointment. 
 Any urinalysis data was also captured.  
 Should the participant have completed the CTIMP, they would continue to 
self-assess their mood and sleep until the post treatment assessment 
(approximately 30 days later) and as such, would be provided with a SA diary and 
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sleep diary, to be completed for 30 days.  Arrangements for the post assessment 
meeting would be arranged.  No participants reached this stage. 
 Post-treatment assessment (Visit 6) 3.3.5.9
As per study procedures manual, a 30-35 day follow up assessment was 
required.  Participants could return to WMH or any other NHS Surrey and Borders 
Partnership Trust service centre.  Participants would complete the psychological 
assessments; HAM-D, HAM-A, LSEQ, LSA, RtM and WHOQOL, as described in section 
3.2.3.  Participants were also submit their daily sleep diaries and self-assessment 
questionnaires.    
No participants reached this stage of the trial.  
 Analysis 3.3.6
There was minimal data available for analysis.  Two participants were 
admitted onto the trial and nil completed the trial.  As such it was not possible to do 
any statistical analysis based on n=2 and therefore there is no means, standard 
deviations or ANOVA calculations.  
The actigraphy data was downloaded and analysed using Actiwatch Activity 
and Sleep Analysis, Cambridge Neurotechnology version 7.23.  Participant 002 did 
not wear his actiwatch during the trial and the actiwatch readings indicated this and 
so there is no data for this participant.  
Following the unblinding procedure, the randomisation list showed that both 
participants were subjected to oxytocin nasal spray and as such there was no 
opportunity to compare any treatment effect of oxytocin to a placebo effect. 
3.4 Results 
Two patients were admitted onto the trial, 1 male (age: 48) and 1 female (age: 
33).  As per research protocol exclusion criteria, neither participant was taking 
antidepressants or anxiolytics during the trial.  Also, according to WMH records and 
NHS patient files, neither participant presented with mental illness on admission 
(see Table 3.2).  Both were administered oxytocin nasal spray.  Based on n=2, there 
is no means, standard deviations or ANOVA calculations. There was actigraphy data 
readings for participant 001. 
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Participant 001 attended visit 1 (screening) visit 2 (baseline), visit 3 (treatment 
day 1) visit 4 (treatment day 2).  She then self-discharged.   
Participant 002 attended visit 1 (screening) visit 2 (baseline), visit 3 (treatment 
day 1) visit 4 (treatment day 2) and two further treatment days. He was then 
discharged from WMH (not due to relapse).  
As such both participants completed psychological questionnaires and self-
assessments (SA).  Participant 001 completed psychological questionnaires at visit 2 
(baseline) and at visit 4 (treatment day 2) as well as self-assessment (SA) questions, 
sleep diary and SOWS every day.  She received 2 treatment days of oxytocin.  This 
totalled four treatments of nasal spray; 6 insufflations per treatment.  
Participant 002 completed psychological questionnaires at visit 2 (baseline) 
and at visit 4 (treatment day 2) and self-assessment (SA) questions, sleep diary and 
SOWS every day.  He received 4 treatment days of oxytocin.  This totalled eight 
treatments of nasal spray; 6 insufflations per treatment.  
The scores and results of the questionnaires and self-assessments fell into the 
5 main categories: (1) depression and mood, (2) anxiety and state of mind, (3) 
sociability, (4) subjective opioid withdrawal symptoms and (5) sleep.  The raw data 
can be found in Tables 3.2 and 3.3 below. Actigraph readings can be found in fig 3.3 
below.  
(Graphical representation of the data, and commentary, can be found in 
appendix 22.) 
Participant 001 (F, age: 33) 
(1) Depression and low mood 
Baseline scores (Visit 2) showed that participant 001 presented with 
depression and low mood following withdrawal and detoxification treatment and 
before she started intranasal oxytocin treatment.  This was seen in the HAM-
depression score: 29 (very severe) and the SA question 2, Mood: 30 (low mood and 
feelings of depression)  
(2) Anxiety and state of mind 
Participant 001 also presented with anxiety following detoxification 
treatment, as seen in HAM-Anxiety: 27 (severe) and SA question 1, Mind: 41 
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(increased anxiety).  She presented with very probable Social Anxiety Disorder, as 
measured on the LSA: 79.    
(3) Sociability 
Participant 001 was comfortable with working in small groups as seen in SA 
question 6: 2 (comfortable) and she scored an average Theory of Mind score: 30. 
She did have decreased feelings of trustworthiness as measured on SA question 3: 5 
and increased feelings of hostility: SA question 4: 6 and her response to SA question 
5, socialising: 8 indicated decreased feelings of sociability. 
(4) Subjective Withdrawal Symptoms 
 Participant 001 scored on the high end of moderate withdrawal symptoms 
following detoxification treatment,  as measured on the SA withdrawal symptoms 
question: 13 and SOWS: 30. 
(5)  Sleep  
Following detoxification treatment and prior to any OT nasal spray, the Leeds Sleep 
Evaluation Questionnaire (LSEQ) showed that participant 001 rated her ability to get 
to sleep (GTS) as “quicker and easier than usual” and her quality of sleep (QOS) was 
“more restful than usual”, with average periods of wakefulness.  She rated that 
awakening was quicker and easier than usual although she rated herself as more 
clumsy than usual.  
Baseline (day 0) sleep diary records that she went to bed at 00h30 and tried to 
sleep one hour later.  She did not record how long it took to fall asleep but noted 
that she woke once at 04h45 and got up at 08h30.  She describes this as not a 
typical night, would have slept longer if permitted and rated her sleep quality as 6 
on a scale of 1-9 (9=worst ever).   
The actigraphy readings, marked as red, show excessive movements between 
00h00 and approximately 03h00.  Between approximately 03h00 and 05h30 there 
was very little movement, an indication of rest and possible sleep.  
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Following 2 treatment days (4 oxytocin intranasal administrations) the 
assessment scores were as follows; 
(1) Depression and low mood 
Both Ham-depression score: 19 (severe) and SA question2, Mood: 24 (normal) 
were reduced and both indicate improved mood and decreased depression 
responses for Participant 001.  
(2) Anxiety and state of mind 
HAM-Anxiety: 17 (mild) and SA question 1, Mind: 34 (normal-moderate) both 
indicate reduced feelings of anxiety. Her scores measured on the LSA: 78 indicated 
that she was still probably suffering from SAD. 
(3) Sociability 
Sociability scores for Participant 001 were relatively unchanged from baseline. 
She continued to have decreased feelings of sociability; SA question 5, socialising: 9 
and remained comfortable with working in small groups; SA question 6: 1.  Her 
score for Theory of Mind remained average: 31. She had increased feelings of 
trustworthiness in others; SA question 3: 1, and no change to the scaled feelings of 
hostility: SA question 4: 5.   
(4) Subjective Withdrawal Symptoms 
Participant 001 remained on the high end of moderate withdrawal symptoms; 
SA withdrawal symptoms question: 12.  The SOWS indicated a decrease in 
withdrawal symptoms: 14 (mild). 
(5) Sleep  
Participant 001 self-discharged during the early hours of the morning of treatment 
day 3 and therefore did not complete a sleep diary for the night following treatment 
day 2.  
She did, however, complete sleep questionnaires following treatment day 1, 
following 2 x spray treatments of oxytocin.  According to the Leeds Sleep Evaluation 
Questionnaire (LSEQ), participant 001 rated her ability to get to sleep (GTS) as 
quicker and easier compared to her previous assessment. Her quality of sleep 
(QOS), however, had deteriorated, as well as her ease of waking (EOW).  She rated 
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her feelings on waking (FOW) as negative and she continued to rate herself as more 
clumsy than usual.   
Her sleep diary reflected that she had gone to bed at about the same time as 
her previous assessment. She recalled falling asleep immediately and again, woke 
up once during the night, in the early hours of the morning (05h00).  She got up one 
hour later (06h00) allowing for more than 6 hours sleep.  She rated this as not a 
typical night and again rated her sleep quality as below average: 6. (0-9; worst ever) 
This was reflected in the actigraphy data (marked green). Following excessive 
movement until a little after 23h00, there was almost no movement until a little 
before 06h00 and an indication of rest and possible sleep.  
As pointed out above, this participant self-discharged early on treatment day 
3 and didn’t complete any sleep diary entries for the night of treatment day 2. She 
did, however, wear the actigraphy unit (watch) up until she left WMH, so we are 
able to capture her sleep behaviour following a second treatment of oxytocin (2x a 
day) marked as yellow. The actigraphy readings indicate excessive movements 
throughout the rest of the night, except for a still period between 03h00 and 04h00.  
As there was little to no periods of inactivity during the night, it would suggest that 
participant 002 had little to no sleep and the readings show a very restless night 
before she self-discharged.  
The raw data for this participant can be found in Table 3.2.  
The actigraphy data for this participant can be seen in fig 3.3. 
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Participant 002 (M, age: 48) 
(1) Depression and low mood 
Baseline scores (Visit 2) showed that participant 002 presented with some 
depression and low mood following withdrawal and detoxification treatment, and 
before he started intranasal oxytocin treatment. This was seen in the HAM-
depression score: 16 (moderate) and the SA question 2, Mood: 14 (normal). 
(2) Anxiety and state of mind 
Participant 002 presented with mild-moderate anxiety following withdrawal 
and detoxification treatment, as seen in HAM-Anxiety: 17 (mild) and SA question 1, 
Mind: 27 (normal-moderate). Participant 002 presented as unlikely to suffer from 
Social Anxiety Disorder, as measured on the LSA: 8.  
(3) Sociability 
 Participant 002 responded feeling uncomfortable in small group activities; SA 
question 6: 9 (uncomfortable). This was reflected in his response to SA question 5, 
socialising: 1.   He scored an average Theory of Mind score: 29.  He did have 
decreased feelings of trustworthiness; SA question 3: 9 but no feelings of hostility: 
SA question 4:4.  His responses to SA question 5, socialising: 1 indicated feelings of 
sociability.  
(4) Subjective Withdrawal Symptoms 
Participant 002 presented with reduced withdrawal symptoms on the SA 
withdrawal symptoms question: 8 although SOWS: 33 indicated extreme 
withdrawal symptoms. 
(5)  Sleep  
Participant 002 did not complete any baseline LSEQ, nor did he wear his 
actigraphy watch.  
His baseline (day 0) sleep diary records that this participant went to bed at 
00h00, attempted to sleep immediately and he indicated that it took him 2 minutes 
to fall asleep.  Participant 002 was unable to recall waking in the night.  He woke up 
at 05h37 and got up at 06h00.  He described this as not a typical night, he could 
have slept longer and that quality of sleep was very good (2). 
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Following 2 treatment days (4 oxytocin intranasal administrations) the assessment 
scores were as follows; 
(1) Depression and low mood 
There was no change to feelings of low mood and depression. Ham-
depression score: 16 (moderate) and SA question 2, Mood: 15 (normal).  
(2) Anxiety and state of mind 
HAM-Anxiety: 13 (mild) and SA question 1, Mind: 20 (normal-moderate) both 
indicate reduced feelings of anxiety. He remained unlikely to suffer from SAD; LSA: 
7.  
(3) Sociability 
Participant 002 reported decreased feelings of sociability compared to 
baseline; SA question 5, socialising: 6.   He had increased feelings of comfort around 
small group activities SA question 6: 4.  His Theory of Mind was improved: 29.  He 
remained untrustworthy of others as indicated on SA question 3: 7 and had 
increased feelings of hostility SA question 4: 6.  
(4) Subjective Withdrawal Symptoms 
 Participant 002 continued to present with reduced symptoms of withdrawal 
on the SA withdrawal question : 12, although these were increased from baseline.  
He continued to score extreme on withdrawal symptoms on SOWS: 39. 
(5) Sleep  
Participant 002 was discharged on day 5 and therefore did not complete a sleep 
diary for the night following treatment day 4. 
 He did, however, complete his sleep diary on the mornings of treatment 1-3, 
following 2x day intranasal oxytocin treatment and we are able to capture his sleep 
behaviour.   
 Following treatment day 1 (2 oxytocin intranasal administrations) participant 
002 diarised that he went to bed at 23h30 and went to sleep immediately.  He 
awoke 4 times in the night and noted that he was cold due to night sweats for each 
of these occasions.  He woke up in the morning at 06h00 due to being cold and also 
noise disturbance and got up at 06h00. He did not rate how typical the night was 
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but did indicate that he would have slept longer if permitted.   He rated the quality 
of sleep as good (3).  
 After treatment day 2 (2 oxytocin intranasal administrations) participant 002 
diarised that he went to bed at 22:45 and fell asleep immediately.  He noted that he 
woke up once in the night (04h00) due to night sweats.  He turned the lights on at 
05h00 and got up.  He rated this as a typical night, would have slept longer if 
permitted and that this was the worst quality of sleep (9). 
 After treatment day 3 (2 oxytocin intranasal administrations) participant 002 
diarised that he went to bed at 00h00 and fell asleep immediately. I woke once in 
the night due to night sweats and feeling cold.  He awoke in the morning at 05h20 
due to noise and got up at 06h00.  He described this as not a typical night, would 
have slept longer if permitted and the quality of sleep was the best ever (1).  
The raw data for this participant can be found in Table 3.3.  
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Table 3.2:  Results and scores from questionnaires and assessments for participant 001  
Sleep Questionnaire and Sleep Diary -1  0 Treat Day 1 
(2 x spray treat; 
am & pm) 
Treat Day 2 
(2 x spray treat; 
am & pm) 
Scoring Scales 
LSEQ -Getting To Sleep (GTS) (in mm) 37 n/a 28 Not completed 0 (positive) -  240 (negative) 
LSEQ - Quality of Sleep (QOS) (in mm)  101 n/a 72 Not completed 0 (negative) - 160 (positive) 
LSEQ - Ease of Waking (EOW) (in mm) 9 n/a 61 Not completed 0 (positive) -  160 (negative) 
LSEQ – Feeling on Waking (FOW)   (in mm) Not completed  n/a 68 Not completed 0 (positive) – 80 (negative) 
LSEQ - Sleep Behaviour (SB) (in mm) 76 n/a 77 Not completed 0 (positive) – 80 (negative) 
Sleep Diary:   
What time did you go to bed (hh:mm)? 22h30 00h30 22:45 Not completed  
At what time did you try to sleep (hh:mm)? 23h45 01h30 22h45 Not completed  
How long did it take you to fall asleep (mins)? 1 Not completed 0 Not completed  
How many times did you wake up (night)? 1 1 1 Not completed  
How long were you awake for (mins)?  Not completed Not completed Not completed Not completed  
What time did you wake up (hh:mm)? 02h00 04h45 05h00 Not completed  
What time did you turn the light on (hh:mm)? 08h00 Not completed 06h00 Not completed  
What time did you get up (hh:mm)? 08h30 08h30 06h00 Not completed  
Would you describe this as a typical night? No No No Not completed  
If permitted, could you have slept longer Yes Yes Yes Not completed  
Sleep quality 6 6 6 Not completed 1=best ever;  9=worst ever 
 
 
     
Psychological Questionnaires  Baseline Day 1 
(2 x spray treat; 
am & pm) 
Day 2 
(2 x spray treat; 
am & pm) 
 
Scoring Scales 
Leibowitz Social Fear  41 n/a 41 0 = none; 72 = severe 
Leibowitz Social Avoidance  38 n/a 37 0 = none; 72= severe  
Leibowitz Social Anxiety Scale (LSAS) Total  79 n/a 78 0-30 = SAD unlikely; 31-60= SAD probable; 61-90= SAD very probable; 
91+= SAD highly probable  
Read Mind Eyes  30 n/a 31 Average social intelligence & social perception = 26 
HAM-Depression  29 n/a 19 0-7= normal; 8-13= mild; 14-18= moderate, 19–22= severe > 23= Very 
severe  
HAM-Anxiety  27 n/a 17 0-17= mild; 18-24= mild to moderate; 25+ = severe 
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 Abbreviations: n/a: not applicable (Participants were not required to complete the tests on these days);  LSEQ : Leeds Sleep Evaluation Questionnaire; LSAS: Lievowitz 
Social Anxiety Scale; SAD: Social Anxiety Disorder; HAM-D: Hamiltons Depression Questionnaire; HAM-A: Hamiltons Anxiety Questionnaire; WHOQOL: World Health 
Organisation Quality of Life questionnaire; SA: Self Assessment; SOWS: Subjective Opioid Withdrawal Symptom Questionnaire. 
WHOQOL  47 n/a n/a Not applicable 
SA 1 : Mind  41 25 34 1-34 = normal-moderate anxiety; 35+ = increased anxiety 
SA 2 : Mood  30 22 24 1-24 = normal mood; 25+ = low mood and feelings of depression. 
SA 3 : Trustworthiness  5 3 1 1-4 = high feelings of trustworthiness in others; 5-9 = decreased 
trustworthiness 
SA 4 : Hostility  6 2 5 1-4 = No feelings of hostility; 5-9= increased feelings of hostility 
SA 5 : Socialising  8 8 9 1-4 = feelings of sociability; 5-9 = decreased feelings of sociability  
SA 6 : Small group activities  2 7 1 1-4= comfortable in small group activities; 5-9= uncomfortable in small 
group activities 
SA W/D : Withdrawal Symptoms  13 5 12 0-14= reduced symptoms of withdrawal; 15+ =increased withdrawal 
symptoms 
SOWS Withdrawal Symptoms  30 5 14 0-15 = mild; 16-30 = moderate; 31-60 = extreme  
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Table 3.3:  Results and scores from questionnaires and assessments for participant 002 
Sleep Questionnaire and Sleep Diary -1 0 Day 1 
(2x spray 
treat) 
Day 2 
(2x spray 
treat) 
Day 3 
(2x spray 
treat) 
Day 4 
(2x spray 
treat) 
Scoring Scales 
LSEQ - Getting To Sleep (GTS)  (in mm) Not completed n/a 95 n/a n/a  0 (positive) -  240 (negative) 
LSEQ - Quality of Sleep (QOS)  (in mm) Not completed n/a 137 n/a n/a  0 (negative) - 160 (positive) 
LSEQ - Ease of Waking (EOW) (in mm) Not completed n/a 6 n/a n/a  0 (positive) -  160 (negative) 
LSEQ – Feeling on Waking (FOW)  (in mm) Not completed n/a 3 n/a n/a  0 (positive) – 80 (negative) 
LSEQ - Sleep Behaviour (SB)  (in mm) Not completed n/a 19 n/a n/a  0 (positive) – 80 (negative) 
Sleep diary :   
What time did you go to bed (hh:mm)?  00h00 23h30 22h45 00h00   
At what time did you try to sleep (hh:mm)?  00h00 23h30 22h45 00h00   
How long did it take you to fall asleep (mins)?  2 0 0 0   
How many times did you wake up (night)?  Not completed 4 1 1   
How long were you awake for (mins)?  Not completed Unknown Not 
completed 
Not 
completed  
  
What time did you wake up (hh:mm)?  05h37 05h45 n/c 05h20   
What time did you turn the light on (hh:mm)?  Not completed 06h00 05h00 
 
Not 
completed 
  
What time did you get up (hh:mm)?  06h00 06h00 05h00 06h00   
Would you describe this as a typical night?  No Not 
completed 
Yes No   
If permitted, could you have slept longer  Yes Yes Yes Yes   
Sleep quality  2 3 9 1  1=best ever;  9=worst ever 
        
 
Psychological Questionnaires -1 Baseline Day 1 
(2x spray 
treat) 
Day 2 
(2x spray 
treat) 
Day 3 
(2x spray 
treat) 
Day 4 
(2x spray 
treat) 
Scoring Scales 
Leibowitz Social Fear  5 n/a 6 n/a n/a 0 = none; 72 = severe 
Leibowitz Social Avoidance  3 n/a 1 n/a n/a 0 = none; 72= severe  
Leibowitz Social Anxiety Scale (LSAS) Total  8 n/a 7 n/a n/a 0-30 = SAD unlikely; 31-60= SAD probable; 61-90= SAD very probable; 91+= 
SAD highly probable  
Read Mind Eyes  26 n/a 29 n/a n/a Average social intelligence & social perception = 26 
HAM-Depression  16 n/a 16 n/a n/a 0-7= normal; 8-13= mild; 14-18= moderate, 19–22= severe > 23= Very 
severe  
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HAM-Anxiety   17 n/a 13 n/a n/a 0-17= mild; 18-24= mild to moderate; 25+ = severe 
WHOQOL  88 n/a n/a n/a n/a Not applicable 
SA 1 : Mind  27 18 20 53 28 1-34 = normal-moderate anxiety; 35+ = increased anxiety 
SA 2 : Mood  14 13 15 15 18 1-24 = normal mood; 25+ = low mood and feelings of depression. 
SA 3 : Trustworthiness  9 4 7 2 4 1-4 = high feelings of trustworthiness in others; 5-9 = decreased 
trustworthiness 
SA 4 : Hostility  4 3 6 9 9 1-4 = No feelings of hostility; 5-9= increased feelings of hostility 
SA 5 : Socialising  1 3 6 9 3 1-4 = feelings of sociability; 5-9 = decreased feelings of sociability  
SA 6 : Small group activities  9 1 4 9 7 1-4= comfortable in small group activities; 5-9= uncomfortable in small 
group activities 
SA W/D : Withdrawal Symptoms  8 22 12 21 18 0-14= reduced symptoms of withdrawal; 15+ =increased withdrawal 
symptoms 
SOWS Withdrawal  Symptoms  33 39 39 40 16 0-15 = mild; 16-30 = moderate; 31-60 = extreme  
Abbreviations: n/a: not applicable (Participants were not required to complete the tests on these days);  LSEQ : Leeds Sleep Evaluation Questionnaire; LSAS: Liebowitz 
Social Anxiety Scale; SAD: Social Anxiety Disorder; HAM-D: Hamiltons Depression Questionnaire; HAM-A: Hamiltons Anxiety Questionnaire; WHOQOL: World Health 
Organisation Quality of Life questionnaire; SA: Self Assessment; SOWS: Subjective Opioid Withdrawal Symptom Questionnaire. 
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Fig 3.3. Participant 001 actigraphy readings, recorded by an actigraphy unit (watch) with hourly intervals. 
Periods of inactivity and no readings are an indication of resting and possible sleep. 
Red indicates baseline sleep/wake behaviour. There was excessive movement during the period of 0h00 and a  
approximately 03h00 followed by little/no movement until approximately 05h30.    
Green indicates sleep/wake behaviour following one treatment of oxytocin.  There was excessive movement until  
a little after 23h00.  There were long periods of inactivity until approximately 06h00 and an indication of rest 
and possible sleep. 
Yellow indicates sleep/wake behaviour following second treatment of oxytocin.  There were excessive movements  
throughout the night, with almost no indication of rest except for approximately 1 hour, between 03h00-04h00.  
The participant self-discharged that morning and handed the actigraphy watch to nursing staff.  
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3.5 Discussion 
The aim of this study was to provide important preliminary evidence of the 
efficacy of oxytocin in treating post-detoxified opioid dependent individuals, 
through a double blind placebo controlled pilot/phase II clinical trial (CTIMP). The 
primary objective of the trial was to investigate the effect of oxytocin in retaining 
post detoxified opioid dependent individuals in an inpatient residential 
rehabilitation programme and preventing relapse to opioid use.  The secondary 
objective of the trial was to investigate the efficacy in reducing opioid craving, 
anxiety, depression, social anxiety, sleep disturbances and in enhancing social 
cognition, quality of life in this specific population. To our knowledge this was the 
first study aimed to investigate both an acute and chronic effect of oxytocin, in this 
specific population, within the NHS, with the aim to prevent relapse following 
detoxification. 
As a phase II pilot study, this CTIMP also sought to assess the processes that 
would be key to the success of a phase III, main study. These processes included the 
time and resource issues that could occur in a main study, participant and any data 
management problems and the assessment of treatment safety as well as the 
eligibility criteria and practical application of the protocol design.  
Due to insufficient participants and no data statistical analysis, the study is 
likely to serve as a feasibility study and not a phase II pilot CTIMP (National Institute 
for Health Research (NIHR), 2015). As such, the study does not evaluate the 
outcome of interest, the primary outcome nor does it evaluate the secondary 
outcome, both of which are outlined above. 
With regards to results, we were unable to complete statistical analysis on 
n=2, however the data does provide some insight into the emotional impairments 
and subjective withdrawal symptoms experienced by detoxified opioid dependent 
individuals.  
According to WMH admittance records and NHS patient files, neither 
participant 001 nor participant 002 presented with mental illness when admitted to 
WMH for the withdrawal and detoxification treatment and neither were taking 
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prescription anti-depressants or anxiolytics, as per protocol exclusion criteria. After 
completing a withdrawal and detoxification treatment regime both participants 
presented with emotional impairments measured through the use of validated 
psychological assessments; increased scores measuring depression, anxiety, social 
anxiety, sociability, withdrawal symptoms as well as some impaired sleep 
behaviour.   
  Following treatment of oxytocin nasal spray, there was some change to these 
measures, although these changes need to be considered with caution as to any 
oxytocin treatment effect. 
Upon completion of an opioid withdrawal and detoxification treatment 
regime, baseline assessments [Visit 2] indicated that both participant 001 and 002 
presented with depression, (HAM-D and SA).  Participant 001 presented with severe 
depression (HAM-D) and low mood (SA).  Participant 002 presented with moderate 
depression (HAM-D) and normal mood (SA). Both participants presented with 
anxiety, (HAM-A and SA).  Participant 001 presented with severe anxiety (HAM-A) 
and increased anxiety (SA).  Participant 002 presented with mild-moderate anxiety 
(HAM-A) and (SA). For both participants, these anxiety assessments reflected the 
likelihood of suffering from Social Anxiety Disorder (SAD), as measured by Liebowitz 
Social Anxiety (LSA) questionnaire.  Participant 001 measured as very probable to be 
suffering from SAD and also highly uncomfortable with socialising, although she was 
comfortable with working in small groups (SA). Participant 002 measured as unlikely 
to suffer from SAD. He rated comfortable with socialising but uncomfortable with 
working in small groups (SA). Both participants scored average Theory of Mind 
scores as measured (RtM), indicating the ability to attribute mental states to 
another person and an indication of social ability. According to the SA questions, 
both participants presented with decreased feelings of trustworthiness towards 
others.  Participant 001 also had increased feelings of hostility while participant 002 
scored no feelings of hostility, although his score was on the boundary of increased 
feelings of hostility. Both participant 001 and 002 presented with withdrawal 
symptoms; participant 001 scored on the high end of moderate withdrawal 
symptoms (SOWS), as well as the SA withdrawal questions.  Participant 002 scored 
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extreme on SOWS and recorded reduced withdrawal symptoms on SA questions. 
Both participant 001 and 002 struggled with sleep and sleep disturbances 
throughout the trial.  
As discussed previously, mental illness and emotional impairments, 
depression and anxiety disorders, including SAD, are common in patients with 
substance use disorders, including opioid addiction, and these disorders present as 
risk factors for relapse following withdrawal from opioid use (Bradley et al., 1989, 
Nunes and Levin, 2004, Chalana et al., 2017, Sinha, 2008) These impairments are 
also correlated with sleep disorders (Wilson and Argyropoulos, 2005, Johnson et al., 
2006, Mahfoud et al., 2009), which further increase the risk of relapse. This CTIMP 
offers support to research findings that such impairments are as a consequence of 
opioid detoxification and withdrawal; post acute withdrawal syndrome (PAWS), and 
our participants presented with emotional impairments following their 
detoxification treatment.  
Research by Chalana et al. (2017), investigating the role of depressive 
symptoms following inpatient detoxification report similar findings.  Reporting no 
depression prior to treatment, a 1 year follow up study after detoxification 
treatment, comparing relapsed and non-relapsed groups found both groups had 
increased and significant depression scores, as measured by HAM-D.  The relapsed 
group scored almost double compared to the non-relapsed group. This would 
suggest that the depression scores were related to the withdrawal and 
detoxification treatment, such as our findings.  
It may be that some individuals have a mood (or anxiety) disorder that is 
independent of substance abuse so these impairments are not as a consequence of 
withdrawal, and this would need to be considered when looking to treat these 
individuals. Because both addiction and depression/anxiety disorders are common 
in the general population, it can be expected that some individuals will have both 
disorders by chance alone which present co-morbidly upon withdrawal from 
substances and will need to be treated together to prevent relapse.  
These arguments highlight the complexity of mental illness-opioid addiction 
comorbidity when looking to treat and maintain abstinence and justify research 
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such as ours, which aimed to address these complex co-morbid disorders and offer 
a potential novel treatment to prevent relapse.  
As well as emotional impairments of depression and anxiety, our results also 
gave some insight into the effects of withdrawal and detoxification on the 
interpersonal and sociability within this population, i.e. theory of mind (TOM), as 
measured by Reading the Mind in the Eyes (Baron-Cohen et al., 2001). A systematic 
mini-review in substance users reported that substance abuse is related to TOM 
deficits; impaired working memory, verbal fluency and executive functions, 
although opioids were not included in this review (Sanvicente-Vieira et al., 2016). 
Our results showed that both participants presented with an average ability to 
attribute mental states to another person following detoxification treatment.  This 
would suggest that both participants had the social ability as well as interpersonal 
skills to engage in social groups, however they both rated as experiencing decreased 
feelings of sociability (participant 001 measured as severe SAD) and decreased 
feelings of trustworthiness towards others was seen in both participants. 
This is important in light of psycho-social treatments such as CBT and support 
groups such as TSP; Narcotics Anonymous and Alcoholics Anonymous, as discussed 
in section 1.3.5.  As such our research into the anxiolytic, antidepressant and 
prosocial properties of oxytocin is warranted.  By attenuating the emotional 
impairments, detoxified opioid dependent individuals such as our participants, 
would be more likely to successfully engage in psycho-social support groups and 
benefit from social support (Hser, 2007)  
As well as reduced feelings of sociability following withdrawal and 
detoxification, our participants showed some increased feelings of hostility towards 
others measured on SA questionnaires (participant 002 scored on the boundary of 
increased hostility). Research by Powell and Taylor (1992) support our findings in 
their research of anger, depression and anxiety following heroin withdrawal. In their 
study residents in a detoxification programme expressed high levels of anger 
following treatment and within the following weeks and Powell and Taylor (1992) 
argue that detoxification treatment programmes should consider this outcome and 
include anger-management interventions within drug and alcohol treatment plans. 
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It is not surprising that participants present feelings of hostility and anger following 
detoxification, as these emotions are highly correlated with the physical symptoms 
of anxiety disorders, including SAD  (Deschenes et al., 2012).  
The scores in our CTIMP as well as the supporting evidence of Rowell and 
Taylor (1992) further justify research into the effects of OT in attenuating 
withdrawal symptoms following detoxification of opioids. As discussed earlier, brain 
OT is seen to increase sociability, trust, mood and coping with stress while reducing 
drug associated aggression and irritation as well as anxiety (Kirsch et al., 2005, 
Kosfeld et al., 2005a, Domes et al., 2007b, Slattery and Neumann, 2008) and this is 
likely to promote engagement in psycho-social therapies and support groups. 
While the results in our CTIMP need to be read with caution as to any OT 
effect, assessments completed by both participants on Visit 4, treatment day 2, and 
following a total of 4 intranasal treatment sprays (2 per day), showed some 
noticeable changes.  
 For participant 001, HAM-D and SA questions indicated an improved mood 
and decreased depression scores although there was no change for participant 002 
in these outcomes.  Both participants measured reduced feelings of anxiety as per 
HAM-A and SA questions. However, the LSA assessments and likelihood of SAD 
remained unchanged for both participants. Participant 001s feelings regarding 
socialising remained relatively unchanged from baseline.  This participant remained 
comfortable working in small groups and there were no changes to feelings of 
hostility. She did, however, have increased feelings of trustworthiness towards 
others. Participant 002 reported decreased feelings of sociability compared to his 
baseline however had increased feelings regarding working in small group activities.  
He remained untrustworthy of others and had increased feelings of hostility.  
With regards to withdrawal symptoms, as measured by Subjective Opioid 
Withdrawal Symptoms (SOWS) and Self Assessment (SA), both participants had 
presented with withdrawal symptoms at baseline.  Participant 001 had scored on 
the high end of moderate while participant 002 had scored extreme on SOWS but 
reduced symptoms on the SA questions.   On Visit 4, treatment day 2, and following 
a total of 4 intranasal treatment sprays (2 per day), these remained relatively the 
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same for both participants on both SA and SOWS, although participant 001 showed 
a slight decrease in the SOWS scores.  
Actigraphy data and the personal sleep diaries for this study suggests that 
sleep was disrupted for the period monitored for this study, with less movement 
seen by the actigraphy in the period following treatment oxytocin nasal spray for 
participant 001  The personal sleep diaries reflect a similar pattern. Pjrek et al. 
(2012) studied inpatients undergoing a tapered methadone/buprenorphine 
detoxification. The researchers reported found disrupted sleep and a decline in the 
rest-activity cycle.  Our actigraphy data and sleep diaries suggests a similar direction 
although it is not possible to determine any reliable sleep patterns and behaviour in 
such a short period of time and with such a small sample. 
Accounting for the above results and remarks, albeit with cautions, research 
into the treating emotional and social impairments following withdrawal and 
detoxification of opioids with the aim to prevent relapse is warranted.  Considering 
the literature, the focus on OT as a way of addressing and improving these 
emotional impairments is also justified.   
As feasibility study, this trial attempted to answer the question “can this study 
be done?” (National Institute for Health Research (NIHR), 2015). Due to n=2, we are 
unable to provide information about the efficacy of OT or how often the drug would 
need to be taken. We were able to show, in our n=2, that the IMP was both safe 
and without any adverse effects. At every intranasal treatment visit participants 
reported no adverse effects and their clinical notes prepared by both doctors and 
clinical staff reflected the same, showing that the nasal spray had no side effects.  
Participants also reported that the nasal pump and actuator system was easy to use 
in order to self-administer the drug and they reported no discomfort at use or after 
use. 
Participant sample size can be used to estimate critical parameters such as 
recruitment rate, which in this case, is an important factor as we failed to recruit 
sufficient participants within the time parameters allowed and this issue is 
addressed below. We were also able to identify other issues which would need to 
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be considered in order to carry out a successful pilot, phase II trial, which would in 
turn lead to a phase III clinical trial and these are discussed below. 
A detailed discussion on the barriers and key issues surrounding the setting up 
and running this CTIMP, in particular the complex and burdensome regulatory and 
governance environment, as well as a reflection on carrying out a CTIMP in this 
challenging population, within the NHS, are covered in chapter 4. Overall the 
onerous legislation, government regulations and governance processes, including 
the overregulation by the MHRA made the setting up and running of the trial a 
laborious task. Further challenges included reduced government funding for 
treatment resources, as well as research within addiction, and these are also 
discussed in chapter 4. 
As a feasibility study the procedures for this trial were found to be 
appropriate and executable. The pre-study baseline measures were fit for purpose 
and the treatment procedures were also easy to execute. The psychological 
assessments used to measure the emotional and social impairments, sleep 
disturbances and quality of life are all valid and reliable measures (as discussed in 
section 3.3.4) and were appropriate for use in further studies within this population.  
The Liebowitz Social Anxiety Scale (LSAS), as a short and easy to answer 
questionnaire, assessed the responses of the participants in range of social 
interactions and performance situations.  The questionnaire was able to identify the 
probability of social anxiety disorder and was also an effective measure of any 
change in the likelihood of social anxiety over time. Social anxiety is a common 
disorder among detoxified opioid addicts and as such appropriate as a measure for 
this trial. The Hamilton Rating Scales for Depression (HRSD) and Hamilton Anxiety 
Rating Scale (HARS) are both multiple item questionnaires used to provide an 
indication of depression and anxiety and also as a guide to evaluate recovery and 
are suitable for measuring any change following treatment. Both these 
questionnaires are completed in an interview style and comprise a number of 
questions. These assessments could usefully be extended in any future studies and 
would be valuable in providing further information and insight into patient 
experiences and the effects of oxytocin on these experiences. For our study, the 
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research protocol required that just the scores for the questionnaires were collated, 
and compared in order to show any significant differences. Some questionnaires, 
for instance, the HAM-D is also designed to allow for extra information and insight 
into the patient’s answers, through semi-structured type questioning. This 
methodology of data collection may give more insight into the experiences of 
maintaining abstinence, following withdrawal and detoxification as well as the 
experience of undertaking relapse prevention treatment and would give subjective 
insight into the effects of oxytocin. This would also identify further research 
questions for future investigation, allowing for the study to be both quantitative 
and qualitative in nature and allow for more comprehensive and better 
understanding of the effects of oxytocin.The researcher would, however, need to 
be trained to carry out qualitative style questionnaires in an interview style, in 
particular around sensitive topics. For example the HAM-D allows for discussion 
around feelings of guilt, low self-esteem and suicide as well as questions about 
thoughts and plans to hurt or kill self.  There are also some questions regarding any 
interest in sex and sexual activity. The answers to these questions would give insight 
into the effects of oxytocin on these thoughts and behaviours, which are seen to 
underpin social and emotional behaviours as well as impairments. 
Reading the Mind in the Eyes (RtM) is a measure of cognitive dysfuntions and 
any subtle individual differences in social sensitivity. The test was easy to execute, 
although it requires the participant to view 37 grey-scale pictures of the area 
around the eyes to determine which of four possible mental states apply to the 
picture. This was time consuming, however the participants reported enjoying the 
task. Social deficits are common in individuals who abuse substances (Kornreich et 
al., 2003a) and this is an appropriate test to measure any positive effects following 
administration of OT. The Leeds Sleep Evaluation Questionnaire (LSEQ) as a visual 
analogue scale was easy to use and a good measure of sleep impairments, a 
common issue within this population (Dimsdale et al., 2007) and also served as a 
validity measure of the actigraphy data and support for the sleep diaries.  The 
World Health Organisation Quality of Life Questionnaire (WHOQOL) measured the 
participant’s perception of their position in life in relation to their goals, 
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expectations, standards and concerns and within the context of their culture and 
value systems.  For this study participants completed the questionnaire at baseline 
and were required to complete it again one month after treatment, in order to 
measure the chronic effects of intranasal OT.  Unfortunately no participants 
reached this stage. 
Participants reported that completing these assessments was straightforward. 
The eight psychological assessments, some of which are quite long, at first 
appeared challenging for this population and some questions were repeated in 
different questionnaires however both participants reported enjoying the tasks.  It 
should be noted however that individuals with long term substance abuse are more 
likely to have cognitive impairments compared to the general population, in 
particular opioid addicts, having undergone methadone treatment (Curran et al., 
2001) and as such completing a large bank of questionnaires could be taxing, 
although these questionnaires were only scheduled to be completed at 4 time 
points and the longest questionnaires (HRSD and HARS) were performed in an 
interview style which the participants reported as easier to complete.  Furthermore, 
the benefits of completing the questionnaires in order to determine any treatment 
effect, outweighs the costs of completing the questionnaires. 
It should also be noted that some of the questions in the different 
questionnaires were evocative and the researcher should be prepared for 
emotional responses from the participant, for instance the WHOQOL-BREF requires 
that the participant rate, on a Likert scale, their quality of life and how much they 
enjoy life.  The HRSD asked participants to reflect on having “done things wrong, let 
others down”.  These types of questions evoked a lot of emotion in the participants 
as they had just completed an opioid detoxification and these were questions they 
were struggling with in their personal therapy, so it appeared difficult to re-address 
these emotions with a researcher. For that reason, the researcher needs to be 
prepared to deal with any emotional outbreaks or difficulties for the client.  In the 
case of the trial, there were occupational therapists and key workers on site for 
assistance and all the participants were engaged in daily group therapies where 
they had the opportunity to discuss any issues that were raised during the trial 
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questionnaires. For further discussion and a reflection on working with vulnerable 
detoxified opioid dependent individuals in a CTIMP, within the NHS, see section 4.4. 
The following issues were also identified and would need to be considered in 
order to carry out a successful pilot phase II trial, leading to a phase III clinical trial. 
For this trial, the use of single treatment centre as trial site for recruitment was 
limiting and not feasible.  Multiple sites would need to be included into the study to 
improve recruitment for a pilot study. The inclusion and exclusion criteria, which 
were amended during the study, would need to remain as amended as such, in 
particular the amendment which sought to include the use of antidepressants.   
Most patients who were admitted for treatment of opioid withdrawal and 
detoxification were using prescribed antidepressants and were initially excluded 
from the study, reducing our recruitment numbers. Research has found that the use 
of intranasal OT with antidepressants has no negative effects (Scantamurlo et al., 
2015).   
Overall, with changes to the protocol as discussed above, and considering 
the issues discussed in chapter 4, this is a feasible research protocol seeking to 
investigate the use of intranasal oxytocin as a pharmacotherapy in preventing 
relapse following detoxification treatment.  Moreover, considering the emotional 
and social impairments research and the measures captured by this study and 
discussed above, further research is warranted. 
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4 CHAPTER 4 
REFLECTION ON CARRYING OUT A DOUBLE BLIND PLACEBO 
CONTROLLED PILOT TRIAL IN NHS SURREY AND BORDERS 
PARTNERSHIP TRUST, WITH VULNERABLE ADULTS AS 
PARTICIPANTS.   
 
Participant recruitment from this pool of vulnerable, high risk and complicated 
patients also proved to be challenging. Most patients reported withdrawal and 
detoxification as effortful and taxing.  Although a few showed interest in the study, 
and understood the benefits of investigating the efficacy of oxytocin, most reported 
that day to day rehabilitation and therapy was all they were able to physically and 
emotionally manage and declined the opportunity to enrol.  Patient requests for 
benzodiazepines and sleep medication was constantly put to the nursing staff and 
doctors and this excluded these patients from the CTIMP as these were both 
exclusion criteria. A high number of patients were on antidepressants and this also 
excluded them from the trial.  A substantial amendment was made to the MHRA to 
include antidepressants, which was approved and allowed for recruitment 
opportunity. For further details on the challenges and difficulties with the trial, 
please see Chapter 4 
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4.1 Introduction 
Over the last decade the National Health Service (NHS) has indicated that research 
is a priority in looking to improve healthcare for patients (Department Of Health, 
2015) and the The Academy of Medical Sciences (2011)(AMS) points out that 
research underpins the prevention and treatment of ill health and brings benefits 
across the UK population.  As such, in the recent years, steps have been taken by 
the National Institute for Health Research (NIHR) (2015) in England to create the 
infrastructure and facilities to increase the standing of the NHS as an academic and 
commercial research entity and work as a partner with the UK’s first-class 
universities and hospitals as well as medical science industries. Almost all health 
research involving human participants is undertaken in NHS hospitals and GP 
practices and so an NHS culture that is supportive of research is therefore vital. The 
NHS treats the largest group of people within a single healthcare system anywhere 
in the world, and keeps detailed records on all patients from birth to death. Access 
to, and analysis of, these data is essential in epidemiological research to improve 
the safety of medicines, to identify potential participants for clinical trials and to 
identify those who would benefit most from targeted health interventions.  
However, despite this drive to increase research within the NHS, The Academy of 
Medical Sciences (2011) point out that UK health research activities are being 
seriously undermined by an overly complex regulatory and governance 
environment. This is evidenced by a fall in the UK’s global share of patients in 
clinical trials, and by the increased time and costs navigating the UK’s complex 
research approval process.  In 2002, 46% of EU products in clinical trials were being 
developed in the UK; by 2007 this had fallen to 24%.  While the data from the 
MHRA show that the number of trials approved has stayed constant between 2004 
and 2008, the UK global market share of patients in trials has dropped from 6% to 2-
3%.  Almost half of the representatives of major pharmaceutical industries surveyed 
in 2008 indicated that they expected to reduce the number of clinical trials in the 
UK.  Commercial and non-commercial researchers have indicated that the 
complexity of the regulation and governance pathway (as outlined in section 4.2 
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and fig 4.1) is limiting the amount of research they do (The Academy of Medical 
Sciences, 2011).   
This complex and burdensome regulatory and governance environment leads 
to delays, increased costs and unnecessary barriers to the recruitment of patients. 
For example, an analysis from Cancer Research UK found that after a study had 
received agreement on funding, it takes, on average, 621 days to recruit the first 
patient due to regulatory processes. While these regulatory and governance 
mechanisms are in place to safeguard research participants from potential risks of 
research, while also ensuring that high quality research can take place for the 
benefit of the public, Cancer Research UK found that delays, costs and barriers had 
not enhanced the safety or well-being of either patients or the public.  A review by 
The Academy of Medical Sciences (2011) concluded that, rather than increasing 
safety, elements of the current environment were detrimental because of the focus 
on form-filling and administration – a ‘box-ticking’ approach – rather than engaging 
with patient and public safety issues.  
This regulatory burden was seen in the set-up and throughout the process of 
our CTIMP, Clinical Research Centre study no 341 (CRC341).  The process was 
fraught with obstacles and delays (see section 4.2.7 and Table 4.1 for details) and 
success was only achieved through sheer motivation, perseverance, resilience and 
some luck. Despite the idea, planning and drafting of the protocol commencing 
from early 2014, the full timeline of events from conception to the end of the trial 
took over 1100 days and disappointingly, failed to gain the full quota of 30 
participants.  
The ‘failings’ of this pilot CTIMP reflects the onerous regulations and 
governance processes imposed on health research, as addressed above. 
Furthermore, conducting this pilot CTIMP highlighted the challenges which the NHS 
face, with departments stretched due to raising costs and reduced staff, as well as 
increased demands, staff pressures and low morale. There was also the added 
complexity of working with this particular population of participants, who were high 
risk, vulnerable and often presented with complex needs. The study aimed to 
investigate the efficacy of an investigative medicinal product (IMP) in treating 
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opioid addicts. The primary objective was to investigate the effect of oxytocin in 
retaining post detoxified opioid dependent individuals undertaking an inpatient 
residential rehabilitation programme and in preventing relapse to opioid use.  The 
secondary objective investigated the efficacy in reducing opioid craving, anxiety, 
depression, social anxiety, sleep disturbances and in enhancing social cognition, 
quality of life in this specific population.  
Clinical trials are research studies designed to assess the safety and efficacy of 
therapeutic interventions. Clinical Trials of Investigational Medicinal Product 
(CTIMP)s involve studying a drug in humans, often with an emphasis on new or 
relatively new drugs, or in our case an alternative use of an existing drug.  These 
trials of new medicines provide important information, not only about their 
effectives but also provide information about how quickly they are absorbed, how 
often they need to be taken, and the nature and frequency of any adverse side 
effects.  As a pilot CTIMP, this study was considered a Phase II CTIMP and involved a 
small group of patients to test whether the drug works and to determine the most 
appropriate doses.  A Phase III would follow, involving larger groups of patients to 
determine if the medicine is both safe and effective and this would be undertaken 
across multiple sites.  This had been the long term plan for CRC341.   
As discussed in earlier chapters, individuals with a dependency on opiates 
make up the largest proportion of those seeking drug and alcohol treatment (52%) 
and also have the lowest rate of successful exits from treatment (Public Health 
England, 2015) with 70% relapse within a month (Broers et al., 2000a, Chutuape et 
al., 2001a). Furthermore, as well as serious societal and economic consequences to 
this debilitating disorder, there are serious individual costs and I was particularly 
interested in the psychological and emotional factors associated with addiction and 
their role in relapse to opioid use.  As such, conducting clinical research, specifically 
research within substance abuse and addiction was an ambition of mine and I was 
pleased to be given the opportunity to carry out a pilot CTIMP in a much needed 
research area, and I am grateful for the experience. 
 This chapter will outline and reflect on the process of conducting a Clinical 
Trial of an Investigational Medicinal Product (CTIMP), both from the mechanisms of 
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setting up a clinical trial as well as conducting a trial. This chapter will consider how 
my trial, Clinical Research Centre study no 341 (CRC341) met the challenges of 
carrying out a pilot CTIMP as well as working with a vulnerable and often difficult 
population of participants, within the stretched and demanding environment of the 
NHS.  
Finally this chapter will include my personal reflection on the experience of 
carrying out research within a drug and alcohol treatment centre.  This reflection 
will follow a framework outlined by Gibbs (1988) which comprises a description of 
what happened, feelings about what I was experiencing, an evaluation of the 
experience, an analysis which helped make sense of the experience, a conclusion 
about what I could have done and an action plan for the future.  For ease of 
reading, the evaluation of the experience and an analysis of this experience (section 
4.4.3) will be combined and the conclusion and action plan will be combined 
(section 4.4.4).  Working through this process helped make sense of the situation 
and issues that occurred and allowed me to consider what could be done differently 
and perhaps better in the future.  
As a whole, CRC341 comprised three interconnected components; the 
government regulatory bodies, the NHS as trial site(s) and finally, participants who 
were complex, detoxified opioid dependant individuals. 
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4.2 The Clinical Trial: The process of setting up, conducting the 
trial and closing down CRC342 
There are a number of points in the development of any clinical trial, including 
CRC341, where a trial may fail, from the planning and design to the end of trial 
declaration and dissemination of results (See Fig.4.1)  
Figure 4.1.  An informative pathway and an indication of the complexity of a clinical trial, 
from planning and design to archiving of the trial documentation. 
The complexity of a clinical trial and an indication of what requirements are needed.  Good Clinical 
Practice Requirements are printed in blue and legal requirements are printed in red.   
Abbreviations: CT: Clinical Trial; R&D: Research and Development; GCP: Good Clinical Practice; CI: 
Clinical Investigator; IRAS: Integrated Research Application System; CTA : Clinical Trial Application; 
R&D: Research & Development; MHRA: Medicines and Healthcare Products Regulatory Agency. 
With permission from http://www.ct.toolkit.ac.uk 
 
There are various organisations and relevant bodies involved in the application 
process:  
• Integrated Research Application System (IRAS)  
• Medicines and Healthcare products Regulatory Agency (MHRA) 
• Research and Development (R&D) department of the NHS Trust 
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• Research and Ethics Committee (REC) of the NHS 
• Health Research Authority (HRA) 
• Sponsor Ethics Committee 
 
To obtain approval from the government regulatory bodies to carry out a clinical 
trial (CT) and in particular a CTIMP, there are a number of applications and 
documents required.   
The documentations for CRC341 comprised: 
 Research Protocol (RP) and MHRA application 
 REC application 
 R&D application 
 Site Specific Information (SSI) application 
 Summary of Product Characteristics (SmPC) 
 Manufacturer’s/Importer’ licence (MIA) 
 Good Clinical Practice Certificates (GCP) for any  persons working on the 
trial, including working with the Investigative Medicinal Product (IMP) 
 Patient consent form (CF) 
 Patient information sheet (PIS) 
 Case Report Forms (CRF), which comprised a screening book and a 
workbook. 
 
As per Good Clinical Practice requirements, CRC 341 was guided by a Trial 
Master File (TMF), and this comprised an expansive amount of paperwork that 
needed to be constantly monitored and updated (See Appendix 23 for TMF content 
pages). The TMF required 94 different documents for example insurance policies, 
standard operating procedure manuals (SOPs) and accountability logs and this was 
a laborious task to compile and manage and while this was a working document, 
many of these documents were required before the trial was given a “green light” 
from the sponsor to proceed.  
 Research Protocol (RP) 4.2.1
 The RP is the core document in any CT.  It focuses on the study objectives, 
design and safety measures.  A concise and comprehensive protocol makes the 
application for approval from the different bodies, via IRAS (see section 4.22), a 
much more straightforward task.  
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 For CRC341, the RP was 60 pages long and took 4 drafts before first 
submission and at the end of the trial we were using version 10, having submitted 4 
substantial amendments and 2 minor amendments to MHRA and REC for approval 
following initial approval.  
 Intergrated Research Application System (IRAS) 4.2.2
 IRAS is an online database, which underpins and aims to streamline the 
application process for submission to the relevant bodies described above, in 
section 4.2.  Once the CT is registered with the EU Clinical Trials Register, discussed 
below in section 4.2.3, and the trial is in receipt of a EudraCT Number, it is both free 
and simple to create an account on IRAS. 
The IRAS application starts with a number of filter questions to identify the 
appropriate application pathway for the trial and it is essential to fill out the 
preliminary section correctly, as IRAS receives large numbers of applications to 
conduct a variety of complex research studies and incorrect completion at this stage 
could result in an incorrect application with costs attached and can time consuming 
to correct.  The IRAS filter ensures that the relevant sections of the application are 
forwarded to the relevant investigation team and regulatory bodies. Once the filter 
questions are completed, the online application is left open for completion and 
submission.  
 Even though the system automatically completes questions which overlap 
with the requirements of different organisations, the IRAS application is 
burdensome. The CRC341 application form was 63 pages long and over 200 
questions to be answered; some quite lengthy and essay type responses. Once the 
application is ready for submission, it has to be electronically signed by both the 
principal investigator (PI) as well as a representative of the sponsor, which in our 
case was the University of Surrey.  It is important to note that any change to a data 
entry or an answer on the application invalidates the signatures and the document 
needs to be re-signed electronically. The PI for CRC341 is a locum consultant for the 
NHS Surrey and Borders Partnership Trust and, at times, it took more than a week 
and a number of telephone calls to get all the signatures completed and ready for 
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submission.  Without a dedicated project manager for CRC341, the submission to 
IRAS fell to myself as the PhD student and researcher.  
 International Registry 4.2.3
 Upon submission to MHRA and R&D, any CT is to be registered on an 
international registry.  The EU Clinical Trials Register online application is very 
comprehensive, with a lot of information on how to register a trial.   
 Registration of CRC341 was frustrating and took several attempts and a 
number of phone calls to EU Clinical Trials Register support desk to get the trial 
registered, with no explanation as to why the registry would not initially accept the 
trial.  Once registered, a quick search of open trials similar to CRC341, identified one 
other trial currently registered to investigate the effects of OT on opioid withdrawal 
symptoms in patients from a detoxification unit, sponsored by University of Bonn. 
The trial start date was 02-08-2011 and marked as on-ongoing and no results 
available.  The protocol differed slightly when compared to CRC341; the participants 
were all male and the primary objective was opioid withdrawal symptoms with no 
indication as to whether these were physical or emotional withdrawal symptoms.  
Also recruitment was aimed at 80 participants compared to 30 participants for 
CRC341. Email communication with University of Bonn confirmed that the study has 
not yet started and there was no anticipated start date.      
 Sponsor 4.2.4
 A sponsor is required for a clinical trial to take place.  It can be an investigator, 
individual or organisation.  The sponsor takes responsibility for indemnity and 
liability and conducts a full review of the documentation during the early phases of 
the trial. The sponsor also confirms that the relevant documentation has been 
completed and monitors the study, particularly in regard to safety reporting.  They 
should ensure that good clinical practice is followed throughout the study.   
 With regard to CRC341, The University of Surrey was the sponsor and partly 
funded the trial, along with NHS R&D.  CRC341 was the first CTIMP the university 
had undertaken as a separate body from the Clinical Research Centre (CRC), 
University of Surrey 
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The CRC is a MHRA Phase 1 accredited facility and are able to advise on and 
execute clinical trials from start to finish, including protocol design and 
development. They are equipped to oversee all regulatory applications, set up, 
manage and conduct trials.   As CRC341 was the first clinical trial set up, sponsor 
and run separately by the University of Surrey, they relied heavily on the CRC for 
guidance with regards to administration and regulation requirements. However, the 
funding provided by the sponsor for CRC341 was not able to budget and include 
payment for any supportive or clinical work by CRC, so CRC341 was not a dedicated 
CRC project, nor did CRC appoint a dedicated experienced project manager, which is 
CRC procedure, and so CRC341 was not always prioritised by CRC.   The University of 
Surrey were also involved in an MHRA routine investigation, which put CRC341 
under intense scrutiny and extra pressure for both sponsor and the CRC and staff 
involved. 
 The University of Surrey, as sponsor was very supportive from a supervisor 
role and continued to ensure that my research remained on track for me to achieve 
a PhD, however, the bulk of my time on my PhD was spent sourcing the 
investigative medicinal product (Oxytocin) from various suppliers, troubleshooting 
and project managing the trial.  What appeared to be a very straightforward study 
at the onset, slowly became more and more difficult.  With no experience in setting 
up and running a clinical trial, at times I felt out of my depth and it became clear 
that what was lacking from the start was experience of setting up and managing a 
CTIMP. Without such a experience, there were a number of unforeseen issues 
which arose and needed to be handled and overcome before CRC341 could proceed 
(see Table 4.1 for an example) all of which delayed the start of the trial and 
recruitment of suitable participants.  
During the final stages/months of the trial, CRC341 was appointed a dedicated 
project manager by the CRC, and this eased up the pressure on all the parties, 
however we were by then approaching the end of my three year PhD study, were 
finally in receipt of IMP with a close expiry date and not in a position to import 
more IMP or recruit more participants.  
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 Funding 4.2.5
Obtaining external funding for a clinical trial requires a long application 
process in itself.  Funds are needed for time, equipment travel and services 
associated with the trial.   
In the case of CRC341, despite applications to various bodies, for example 
British Society for Neuroendocrinology and Society for the Study of Addiction, 
funding was limited to that provided by sponsor and the NHS R&D. The funding 
covered the investigative medicinal product (IMP) and costs surrounding the 
importation.  This was also sufficient to cover any incentive payments should 
participants complete the trial, which was not the case and the bottles, sprays and 
actuators were supplied free of charge and time and costs involved in the handling 
and dispensing of the IMP, as per GCP regulations, were to be absorbed in the day-
to-day running costs of the NHS pharmacy. There was, however, no funding for a 
dedicated research team or an experienced project manager.  
Upon reflection, funding would have allowed for a clinical/contract research 
organisation (CRO) to be entrusted with certain tasks such as working with the 
MHRA and submission of regulatory dossiers as well as handling the importation 
and delivery of the IMP and this would have prevented a number of delays to the 
start of the trial (see Table 4.1 for examples of delays which a project manager or 
CRO would have managed or prevented).  
 Good Clinical Practice (GCP) 4.2.6
 A clinical trial, and in particular a CTIMP, has to meet the standards outlined 
by Good Clinical Practice (GCP). Investigators and anyone involved in the handling 
and administration of the IMP must comply with GCP and should hold a valid GCP 
training certificate.  Training and certification is only valid for 2 years and 
recertification requires completing an on-line course and exam.  
 I completed the GCP certification twice during the trial, and the PI and other 
staff involved in the trial were required to update their training and complete the 
exam prior to the start of the trial.  During a monitoring visit to the NHS pharmacy, 
who were responsible for importing and dispensing the IMP, it became apparent 
that some pharmacy staff did not hold GCP certificates.  While this certification is 
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not a requirement for the day to day work carried out by pharmacy staff, it was 
required for those working within a CTIMP.  As such, arrangements, funding and 
time needed to be allocated to the pharmacy so the staff involved in the trial could 
do the course and pass the exam for certification. This took some time, but by the 
start of the trial all pharmacy staff working on CRC341 held GCP certificates. 
 Medicines and Healthcare products Regulatory Agency (MHRA) 4.2.7
All studies involving medicines require authorisation from MHRA, an organisation 
responsible for the clinical safety of trials and who carry out a review of the study 
design before approval. An application to the MHRA costs £250, with an additional 
charge of £250 for each substantial amendment made to the application and is part 
of the IRAS application. 
The MHRA allows 35 days for approval, regardless of whether this is a first 
submission or amendment application and this can delay the start of a study.  
 There are easy to follow instructions and guidance available online 
(https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-authorisation-
in-the-uk) which outlines all the necessary documentation to be submitted to the 
MHRA, following the IRAS submission.  Despite the clear instructions, the process of 
submitting an application to the MHRA is cumbersome and can lead to long delays.  
As well as the initial application, CRC341 required 4 substantial amendments to 
MHRA and 2 minor amendments to the REC, which added to the costs and 
contributed to the delay to the start of the trial.  
Each application, following a lengthy submission through IRAS, also required 
that the following to be delivered by post to MHRA, London: 
 A cover letter with explanation for the changes 
 A CD or DVD which contained 
o A PDF copy of the electronically signed IRAS application 
o An XML version of the electronically signed IRAS application 
o Research Protocol 
 In the case of an amendment 
o Copy of the previous RP  
o Copy of previous RP with highlighted changes 
o Copy of new amended RP 
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o Copy of new amended RP with highlighted 
changes 
 SmPC 
 Content of IMP labelling 
 MIA (IMP) including importer’s authorisation and Qualified Person (QP) 
declaration, if the manufacturing site of the product is outside the EU  
 Evidence of payment 
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Table 4.1   Timeline of applications made to Medicines Health Products Agency  
  (MHRA) for CTIMP CRC341.  
Month/Year Application to MHRA 
August 2014 Initial IRAS, MHRA, REC, R&D submission 
August 2014 Application not approved with right to amend.  
 1] The IMP was to be imported from outside of the EU (Switzerland) by NHS 
Surrey and Borders Partnership Trust, who did not hold Manufacture of 
Investigational Medicinal Products licence (MIA(IMP)).   
2] The NHS Surrey and Borders Partnership Trust do not have a Qualified 
Person (QP) for the process of importing medicines from outside of the EU.   
 
The NHS pharmacy were exempt under MHRA Regulation 37, which allows for 
hospitals and health centres to perform assembly activities for IMPs, without 
the need to hold a MIA(IMP) licence. This meant that the pharmacy could be 
held as the clinical site for the trial. They could receive the IMP, store and 
dispense it, but could not directly import the drug.  
September 2014 Right to amend submitted: IMP was to be imported from a manufacturing site 
within the EU; Slovenia.  There was no requirement for MIA (IMP) or QP. The 
IMP was to be directly supplied to the NHS pharmacy for dispensing under 
exemption regulation 37. 
October 2014 Amendment approved 
January 2015 NHS did not hold a purchase or wholesale contract with Slovenia wholesalers 
for any of their drugs or products.  The process of applying for a purchase or 
wholesale contract between the NHS and Slovenia would take more than 6 
months, before consideration by the NHS.   
March 2015 Substantial amendment 2:  IMP to be was to be imported from a 
manufacturing site outside of the EU (Switzerland).  Importing would be done 
through a private pharmaceutical company, IDIS, who held an MIA(IMP) for 
this process and appoint an IDIS QP for certification and release to the NHS 
pharmacy, as per MHRA regulations.  
The NHS pharmacy were exempt under MHRA Regulation 37 and would 
receive the IMP, re-bottle and dispense.  
Significant delays awaiting approval from MHRA.  
a.  After the obligatory 35 day wait, and numerous telephone 
calls, it came to light that the MHRA hadn’t received the CD in 
the post and had not processed the amendment application 
submitted through IRAS. 
b. A new CD was compiled and resent by post.  
c. MHRA application failed (on receipt of the resent CD) as 
processed the incorrect RP on the CD [MHRA require old and 
new versions of RP on the CD]. 
d. Following correspondence and telephone calls the MHRA 
administration re-processed the application, noting the new 
version on the resent CD and supporting documentation. 
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e. MHRA application failed as they considered the re-sent CD as 
a new application and requested another payment.  This was 
resolved after a number of telephone calls. 
August 2015 Substantial amendment approved. 
October 2015 Significant delays as IMP was temporarily unavailable on the market.  IDIS 
underwent company restructuring and eventually formed part of the Clinigen 
Group.   There was no purchase contract in place between NHS pharmacy and 
Clinigen Group and a new wholesaler needed to be identified and 
approached. 
November 2015 Substantial amendment 3: IMP was to be imported through a pharmaceutical 
company, Mawdsley-Brooks, who held an MIA(IMP) for this process and 
would appoint a QP for certification and release, as per MHRA regulations. 
The pharmacy were still exempt under MHRA Regulation 37 and would 
receive the IMP, re-bottle and dispense.  There was already a purchasing 
contract in place between Mawdsley-Brooks and NHS pharmacy. 
December 2015 Substantial amendment approved. 
April 2016 IMP was imported and released to NHS pharmacy. 
June 2016 Delay to start date as pharmacy IMP fridge temperatures were found to be 
unmonitored by the pharmacy, as per GCP regulations.  Following an audit, 
the IMP was discarded and a new batch reordered with a delivery date 
approx. Sept/October 2016.  Further monitoring to be carried out to ensure 
that the pharmacy is GCP compliant and that the trial could progress.   
November 2016 Further delays as there were no GCP compliant temperature loggers available 
at pharmacy and a delay in the processing of NHS stock. This also meant a 
delay in the receipt of scales for use by pharmacy.  
PI and WMH staff GCP certificates expired and staff needed to redo the GCP 
course and complete online exam prior to trial starting.  
January 2017 Trial officially started.  Recruitment began. Participant 001. 
Admissions to WMH for opioid detoxification slowed while alcohol 
detoxification increased.  This was monitored for 2 months and found the 
exclusion of patients using antidepressants was also preventing recruitment.   
Application for substantial amendment to remove this exclusion, and change 
destruction process of used left over IMP. 
CRC blinded monitor became unblinded.  Recruitment for new blinded 
monitor / project manager started and procedures put into place to ensure 
the researcher does not become unblinded in the interim.  
 
May 2017 Substantial amendment 4:  Amendment of exclusion criteria section 9.3, to 
allow for participants taking antidepressants. Amendment to also change the 
process and site for destruction of used and left over IMP, to now be carried 
out at the pharmacy.   
July 2017 Substantial amendment approved and trial amended to include patients on 
antidepressants. 
30 September 2017 The MHRA was notified of end of trial and the start of closing down process 
and destruction of bottles. 
02 March 2018 MHRA approved unblinding of the trial.  
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 NHS Trust Research & Development department (R&D) 4.2.8
 Trials in the UK which are conducted within the NHS also involves the Trust 
Research & Development (R&D) departments and in some trials the R&D act as 
both monitor and sponsor and the R&D is answerable to the MHRA and Health 
Research Authority with regards to documentation of the study.  
In the case of CRC341 the sponsor was the University of Surrey and 
collaborated with NHS Surrey and Borders Partnership Trust.  The Surrey and 
Borders R&D department still played a role in the approval of the study and 
reviewed all documentation including the substantial amendments and the 
outcomes and we needed written approval from the R&D department in order to 
proceed in each case. This added to some delay, however the sponsor and R&D 
department worked well during the trial.  
 Research and Ethics Committee (REC) 4.2.9
 The role of the REC is to ensure that the safety, dignity and health of the 
participants in the study are not disproportionately compromised and is answerable 
to the Health Research Authority (HRA). Committee members have up to 60 days 
per submission to give an opinion and studies might require a number of 
amendments before a favourable opinion is obtained.  There are five possible 
outcomes following a REC meeting: 
 Full favourable opinion for the study to proceed. 
 Favourable opinion with clarifications required. 
 Likely favourable opinion following a review of the submitted 
clarifications by a REC sub-committee. 
 Possible favourable opinion following a review of the submitted 
clarifications by a full REC committee. 
 Not approved as a clinical study, usually due to problems with core 
aspects of study concept or design. 
 
It is at this stage that many trials halt.  It is extremely rare for a trial to obtain full 
favourable opinion at first review with REC and could it could take months of 
revised submissions before approval.  
 In the case of CRC341, the first REC decision was that minor clarifications 
should be made and it took a further month from submission to obtaining REC 
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approval.  Subsequently two amendments were submitted to REC during the trial 
process: 
1. Change of supervisor due to the re-structuring of the University of Surrey 
and subsequently Dr Bailey taking up a post at St George’s University of 
London. Dr Bailey was my original academic supervisor and the initiator of 
the study. 
 
2. Removal of exploratory investigation of saliva and/or urinary metabolomics 
biomarkers for the prediction of relapse vulnerability and severity of 
emotional consequences of opioid withdrawal.  
 Health Research Authority (HRA) 4.2.10
 The HRA oversees the REC and ethical applications for research within the UK. 
HRA approval is needed for any research that involves NHS organisations or where 
the NHS organisation has a duty of care to patients, either as patient/service users 
or NHS staff/volunteers.  Applications to REC are automatically sent to HRA for 
consideration. 
 In the case of CRC341, HRA approval was received with REC approval as part 
of the process and no separate applications had to be made.  
 Completing and closing down the trial 4.2.11
On 30 September 2017 the drug expired and end of trial was declared.  The 
process of closing down the study started.  This was a long and arduous task and 
again I found myself in a situation that I had no experience in.  As per MHRA 
regulations, the trial could not be unblinded until the study was signed off by a 
monitor and all paperwork was accounted for as per the TMF checklist.   The MHRA 
had to be notified of any breaches, which included any issues that did not meet 
with GCP, through a written report.  The CRC appointed a monitor to check all trial 
paperwork and write up a report which would be sent to MHRA prior to unblinding.  
Following a visit to site and inspection of paperwork the report listed a number of 
issues that did not meet GCP.  For example the date written in the workbooks was 
not in GCP format, which requires that the month is written in an abbreviated 3 
letter word and not be written as a number, the time written on the psychological 
tests was not in GCP format, which requires that the time be in 24 hour clock 
format, there were some irregularities with regards temperature monitoring in the 
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clinic room.   Each issue required a written enquiry, a written response by the PI and 
a competed file note to be signed by the PI. This took weeks to complete. Once all 
the issues had been addressed and preventative actions for the future were put in 
place, the report was sent to the MHRA by the sponsor.  
The necessary paperwork was completed for the transport of the left over 
IMP and any used bottles to be taken to the pharmacy for destruction.  The MHRA 
was notified of this process. 
On the 02 March 2018 the trial was unblinded and I could proceed with 
analysing and writing up the results.    
4.3 Trial Sites: Windmill House, St Peters Hospital and NHS pharmacy 
The trial was a collaboration between University of Surrey (Sponsor) and NHS 
Surrey and Borders Partnership (SABP) Trust.  The trial site was Windmill House 
(WMH), an inpatient residential drug and alcohol unit, situated at St Peters Hospital, 
Chertsey. The SABP pharmacy was the clinical site, responsible for the handling and 
dispensing of the investigative medicinal product (IMP) and the placebo and was 
originally situated Redhill, Reigate.  Halfway through the setup of the trial the 
pharmacy relocated to Guildford, which contributed significantly to a delay in trial 
as they were not in a position to import or store IMP until the relocation was 
completed and the pharmacy met with GCP to handle IMP.  
Due to the complex and bureaucratic regulatory environment described 
above, importing the IMP was a long and drawn out process.   Neither the Clinical 
Research Centre, University of Surrey, nor the Faculty of Health and Medical 
Sciences, University of Surrey or Surrey and Borders NHS Trust were able to import 
the IMP as none held a Manufacturing and Importers Authorisation.  The NHS 
pharmacy, however, were exempt under MHRA Regulation 37, which allows for 
hospitals and health centres to perform assembly activities for IMPs, without the 
need to hold a MIA(IMP) licence. This meant that the pharmacy could be held as the 
clinical site for the trial. They could receive the IMP from a wholesaler with 
MIA(IMP), and on receipt, store and dispense it, but could not directly import the 
drug.  As such, the pharmacy played a vital part in the success of the CTIMP.     
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 Windmill House NHS Staff 4.3.1
At WMH there are a few core members of nursing staff who work on a rota 
system which includes overnight shifts, a regular doctor as well as a manager and 
one administrative staff member who work office hours.  Dr Fiona Robinson, the 
Principal Investigator (PI) for the trial, is a locum consultant and is scheduled to 
work at WMH on a Thursday.  She is very effective but is extremely busy and 
appointments need to be booked in advance to secure a formal meeting with her.  
A review by The Academy of Medical Sciences (2011) discusses, at length, the 
research culture among NHS staff and their concerns about the approach to 
research held by many NHS healthcare professionals, managers and administrative 
staff. Responses to the review highlighted that healthcare professionals fail to 
understand the process of health research and its potential value and a cultural 
change is needed before research is treated as a core NHS activity throughout the 
UK.  
 Upon reflection, I experienced this disconnect within WMH.  None of the staff 
at WMH had been involved in a CTIMP before and while they were interested in the 
process, they were reluctant to commit to assisting on the trial, voicing their 
concerns regarding their availability and their workload.   Working with vulnerable 
and often difficult and sometimes aggressive patients, and under pressure to meet 
their daily and endless targets, meant that the staff had little time for anything else.  
As such there was little help on hand and I needed to work around staff and therapy 
timetables to be able to recruit as well as administer the IMP to patients. For 
example, although the clinic room was scheduled to be available between 09h00 
and 11h00 exclusively for the trial in order to meet with participants, and 
administer the trial drug, patient visits and appointments with the clinical staff and 
physicians, which are carried out in the clinic room, could take longer than 
anticipated, due to patient needs.  This meant the room and the stored IMP was 
unavailable to me and I was under pressure to meet with my participant and 
administer the nasal spray before the patient attended their therapy appointment. 
While I did voice this issue with the staff at the time, I felt they didn’t appreciate the 
importance of adhering to the protocol times. 
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Also, designing the trial using residential inpatients rather than outpatients 
meant that the research protocol was controlled, however it was not as controlled 
as I would have liked. While I was available at all times for the trial intranasal 
treatments and measurements, including weekends, I was often not informed by 
staff on patient’s movements and experiences.  For example, patients were allowed 
to go out shopping or for walks off site at the consent of the duty staff and part of 
their relapse prevention or contingency maintenance treatment programme.  On 
one occasion participant 002 was given impromptu permission by his therapist to go 
out for the afternoon once he completed his group therapy.  This left very little time 
for me to complete the daily afternoon questionnaire completely and he appeared 
to just want to rush the answers without really considering the questions, as he was 
more focused on leaving the unit for the afternoon.  
 At times the situation at WMH could be unsettled.  Unexpected situations 
such as random drug raids, hostility towards staff and other patients and on one 
occasion a serious suicide attempt meant that patients were often distracted and 
sometimes not very cooperative.  Staff had to spend much of their working day 
completing paperwork and administrative tasks and had little time to meet patient 
needs. Moreover it meant there was little cooperation from staff or patients with 
regards to the clinical trial.  
 Pharmacy NHS Staff   4.3.2
The pharmacy was not involved in the planning and design of the trial, 
however, as they form part of the NHS SABP Trust, they were, I felt reluctantly, 
recruited and played a vital role in the trial.    
 Again there was clear disconnect between a research culture and the 
pharmacy staff.  From our first meeting in January 2015, following initial MHRA 
approval, only one pharmacy staff member voiced experience of carrying out 
clinical trials and had little experience of carrying out a CTIMP.  Pharmacy had some 
experience of investigations of NHS medicines, using standardised NHS 
documentation, however they had no protocols or SOPs for a CTIMP and not much 
idea on where to start. The CRC offered to forward templates for them to use to 
produce SOPs, however there was  resistance from pharmacy due to time 
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constraints and staff availability to amend and seek NHS approval and 
standardisation for new documentation and I took it upon myself to design 
appropriate SOP’s, using templates provided by CRC.  Having no experience in this, 
it took some time before it could be agreed upon what was pragmatic and met with 
requirements and NHS standards. 
Half through the trial the pharmacy was notified of relocation. The move took 
months and the pharmacy was working with a skeleton staff and no time for 
anything that wasn’t vital.  As such, the allocation and importation process of the 
trial drug was slowed down.  A large number of the pharmacy staff did not transfer 
over to the new location and so pharmacy needed to advertise and recruit new 
staff. On the whole, the pharmacy remained short of staff throughout the trial and 
staff were mostly daily supply staff who performed main pharmacy duties and had 
little, to no experience of working on a CTIMP and were not GCP certified either.   
The new premises was initially not suitable for CRC341 as there was no dedicated 
trial fridge with suitable temperature monitoring nor a dedicated research work 
area for dispensing.  This needed to be attended to before the importation could 
proceed. The limited funding available for the trial meant the sponsor could not 
assist with these issues and the trial fridge and dedicated work area within the 
pharmacy had to be put through the NHS budget and approval for this took some 
time.  
 NHS Pharmacy stock and devices 4.3.3
We had been notified by the supplier that the imported bottles of oxytocin 
were designed for syringe use.  The clinical trial required bottles that would be used 
intranasally and as such the oxytocin needed to be transferred into bottles with a 
screw-top which would attach an actuator, spray and pump.   As the study was a 
double blind trial, it also meant that the placebo was to be transferred into identical 
bottles used for the IMP.  These bottles had to be sourced by myself as the 
pharmacy did not hold such stock.  The bottles, actuators pumps and spray units 
also needed to match the MHRA approved actuators and pumps.   
 I was able to source the glass bottles as well as separately source the 
appropriate actuators, pumps and sprays. However, it took months to get pharmacy 
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SOPs completed for the process of receiving the IMP and also an approved protocol 
for dispensing IMP or placebo into the bottles, ready for dispatch to WMH upon 
prescription.  
Moreover, the pharmacy did not have any equipment that would prise open 
and release the cap of the original syringe bottles, in order to transfer the IMP into 
new bottles.  It took months before suitable equipment that would not break the 
top of the bottle or spill any content, could be located.  Likewise the pharmacy took 
equally long to acquire temperature loggers for monitoring the IMP/placebo during 
transit, to secure scales for use during decanting and dispensing of IMP and a 
suitable temperature controlled fridge for storage. Due to budgeting and funding 
acquiring these stocks was constantly delayed.   
 Process Issues and delays within the NHS Pharmacy 4.3.4
 In April 2016 the pharmacy received the IMP from Mawdsley –Brookes, 
however the study was still not ready to commence recruitment as the temperature 
loggers for transit were outstanding as well as scales, although the pharmacy had 
now fitted a trial fridge. The IMP was therefore quarantined in the trial fridge and in 
order to speed up the process I purchased the necessary scales from a wholesaler 
found on the internet and sourced temperature loggers, which pharmacy purchased 
with subsidiary funds.  In June 2016, all the necessary equipment had been received 
at pharmacy and we were ready to recruit the first participant.   
 However, following a mandatory monitoring visit to the pharmacy from CRC, 
prior to the start of the trial, it was found that the fridge had not been temperature 
monitored and there were no records of the temperature throughout quarantine. 
This meant that the IMP was at risk of going out of acceptable temperature range; 
constituting a serious breach of GCP and MHRA regulations.  Following a week of 
meetings, it was decided that the batch had to be discarded and a new batch 
ordered and imported, creating a delay until October 2016.   
 Following a slow intake and admission of opioid addicts seeking detoxification 
and an increase in alcohol addicts seeking detoxification, the trial commenced in 
January 2017 with an IMP expiry date in September 2017.  During this period the 
pharmacy still struggled with the process, for instance on two occasions the delivery 
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of the prescription to WMH had to be returned to pharmacy and a new prescription 
was to be filled and redelivered.  On the first occasion the drug was not stored 
appropriately and while in transit the temperature went out of range and the drug 
could not be accepted at WMH.  On another instance there was no active 
temperature loggers during transit and so there was no temperature monitoring of 
the IMP and it could not be accepted at WMH.  
 As discussed above, in light of their exemption under MHRA regulation 37,  
the pharmacy were vital in their role in the trial.   Upon reflection, the pharmacy 
and their staff was not equipped to play such a crucial role in this CTIMP.  It also 
highlighted the importance of a dedicated and experienced project manager, who 
was familiar with the regulatory and governance processes and from the onset of 
the trial would have overseen the whole processes.  
234 
 
 
4.4 Research within a NHS residential drug treatment centre with 
vulnerable, detoxified opioid dependent individuals: A reflection 
on this experience.  
 
Between the planning of this research and the start of recruitment there were 
significant changes to NHS drug and alcohol misuse treatment structures and 
processes. One change was move to a recovery focused treatment model, with the 
aim that individuals, in addiction to overcoming dependence on drugs and alcohol, 
they improved in a range of recovery domains.  These included improvements in 
social and cultural capital such as housing and positive integration in the 
community, better health and wellbeing, having a legitimate income and no 
criminal involvement (Advisory Council on the Misuse of Drugs (ACMD), 2017).  As 
such, I was enthusiastic about the trial and the possible efficacy of oxytocin in 
supporting this recovery model through its treatment potential.   
Between 2004-09, the government continued to invest large amounts of 
funding to local areas in England and Wales to assist with a ten-year drug strategy 
“to double the number of people in drug treatment” and increase the quality of 
services (The Academy of Medical Sciences, 2011), which was promising in light of 
research in treating opioid addicts.. 
 However, from 2013 reductions in treatment resources for drug dependency 
were noticeable, and these are expected to continue up to 2021.  The Advisory 
Council on the Misuse of Drugs (ADMD) predict reductions of just under £3 billion 
by 2020-21 (Health Foundation, 2016) and Public Health England (2014) report a 
72% cut to funding for drug and alcohol services by the end of 2017.   
As a consequence, the capacity and coverage of treatment services remains 
negatively impacted as well as the quality and effectiveness of drug treatment, 
especially where service users present with significant and complex long-term 
treatment needs.   
235 
 
It felt like this reduction in treatment resources for drug dependency put 
pressure on the “staff on the ground”, with stretched departments and 
overstretched clinical staff.  Coupled with vulnerable and sometimes difficult 
participants, complex and burdensome regulatory and governance processes and a 
negative research culture among much of the NHS staff, reflecting back, this trial 
may not have only been overambitious it was also the “perfect storm” .   
 Description 4.4.1
Setting up and carrying out research within an NHS drug and alcohol 
treatment centre was both a humbling and frustrating experience.  I came to this 
research with an understanding of compulsive behaviour and addiction from my 
earlier studies as well as from my experience as a volunteer in a support group for 
depression and anxiety, where comorbid substance abuse was common. As a long 
term career I had always focused on mental health disorders and their treatments 
and I so welcomed the opportunity to do research in such an area.  When I joined 
University of Surrey in 2014 to do my PhD, the process of setting up the pilot 
CTIMP, conducting the research and disseminating the results in preparation for a 
larger trial at a later date appeared to be straightforward and exciting. The Faculty 
of Biosciences and Medicine had an excellent track record, the results of their 
preclinical trials in this area were promising and the research protocol for the pilot 
trial was in the process of being completed for submission to the MHRA.  Research 
and Development (R&D) of NHS Surrey and Borders Partnership Trust appeared 
positive about being involved in the trial and the NHS pharmacy had been assured 
that all processes would be in place prior to the start of the trial. Windmill House 
was a suitable trial site, with a waiting list of opioid dependent individuals seeking 
treatment, offering a promising number of potential participants for the research. 
The detoxification programme at Windmill House was structured in such a way that 
it would be easy to apply the research protocol and procedures without impacting 
on the day to day lives of the patients and staff.  Initial enquires as to the availability 
of intranasal oxytocin spray on the market was positive and although it was no 
longer licenced to be sold in the UK, it was easily accessible through importation.  
Visits to Windmill House and the outpatient community centres was reassuring as 
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the staff response at these facilities was positive as to the potential outcomes of the 
trial.  
So we set the application to the regulatory bodies in motion (as outlined in 
section 4.2) and waited for approval to the application and an official start date. 
Upon reflection, and without experience of CTIMPs, there was no way to 
predict the many obstacles that would hinder this process, how burdensome the 
regulatory and governance procedures were and that the trial would not start until 
January 2017, with an IMP that would expire in September 2017. 
 Feelings 4.4.2
My feelings throughout the process, from the setting up of the trial to the 
closing down and unblinding of the IMP, varied enormously depending on the 
situation at the time.  Initially, as it was clear how important this research was and 
that this treatment had the potential to positively impact so many lives, I felt 
privileged to be involved and excited to get started.  I had expected the process of 
setting up a CTIMP and getting approval from MHRA and REC to be challenging in 
light of the fact that we were proposing to treat vulnerable opioid dependent 
individuals with a treatment which was investigatory and “off-label”. So when we 
came up against the first few issues, such as the initial MHRA non-approval and the 
subsequent amendments, I approached these as challenges and, as they were 
systematically resolved and overcome, I remained optimistic.  However, as time 
moved on and the issues and delays mounted and the challenges became more 
difficult, it was hard to remain motivated.   
After a while, working within the requirements and regulations of the MHRA 
and other regulatory bodies, a lot of my frustration was aimed at my lack of 
knowledge and experience in setting up and running CTIMPs and at times I felt 
overwhelmed as the questions and challenges piled up. It became clear that the 
trial needed a dedicated project manager and someone who had experience in this 
area to guide us.  Upon reflection, appropriate funding would have also allowed for 
the outsourcing of a contract research organisation (CRO), which specialise in 
clinical trial services and are experienced in preventing or resolving some of the 
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issues experienced from the start of the study.   While a number of applications for 
funding were made, for example the Society of Neuroendocrinology and Society for 
Study of Addiction, these applications were not successful and the funding provided 
by Sponsor and NHS R&D was stretched enough and did not allow for appointing a 
CRO.  
I found working with the NHS pharmacy particularly challenging and will 
always remain grateful to the pharmacy technician, who had the most experience of 
carrying out a CTIMP at the pharmacy and he remained a source of knowledge and 
support throughout the process.  He was, however, overwhelmed with work and 
deadlines, constantly understaffed and always very busy.  As such, he wasn’t always 
readily available and the needs of the CTIMP were often low on the pharmacy list of 
priorities.  Despite the pharmacy playing a key role in the trial, due to poor 
infrastructure, they were also responsible for many of the major delays in the trial, 
as described above, and I found this extremely frustrating. 
My time spent working at Windmill house was humbling and I hold a lot of 
admiration for nursing staff who work tirelessly within this service.  It quickly 
became clear how the staff were undervalued and under enormous pressure and, 
due to their demanding days, had little time to assist me, despite their interest in 
the study.  Working at WMH is a very challenging job and the patients are 
demanding, from physical ailments to mundane and persistent complaints about 
the food menus and activity timetabling. Staff working days are filled with 
administrative tasks such as updating patient notes and dealing with the issues 
surrounding patients undergoing withdrawal and detoxification from drugs and 
alcohol. Most times these issues appear small and insignificant to staff but can be 
overwhelming to the patient and can interfere with the patients daily functioning 
and so cannot be ignored by staff.    
However, it was the histories and “back-stories” of the patients at WMH that 
touched me the most.  All their stories varied enormously and each one comprised 
different levels of trauma, which became evident as their treatment continued.   It 
was hard to imagine what it must have been like for some of these individuals to 
experience the emotional, physical and sexual abuse that they had experienced, 
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some at a very young age and I could empathise with them for turning to 
substances “for relief and escape”.   All of the patients I spoke to spoke of guilt and 
regret about the choices they had made in their lives.  I admired that they were 
attempting to turn their lives around, although it was very difficult for them. For 
example participant 002 of the trial was one life-long opioid addict and undergoing 
his 5th attempt at complete detoxification and abstinence.  He regretted so many of 
the choices he had made in life, including how much he had hurt his parents.  He 
was grateful for the chance to make amends with his parents as they were now 
quite elderly and  I recall him being very emotional as he reflected;  
“The worst worry is my parents.  They are getting on, you know old, and they 
have put up with so much from me.  I need to get better and look after them.  
Especially my mum. My dad… we don’t have much of a relationship now.  But 
that’s my fault, my addiction. I need to gain his trust again. This is my last 
chance and I am going to do it.  Really. I know this. My last chance. To put 
things right.  When I hear my mum on the phone while I am here…. I feel really 
really bad”. 
 Like most of the patients at WMH, he recounted his childhood as an unhappy 
time with a lot of emotional trauma and abuse.  I found some of his story difficult to 
process and was grateful to be able to engage in personal therapy myself, and so 
discuss my thoughts and emotions with my therapist, in confidence.  I also felt 
empathy for him as he struggled with pain as he was no longer using opioids. He 
described excruciating dental and joint pain. I recall him also being very frustrated 
and sometimes very hostile towards the WMH staff.  During every meeting with me 
he would point out how much pain he was experiencing;  
“I have this pain, in my legs and I have asked over and over for something [to 
help with the pain] and they just fob me off.  No-one listens.  I am in pain!  I 
can’t sit for 50 minutes in the group, even if I have to, I just can’t …. I have 
spoken to so many of the staff, I need something for the pain if I have to sit in 
a [..] group. Anything… Deep HeatⓇ would work but they won’t give [it to] me” 
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I personally enquired as to any treatment for his pain, but I got the impression 
from staff that this was something they experienced from most patients on a daily 
basis and it was unlikely they were going to respond to his request, although they 
did say it had already been noted on his chart for the doctor to attend to.  It was 
clear to me how easily staff working in this environment can become desensitised 
to the demands and needs of the patients and how the ongoing pressure of their 
workload could lead to burnout.  Burnout is seen as a condition in which individuals, 
like the staff at WMH, are left exhausted by long‐term unmanageable job stressors 
and the symptoms are a reflection of depression as a result of this unresolvable 
stress (Bianchi and Schonfeld, 2018).    I asked one nurse about how he coped with 
what felt like the emotional exhaustion due to his work at WMH.  I was filled with 
admiration for him as he explained that he had the added pressure of being a 
recovered alcoholic and that he attended daily Alcoholic Anonymous (A-ANON) 
meetings for his own recovery, often on the way home from his work shift.  He 
disclosed how challenging it can be to work with recovering addicts, in particular 
detoxifying alcoholics, as so many of their stories are similar to his experiences.  
However, he was a big advocate for supportive groups such as A-ANON and that 
social and emotional support for all individuals working in a caring environment was 
crucial and all staff should have access to such support. He also noted that often 
this is low down on the list of priorities of both the staff and management due to 
limited time. 
  I felt very emotional when participant 002 was discharged from WMH 
following a breach to his contract; he had failed to attend two group therapies and 
also smoked cigarettes in his bedroom.  It was also very frustrating for me as he had 
appeared so determined to complete his detoxification and he was now at risk of 
relapse once he was discharged for breaking the “rules” he had agreed to.   I had to 
remind myself that past behaviour is the strongest predictor for future behaviour, 
but deep down I really hoped that this time it would be different and he would 
make better choices in his life.  I got to speak to him while he waited for a taxi to 
collect him from WMH and he was very emotional and tearful.  I recall him saying 
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“yea, I am a little fearful. It’s about relapsing again.  In my flat and in the block 
there are addicts living there.  My mates I suppose.  Well they can’t be 
anymore.  I can’t socialise with the same people anymore.  I understand that 
now, from groups.  Need new people in my life, different people.  I am worried 
about my parents now, how I have let them down, again”.  
I recall speaking to the nursing staff on duty that morning and remember 
thinking that their acceptance of this outcome was probably just part of their daily 
work load and, for the staff, the most difficult part of that morning was all the 
paperwork that needed to be completed now that he was being discharged early.   
This attitude was also evident, following a serious suicide attempt on the ward 
and I recall the staff, having ensured that the patient was safe and had been 
removed from the ward to a secure unit, reporting that the extra paperwork which 
they had not prepared for, was the most difficult part of their already full work day.   
 It was also frustrating to work with some patients.  When looking to recruit 
participants, patients offered various reasons for not wanting to take part in the 
trial, for example one patient undergoing detoxification following a history of 
heroin, crack, cannabis, ecstasy, ketamine and methadrone, was quite emphatic in 
his response that he was not going to put an unknown chemical into his body! 
Another potential participant presented with high levels of anxiety 
surrounding social activities and future work opportunities. He was also very 
knowledgeable and particularly interested in the research findings within the area 
of oxytocin and we had a number of meetings and discussions around the 
treatment potential of oxytocin.  However, he just couldn’t commit himself to the 
trial and continually requested medication for his anxiety and disturbed sleep.  Over 
halfway through his treatment he self-discharged from WMH and had relapsed to 
heroin use later that day.  
 The motivation for treatment also varied and patients at WMH fell into one 
of two categories; they were either undergoing treatment to improve their lives and 
were self-motivated or they were admitted into WMH following pressure from 
others such as family or social services.  The self-motivated patients were more 
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receptive to the idea of taking part in the up-coming trial and also more willing to 
engage in the WMH treatment programme, however, even these patients found the 
process of withdrawal and detoxification from opioids physically and emotionally 
overwhelming and many patients requested daily prescriptions for sleep 
disturbances or anxiety related withdrawal symptoms, and so were excluded from 
the trial.  While I could sympathise with these patients, it was becoming apparent 
that the number of potential participants for the trial was not as high as first 
thought.  
   I also had to check my prejudice when working with some patients.  For 
instance participant 001 recalled a traumatic childhood and a history of sexual 
abuse which she found very difficult to deal with without the use of drugs. As she 
recounted her life as an addict mother with two small children, it was very hard for 
me not to judge her and her behaviour.  I recall her denial that her lifestyle was 
having a negative impact on her children; 
“I think my children were innocent of my drug use.  But sometimes I would 
have to put them in the buggy to go out in the rain, in the night, to draw 
money to buy…. but I didn’t think they knew.  Now, I am not sure..I have 
wasted a lot of my life and I am sorry about what they [children] have had to 
do.” “I tried to hide my withdrawal from them.  I would wake in the night with 
them in the bed, feeling sh*t but I would just say I was feeling sick.  They never 
knew.  I think………..” 
This patient had agreed to enrol in WMH residential treatment as social services 
had become involved with her children.  Unfortunately she was not motivated 
enough to remain in the treatment programme and she self-discharged and the 
WMH staff confirmed that it was unlikely she would get her children back. As a 
mother myself, I found this difficult to comprehend and highlighted the power of 
addiction. 
For other patients, committing themselves to the trial was too much for them 
to do.  Two patients told me that all they wanted to do was just get through the 
WMH programme and anything else would be too difficult.  They just wanted to 
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concentrate on themselves and getting out of bed and attending groups was 
enough to cope with.  
 Evaluation and Analysis 4.4.3
Overall, I am appreciative for the opportunity to have carried out this 
research, investigating a novel treatment for such a debilitating disorder which 
touches so many lives on so many levels. My understanding of the biology of 
addiction and in particular opioid addiction as well as treatments in this area has 
grown extensively and spending time with those individuals undergoing the battle 
with addiction was both an informative and emotive experience and I have learned 
a lot about myself though this process.  I have learned that I am resilient and able to 
remain positive even in circumstances that look hopeless and unattainable.  I am 
now aware how solution-focused I am in the face of adversity and welcome this 
outlook in future challenges. My experience has made me aware that I have the 
ability to empathise as well as establish a good therapeutic alliance with patients 
and as a consequence, I aim to remain working in the area of mental health and I 
welcome these skills in this work in the future.  
I remain convinced that intranasal oxytocin has the potential, as a treatment, 
to prevent relapse in detoxified opioid addicts through its action on the emotional 
impairments that often present co-morbidly in these individuals. I also remain 
convinced that the pro-social effects of oxytocin will help treated patients remain in 
social and peer support groups which will further ensure their recovery.  As such, I 
found the process of setting up and running the pilot trial disappointing and 
frustrating.  I am disappointed that we were not able to recruit enough participants 
timeously but am now aware of the challenges of carrying out research, with 
complicated high risk patients with dual diagnosis.      
With insufficient participants, the trial will be considered a feasibility study 
and the data we collected can only be viewed cautiously, although the study does 
warrant further investigation of oxytocin as a treatment for co-morbid addiction-
mental health treatments.   
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 Conclusion and Action Plan 4.4.4
In conclusion I found the whole process a worthwhile experience, albeit very 
disappointing that there was no decisive outcome with regards to the hypotheses 
and so the efficacy of oxytocin as a potential treatment for opioid dependent 
individuals undergoing detoxification remains unclear.  However, as I stated above, I 
remain confident that future research will support the theory that oxytocin is able 
to offer potential treatment in preventing relapse in detoxified by attenuating the 
emotional impairments associated with relapse.  So while the data gathered in our 
study needs to be viewed cautiously, I take some solace in the outcome scores and 
that further research is warranted.  
My disappointment and frustration lies at the substantial delays outlined 
above, which resulted in a small window of opportunity to recruit participants. 
While some of the delays are due to the bureaucratic regulatory environment 
involved in setting up a CTIMP, some of the obstacles and delays could have been 
prevented or overcome with the appointment of someone experienced in setting 
up and running a CTIMP.  This would, however, require more funding that we had 
available. With the drive by the government to reduce drug dependence, as 
discussed earlier, applications for funding should be met favourably and 
submissions to the appropriate funding bodies need to made early.   
Fig 4.1 (see section 4.2) outlines the pathway of a clinical trial from planning 
to archive of the trial documentation. This pathway allows for funding proposal and 
securing of funding and this seen early in the process and prior to the finalising of 
the protocol and application submission to IRAS.  In a future study, funding needs to 
be secured even earlier than proposed in this pathway, followed by the 
appointment of a CRO.  In our trial, Mawdsleys, who imported and released the IMP 
to the NHS pharmacy offer such a service (see appendix 24 for an example of their 
full service) and with hindsight this would have been the best route to have 
followed.  
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5 CHAPTER 5 
 
GENERAL DISCUSSION 
246 
 
5.1 General Discussion 
This thesis was set in the context of identifying risk and protective factors 
associated with relapse in opioid dependent individuals undergoing withdrawal and 
detoxification treatment, as well as investigating the efficacy of a novel treatment in 
order to prevent relapse within this population by targeting social and emotional 
impairments. 
 Summary of Findings 5.1.1
Study 1 (chapter 2), a retrospective study, identified that an inpatient 
residential treatment, with a social and peer support group programme, was a 
protective factor against relapse, compared to a community outpatient treatment 
programme.  Also, remaining in and completing treatment was a protective factor 
against relapse within 30 days. Other associations included completing a treatment 
programme and relationship status, positive mental illness diagnosis and current 
crime conviction at time of treatment admission, family support and past 
employment and pre-adolescent drug use was associated with engaging in an 
inpatient detoxification treatment rather than community treatment programme.  
Study 2 (chapter 3) a feasibility study for further investigation of intranasal 
OT as a CTIMP, provided some guidance and highlighted the difficulties in carrying 
out clinical trials.   Although presented with caution due to the low number of 
participants recruited to our study (n=2), there did appear to be an improvement in 
the psychological assessment scores following administration of OT intranasal 
spray, with improved mood scores, some improved sociability, reduced anxiety 
scores and reduced sleep disturbances.  
Overall, we are reminded of the high relapse rate to opioid misuse and the 
ongoing need for a reliable treatment to ensure long term abstinence following 
treatment.  As we were able to identify the positive benefits of social support as a 
protective factor against relapse to opioid dependency, it could be argued that 
promoting psychosocial treatments and sustaining positive social interaction may 
be the way forward to maintaining abstinence and recovery following detoxification 
treatment. 
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 Positive social interaction and support as protective factors for relapse  5.1.2
 This thesis offers support to the ongoing research into the benefits of social 
support in the treatment of addiction.  As outlined previously, the primary 
treatment, in accordance with NICE (2009) recommendations, for those seeking to 
withdraw and abstain from opioid misuse, is a medical, drug assisted withdrawal 
and detoxification treatment. Psychosocial treatment for opioid addiction is 
recommended as an adjunct during and/or following detoxification.  Nonetheless, 
this type of treatment is notoriously underdeveloped and yet may be the 
component required to ensure long term abstinence from opioid misuse.  
Currently, contingency management (CM) is recommended as psychosocial 
treatment for those undergoing detoxification and withdrawal and this may be 
followed by a short course of CBT once the patient is stabilised or has demonstrated 
a period of abstinence (NICE, 2009).  Thereafter some patients are often left 
vulnerable to relapse without formal and regulated interventions in place and they 
most often rely on social and peer support groups within the community as a way 
to sustain their recovery and abstinence.    
The results of my research found that the odds of relapse within 30 day of 
starting treatment within the community were 3 times the odds of relapse when 
compared to being treated within a residential treatment facility.  As discussed, a 
residential treatment programme includes mandatory peer and group therapies as 
well as attendance at self-help meetings provided by Narcotics Anonymous (N-
ANON) and it could be concluded that this is an explanation for the reduced relapse 
rates reported in my research.    
Self-help programmes such as 12-step programmes (TSP), A-ANON and N-
ANON,  have long been seen as the most popular and most referred support groups 
held outside the formal settings for addiction treatment and NICE (2009) 
recommend that patients are steered to voluntarily attend such meetings, even as 
an ad hoc support while undergoing treatment. These programmes are seen as 
effective in promoting abstinence for those who regularly attend and contribute to 
meetings (Kaskutas, 2009) and also seen to produce self-efficacy and motivation for 
change in many individuals (Ronell et al., 2001).  There are, however, limitations to 
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the 12-step approach, for example the meetings are informal, are facilitated by a 
group member(s) who have no training in recovery treatment and the groups are 
run with very little structure other than promoting and adhering to the 12 steps.  
Attendance at the meetings are entirely voluntary, members remain anonymous, 
most often do not need to provide any personal information including their real 
names and failure to attend the meetings is not challenged by the group. 
Krentzman et al. (2010) reported high rates of attrition from A-ANON and N-ANON, 
within one month from joining, (85% and 91%, respectively) with attendance and 
involvement decreasing over time. Sussman (2010) report that the average 
attendance to meetings is 9 months with approximately 26% weekly attendance by 
individuals. One possible explanation for high attrition and low attendance at these 
meetings is due to the high instances of social anxiety experienced by those 
recovering from addiction.  Book et al. (2009) report that social anxiety negatively 
impacts willingness to participate in addiction treatment and this is seen in all four 
aspects of addiction treatment participation; i.e. willingness to talk to a therapist, 
willingness to talk or “share” in group therapy, willingness to ask for a N-ANON 
sponsor and even reluctance to attend the group therapy. Also, these programmes 
only offer a single pathway for recovery from some very complex disorders, with a 
focus on sobriety (Alcoholics Anonymous, 2018). In 2010 the UK Government put 
forward a strategy to move away from a single-focused approach which had 
previously focused on meeting process-driven targets, getting people into 
treatment and off drugs and alcohol for good.  The 2010 policy was to focus on 
recovery, which means to include jobs, housing, training and something to recover 
to, and the 2017 UK Government strategy continues to move in that direction, 
although hard to deliver such programmes effectively due to cuts to local drug 
services and community treatment services (HM Government, 2017). 
An alternative group treatment programme, and more in line with what the 
Government strategy proposes, is peer supported programmes, although these 
programmes do not fall within NICE (2009) recommendations. These groups are 
managed and facilitated by peer workers who seek to engage each individual in a 
personal recovery programme (Tracy and Wallace, 2016).  Recovery programmes 
249 
 
such as these differ from A-ANON or N-ANON as facilitators are trained as peer 
workers and work either within the NHS organisation, as employees or volunteers, 
or the groups are run by charity organisations. The training of facilitators means the 
programmes are more formal and structured than TSP and recovery programmes 
work from common sets of core activities.  These are aimed at helping individuals 
set recovery goals, develop a plan and work towards maintaining their abstinence 
as well as providing a holistic approach to recovery (Tracy and Wallace, 2016).  
One such charity is UK Self Management and Recovery Training (SMART) 
(https://www.smartrecovery.org/), which support those looking to recover from 
addictive behaviour and lead meaningful and satisfying lives. The programme 
comprises tools and techniques based on cognitive behavioural principles, face to 
face meetings are held worldwide, as well as daily on-line meetings and 24 hr chat 
line for those in crises or struggling with relapse. Those seeking to train and 
volunteer as SMART facilitators are required to meet a number of personal 
qualities, including being in recovery themselves.  They need to complete a number 
of modules which cover the principles of recovery and training on facilitating 
meetings as a peer mentor.  Overall, SMART provide a science-based therapeutic 
programme of training with ongoing peer support. 
Like TSP, peer support is valuable.  It is the process of giving and receiving 
nonclinical, nonprofessional assistance from individuals with similar conditions and 
circumstances, which in turn helps achieve long term recovery from drug related 
problems.  Peer support can also be seen as different from social support (Reif et al 
2014) as often those providing social or psychosocial support (family, friends, key 
recovery workers and substance misuse workers) most often do not have a 
substance use disorder whereas peers are able to highlight their own lived 
experience of recovery, offering support from a “been there” approach, thereby 
motivating and empowering the individual to continue with their recovery 
processes.  As such, peers offer several kinds of support which range from non-
judgmental, emotional, motivational, informational and affiliational, which 
promotes social connectedness.  In this way, peers and peer social groups positively 
reinforce each other, creating rewards and promoting abstinence earlier.   
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Bassuk et al. (2016) carried out a systematic review identifying 9 
intervention studies which had a trained peer support worker as a role model or 
leader, who had a personal experience of addiction, and were themselves in 
recovery. These studies comprised 4 randomised control trials, 3 quasi-
experimental studies, one comparison group study and a programme evaluation 
report. For all studies, the programme followed a standard manual or workbook, 
had a holistic approach and recovery involved processes related to hope, 
empowerment, functioning, housing stability, employment and improved health. 
One study used a biological measure of abstinence, radioimmune assay of hair 
testing and the other studies relied on self-report.  The findings were that peer 
interventions positively impacted the lives of those attending peer support groups; 
eight studies reported statistically significant findings in a number of recovery 
outcomes, including recovery from substance use.  Reif et al., (2014) offer support 
for this approach with findings from a separate systematic review which found in 
three studies, including one RCT, that peer recovery support services improved 
substance abuse outcomes including increased engagement in completing 
treatment, readiness to change and control over substance misuse. Tracy & Wallace 
(2016), in their literature review, also pointed to the benefits of social support in 
treating substance misuse, engaging in substance misuse treatment and also 
significantly reducing secondary substance related behaviour such as craving and 
self-efficacy.  
In summary, studies find that positive social interactions such as TSP and 
peer-led supportive and structured programmes, such as that of SMART, have 
significant benefits in the treatment and recovery of addiction. This is reflected in 
the results of my research investigating the protective factors against relapse. 
Patients who undertook a structured supportive and group based treatment 
programme were protected against relapse within 30 days from the start of 
treatment.    
As such, it is important that positive social interaction and peer-led support 
programmes form part of a structured and long term treatment plan, and so should 
be part of recommended treatment guidelines.   This may be the way forward to 
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ensure opioid addicts recover and remain abstinent following treatment and 
reintegrate back into society.   
One major challenge to promoting recovery from opioid addiction through 
social and peer support programmes is the high instances of anxiety in this 
population, in particular social anxiety. Social anxiety disorder (SAD) is common in 
those being treated for substance abuse, with prevalence rates reported between 
23-31% (Lydiard et al., 1992, Terra et al., 2006, Thomas et al., 1999, Grenyer et al., 
1992).  The challenge is that the core feature of SAD is fear of scrutiny or judgment 
in social situations, for example when participating in small groups or speaking in 
public.  This fear results in adopting negative “safety” behaviours aimed to reduce 
the anxiety, most often this includes the avoidance of social interactions as well as 
substance use and unhelpful behaviours (Westbrook et al., 2011). As addiction 
recovery treatment increasingly includes group therapies and social meetings (NICE, 
2009), engaging in recovery becomes difficult for those struggling with anxiety 
disorders.   
It has been hypothesised that drugs of abuse hijack the motivational reward 
system evolved for social interaction (Insel, 2003) and with limited social reward 
due to social avoidance, coupled with the anxiety experienced in group/social 
interaction, substances of abuse such as opioids, become the most salient coping 
strategy when faced with stressors (Stauffer and Woolley, 2014), which is reflective 
of the desire to re-use (cravings) and high instances of relapse.   
While the benefits of engaging in social and peer-supported recovery 
groups, as discussed above, is clear and with positive clinical outcomes, ironically 
therein lies the challenge; motivating detoxified opioid dependent individuals, in 
spite of the high prevalence of emotional and social impairments, to engage with 
these positive peer and social support networks as part of treatment and relapse 
prevention.   
 Oxytocin as a novel treatment in promoting abstinence and recovery 5.1.3
In light of the above mentioned research, one of the beneficial therapeutic 
effects of OT may be the ability to shift focus away from the consequences social 
anxiety and the negative effects of substance dependence and focus on social 
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reward by engaging in the support provided by peers and social groups.  As such OT 
may be a potential treatment option to ensure long term recovery and prevent 
relapse in opioid dependent individuals.  
 Studies on the effects of OT on substance use with a focus on treatment, are 
however, in their infancy, and the results are mixed. McRae-Clark et al. (2013) 
examined the effect of OT on marijuana-dependent individuals.   As well as 
measuring for craving and stress response, the examiners measured for anxiety in a 
social anxiety-provoking situation, the Trier Social Stress Test (TSST), where 
individuals are required to respond to a task in front of an audience or small group. 
The results were that there was a significantly lower anxiety response to the TSST in 
oxytocin versus placebo-treated participants. OT dose participants also scored 
lower on the cravings questionnaire and had lower stress reactivity compared to 
placebo.  Woolley et al (2016) assessed the effects of intranasal OT in individuals 
undergoing opioid replacement treatment (OTR) for opioid dependency.  They 
report that OT is well tolerated by patients receiving ORT, however they found no 
significant effects on craving and some evidence that social perception worsened.  
This research is important in demonstrating that intranasal OT is tolerable in this 
population but the authors point out further investigation is required on the role OT 
in treatment of opioid use disorder.  It may be that cravings and social impairments 
only present once individuals are completely withdrawn from opioids and that OT, 
as a treatment, might only be necessary at the point of presentation of such effects.  
Pedersen et al. (2013b) report that intranasal oxytocin decreased alcohol 
withdrawal symptoms compared to placebo, in that withdrawal self-ratings were 
lower in the OT group, also alcohol cravings were lower and anxiety scores were 
significantly lower in the OT group compared to placebo.  While these results are 
not definitive and focused on the effect of OT on symptoms while patients undergo 
withdrawal, they do suggest that that oxytocin may have a positive therapeutic 
outcome. 
Considering the above research findings within the field of addictions, OT 
appears to prevent relapse through its ability to reduce withdrawal symptoms.  In 
particular OT is seen to reduce anxiety symptoms (Labuschagne et al., 2010, 
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Labuschagne et al., 2012) and has shown significant positive effects when used as 
an adjunct treatment for social anxiety (Guastella et al., 2009).  As such, OT may 
provide the mechanism needed to ensure that addicts remain engaged in valuable 
social and peer-supported recovery programmes, following detoxification and 
withdrawal, thereby reducing risk of relapse.  
One way this could be achieved is by the individual responding to the 
symptoms of anxiety and social anxiety related behaviours, including cravings, 
through self-administered intranasal oxytocin, as needed and on an ad hoc bases.  If 
In this way oxytocin administered when required, may reduce the vulnerability to 
relapse due to social avoidance and social withdrawal (see section 5.1.4 for future 
research). Intranasal administration might also promote endogenous oxytocin 
secretion directly through PVN OT autoreceptors or indirectly through peripheral 
OT receptors, which might increase the likelihood of the individual remaining in 
group treatment.   As such, intranasal OT may prove to be an effective 
pharmacological treatment to prevent relapse though its promotion of psychosocial 
treatment.  Stauffer & Woolley (2014) went so far as to ask “can we bottle 
psychosocial treatments for addiction?”  
 Future research work 5.1.4
The above discussion points and the related research offers insight into an 
approach to prevent relapse to opioid abuse, thereby maintaining long term 
abstinence and recovery from addiction.  The research highlights the value of 
engaging in psychosocial and peer group treatment programmes. As such, future 
work should focus on this area and investigate ways to promote this, which OT as a 
treatment may provide.  
Investigating the prosocial effects of OT in engaging addicts in psychosocial 
treatment programmes would be of great interest, i.e. investigating whether self-
administered OT nasal spray reduces social anxiety which in turn promotes 
attendance as well as engagement in social-based treatment programmes.  
 As discussed in Chapter 4, a rigid clinical trial within this population, and 
within the NHS is difficult and desperately underfunded. The process of setting up 
and conducting a trial is time-consuming and costly and the complex and 
254 
 
bureaucratic regulatory environment is extremely challenging. Moreover the 
complexity of the patients, difficulties in compliance within this population and 
recruitment of appropriate participants further adds to the challenge of research 
into addiction research. However, research into new treatments for opioid 
addiction is desperately needed.  Worldwide the number of people consuming 
opiates and overdose deaths is increasing. Anecdotal evidence gathered though my 
experience and time with opioid detoxified addicts at WMH, while not part of this 
thesis, found that most individuals reported being desperate to break the cycle of 
addiction and for many, this was not their first time undergoing detoxification and 
withdrawal, with high counts of relapse. The objective of the pilot RCT trial was to 
explore a novel treatment to prevent relapse with an aim to “break” the cycle of 
addiction and prevent relapse. 
There is no alternative way of developing and testing of new treatments other 
than undertaking randomised placebo controlled clinical trials but the way forward 
would be to refine protocols, characterise the subjects better and more thoroughly, 
develop better and more valid tools, for example making use of triangulated data 
though the use of questionnaires and develop a targeted infrastructure tailor-made 
to the complexity of the individuals with a focus on improving compliance and 
recruitment. 
The use of semi-structured interviews along with standardised questionnaires, 
in future research, would allow for a triangulation of data and a way of assuring the 
validity of the research through a variety of methods of data collection by capturing 
different dimensions of the same experience or situation (Gill et al. 2008) 
Interviews are an important data collection strategy, in particular with the 
complex population such as that used for this pilot trial.  Interviews would give 
insight into the physical as well as emotional and psychological experiences of 
withdrawing and detoxification as well as the motivation for undergoing treatment 
and undertaking the study. These were some of the barriers to recruiting 
participants for the study and will provide  guidance in setting up and running 
future research studies.  
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A semi-structured interview involves a set of open-ended questions which 
allow for spontaneous and in-depth responses and offers a rich description and 
detailed account of the patient’s physical and emotional experiences. This would 
also give a better understanding of the psychological and emotional effects of using 
the medicinal product and the open-ended questions would allow for further 
exploration of the answers.  The standardised questionnaires will provide data on 
the efficacy of the drug compared to a placebo control and would provide a 
definitive treatment effect with the use of statistical analysis.  
Research qualitative data through an interview as well as quantitative data 
provided through questionnaires would put forward a possible treatment for opioid 
addiction as well as an explanation as to its efficacy and as a feasibility pilot trial this 
data will also provide information as to what changes need to be done before a 
main study 
Investigating the efficacy of OT as a self-administered anxiolytic treatment 
could be measured at multi-centre trial sites, for instance, social-based treatment 
programmes such as N-ANON meetings or group meetings in community treatment 
centres.  OT could be self-administered at a number of time points (see Fig 5.1 for a 
possible treatment procedure during social anxiety experience).  Attendance and/or 
relapse rates could be measured through self-report or through feedback from 
facilitators.  This may lead to OT becoming part of a treatment and relapse 
prevention programme. 
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Fig 5.1. Cycle of anxiety experienced by an addict in social situation, with 
proposed oxytocin intranasal treatment options.  
People, including those with addiction disorder, who experience social anxiety hold negative beliefs 
about themselves and how others see them. These beliefs and thoughts are experienced before, 
during and after group and social interactions. The negative thoughts lead to strong symptoms of 
anxiety (increased heart rate, sweating, shaking) and cravings. The individual adopts “safety” 
behaviours, which includes social avoidance and isolation, low mood, cravings and possible 
substance use. 
Administration of OT intranasal spray at various junctures, when necessary, may attenuate these 
negative symptoms, which are risk factors to relapse and may break the vicious cycle, leaving the 
addict less vulnerable to negative anxiety and more likely to engage in group therapies. 
           OT intranasal spray.   (Modified from Westbrook et al., 2011) 
Before group 
therapy 
Negative Automatic 
Thoughts: "others will 
judge me, I cant 
cope" 
Physical symptoms Tense, 
anxiety symptoms, cravings 
During group 
therapy 
Focus on self: "I 
look/sound 
stupid. I don't 
know what to 
say" 
Increased 
feelings of 
anxiety. Tense, 
cravings 
Safety Behaviours: 
non-engagment in 
group, no 
speaking, 
avoidance 
After group 
therapy 
Negative thoughts/low 
mood: "I looked stupid, I cant 
cope" 
Avoidance, 
isolation, low mood, 
cravings - relapse 
Avoidance,  
isolation, low mood, 
cravings - relapse 
Long held beliefs about self and 
others 
“I am no good” “I am stupid” “Others 
will judge me for what I have done 
and become” “I am an addict” 
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Future work could also focus on the role of OT in other compulsive and 
addictive behaviours where social isolation and social impairments are seen to play 
a prominent role, in both cause and effect.  There is increasing interest surrounding 
social media and internet addiction and in particular, the increase in cybersex or 
pornography addiction. While still in its infancy, new research is questioning how 
addictive on-line/computer games and social media platforms are, with findings 
indicating tolerance, salience and relapse in those who are compulsive users 
(Cabral, 2011). With regards to pornography addiction, this compulsive behaviour 
has ongoing and extensive neuroscience-based research indicating cravings, 
tolerance and withdrawal symptoms with high instances of relapse, not dissimilar to 
drug addiction (Bőthe et al., 2018, Kuhn and Gallinat, 2014).  Moreover, the 
prevalence and severity not only increases with consumption (Zillmann and Bryant, 
1986, Donevan and Mattebo, 2017) but is also seen at a younger and younger age 
as pornography becomes more available via increased social media platforms and 
portable internet devices such as smartphones.  The behaviour itself reduces 
sociability and social interaction and increases social anxiety, as the user 
compulsively chooses the internet and images over human interaction (Griffiths, 
2012).  While research in this area still in its infancy, it is growing (Wilson, 2018), 
and future work could focus on the neurological mechanisms underlying addiction 
and the role of OT in these changes.  There is also a correlation between 
cybersex/pornography addiction and mental health disorders; anxiety, social 
anxiety and depression, with suicide attempts on the increase.  Research in this field 
has found that 17% of compulsive users have attempted suicide and 72% have 
considered it (Griffiths, 2012, Stein et al., 2001).  With increased unemployment, 
increased imprisonment and social isolation and relationship break-down, there is 
an increasing need for effective treatment of this addiction (Young et al., 1999).  It 
would be interesting to investigate the role of OT in early stages of pornography 
addiction as well as its role in treatment, with a focus on social withdrawal and 
social anxiety. Like most addictive behaviours, cybersex, pornography and sex 
addicts are offered psychotherapy as a primary treatment but could mostly benefit 
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from engaging in long-term non-judgmental, peer supported recovery treatments 
such as Sex Addicts Anonymous (SA-ANON) to prevent relapse and it may be OT 
that could promote this.   
 Issues to consider when using oxytocin as a relapse prevention treatment 5.1.5
While the evidence and discussion within this thesis supports the 
considerable and growing interest in oxytocin as a novel treatment for addiction, 
there are limitations to the use of intranasal oxytocin as a treatment, and a number 
of questions still remain unanswered. For example, there is an ongoing debate 
regarding the efficacy of the intranasal route of oxytocin to target the brain 
oxytocin system due to poor brain penetration (Leng 2016). Also the mechanism of 
brain uptake is uncertain as well as questions around oxytocin’s dose-response and 
dose requirements due to OT short half-life.  Research by Quintana et al (2017) has 
attempted to offer some answers as to the optimum dose-response as well as 
oxytocin delivery methods. Using a Breath Powered intranasal delivery device they 
demonstrated a novel, and possibly improved, nose-to-brain delivery. They were 
able to demonstrate, in a double blind, crossover, randomised placebo controlled 
trial that 8 international units (IU) delivered through this method, was able to 
significantly increase overt emotion salience in male adults with autism.  Moreover, 
there was no statistically significant increase after 24IU treatment and also the 
effects after 8IU were observed despite no significant increase in peripheral blood 
plasma.  Quintana et al (2015) had previously shown that 8IU of oxytocin delivered 
with Breath Powered device significantly reduced angry ratings for ambiguous faces 
and participants indicated ratings of trustworthiness in happy faces.  These studies 
are important as they suggest low doses of OT are effective in modulating social 
cognition and also provide behavioural evidence that OT delivered intranasally, 
using a Breath Powered device, reaches the brain and influences social cognition. 
Moreover, this reduces any risk or side effects which may be as a consequence of 
high or chronic doses of oxytocin and may be an effective treatment delivery 
method. 
Peters et al. (2014) demonstrated that the effects of chronic OT 
administration is dose-dependent and at high doses, is seen to have negative 
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effects in mice, with the induction of anxiety behaviours and a reduction of OTR 
binding following 15 days of ICV infusion of OT. This was, however, not seen at low 
doses, which was seen as having positive anxiolytic effects. These studies offer 
some indication that low doses of OT are effective, even for an extended period of 
time.  
There is still the question, however, of whether OT based interventions are 
rewarding and if individuals are likely to become dependent on OT. There are only a 
limited number of human trials of intranasal OT in addicted populations, with small 
sample sizes.  The majority of trials are carried out in animal studies, of which there 
are no reported findings of OT dependency.  Animal studies, however, are seen to 
use central administration of OT or very high peripheral doses, which are not 
practical in human trials and the question remains about whether the effects and 
findings can be translated to clinical populations. 
   Concluding remarks. 5.1.6
Overall, the research in this thesis has highlighted the following: Positive 
social interaction and peer-social support are beneficial and protective against 
relapse to opioid dependency following treatment. Treating opioid addiction is 
currently focused on a medical detoxification and treating co-morbid emotional 
impairments is seen as secondary in a treatment plan. These emotional 
impairments; depression, anxiety and social withdrawal are part of the withdrawal 
syndrome experienced following detoxification from opioids and as such should 
receive equal treatment focus as they are part of the relapse syndrome. Currently 
the drive by the government is to ensure that opioid dependent individuals move 
towards recovery and not solely abstinence.  As such, structured peer focused 
support groups, managed by trained peer support workers need to be highlighted 
within the NICE recommendations, as these are valuable in maintaining this 
recovery. One of the obstacles needed to be addressed in order that individuals 
engage in peer supported programmes is the negative emotional impairments and 
anxiety disorders in particular. Social anxiety appears to prominent play a role in not 
only development and maintenance of addiction but also relapse by disengaging 
individuals in group therapies.  This can be addressed through the use of OT. 
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Intranasal OT may be the way forward in promoting and sustaining positive social 
interaction and engagement in group treatment and may be used as a self-
administered treatment in the event of high feelings of anxiety and vulnerability to 
relapse. As such, research in this area warrants further investigation.  
This thesis also highlighted the difficulties and provided some insight into 
successfully carrying out a clinical trial within the NHS, under the current legislation 
and governance as pointing to the difficulties in recruiting appropriate participants 
for clinical research. 
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Appendix 1 
Windmill House, Surrey and Borders NHS Partnership Trust 
Windmill House (WMH) is a 12 bed specialist residential unit situated within 
the hospital grounds of St Peters Hospital, Surrey and Borders Partnership NHS 
Foundation Trust (SABP), Chertsey, UK. It is a 24 hour residential unit, with full time 
staff on the unit 24 hours a day and a doctor on call.  WMH offers medically assisted 
as well as psycho-social support for those who wish to withdraw and undergo 
detoxification from drugs and/or alcohol dependency.  As well as accommodating 
12 individuals, WMH comprises full cooking facilities and separate female sleeping 
and washing/bathing facilities. Patients are provided with all meals but kitchen 
facilities are also available to patients in between main meals.  There is a secure 
garden for recreation and patients may, with permission, walk around the larger 
hospital grounds.  Also, as part of the maintenance treatment plan, patients may 
meet with family and friends off site, for a restricted time period, outside of the 
unit.   As well as medically assisted withdrawal and detoxification from drugs and 
alcohol, patients also complete a four week recovery focused therapeutic 
programme where patients attend daily group activities and therapy groups (see 
appendix 25 for the programme). Upon completion of their treatment programme 
patients are discharged from the unit and continue receiving support within 
community teams.   
While in the unit, patients are regularly screened for illicit drug and/or alcohol 
use and if the tests were found to be positive, patients were discharged and 
expected to complete their treatment programme through the community teams.  
Windmill House is subjected to regular drug and alcohol checks. 
Patients are admitted to Windmill House on a volunteer basis and as such are 
entitled to withdraw from treatment and self-discharge at any time, although 
patients are asked that they only self-discharge under their doctor’s advice and 
counsellors and therapists are on hand to encourage patients to remain and 
complete the treatment within the residential setting. 
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Appendix 2 
MHRA Grounds for Non-Acceptance and Right to Amend 
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Appendix 3 
MHRA Approval Substantial Amendment 2 
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Appendix 4 
MHRA Approval Substantial Amendment 3 
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Appendix 5 
MHRA Approval Substantial Amendment 4 
 
303 
 
 
Appendix 6 
NHS REC Approval 
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Appendix 7 
Pharmacy Procedures 
CRC341:  RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED PILOT TRIAL OF OXYTOCIN 
EFFICACY IN TREATING DETOXIFIED OPIOID DEPENDENT INDIVIUDALS. 
PHARMACY PROCEDURES 
 
RECEIPT OF THE SYNTOCINON, SALINE AND INTRANASAL PUMPS 
1 
CRC341 Surrey CRC Drug Shipment Accountability Form: Syntocinon 1.1 
CRC341 Intranasal Administration Device Accountability Form  1.2 
CRC341 Surrey CRC Drug Shipment Accountability Form: Saline 1.3 
  
STORAGE OF SYNTOCINON AND SALINE 2 
SmPC for Syntocinon 2.1 
SmPC for Saline 2.2 
CRC341 Temperature Log 2.3 
  
DISPENSING AND RANDOMISATION 3 
  
CRC341 Fax to pharmacy for allocation of randomisation number 3.1 
CRC341 Prescription order for bottle 3.2 
CRC341 Surrey CRC Bottle and Spray Device Dispensing Log 3.3 
CRC341 Syntocinon Bottle Assembly Checklist 3.4 
CRC341 Saline Bottle Assembly Checklist 3.5 
CRC341 Bottle weigh log 3.6 
  
TRANSIT TO SITE 4 
  
CRC431 Transit Log 4.1 
  
ADMINISTRATION 5 
  
CRC341 IMP Administration log 5.1 
  
DESTRUCTION 6 
  
CRC341 Bottle Weigh Log 3.6 
CRC431 Surrey Drug Destruction Accountability Form 6.1 
  
PHARMACY TRAINING LOG 7 
  
CORRESPONDENCE 8 
Copies of faxes received 
Copies of prescription orders 
8.1 
8.2 
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1. RECEIPT OF THE SYNTOCINON, SALINE AND INTRANASAL PUMPS 
 
 The supplier will notify the Pharmacy department of the anticipated delivery date of 
the product. The product will arrive in a cold box with a temperature logger. The 
product must be received into the department by a GCP trained member of staff. 
 On receipt of the product it must be unpacked and put in the Clinical Trials Fridge 
and the temperature data logger downloaded and emailed to the supplier as 
confirmation that the cold chain has been maintained and meets with SmPC 
requirements. 
 Upon receipt of the Syntocinon the “CRC341 Surrey CRC Drug Shipment 
Accountability Form: Syntocinon” should be completed. Signed by two signatures. 
 The accountability form is stored in the Oxytocin Pharmacy file in the clinical trials 
room. 
 The product remains under quarantine in the clinical trials fridge until it is authorised 
for release by the QP, which will be after they have received download of the data. 
 Upon receipt of the Saline the “CRC341 Surrey CRC Drug Shipment Accountability 
Form: Saline” should be completed. Signed by two signatures.  
 Upon receipt of the intranasal pumps the “CRC341 Intranasal Administration 
Device Accountability Form” should be completed.  There should be four 
components: Bottle, Spray Pump, Actuator and Cap.  Signed by two signatures.  
 
2. STORAGE OF SYNTOCINON AND SALINE 
 The Syntocinon should be stored according to the SmPC.  The SmPC is held in the 
Master Trial File and Pharmacy File.  
 Do not use after the expiry date (= EXP) printed on the pack 
 Special precautions for storage for nasal spray: Store in a refrigerator  (2-8 degree 
Celsius)  
 After opening the bottle, store the nasal spray at room temperature (15-25 degree 
Celsius) 
 Use within 1 (one) month. 
 The maximum and minimum temperature recorded each working day the Syntocinon 
is refrigerated should be documented on the “CRC341 Temperature Log”.  
 The Saline should be stored according to the SmPc. The SmPC is held in the 
Master Trial File and Pharmacy File. 
 Shelf life for 5ml, 10ml, 20 ml : 30 months. 
 There are no special precautions for storage. 
 To maintain the study blind the saline should be stored at the same temperature of 
the Syntocinon once dispensed into the intranasal spray bottles (room temperature 
15-25 degree Celsius). 
 
3. DISPENSING AND RANDOMISATION 
 
 The Sponsor will provide a Randomisation List which will detail the IMP allocation 
for each randomisation number. The randomisation number for each participant will 
be allocated from this list by the pharmacy, according to the screening number 
provided by the sponsor/researcher. 
  This list should be stored in a secure location.  
 The researcher, Carol Weber, or designee will contact the pharmacy by fax when an 
eligible participant has been identified and screened and will confirm that they will 
take part in the clinical trial. 
 Carol Weber, or designee, will confirm the allocated screening number, Date of Birth 
and proposed start date and first day of dosing, when IMP is required.   
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 The faxes will be stored in the trial paperwork held by pharmacy.  
 This will be followed up by a telephone call by Carol Weber to receive the 
randomisation number. 
 The pharmacist will confirm the next randomisation number on the list for Carol 
Weber, or designee. This will be checked and confirmed by a second person. 
 When a randomisation number is allocated to a patient the number must be ticked 
off on the list and initialled, so that it cannot be allocated by mistake to another 
patient. 
 If Carol Weber or designee requests a replacement randomisation number (due to 
the withdrawal of a participant), the pharmacist will use the replacement 
randomisation list and assign the new participant with the associated replacement 
number (e.g. if participant 003 withdraws, they should be replaced with replacement 
number 1003 to ensure the correct allocation of IMP or Saline is given to the new 
participants). 
 
 Carol Weber, or designee, will fax a prescription order to pharmacy for the 
dispensing and delivery of required treatment. 
 The “CRC341 Surrey CRC Bottle and Spray Device Dispensing Log” will be 
completed which will confirm the Screening Number, Randomisation Number, Date 
of Birth of participant.  This log will also confirm bottle number and whether this 
bottle contains IMP or saline.   
 The bottles should be assembled according to the “CRC341 Syntocinon Bottle 
Assembly Checklist” or “CRC341 Saline Bottle Assembly Checklist”, as appropriate 
and as per randomisation list and “CRC341 Dispensing Bottle and Spray Device 
Log”.  
 Bottles will be labelled and completed with relevant information according to the 
approved MHRA label. 
 Once dispensed the IMP or Saline/placebo can be stored according to the relative 
SmPC.  
 Each bottle will contain sufficient volume for 4 days of dosing (2 administrations per 
day).  Therefore each participant will require 4 bottles in total. 
 To maintain the study blind, both Syntocinon and saline bottles will have a 1 week 
expiry date.  
 
4. TRANSIT TO SITE 
 
 The temperature of the IMP and saline during transit should be in accordance with 
the SmPC, room temperature between 15-25 degree Celsius.   
 The IMP will be transported to Windmill House from the pharmacy at the 12h00 
delivery, where it will be received by Carol Weber or designee.  
 The “CRC431 Transit Log” should be used.  The pharmacy should complete part 1 
and a copy of the log transported with the IMP/saline where part 2 should be 
completed and the Log filed. 
 On receipt (IMP/Saline) each bottle should be weighed by Carol Weber or designee 
and the “CRC341 Bottle weigh log” filled in.  When the bottle is returned to pharmacy 
the “CRC341 Bottle weigh log” is to be completed. 
 The bottles are to be stored in locked pharmacy dispensing room at Windmill house.  
 
5. ADMINISTRATION 
 
 Carol Weber or designee will be responsible for the administration of the 
IMP/Saline Placebo. 
 This will be in accordance with the research protocol 
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 “CRC341 Administration log” will be completed after each administration by 
Carol Weber or designee.  
 
6. DESTRUCTION 
 
 The used bottles will be weighed by Carol Weber and “CRC341 Bottle Weigh 
Log” will be completed. 
 The empty bottles will be stored at Windmill House to later be destroyed as per 
protocol.  
 The “CRC431 Surrey Drug Destruction Accountability Form” should be 
completed and the study drug destroyed as per protocol.  
 
7. PHARMACY TRAINING LOG 
 
 All pharmacy staff involved in and handling IMP and associated material will be 
briefed and trained.  This is to be logged and signed by both staff member and 
pharmacist. 
----------------------------------------------------------------------------------------------------------------  
MHRA APPROVED LABEL 
 
Investigator: Dr Fiona Robinson 
Surrey and Borders Partnership NHS Foundation Trust, Abraham Cowley Unit, Chertsey, UK.   Tel: 
01932722096 
Clinical Study Protocol No: CRC341 
Dose 4 IU Syntocinon or placebo per 0.1ml actuation 
Dose Form: Nasal Spray 
Administer 6 actuations twice daily (a.m. and p.m.), 0.1 ml/actuation.  Use alternate nostrils for each 
actuation. 
 
Total quantity: 5 ml 
Randomisation No: ______ 
Assembly Date: ________ 
Bottle No: _____of  4____ 
Expiry Date: __/__/__ 
 
For clinical trial use only. 
Store at temperature below 25 degree Celsius.  
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Appendix 8 
Participant information sheet and consent form.  
 
 
INFORMATION SHEET FOR PARTICIPANTS 
REC Reference Number: 14/LO/1495 
Project reference Number: CRC341 
 
YOU WILL BE GIVEN A COPY OF THIS INFORMATION SHEET 
 
“Randomised Double Blind Placebo Controlled Trial of Oxytocin (Syntocinon) for the 
treatment of Opioid Dependence” 
 
We would like to invite you to participate in this original research project. This study will 
allocate participants, at random, to one or another condition.  One condition will be a control 
or placebo and the other condition will be the treatment condition (Oxytocin Spray).  The 
study has been reviewed and approved by the NRESResearch Ethics Committee-London 
Bridge. You should only participate if you want to; choosing not to take part will not 
disadvantage you in any way. Before you decide whether you want to take part, it is 
important for you to understand why the research is being done and what your participation 
will involve.  Please take time to read the following information carefully and discuss it with 
others if you wish.   
Participants will receive standard care as normal. 
 Part 1 of this Volunteer/Patient Information Sheet tells you the purpose of this study and 
what will happen to you if you take part.   
 Part 2 gives you more detailed information about the conduct of the study.   
 
Ask us if there is anything that is not clear or if you would like more information. 
 
What is the purpose of this study?  
The major problem for opioid (typically heroin) dependent individuals who are recovering 
from their addiction is the maintenance of a drug free state. Following detoxification from 
opioids, many individuals struggle with their emotions and these emotions can be triggers for 
relapse. Drugs currently used to treat heroin addiction have limited success in reducing 
these emotional withdrawal symptoms and in preventing relapse. Previous research has 
shown that oxytocin, a hormone produced by our body, can reduce anxiety (including social 
anxiety) when administered as a nasal spray. Oxytocin may also reduce feelings of 
depression and may enhance the motivation to socialise. This research will measure if 
oxytocin, administered as a nasal spray, is effective in assisting opioid dependent individuals 
on the 4 week programme post detoxification at Windmill House to maintain abstinence from 
drug use.  
There is currently no effective way of predicting relapse vulnerability of opioid dependent 
individuals.  Predicting vulnerability to relapse would be of assistance to both the individual 
and their advisors and allow for increased support.  
 
Are you suitable for this study?  
You have been given this information sheet as you have expressed an interest in our 
research. You have been invited to take part in this study because you have a primary 
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diagnosis of opioid dependence.  In order to participate in this study you need to be able to 
answer ‘Yes’ to all of the following:  
 
 I am aged between 18 and 65 years 
 I am a male or female who is not pregnant or breast feeding 
 I am diagnosed with opioid dependence 
 I will be undergoing an opiate detoxification programme and intend to enter the 4 
week inpatient drug free programme at Windmill House 
 I do not have a history of severe psychosis, manic depression, severe depression 
with suicidal tendencies or severe neurological, kidney or cardiovascular disorders 
 I will not be taking anxiolytics, antipsychotics, sedatives, prostaglandins, certain 
inhalation anaesthetics (e.g. cyclopropane, halothane), or opioids for pain 
management during the drug free post-detoxification programme at Windmill House 
 
There may be other reasons why you may not be able to participate in this study. The study 
doctor or staff will discuss these with you. You may not be able to take part in this study if 
you do not satisfy all of the study criteria. 
 
A minimum of 30 participants will take part in this study all at Windmill House, Surrey, UK 
  
Do I have to take part? 
It is entirely up to you to decide to join the study.  We will describe the study and explain this 
information sheet.  If you agree to take part, we will then ask you to sign a consent form. If 
you do decide to take part you will be given this information sheet to keep and a copy of your 
signed consent form.  You are free to withdraw at any time, without giving a reason.  This will 
not affect the standard of care you receive.  
 
What will happen to you if you take part?  
Your involvement would only be a maximum of 46 days.  During this time, you will be asked 
to visit the researcher at Windmill House on up to 6 occasions.  Each visit will last between 
1-1½  hours.  See below for details about what will happen at each visit.  
 
If you answered ‘yes’ to the above questions and remain interested in participating, we will 
ask some further questions about your health over a screening session (visit 1) with Ms. 
Carol Weber (PhD student) at Windmill House. During this first visit, the study will be 
explained in detail and you will have the opportunity to ask any questions you may have in 
order to ensure you will be giving fully informed consent. If you would like to participate in the 
study, we will then ask you to sign a consent form. Eligible participants will be invited to take 
part in the study and will be given an diary (electronic or paper) where you would be asked to 
record any daily information on your drug intake including illicit drugs, alcohol and 
prescription medication, timing of period (for females to monitor pregnancy possibility) and to 
record your craving, withdrawal symptoms, sleep quality, alertness, calmness, anxiety, 
happiness, sadness, sociability with the use of scoring scale.  
 
We will need to obtain details about your medical history including blood test results upon 
admission, medication and psychiatric history and complications from your medical notes. 
Blood pressure, temperature and heart rate will also be measured on each visit.  
 
You will also be given an Actiwatch to record activity and sleep patterns (day-time and night-
time) throughout the whole duration of the study. You will be required to wear the Actiwatch 
(Figure 1) at all times apart from when in the shower or the bath.  
Fig. 1 Actiwatch 
At least 2 days after the last dose of opioid detoxification, a second visit (visit 2) will be 
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planned at Windmill House. At that visit, you will be asked to complete a range of 
questionnaires which will enable us to quantify your mood state, anxiety, social cognition, 
opioids craving and severity of withdrawal symptoms, social anxiety, quality of life and sleep. 
You will also be asked to provide a saliva and urine sample. This should take 1-1½ hours. 
A third visit  (visit 3) will be planned where you will be given a bottle containing 5 ml of either 
oxytocin (Syntocinon) or placebo (spray containing saline) which you will administer nasally 
(see Figure 2 for illustration of the spray). Each test dose will consist of 6 sniffs of oxytocin or 
placebo spray (with each insufflation given 30 seconds apart and alternating between 
nostrils) which will be administered twice a day between 09:00-11:00 h and 16:00-18:00 h for 
14 days. Each dose will be administered under the supervision of Ms. Carol Weber or 
member of the care team.  
Figure 2: Picture of the spray 
Then, you will be asked to carry out two more visits at Windmill House, one on day 2 (visit 4) 
and one on day 14 (visit 5) after the start of the treatment.  At those visits you will be asked 
to complete a range of questionnaires which will enable us to quantify your mood state, 
anxiety, social cognition, opioids craving, and severity of withdrawal symptoms, social 
anxiety and sleep.. This should take 1-1 ½ hrs. 
You will undergo a post-study safety assessment after last treatment before you get released 
from the inpatient post detoxification programme. 
A final visit (visit 6) will take place 30-35 days after the administration of the last dose of 
placebo or oxytocin, subsequent to being discharged from Windmill House program. You will 
be asked to return to one of the Surrey & Borders rehabilitation centers. At that visit, you will 
be asked to complete the same set of questionnaires as on visit 2. This should take 1-1½ 
hrs.  
Testing for illicit drugs (urine screen) and breathalysing for alcohol will be done twice weekly 
during the 14 day duration of the treatment according to Windmill House procedures.  In the 
event of any positive urine samples or breathalysing for alcohol, the subject will discharged 
from the rehabilitation centre and will be deemed as having lapsed/relapsed. Subjects will 
also be discharged if they admit self-reported opioid or any other illicit drug (or alcohol) use. 
Where participants missed periods of time in treatment, they will be deemed to have 
discontinued from the study (and dropped out of treatment). 
 
A diagram of the study schedule can be found which simplifies the study plan, but please ask 
us if anything is not clear (Fig. 3).   
  
Randomised Trial   
This study is a randomised trial.  This means that you will be put in one of two groups. One 
group will receive the Oxytocin spray, the other will receive a ‘placebo’ or mock spray. No 
one in Windmill House will know whether you are in the study or control group.   
 
Expenses and Payments 
You will not be charged for any study medications you receive.   
 
You will receive an inconvenience allowance for participating in this study. This will be in the 
form of vouchers (which will exclude purchase of tobacco and alcohol) and the value will 
accord to the number of visits completed by the subject. The subject will be reimbursed at 
the end of their participation of the study. The maximum inconvenience allowance payable is 
£40 if you complete the study.  
 
Please note that non-compliance with any of the procedures or tests/measurements under 
investigation may result in a decrease of the inconvenience allowance.  
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The following may also affect your compensation payment: 
o you pass the screening medical, but decide not to take part in the study 
 
What are the alternatives for diagnosis or treatment? 
If you decide not to take part in this study, your study doctor will provide appropriate 
alternative treatment. Your study doctor will discuss with you what the alternative treatments 
are. 
 
Are there any risks associated and disadvantages with taking part in the study? 
There are relatively low risks associated with this study. That low risk is associated with the 
use of intranasal oxytocin (see below). 
Before participating you should consider if this will affect any insurance you have and seek 
advice if necessary.  Some insurance companies treat participation in studies of this nature 
as a material fact that should be mentioned when making any proposal for health related 
insurance. Accordingly, your participation in this study should be disclosed to any insurer if 
you are in the process of seeking or renewing any such insurance, and you should check 
that participation does not affect any existing policies you may hold.  
 
What are the possible side effects of any treatment received when taking part? 
Previous research studies have shown that intranasal oxytocin at the doses given in this 
study is relatively safe. There are, however, special warnings for prolonged use of excessive 
doses together with large volumes of fluid as this has been known to cause water 
intoxication with hyponatraemia which may result in low levels of sodium in your blood . This 
is extremely low risk as there will be no risk of overdosing as dosing will be supervised. 
Caution is required when using oxytocin in patients with impaired hepatic or renal function 
and patients with a history of cardiovascular diseases, this why patients with severe renal 
problems and severe cardiovascular diseases will be excluded. Caution is also requited 
when using oxytocin in patients with severe psychosis, Bipolar Affective Disorder I, severe 
depression with suicidal ideation and intention, brain trauma or other severe neurological 
disorders (e.g. pan-hypopituitarism), this is why patients with such diagnosis will be excluded 
from the study. Therefore if you have been approved to take part in the study, it will be highly 
unlikely that you will be in danger of any serious side effects currently known. 
 
Oxytocin/Syntocinon spray is absolutely contraindicated in pregnancy. There may also be 
risks to an unborn child.  For this reason, women of child-bearing potential must use suitable 
contraception, as agreed with the study doctor, during their participation in the trial and will 
be tested for pregnancy before the start of the study.   
 
There may also be other risks that we don’t yet know about.  For this reason it is very 
important that you notify your study doctor immediately of any new illnesses/medical 
conditions or any worsening of an existing condition as soon as possible. 
 
What are the possible benefits of taking part? 
We cannot promise the study will help you but the information we get from this study may 
help improve the treatment of opioid dependent individuals. 
 
What happens when the research study stops? 
At the end of the study, you will be thanked for your participation and you will be reimbursed 
as described in this volunteer information sheet. Study drug will only be available to you 
while you participate in the study. 
 
Sometimes, the sponsor or your study doctor may decide to stop the study early.  If this 
happens, your study doctor will explain the reasons why and either arranges appropriate 
care for you or thank you for your participation in the study. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed.  The detailed information on this is given in Part 2. 
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Will your participation be kept confidential?  
Information collected about you during this research will be kept strictly confidential and we 
will follow an ethical and legal practice, as outlined in Part 2 of this information sheet. Patient 
confidentiality and anonymity will be maintained throughout the study by use of identification 
codes in place of names, and the storage of subject details in a secure place. Only 
investigators have access to this data and only anonymised data will be shared with other 
researchers.  
 
Data will be stored securely in accordance with the Data Protection Act 1998. 
 
Should you wish to find out the results of this study you are welcome to contact Carol Weber 
(details below) for a copy of the final report once the study is finished.   
 
This completes Part 1 of the Patient/Volunteer information sheet.   
 
If the information in Part 1 has interested you and you are considering participation, please 
read the additional information in Part 2 before making any decision. 
 
Part 2  
 
What if relevant new information becomes available? 
Sometimes we get new information about the treatment being studied.  If this happens, your 
research doctor will tell you and discuss whether you should continue in the study.  If you 
decide not to carry on, your research doctor will make arrangements for either your care to 
continue or you to end your participation in the study.  If you decide to continue in the study 
the study doctor may ask you to sign an updated version of the informed consent form. 
 
What will happen if I don’t want to carry on with the study? 
You may decide to withdraw from the study at any time.  This will not affect the standard of 
care you receive.  Your study doctor will discuss arrangements for your continued treatment 
with you.  
 
If you decide to withdraw and have taken a study medication you will be asked to return to 
see the research team for a final follow-up visit. 
 
Information that has already been collected from you will continue to be used for the 
purposes of the study.  However, no new information will be collected from you.  It will be up 
to you to decide if data from your final visit can be used or not. 
 
The study doctor may decide to withdraw you from the study if he/she feels this is in your 
best interests, for example if you get side effects to the study medication.   
The sponsor may decide to stop the study at any time, for any reason.  
We may withdraw you without your consent if you do not follow the study instructions given 
to you by the study team.    
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions (Carol Weber, 
c.weber@surrey.ac.uk).   If you remain unhappy and wish to complain formally, you can do 
this in writing to Ann Ward, Head of Operations and Quality Systems, Surrey Clinical 
Research Centre, Egerton Road, Guildford, Surrey, GU2 7XP.  
 
Harm 
Compensation for Trial-related injury 
In the event that something does go wrong the sponsor agrees to compensate participants 
who suffer any significant worsening in health or well-being caused directly as a result of 
taking part in the study.  The sponsor, University of Surrey agrees to compensate volunteers 
according to the guidelines of the Association of the British Pharmaceutical Industry. A copy 
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to read is available on request. The sponsor has clinical trials insurance that covers both 
negligence and no-fault compensation, which is intended to provide compensation to clinical 
trial participants in the event of their suffering a significant and enduring injury (including 
illness or disease) which is probably caused by their involvement in the study. If you were to 
become ill while at Windmill House, we would give you any immediate treatment that was 
needed. If you became ill soon after leaving Windmill House you should contact us 
immediately on the numbers provided on the emergency contact card. Your rights at law to 
claim compensation where you can prove negligence are not affected.  Claims for 
compensation should be made in the first instance to the Sponsor Mr Ali Alshukry, RIGO, 
University of Surrey, 4th Floor, Senate House, Guildford, GU27XH, tel. 01483 683491, email. 
a.alshukry@surrey.ac.uk. 
The Association of British Pharmaceutical Industry Guidelines clarify in which circumstance 
the Sponsor should pay compensation but the sponsor would not be bound by these 
guidelines to pay compensation where: 
 
 The injury resulted from a drug or procedure outside the trial protocol 
 The protocol was not followed. 
 
 
Amount of compensation payment 
The amount of compensation would be similar to the amount commonly awarded for similar 
injuries by an English court if the sponsor admits fault, provided that the amount of 
compensation may be reduced if you are partly responsible for the injury. 
 
Will my taking part in this study be kept confidential? 
If you join the study, some parts of your medical records, including your name and address, 
and the data collected for the study will be looked at by authorised persons from the 
University of Surrey and Surrey & Borders NHS Trust sponsoring and/or organising the 
research.  They may also be looked at by authorised people from regulatory bodies to check 
that the study is being carried out correctly.  The information that we store may include some 
‘sensitive’ information about your health. All will have a duty of confidentiality to you as a 
research participant and we will treat your data appropriately. Data will be stored securely in 
accordance with the Data Protection Act 1998. 
 
The information and any materials or items that you are given about or during the study - 
such as information regarding the study drug(s) or the type of study being performed should 
be considered the confidential business information of the study sponsor. You are of course 
free to discuss such information in confidence with your doctor or with your friends and 
family while considering whether to participate in this study or at any time when discussing 
your present or future healthcare. 
 
What will happen to your study results?  
The anonymised study results will be presented in a report and we will publish them in a 
scientific journal. You will not be identified in the results of the study or any publication that 
might arise from this study. We will be happy to discuss the overall results with you when the 
study is completed, and will let you know how you can get a copy of the published results if 
you wish.  
 
Who is organising and funding the study?  
The study is organised and funded by the Faculty of Health and Medical Sciences, University 
of Surrey, Stag Hill, Guildford, GU2 7XH and Surrey & Borders Partnership NHS Foundation 
Trust, Holloway Hill, Chertsey, KT16 0AE 
 
Who has reviewed the study? 
This study has been looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests.  This study has been reviewed and given favourable 
opinion by NRES Research Ethics Committee-London Bridge. 
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You will be given a copy of this information sheet and the signed consent form to take home 
with you. 
 
 
Further information and contact details. 
For further information about taking part in clinical trials, please visit the following website: 
 
http://www.ukcrc.org/publications/news/clinicaltrialsinformation.aspx 
 
For further information on this specific trial including more information about oxytocin and its 
effects visit the study web site http://www.surrey.ac.uk/ 
 
Thank you for your interest. 
For further information, please contact:  
Carol Weber by email on c.weber@surrey.ac.uk or by telephone on 01483-683342 
Dr Fiona Robinson on 01932-722096 (emergency contact) 
 
If this study has harmed you in any way you can contact Surrey University using the details 
below: 
Prof. Debra Skene (d.skene@surrey.ac.uk) 
Department of Biochemistry & Physiology 
Faculty of Health & Medical Sciences 
University of Surrey 
Guildford  
Surrey GU27XH 
tel: ++44(0)1483682564 
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Study Number:CRC341 
 
Subject/Patient Number for this trial: _____________ 
 
Title of Project: Pilot RCT of oxytocin for the treatment of opioid dependence 
 
Name of principle Investigator: Fiona Robinson 
 
1. I confirm that I have read and understand the information sheet version number 
9 dated 23 May 2017 for the above study.   
I have had the opportunity to consider the information, ask questions and have 
had these  answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at  
any time without giving any reason, without my medical care or legal rights being  
affected. 
 
3. I understand that relevant sections of my medical notes and data collected during  
the study may be looked at by individuals from Surrey and Borders NHS Trust,  
      members of the research team at the University of Surrey, from regulatory  
authorities or from the NHS Trust, where it is relevant to my taking part in this  
research.  I give my permission for these individuals to have access to my 
records. 
 
 
4. I consent to my personal data, as outlined in the accompanying information 
sheet, being used for this study and other research.  I understand that all 
personal data relating to volunteers is held and processed in the strictest 
confidence, and in accordance with the Data Protection Act (1998).   
 
5. I agree to take part in the above study. 
 
 
____________________ ___________________ ____________________ 
Name of Patient  Date & Time   Signature 
 
____________________ ___________________ ____________________ 
Name of Person taking Date & Time   Signature 
Consent 
 
 
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in 
medical notes. 
 
Please initial 
box 
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Appendix 9 
Screening and Randomisation Log 
 
 
 
Screening and Randomisation Sheet 
  Subject 
name 
Subject 
initials 
Date of Birth 
Screen. 
No. 
Date of 
Screening 
Screen Fail  
Reason 
(Inc/Exc 
number/n/a) 
Date Randomised  
Randomisation 
number  
  
   
 
 
           
d d  m m m  y y y y 
  
901  
           
d d  m m M  y y y y 
 
 
 
           
d d  m m m  y y y y 
 
 
  
   
 
 
           
d d  m m m  y y y y 
  
902  
           
d d  m m M  y y y y 
 
 
 
           
d d  m m m  y y y y 
 
 
  
   
 
 
           
d d  m m m  y y y y 
  
903 
           
d d  m m M  y y y y 
 
 
 
           
d d  m m m  y y y y 
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Appendix 10 
Study Screening Workbook 
 
 
 
CRC 341 
Screening Workbook 
 
 
Study 
Number : 
 CRC 341 
Site :    Windmill 
House 
NHS Surrey 
and Borders 
Trust 
Clinical 
Principal Chief 
Investigator : 
  
Dr Fiona 
Robinson  
 
Academic 
Principal 
Investigator :  
  
Dr Alexis 
Bailey/ 
Prof Debra 
Skene 
 
 
 
 
Screening Number ___________ 
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Date of Visit 
 
 
Informed Consent Date 
 
 
Demography  Sex   
 
   Date of Birth  
 
 
   Age 
 
Weight 
 
Height  
Performed by : 
 
____________________________
_ 
 
Confirm Age between 18 – 65 years       __________________________ 
 
Medical History Questionnaire reviewed    __________________________ 
 
Clinical Laboratory Tests reviewed  
(haematology,Clinical History, Urinalysis   __________________________ 
& Microscopy if required) 
 
 
 
 
 
__ __ / __ __ __ / __ __ __ 
__ 
__ __ / __ __ __ / __ __ __ 
__  
__ __ / __ __ __ / __ __ __ 
__ 
  Male      / Female 
__ __ / __ __   
Years Months  
 
 
 
   
   (kg) 
 
 
 
 
   
     (m) 
 
 
 
 
SCREENING (Visit 1) 
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MEDICAL STATUS  
VITAL SIGNS 
Date Performed  
__ __ / __ __ __ / __ __ 
__ 
 
Actual Time (24 hr 
clock) 
Systolic BP(mmHg) Diastolic BP (mmHg) Heart Rate (bpm) 
 Normal Range 90-150 Normal Range 50-100 Normal Range 40-100 
 
__ __ : __ __ 
   
 
 
_______________________________________________________________ 
 
URINALYSIS TEST Date Performed  
__ __ / __ __ __ / __ __ 
__ 
 
BatchNo Expiry Date  Time of Sample 
 
______________ 
 
_____________ 
 __ __ : __ __ 
(24 Hr clock) 
 
Result    Normal 
  
 
Actual Time (24 hr 
clock) 
Procedure Result 
  
__ __ : __ __ 
Respiratory Rate  
___ ___ (breaths per min) 
 
__ __ : __ __ 
Oral Temperature  
__ __. __ (°C)  
Normal range 35-37°C 
Performed by: 
 
_______________
___ 
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AE AND CONMED REVIEW  
 
  
Has the subject experienced any AEs since the last 
visit? 
□ Yes  □ No 
 Has the subject taken any ConMeds since the last 
visit? 
□ Yes  □ No 
  
Has the subject taken any non-steroidal anti-
inflammatory drugs (e.g. Asprin, Ibuprofen, Nurofen), 
vitamins or other supplements, or any prescribed 
medication (except oral contractive, if appropriate). 
 
□ Yes  □ No 
If the answer to any question is YES, an AE form or Conmed 
entry to be completed.  
 
 
 
PREGNANCY TEST     N/A 
 (Tick box if post  menopausal) 
        
Date of Test  
__ __ / __ __ __ / __ 
__ __ __ 
BatchNo Expiry Date   
 
______________ 
 
_____________ 
  Result:  
Positive        Negative 
  
 
 
ALCOHOL BREATH TEST  
 
Test Result : Negative  Positive  
 
AE Number _________ 
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Please list significant, relevant 
Medical / Psychiatric History ………………… NONE 
 
  
Medical/Psychiatric Condition 
Date condition 
started 
 
Month  /  Year 
Date condition 
ended 
 
  Month  /  Year 
 
 
Ongoing 
 
 
CS/NCS? 
 
1 
 
 
 
 
 
------/------ 
 
 
------/----- 
     
     Y 
     N 
 
 
   cs 
   NCS 
 
 
2 
 
 
 
 
 
------/------ 
 
 
------/----- 
     
     Y 
     N 
 
 
   cs 
   NCS 
 
 
3 
 
 
 
 
 
------/------ 
 
 
------/----- 
     
     Y 
     N 
 
 
   cs 
   NCS 
 
 
4 
  
 
------/------ 
 
 
------/----- 
     
     Y 
     N 
 
 
   cs 
   NCS 
 
 
6 
 
 
 
 
------/------ 
 
 
------/----- 
     
     Y 
     N 
 
 
   cs 
   NCS 
 
 
7 
 
 
 
 
------/------ 
 
 
------/----- 
     
     Y 
     N 
 
 
   cs 
   NCS 
 
 
8 
 
 
 
 
------/------ 
 
 
------/----- 
     
     Y 
     N 
 
 
   cs 
   NCS 
 
 
9 
 
 
 
 
 
------/------ 
 
 
------/----- 
     
     Y 
     N 
 
 
   cs 
   NCS 
 
 
10 
  
 
------/------ 
 
 
------/----- 
     
     Y 
     N 
 
 
   cs 
   NCS 
 
 
MEDICAL/PSYCHIATRIC HISTORY 
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Please list all 
Recent/Concomitant 
Medication …………………  NONE 
 
 
 Medication 
(trade name) 
Total 
Daily 
Dose 
and 
Unit 
Route Start Date Stop Date Ongoing 
at end of 
study? 
Indication 
 
1 
    
---------/-------
-/ 
 
------------------ 
 
---------/-------
-/ 
 
------------------ 
     Y 
 
     N 
 
 
 
2 
    
---------/-------
-/ 
 
------------------ 
 
---------/-------
-/ 
 
------------------ 
     Y 
 
     N 
 
 
 
3 
    
---------/-------
-/ 
 
------------------ 
 
---------/-------
-/ 
 
------------------ 
     Y 
 
     N 
 
 
 
4 
    
---------/-------
-/ 
 
------------------ 
 
---------/-------
-/ 
 
------------------ 
     Y 
 
     N 
 
 
 
5 
    
---------/-------
-/ 
 
------------------ 
 
---------/-------
-/ 
 
------------------ 
     Y 
 
     N 
 
 
RECENT/CONCOMITANT MEDICATION 
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The following must all be answered YES 
otherwise the subject is not eligible for 
       the study. 
 
1 
 
The subject is between 18 and 65 
years of age.  
     
Yes 
 
     
No 
 
 
Initials 
 
________ 
 
2 
 
The subject has a primary 
diagnosis of opioid dependence 
according to DSMIV criteria. 
     
Yes 
     
No 
 
 
Initials 
 
________ 
 
3 
 
The subject is either male or non-
pregnant,non- lactating female 
     
Yes 
     
No 
 
 
Initials 
 
________ 
 
4 
 
The subject is willing and able to 
give informed consent 
     
Yes 
     
No 
 
 
Initials 
 
________ 
 
5 
 
The subject has a full 
understanding of English. 
     
Yes 
    
No 
 
 
Initials 
 
________ 
 
6 
 
The subject has completed an 
opioid detoxification programme 
at Windmill House. 
     
Yes 
     
No 
 
 
Initials 
 
________ 
 
7 
 
The subject has agreed to wear 
actiwatches and complete written 
or electronic self-assessment 
questionnaires while undertaking 
the study at Windmill House.   
     
Yes 
     
No 
 
 
Initials 
 
________ 
 
INCLUSION 
CRITERIA 
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The following must all be answered NO 
otherwise the subject is not eligible for 
       the study. 
 
 
     
 
1 
 
The subject has a history of 
suffering from a clinically significant 
systemic, psychiatric or 
neurological disease which includes 
severe psychosis, bipolar affective 
disorder I, severe depression with 
suicidal ideation and intention, 
brain trauma or other severe 
neurological disorders (e.g. 
panhypopituitarism) 
 
 
 
Yes 
 
No 
 
 
 
 
 
Initials 
 
 
 
 
________ 
 
2 
 
The subject is taking anxiolytics, 
antipsychotics, sedatives, 
prostaglandins, certain inhalation 
anaesthetics (e.g. cyclopropane, 
halothane) opioids for pain 
management during post opiate 
detoxification.  
Yes 
 
No 
 
 
Initials 
 
________ 
 
3 
 
The subject is a pregnant female or 
lactating mother. 
Yes 
 
No 
 
 
Initials 
 
________ 
 
4 
 
The subject has a history of kidney 
disease. 
Yes 
 
No 
 
 
Initials 
 
________ 
 
5 
 
The subject has a history of 
cardiovascular disease (heart 
disease, heart attacks, high blood 
pressure, heart surgery). 
Yes 
 
No 
 
 
Initials 
 
________ 
 
6 
 
The subject has a habitual drinking 
of large volumes of water.  
Yes 
 
No 
 
 
Initials 
 
________ 
EXCLUSION 
CRITERIA 
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7 
 
The subject has a current or history 
of nasal bleeding. 
Yes 
 
No 
 
 
Initials 
 
________ 
 
8 
 
The subject would be considered 
unsafe to participate as determined 
by the judgement of the 
investigator.  
Yes 
 
No 
 
 
Initials 
 
________ 
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Tick Comments Initials 
 
Actiwatch given 
 
   
 
Explanation about 
use of actiwatch  
 
   
 
Self Assessment 
questionnaires 
explained. In 
patient diary and 
on-line app. 
 
   
 
Subject has been reminded to adhere to study restrictions:  ..   
Initials: __________ 
 
Subject has been given information sheet:       
Initials: __________ 
 
Subject signed consent form and is in receipt of a copy    
Initials: __________ 
 
 
Subject eligible to take part in the 
study?  
 
 
 
 
 Yes 
 
 
 No 
 
ADMISSION TO STUDY 
 
 
 
_______________________ 
Signature  
 
Name 
 
__ __ / __ __ __ __ / __ __ __ __ 
 DAY MONTH  YEAR 
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Appendix 11 
File stickers 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
  
  
  
  
  
  
  
 
     THIS PATIENT IS IN A CLINICAL RESEARCH TRIAL  
Subject No ________________     PI: Dr Fiona Robinson 
Consent Date: ____ / ____ / ____   
Start Date: ______ / _____ / ____  Finish Date:  _____ / ______ / _____ 
 
 SAE ALERT NOTICE 
PLS REPORT ANY ADVERSE EVENT THAT IS SERIOUS IMMEDIATELY  
An SAE is ANY untoward Medical Occurrence that either: 
• Results in death  
• Is life threatening 
• Requires hospitalization or prolongation of existing hospitalization   
• Results in persistent or significant disability or incapacity 
• Consists of a congenital anomaly or birth defect 
• Other medically significant event 
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Appendix 12 
Study Workbook  
 
 
 
 
 
 
CRC 341 
Workbook 
 
 
Screening Number  
 
  
Random. Number  
 
 
 
 
  
 
 
 
 
 
Date of 
Screening: 
 
__ __ / __ __ __ / __ __ __ 
 
 
Screening No: 
 
 
 
____________________ 
 
____________________ 
SCREENING (Visit 1) 
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Informed 
Consent Date: 
 
__ __ / __ __ __ / __ __ __ 
 
 
 
Acti-watch provided with  
instructions 
 
 
 
 
 
Date of 
Visit: 
__ __ / __ __ __ / __ __ __     
 
 
 
BASELINE MEASUREMENTS (PART 1) 
 Time: ___  ___ : __ __ 
   (24 Hr) 
 
AE AND CONMED REVIEW  
 
 Has the subject experienced any AEs since the 
last visit/dose? 
□ Yes  □ No 
 Has the subject taken any ConMeds since the 
last visit/dose? 
□ Yes  □ No 
 Has the subject taken any non-steroidal anti-
inflammatory drugs (e.g. Asprin, Ibuprofen, 
Nurofen), vitamins or other supplements, or 
any prescribed medication (except oral 
contractive, if appropriate). 
□ Yes  □ No 
 
BASELINE DAY (Visit 2) 
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If the answer to any question is YES, an AE form or 
Conmed entry to be completed.  
EDICAL STATUS  
VITAL SIGNS 
 
 
Actual Time 
(24 hr clock) 
Systolic BP(mmHg) Diastolic BP (mmHg) Heart Rate (bpm) 
 Normal Range 90-
150 
Normal Range 50-100 Normal Range 40-
100 
__ __ : __ __    
 
 
Actual Time (24 
hr clock) 
Procedure Result 
 __ __ : __ 
__ 
Respiratory Rate ___ ___ (breaths per min) 
__ __ : __ __ Oral Temperature 
 
__ __. __ (°C)  Normal range 35-37°C 
 
 
PREGNANCY TEST 
    N/A 
 (Tick box if post  menopausal) 
        
Date of Test __ __ / __ __ __  
Result:  Positive             
 
  Negative 
 
  
 
ACTI-WATCH CHECK AND SLEEP DIARY COMPLETED 
 
Performed by: 
 
__________________ 
AE Number _________ 
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 Has the Actiwatch Data been 
checked/functioning? 
□ Yes  □ No 
 Has the sleep diary been completed? □ Yes  □ No 
 
BASELINE MEASUREMENTS (PART 2) 
  
Time: ___  ___ : __ __  
 (24 Hr) 
 
Subjective Opiate Withdrawal Scale  (SOWS) 
 
□ Yes □ No 
Self Assessment Diary □ Yes □ No 
 
 
! WAIT (approx) 50 MINUTES! 
 Time: ___  ___ : __ __ 
   (24 Hr) 
 
 
QUESTIONNAIRES / TESTS 
 
Name Completed 
Reading the Mind in the Eyes Test  -Revised □ Yes □ No 
Liebowitz Social Anxiety Test □ Yes □ No 
Hamilton Psychiatric Scale of Depression (HDRS) □ Yes □ No 
Hamilton Psychiatric Scale of Anxiety (HARS) □ Yes □ No 
Leeds Sleep Evaluation Questionnaire □ Yes □ No 
WHO- Quality of Life Questionnaire – BREF □ Yes □ No 
 
TREATMENT DAY 1 (Visit 3) 
 
Date: __ __ / __ __ __  Time:   ___  ___ : __ __ 
(24 Hr) 
 
Has the subject’s identification been checked? □ Yes  □ No 
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     Initials and date : _________________ 
Has the subject confirmed that they wish to proceed with trial? □ Yes  □ No 
 
      Initials and date : ________________ 
 
AE AND CONMED REVIEW  
 Has the subject experienced any AEs since the 
last visit? 
□ Yes  □ No 
 Has the subject taken any ConMeds since the 
last visit? 
□ Yes  □ No 
 Has the subject taken any non-steroidal anti-
inflammatory drugs (e.g. Asprin, Ibuprofen, 
Nurofen), vitamins or other supplements, or 
any prescribed medication (except oral 
contractive, if appropriate). 
□ Yes  □ No 
If the answer to any question is YES, an AE form or 
Conmed entry to be completed.  
 
VITAL SIGNS  
 
Actual Time (24 
hr clock) 
Systolic 
BP(mmHg) 
Diastolic 
BP(mmHg) 
Heart Rate 
(bpm) 
 Normal Range 
90-150 
Normal Range 
50-100 
Normal Range 
40-100 
__ __ : __ __    
 
Actual Time (24 
hr clock) 
Procedure Result 
__ __ : __ __ 
 
Respiratory Rate ___ ___ (breaths per min) 
__ __ : __ __ Oral Temperature __ __. __ (°C)  
            Normal range 35-37°C  
 
         Initials : _________________ 
AE Number _________ 
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PREGNANCY REVIEW N/A  □  First day of last 
period 
__ __ / __ _ __ / _ _ _   
                  Day  /  Month   /   Year 
ALCOHOL BREATH TEST  N/A  □ 
Date of 
sample 
 
__ __ / __ __ __ / _ _ _ _     
Day        Month         Year 
 Time of Visit  
____ ____ : ___ ___ 
(24 Hr) 
Test result  □ Negative  
  □ Positive   Signature: _________________________ 
ACTI-WATCH CHECK AND SLEEP DIARY TEST CHECK 
 Has the Actiwatch Data been checked/functioning? □ Yes  □ No 
 Has the sleep diary been completed? □ Yes  □ No 
Is the participant still eligible to be dosed?     □ Yes  □ No 
Confirmed by Initials and date: __________________ 
QC checked by Initials and date: __________________ 
TREATMENT ADMINISTRATION (1st) [9:00am-11:00am] 
Bottle check Y/N  □ 
Bottle No __________ 
Confirmed by Initials/date:  
QC check by Initials/date:  
____________________ 
6 Insufflations of spray administered, alternating nostrils (30 secs apart) 
If necessary, please 
complete a 
COMPLETION / 
WITHDRAWAL  form 
 
Confirmed by Initials/date: __________________ 
 
QC check by Initials/date: ____________________ 
TREATMENT ADMINISTRATION (2nd)  [16:00-18:00pm] 
Bottle check Y/N  □ 
Bottle No __________ 
Time of administration:__ __ : __ __(24 Hr) 
□ Yes     
□ No : Reason ___________________________________ 
 
Time  ____ ____ : 
___ ___(24 Hr) 
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Confirmed by Initials/date: 
____________________ 
QC check by Initials/date: 
____________________ 
AE AND CONMED REVIEW  
 
 Has the subject experienced any AEs / side 
effects since the last dose? 
□ Yes  □ No 
 If the answer to any question is YES, an AE entry 
to be completed. 
AE number :  
 
6 Insufflations of spray administered, alternating nostrils (30 secs apart) 
If necessary, please 
complete a 
COMPLETION / 
WITHDRAWAL  form 
 
 
Confirmed by 
Initials/date: __________________ 
QC check by Initials/date: ____________________ 
 
! WAIT (approx) 50 MINUTES! 
 Time: ___  ___ : __ __ 
   (24 Hr) 
 
Self Assessment Diary □ Yes □ No 
SOWS completed □ Yes □ No 
 
TREATMENT DAY 2 (Visit 4) 
 
Date: __ __ / __ __ __ / Time:   ___  ___ : __ __ 
(24 Hr) 
 
Has the subject’s identification been checked? □ Yes  □ N 
□ Yes     
□ No : Reason ___________________________________ 
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     Initials and date : _________________ 
Has the subject confirmed that they wish to proceed with trial? □ Yes  □ No 
 
      Initials and date : ________________ 
 
 
AE AND CONMED REVIEW  
 
 Has the subject experienced any AEs since the 
last dose? 
□ Yes  □ No 
 Has the subject taken any ConMeds since the last 
dose? 
□ Yes  □ No 
 Has the subject taken any non-steroidal anti-
inflammatory drugs (e.g. Asprin, Ibuprofen, 
Nurofen), vitamins or other supplements, or any 
prescribed medication (except oral contractive, if 
appropriate). 
□ Yes  □ No 
If the answer to any question is YES, an AE form or 
Conmed entry to 
 be completed.  
 
 
VITAL SIGNS  
 
Actual Time (24 
hr clock) 
Systolic BP 
(mmHg) 
Diastolic BP 
(mmHg) 
Heart Rate 
(bpm) 
 Normal Range 
90-150 
Normal Range 
50-100 
Normal Range 
40-100 
__ __ : __ __    
 
Actual Time (24 
hr clock) 
Procedure Result 
 __ __ : __ _ 
 
Respiratory Rate ___ ___ (breaths per min) 
__ __ : __ __ Oral Temperature __ __. __ (°C)  
AE Number _________ 
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            Normal range 35-37°C  
         Initials : _________________ 
 
ACTI-WATCH CHECK AND SLEEP DIARY TEST CHECK 
 Has the Actiwatch Data been checked/functioning? □ Yes  □ No 
 Has the sleep diary been completed? □ Yes  □ No 
 
Is the participant still eligible to be dosed?     □ Yes  □ No 
 
Confirmed by Initials and date: __________________ 
QC checked by Initials and date: __________________ 
TREATMENT ADMINISTRATION (1st) [9:00am-11:00am] 
Bottle check Y/N  □ 
Bottle No __________ 
Confirmed by Initials/date: 
____________________ 
QC check by Initials/date: 
____________________ 
 
6 Insufflations of spray administered, alternating nostrils (30 secs apart) 
If necessary, please 
complete a 
COMPLETION / 
WITHDRAWAL  form 
 
Confirmed by 
Initials/date: 
__________________ 
QC check by Initials/date: ____________________ 
 
TREATMENT ADMINISTRATION (2nd) [16:00am-18:00pm] 
 
Time ____ ____ : ___ ___(24 Hr) 
□ Yes     
□ No : Reason ___________________________________ 
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Bottle check Y/N  □ 
Bottle No __________ 
Confirmed by Initials/date:  
____________________ 
QC check by Initials/date:  
____________________ 
AE AND CONMED REVIEW  
 
 Has the subject experienced any AEs / side 
effects since the last dose? 
□ Yes  □ No 
 If the answer to any question is YES, an AE entry 
to be completed. 
AE number :  
 
6 Insufflations of spray administered, alternating nostrils (30 secs apart) 
If necessary, please 
complete a 
COMPLETION / 
WITHDRAWAL  form 
 
 
Confirmed by Initials/date: __________________ 
 
QC check by Initials/date: ____________________ 
 
 
! WAIT (approx) 50 MINUTES! 
 Time: ___  ___ : __ __ 
   (24 Hr) 
 
Time  
____ ____ : ___ ___ 
(24 Hr) 
□ Yes     
□ No : Reason ___________________________________ 
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QUESTIONNAIRE / TESTS  Time____ ____ : ___ ___ 
(24 Hr) 
 
Name Completed 
Reading the Mind in the Eyes Test  -Revised □ Yes □ No 
Liebowitz Social Anxiety Test □ Yes □ No 
Hamilton Psychiatric Scale of Depression (HDRS) □ Yes □ No 
Hamilton Psychiatric Scale of Anxiety (HARS) □ Yes □ No 
Leeds Sleep Evaluation Questionnaire □ Yes □ No 
Subjective Opiate Withdrawal Scale  (SOWS) □ Yes □ No 
Self Assessment  □ Yes □ No 
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1. Introduction 
 
This Study Procedures Manual (SPM) has been compiled to assist study personnel 
in conducting study CRC341, Study Title: A randomised double blind placebo 
controlled pilot trial of oxytocin efficacy in treating detoxified opioid dependent 
individuals 
 
The SPM serves as a supplement to the protocol and contains study conduct 
information in the form of administrative or detailed technical information that is not 
mandated for the protocol or protocol amendment.  The SPM must be reviewed 
carefully in conjunction with the protocol.  
 
Study Personnel and Contact Details 
 
Study Site 
Windmill House,  
St Peter's Hospital,  
Surrey and Borders Partnership NHS Foundation Trust 
Guildford Road 
Chertsey 
Surrey 
KT16 0QA  
Telephone Number: 01932 722096 
 
Principal Investigator  
Name: Fiona Robinson 
Email: fiona.robinson@sabp.nhs.uk 
Telephone: 01932 723309 
 
Academic Principal Investigator:  
Name: Professor Debra Skene 
Email: d.skene@surrey.ac.uk  
Telephone: +44 (0)1483 689706 
 
Researcher:  
Name: Carol Weber 
Email: c.weber@surrey.ac.uk 
Telephone: 07754414017 
Study mobile number:  
  
Pharmacovigilance Team  
 
SAE’s to be reported to  
Email: CRC341_pharmacovigilance@surrey.ac.uk 
Fax: +44 (0)1483 689796  
Fax (back-up): +44 (0)1483 689786 
Phone: 07716759542 
Physician: Dr Pratiksha Dokhe 
Head of Strategic Development: Dr Victoria Revell 
 
Monitoring team 
 
Blinded Monitor 
Name: Josie Thorne 
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Tel: +44 (0) 1483 683797 
Email: j.thorne@surrey.ac.uk 
 
Unblinded Monitor 
Name: Aoife Walker   
Tel: +44 (0) 1483 686719 
Email: a.walker@surrey.ac.uk 
 
 
Sponsor  
University of Surrey (RIGO) 
Name: Gill Fairbairn 
Email: g.fairbairn@surrey.ac.uk 
Tel: +44 (0) 1483 (68 3491)    
 
 
Pharmacy 
Surrey and Borders Partnership NHS Foundation Trust 
Pharmacy Department 
Farnham Road Hospital 
Farnham Road 
Guildford 
Surrey 
GU2 7LX  
Telephone Number: 01483 443697 
Fax Number: 01483 443713 or 443714  
 
2.  Communication  
The Principal Investigator and / or researcher are responsible for ensuring the 
Sponsor and Blinded Monitor are made aware of any urgent issues.  These 
communications will be documented (e.g. copy of email or record of telephone 
conversation) and filed in the TMF. 
 
3. Training 
All staff allocated to the study will sign the delegation log and be delegated tasks 
by the prior to working on study specific tasks.  
 
Study Specific Training 
Prior to commencement of the study, members of the staff team will be provided 
with all study documents. Any staff completing study specific tasks will be asked 
to confirm that they have read and understood the documents via email.  This 
will be documented. Where possible, staff will also attend a site initiation training 
session run by the researcher and blinded monitor.  
 
4. Risk  
A Risk Management Plan (RMP) will be prepared by the Principal Investigator or 
designee prior to study start. The RMP will be reviewed and updated as 
necessary. 
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5. SAE Reporting 
Any SAEs which occur during the course of the study must be notified to the 
Sponsor within 24 hours of a member of the Study Team becoming aware of the 
SAE using the contact information in Section 2 and following the Safety 
Management Plan.  All SAEs should also be reported to the MHRA as per the 
Safety Management Plan.  
 
6. Randomisation Codes 
Participants will be randomised following screening to either IMP or placebo. 
 
Two sets of randomisation codes will be provided for this study. 
 1 set to be stored in Surrey and Borders Partnership NHS Foundation Trust 
pharmacy 
1 set to be stored in the Trial Master File 
 
Code break envelopes will be kept in a locked cupboard at Windmill House.  
 
7. Green light for commencement of the study 
The researcher will complete the Regulatory Document checklist and notify the 
Principal Investigator.  The Principal Investigator will then confirm that the study 
can commence. 
 
8. Study Procedures  
 
4 phases:  
1. Screening (Day 1) 
2. Baseline (Day 2) 
3. Placebo/Syntocinon treatment (Days 3 -16) (14 days) 
4. Post Treatment follow up (Day 46) (30-35 days after the last dose of 
treatment) 
 
Pre- study 
Upon admission 
Upon admission routine vital signs measured by doctor (blood pressure, heart rate 
and temperature) and blood samples analysed (haematology, serology, and 
biochemistry) 
Urine sample will be obtained for drug screening (illicit drugs screening) for 
pregnancy test (only females) and patients will be routinely breathalysed for 
alcohol.  
Medical and psychiatric history will also be recorded and reviewed. 
Patient suitability considered. 
Patient informed about trial.  
Patient offered information sheet. 
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Once detoxification completed  
 
Patient informed about trial 
Patient offered information sheet, fully informed about trial and signs consent form. 
Copy of information sheet and consent form given to patient. 
Patient offered screening for admission onto trial. 
 
Study 
Screening 
 
Informed consent confirmed  
Screening will take place to assess eligibility 
Screening workbook completed and signed by PI 
Researcher to inform pharmacy of new participant: Researcher to provide 
pharmacy with screening number, date of birth and proposed start date and day of 
first treatment.  
Pharmacy will provide randomisation number for the participant.   
Randomisation number allocated to documentation.  
Patient enrolled onto the study and given subject number 
Patient given acti-watch and instructed on use.  
Asked to attend baseline visit  
 
Baseline Day 
 
Subject to arrive at the investigation room between 9.00-11.00. 
Sleep Diary to be completed  
Acti-watch log downloaded 
Approximately 50 minutes after arrival to the investigation room Psychological 
Assessments, Self-Assessment and SOWS to be completed as baseline 
measurements. 
Workbook completed and signed. 
 
Treatment day 1  
 
Subjects will arrive at the investigation room between 09:00-11:00. 
Subjects to complete their sleep diary. 
Subjects will be given allocated treatment bottle. 
The researcher will instruct subjects in the correct intranasal self-administration 
technique and will observe the administration.  
Subjects will return to the investigation room between 16:00-18:00  
Subjects will self-administer intranasal spray under supervision of researcher 
50 minutes after intranasal administration the subjects will be instructed complete 
self-assessment diary and SOWS 
Workbook completed and signed.  
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Treatment day 2 
Subjects will arrive at the investigation room 09:00-11:00 
Subjects will complete their sleep diary 
Their medical status, adverse events, prior and/or concomitant medications, will be 
reviewed and vital signs will be assessed from patient files/verbally from subject. 
Subject will be given their bottle of intranasal spray for self-administration under 
supervision of researcher  
Bottle will be returned to locked storage. 
Subject will return to the investigation room 16:00-18:00 
Subject will be given their bottle of intranasal spray for self-administration under 
supervision of researcher 
50 minutes later, subject will complete psychological assessments, self-assessment 
diary and SOWS 
Vital signs will be recorded (blood pressure, heart rate and temperature)from 
patient file 
Workbook completed and signed. 
 
3.3 Treatment days 3-13 
 
Subjects will arrive at investigation room 09:00-11:00 
Subjects will complete their sleep diary 
Their medical status, adverse events, prior and/or concomitant medications, will be 
reviewed and vital signs will be assessed from patient files/verbally from subject. 
Subject will be given their bottle of intranasal spray for self-administration under 
supervision of researcher  
Bottle will be returned to locked storage. 
Subject will return to the investigation room 16:00-18:00 
Subject will be given their bottle of intranasal spray for self-administration under 
supervision of researcher 
50 minutes after administration, subject will complete self-assessment diary and 
SOWS 
Vital signs will be recorded (blood pressure, heart rate and temperature)from 
patient file 
Workbook completed and signed. 
 
Treatment day 14  
 
Subjects will arrive at the investigation room 09:00-11:00 
Subjects will complete their sleep diary 
Their medical status, adverse events, prior and/or concomitant medications, will be 
reviewed and vital signs will be assessed from patient files/verbally from subject. 
Subject will be given their bottle of intranasal spray for self-administration under 
supervision of researcher  
Bottle will be returned to locked storage. 
Subject will return to the investigation room 16:00-18:00 
Subject will be given their bottle of intranasal spray for self-administration under 
supervision of researcher 
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50 minutes later, subject will complete psychological assessments, self-assessment 
diary and SOWS 
Vital signs will be recorded (blood pressure, heart rate and temperature)from 
patient file 
Workbook completed and signed. 
 
4. Post treatment assessment (30-35 days after last intranasal administration) 
 
Subjects will be asked to return to one of the Surrey & Borders rehabilitation 
centers between 9:00-11:00 and will be met by the researcher in person.  
(If this proves impossible then only we will resort to telephone interview.) 
Their medical status, adverse events, concomitant medications will be reviewed.  
Subject will complete psychological assessments (including QOL, self-assessment 
diary and SOWS. 
Vital signs will be subsequently measured (blood pressure, heart rate and 
temperature) 
After completing this final visit, their participation in the study will be complete. 
Subjects will receive an inconvenience payment in the form of vouchers according 
to the number of visits completed. Subjects completing all visits will receive an 
amount in the form of vouchers. 
Workbook completed and signed. 
 
9.  Monitoring  
 
The Surrey CRC is responsible for monitoring the study and writing the follow up 
report to the Principal Investigator confirming the tasks performed at the visit and 
any issues raised. This will be documented in the study specific monitoring plan. 
 
10. Protocol Violations and Deviations 
 
These will be reported to the Sponsor as soon as possible after the event and a File 
Note written and filed in the ISF. 
 
11. Archiving 
After the Clinical Study Report has been signed off, all study documents will be 
prepared for archiving and the researcher will arrange storage with the Archivist.   
 
Appendix A – Current versions of study documents 
 
Document Version Date 
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Appendix 14 
Sleep Diary and Self Assessment Questionnaire 
 
This form is to be completed in the morning EACH DAY throughout the entire 
study. 
 
 
What time did you go to bed? (hh:mm) 
 
 
 
At what time did you try to sleep? (if 
different to above answer) 
 
 
 
How long did it take you to fall asleep? 
(minutes) 
 
 
 
How many times did you wake up? 
 
 
 
How long were you awake for? 
(minutes) Please estimate the time & 
duration of each night awakening! 
 
For what reason? Please state for 
each awakening a single word 
description!  
 
Woke up Fell asleep Reason 
1.   
2.   
3.   
4.   
5.   
 
What time did you wake up? (hh:mm) 
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What was the reason for waking up? 
Alarm Noise Person Just 
awoke 
What time did you turn on the light? 
(hh:mm) 
 
 
What time did you get up? (hh:mm) 
 
 
 
Would you describe this as a typical 
night? 
 
 
 Yes    No 
 
If permitted, could you have slept 
longer? 
 
 
 Yes    No 
 
How would you rate your quality of sleep? (circle one) 
 
best ever 1 2 3 4 5 6 7 8 9worst ever 
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Adverse events DIARY 
 
Have you experienced any unusual, outside the norm adverse events in the 
last 24 hrs? If yes what adverse event did you experience (e.g. nausea, 
dizziness, headache, insomnia, tachycardia, stomach problems)  
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In the questions below, you will be asked to score your mood, anxiety, withdrawal 
symptoms, craving, sociability state, state of mind after placebo/Syntocinon 
administration, throughout the whole duration of the study.  You will also complete 
these questions everyday up to 1 month following the last dose of 
placebo/Syntocinon administration – these questions can be answered 
electronically after completion of programme.  
 
                  Self-assessment of mood and sociability state 
 
Q1. How would you rate your state of mind? (circle one) 
 
untroubled 1 2 3 4 5 6 7 8 9 worried 
 
calm    1 2 3 4 5 6 7 8 9 Pressured 
 
Focused 1 2 3 4 5 6 7 8 9 Distracted 
 
Cheerful 1 2 3 4 5 6 7 8 9 Irritable 
 
Fearless 1 2 3 4 5 6 7 8 9 Fearful 
 
Rested 1 2 3 4 5 6 7 8 9 Sleepless 
 
Safe     1 2 3 4 5 6 7 8 9 unsafe 
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Q2. How would you rate your mood? (circle one) 
 
Feeling Sad, hopeless, worthless 
 
Absent  1 2 3 4 5 6 7 8 9 worst ever 
 
Feelings of Guilt 
 
Absent  1 2 3 4 5 6 7 8 9 worst ever 
 
Feeling suicidal 
 
Absent  1 2 3 4 5 6 7 8 9 worst ever 
 
Ability to carry out work or activities 
 
No difficulty 1 2 3 4 5 6 7 8 9 worst ever 
 
Ability to concentrate  
 
Best ever 1 2 3 4 5 6 7 8 9worst ever 
 
Q3. How would you rate your Trustworthiness? (circle one) 
 
Best ever 1 2 3 4 5 6 7 8 9worst ever 
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Q4. How would you rate your feeling of hostility? (circle one) 
 
No hostility 1 2 3 4 5 6 7 8 9worst ever Feeling Very 
            hostile 
Q5. How would you rate your feeling of socializing? (circle one) 
 
Feeling   1 2 3 4 5 6 7 8 9    Feeling very 
very sociable                antisocial 
 
Q6. How would you feel about participating in small group activities? 
(circle one) 
 
 
Not   1  2 3 4 5 6 7 8 9  very uncomfortable   
uncomfortable     
 
Self-assessment of withdrawal symptoms 
             
Q1. Have you experienced any symptoms of runny nose or tearing in the last 5 
hours?             
Not at all 1 2 3 4 5 6 7 8 9 very much 
 
Q2. Have you experienced any symptoms of tremor in the last 5 hours?     
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Not at all 1 2 3 4 5 6 7 8 9 very much 
 
Q3. Have you experienced any other withdrawal symptoms (e.g. 
Gastrointestinal upsets, yawning, sweating)  in the last 5 hours?    
 
Not at all 1 2 3 4 5 6 7 8 9 very much 
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Appendix 15 
Subjective Opiate Withdrawal Scale (SOWS) 
 
This needs to be completed every day throughout the trial.  
Answer the following statements as accurately as you can. Circle 
the answer that best fits the way you feel right now. 
 
 
 Not at all A little Moderate Quite a bit Extremely 
I feel anxious.  0 1 2 3 4 
I feel like yawning.  0 1 2 3 4 
I’m perspiring.  0 1 2 3 4 
My eyes are tearing.  0 1 2 3 4 
My nose is running.  0 1 2 3 4 
I have goose flesh.  0 1 2 3 4 
I am shaking.  0 1 2 3 4 
I have hot flashes 0 1 2 3 4 
I have cold flashes.  0 1 2 3 4 
My bones and muscles ache.  0 1 2 3 4 
I feel restless.  0 1 2 3 4 
I feel nauseous.  0 1 2 3 4 
I feel like vomiting.  0 1 2 3 4 
 My muscles twitch.  0 1 2 3 4 
I have cramps in my stomach 0 1 2 3 4 
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Appendix 16 
Hamilton Rating Scale for Anxiety 
 
1. Anxious Mood (Worries, anticipation of the worst, fearful anticipation, 
irritability) 
 
What’s your mood been like this past week? Have you been anxious, nervous?  
Have you been worrying? Do you feel something bad will happen? Feeling 
irritable  
 
 
0 No anxious mood 
1 Mild worry or anxiety indicated only on questioning, no change in functioning. 
2 Preoccupation with minor events, anxiety on as many days as not 
3 Near daily episodes of anxiety / worry with disruption of daily activities; daily 
preoccupation 
4 Nearly constant anxiety, significant role disruption 
 
 
2. Tension 
 
Have you been feeling tense?  Do you startle easily?  Cry easily? Easily 
fatigued?  Have you been trembling or feeling restless or unable to relax? I’d 
like to ask you some questions about the past week.  What’s your mood been 
like this past week? Have you been anxious, nervous?  Have you been 
worrying? Do you feel something bad will happen? Feeling irritable  
 
 
0 No tension 
1 Several days of tension or occasional (e.g. 1-2 episodes of exaggerated startle 
mood) 
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2 Muscle tension or fatigue 50% of the time, more than two repeated episodes of 
trembling exaggerated startle etc. 
3 Near daily muscle tension, fatigue and/or restlessness more than 75% of the time 
or persistent, disruptive symptoms. 
4 Constant tension, restlessness, agitation, unable to relax in this interview 
 
 
3. Fears 
 
Have you been feeling fearful (phobic) of situations or events? 
 
For example, have you been afraid of the dark? Of strangers? Of being 
left alone? Of animals? Of being caught in traffic? Of crowds? Other 
fears? 
 
 
0 No fears 
1 Mild phobic concerns that do not cause significant distress or disrupt 
functioning 
2 Fears lead to distress or avoidance on one or more occasions 
3 Fears are an object of concern on a near daily basis (75%); patient may 
need to be accompanied by others to a fearful event. 
4 Fears or avoidance that markedly affect function. Patient may avoid multiple 
situations even if accompanied; extensive agoraphobia 
 
4. Insomnia 
 
How has your sleeping been this week? Any difficulties falling asleep? 
Any problems with waking during the night? Waking early or not being 
able to return to sleep? Do you feel rested in the morning? Do you have 
disturbing nightmares? 
0 No sleep disturbances 
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1 Mildly disrupted sleep (e.g., one or two nights of difficulties falling asleep or 
nightmares) 
2 Several episodes of sleep disturbance that is regular but not persistent (e.g. 
over one-half hour falling asleep) 
3 Persistent sleep disruption (more days than not) characterise by difficulty 
falling (e.g. over an hour) or staying asleep or frequent nightmares, or 
fatigue 
4 Nightly difficulties with sleep onset or maintenance, or daily severe fatigue 
on waking in the morning 
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5. Intellectual 
 
Have you had trouble concentrating or remembering things? 
 
0 No difficulties 
1 Infrequent episodes of forgetfulness or difficulty concentrating that are no 
distressing to the patient 
2 Recurrent episodes of forgetfulness or difficulty concentrating, or episodes of 
sufficient  intensity to cause the patient recurrent concern 
3 Persistent concentration or memory impairment interferes with daily tasks 
4 Significant role impairment due to concentration difficulties 
 
6. Depressed Mood  
 
Have you been feeling depressed?  Have you lost interest in things? Do 
you get pleasure from friends or hobbies? 
 
0 No depression 
1 Occasional or mild blue or sad mood, or reports of decreased enjoyment of 
activities 
2 Sad or blue mood or disinterest 50% of the time, mood does not generally 
interfere with functioning. 
3 Persistent depressed mood or loss of pleasure, mood is significantly 
distressing to the patient or may be evident to others 
4 Daily evidence of severe depression with a significant role impairment 
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7. Somatic (muscular) 
 
Have you been experiencing aches, pains or stiffness in your muscles?  
Have you experienced muscle twitching or sudden muscle jerks? Have 
you been grinding your teeth? Have you had an unsteady voice? 
 
0 No muscular symptoms 
1 Infrequent presence of one or two symptoms, no significant distress 
2 Mild distress over several symptoms or moderate distress over a single 
symptom 
3 Symptoms occur on more days than not, symptoms are associated with 
moderate to severe distress and /or regular attempts at symptom control by 
limiting activities or taking medications 
4 Daily or near daily episodes of symptoms that cause the patient significant 
distress and lead to restriction of activities or repeated visits for medical 
attention.  
 
8. Somatic (sensory) 
 
Have you experienced ringing in your ears, blurred vision, hot or cold 
flashes, feelings of weakness or prickling sensations? 
 
 
0 No symptoms 
1 Infrequent presence of one or two symptoms, no significant distress 
2 Mild distress over several symptoms or moderate distress over a single 
symptom 
3 Symptoms occur on more days than not, symptoms are associate with 
moderate to severe distress and/or regular attempts at symptom control 
by limiting activities or taking medications..  
4 Daily or near daily episodes of symptoms that cause the patient significant 
distress and lead to restriction of activities or repeated visits for medical 
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attentions.  
9. Cardiovascular symptoms 
 
Have you had episodes of a racing, skipping or pounding heart?  How 
about pain in your chest or fainting feelings.  
 
 
 
0 No symptoms 
1 Infrequent presence of one or two symptoms, no significant distress 
2 Mild distress over several symptoms or moderate distress over a single 
symptom 
3 Symptoms occur on more days than not, symptoms are associate with 
moderate to severe distress and/or regular attempts at symptom control 
by limiting activities or taking medications..  
4 Daily or near daily episodes of symptoms that cause the patient significant 
distress and lead to restriction of activities or repeated visits for medical 
attentions.  
 
10. Respiratory symptoms 
 
Have you had trouble with your breathing? For example pressure or 
constriction in your chest, chocking feelings, sighing or feeling like 
you can’t catch your breath? 
 
 
0 No symptoms 
1 Infrequent presence of one or two symptoms, no significant distress 
2 Mild distress over several symptoms or moderate distress over a single 
symptom 
3 Symptoms occur on more days than not, symptoms are associate with 
moderate to severe distress and/or regular attempts at symptom control 
by limiting activities or taking medications..  
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4 Daily or near daily episodes of symptoms that cause the patient significant 
distress and lead to restriction of activities or repeated visits for medical 
attentions.  
11. Gastrointestinal symptoms  
 
 
Have you had any difficulties with stomach pain or discomfort? 
Nausea or vomiting Burning or rumbling in your stomach? Heartburn? 
Loose bowls? Constipation? Sinking feeling in your stomach? 
 
0 No symptoms 
1 Infrequent or minor episodes of gastric discomfort, constipation, or 
loosening of bowels, fleeting nausea.  
2 An episode of vomiting or recurrent episodes of abdominal pain, loosening 
of the bowels, difficulty swallowing. 
3 Symptoms occur on more days than not, are very bothersome to the 
patient or lead to concerns of eating, bathroom availability or use of 
medication.  
4 Daily or near daily episodes of symptoms that cause the patient significant 
distress and lead to restriction of activities or repeated visits for medical 
attentions.  
 
12. Genitourinary symptoms  
 
 
Have you been experiencing urinary difficulties?  For example, do you 
have to urinate more frequently than usual?  Have you had more 
urgency to urinate?  Do you have decreased sexual interest / libido? 
 
For women: Have your periods been regular? Have you experienced a 
change in your ability to have an orgasm? 
 
For men: Have you had trouble maintaining an erection.  
 
0 No symptoms 
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1 Infrequent or minor episodes of urinary symptoms or minor changes in 
sexual interest. , constipation, or loosening of bowels, fleeting nausea.  
2 Urinary symptoms several days during the week, occasional difficulties 
with sexual function. . 
3 Urinary or sexual symptoms occur on more days than not, amenorrhea.  
4 Daily urinary or sexual symptoms that cause the patient significant 
distress and lead to visits for medical attentions.  
 
13  Autonomic symptoms  
 
 
Have you been experiencing flushing in your face? Getting pale? Light 
headedness? Have you been having tension headaches? Have you felt 
the hair rise on the back of your neck or head as though something 
frightened you? 
 
0 No symptoms 
1 Mild episodes occurring infrequently 
2 Symptoms occurred several times during the week and were bothersome  
3 Near daily symptoms with distress or embarrassment about the symptoms 
4 Daily symptoms that are a focus of distress and impair function (e.g. daily 
headaches or light headedness leading to limitation of activities) 
 
14.  Behaviour at interview 
 
Fidgeting, restless or pacing, tremor of hands, furrowed brow, 
strained face, sighing or rapid respirations, facial pallor, frequent 
swallowing etc.  
 
0 No apparent symptoms 
1 Presence of one or two symptoms to a  mild degree 
2 Presence of several symptoms of mild intensity or one symptom of 
moderate intensity 
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3 Persistent symptoms throughout the interview 
4 Agitation, hyperventilation, difficulty completing the interview 
 
Total Score  
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Appendix 17 
Hamilton rating scale for depression 
 
 
One response per question 
1.  Depressed Mood (Sadness, Hopeless, Helpless, Worthless) 
 
I’d like to ask you some questions about the past week.  How have you been feeling 
since last (day of week)?   
 
What’s your mood been like this past week, compared to when you feel OK? 
Have you been feeling down or depressed? Sad? Hopeless? Helpless? Worthless?  
 
- If YES : Can you describe what this feeling has been like for you?  How bad is the feeling? 
Have you been crying at all? 
 
How have you been feeling about the future? (optimistic/pessimistic). Do you feel better with 
encouragement / reassurance from others? Do you feel things will get better, improve, work 
out? 
 
If DEPRESSED: in the past week, when something good, even small things have happened, did 
your mood brighten up? How long did this brightened mood last? Were there things that 
occurred that should have brightened your mood, but did not? 
 
 
0 Absent 
1 These feelings indicated only on questioning 
2 These feelings states spontaneously reported verbally 
3 Communicates feeling states non-verbally – i.e., through facial expression, posture, voice 
and tendency to weep 
4 Patient reports VIRTUALLY ONLY these feeling states in his spontaneous verbal and non-
verbal communication 
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13.  2 Feelings of Guilt 
Have you been putting yourself down this past week, feeling you’ve done things 
wrong, or let others down?  If YES: What have your thoughts been?  Has this been more 
than is normal for you? 
 
In the past week, how have you felt about yourself? 
Have you noticed your self-esteem has been put down in the past week? How would you rate 
your worth as a person compared to others? 
Have you been feeling guilty about anything that you have or not done?  What about things 
that happen a long time ago? 
Have you thought that you have brought (this depression) on yourself in some way? 
Have you been hearing voices or seeing visions in the last week?  If YES: tell me about 
them.  
 
0 Absent 
2 Self-reproach, feels he has let people down 
3 Present illness is a punishment. Delusions of guilt 
4 Hears accusatory or denunciatory voices and/or experiences threatening visual hallucinations 
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3 Suicide 
 
This past week, have you had thoughts that life is not worth living? What about 
thinking you’d be better off dead or wishing you were dead? Have you had thoughts of 
hurting or killing yourself? 
 
IF YES: What have you thought about? 
How often do these thoughts come? How long do they stay? Have you thought of a plan in the 
last week? 
 
Have you done anything to try to hurt yourself or taken any steps toward ending your 
life? 
 
0 Absent 
1 Feels life is not worth living 
2 Wishes he/she were dead or any thoughts of possible death to self  
3 Suicidal ideas or gesture 
4 Attempts at suicide (any serious attempt = rate 4) 
 
4 Insomnia early  
 
Now let’s talk about your sleep. What were your usual hours of going to sleep and 
waking up, before this began? 
 
When have you been falling asleep and waking up over the past week? 
Have you had any trouble falling asleep at the beginning of the night?  
(Right after you go to bed, how long has it been taking you to fall asleep?) How many nights this 
week have you had trouble falling asleep? 
 
0 No difficulty falling asleep 
1 Complains of occasional difficulty falling asleep – i.e. more than ½ hour, 2-3 nights 
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2 Complains of nightly difficulty falling asleep – i.e. ½ hour or more, 4 or more nights 
 
4 Insomnia middle 
 
During the past week, have you been waking up in the middle of the night? IF YES: Do 
you get out of bed? 
What do you do? (Only go to the bathroom?) 
When you get back in bed, are you able to fall right back asleep? 
How long do you stay awake? 
How many nights this week have you had that kind of trouble? 
(IF NO INSOMNIA) Has your sleep been restless or disturbed some nights? 
 
0 No difficulty 
1 Patient complains of being restless and disturbed during the night (or occasional i.e. 2-3 
nights difficulty, ½ hour or more) 
2 Waking during the night – any getting out of bed rates 2 (4 or more nights of difficulty, ½ 
hour or more). 
 
6 Insomnia late (terminal insomnia) 
 
What time have you been waking up in the morning for the last time, this past week? 
IF EARLY: Is that with an alarm clock, or do you just wake up yourself? What time do you 
usually wake up (that is, when you feel well)? 
How many mornings this past week have you awakened early? Are you able to go back to sleep? 
 
0 No difficulty 
1 Waking early hours of the morning but goes back to sleep 
2 Unable to fall asleep again if he/she gets out of bed 
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7. Work and Activities 
 
How have you been spending your time this past week (when not at work)? 
Is that normal for you? Have you felt interested in doing (THOSE THINGS), or do you feel you 
have to push yourself to do them? 
 
How would you describe your level of interest and motivation to complete daily activities? 
Have you stopped doing anything you used to do? (What about hobbies?) 
IF YES: Why? 
About how many hours a day do you spend doing things that interest you? 
Is there anything you look forward to? 
 
Have you had any fun this past week? (IF NO), Has there been anything you enjoyed 
(meal, movie, spending time with friends)? (IF YES), was the enjoyment you experienced at a 
normal level for you? 
IF WORKING (IN OR OUT OF THE HOME): Have you been able to get as much (work) done as 
you usually do? 
 
0 No difficulty 
1 Thoughts and feelings of incapacity, fatigue or weakness related to activities; work or 
hobbies 
2 Loss of interest in activity; hobbies or work – either directly reported by patient, or indirect 
in listlessness, indecision and vacillation (feels he has to push self to work or activities) 
3 Decrease in actual time spent in activities or decrease in productivity 
4 Decrease in actual time spent in activities or decrease in productivity 
 
8. Retardation : Psychomotor 
(Slowness of thought and speech; impaired ability to concentrate, decreased motor 
activity) 
 
Have you felt slowed down in your thinking, speaking, or movement in the past week? 
Have others commented on this? 
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0 Normal speech and thought 
1 Slight retardation at interview 
2 Obvious retardation at interviews 
3 Obvious retardation at interview 
4 Complete stupor 
 
9. Agitation 
 
Have you noticed feeling restless or fidgety in the past week? Have you found yourself 
unable to stay seated or needing to move around? 
 
0 None 
1 Fidgetiness 
2 Playing with hands, hair etc. 
3 Moving about, unable to sit still 
4 Hand wringing, nail biting, hair-pulling, biting of lips 
 
10.  Anxiety (Psychological) 
 
Have you been feeling especially tense or irritable this past week? IF YES: Is this more 
than is normal for you? 
Have you been unusually argumentative or impatient? Have you found yourself becoming angry 
with others for little apparent reason? More so than normal for you? How much of the time in 
this past week? 
 
Have you been feeling especially anxious, nervous or on edge in the past week? How 
much of the time? 
Have you been worrying a lot about little things, things you don’t ordinarily worry about? 
IF YES: Like what, for example? 
 
0 None 
1 Subjective tension and irritability 
2 Worrying about minor matters 
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3 Apprehensive attitude apparent in face or speech 
4 Fears expressed without questioning 
11. Anxiety Somatic : Physiological concomitants of anxiety 
 
 (i.e. effects of autonomic over activity, “butterflies”, indigestion, stomach cramps, 
belching, diarrhoea, palpitations, hyperventilation, paraesthesia, sweating, flushing, 
tremor, headache, urinary frequency).  
 
Avoid asking about possible medication side effects (i.e., dry mouth). 
Tell me if you’ve had any of the following physical symptoms in the past week. (READ 
LIST) 
GI - dry mouth, gas, indigestion, constipation, diarrhoea, stomach cramps, belching, urinary 
frequency 
C-V - heart palpitations, headaches 
RESP - hyperventilating, sighing, difficulty breathing (dyspnoea); sweating 
OTHER - tremors; ringing in your ears (tinnitus); blurred vision; hot and cold flashes; chest pain 
 
FOR EACH SYMPTOM ACKNOWLEDGED AS PRESENT: 
How much has (THE SYMPTOM) been bothering you this past week? (How bad has it gotten? How 
much of the time, or how often, have you had it?) 
 
NOTE: DO NOT RATE SYMPTOMS THAT ARE CLEARLY RELATED TO A DOCUMENTED PHYSICAL 
CONDITION. 
 
0 Absent 
1 Mild 
2 Moderate 
3 Severe 
4 Incapacitating 
 
12.  Somatic Symptoms (Gastrointestinal) 
 
How has your appetite been this past week? What about compared to your usual 
appetite? 
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IF LESS: How much less? 
Have you had to force yourself to eat? 
Have other people had to urge you to eat? (Have you skipped meals?) 
Have you found yourself eating more than usual? Every day? Have you noticed you eat more at 
meals? Have you noticed you are snacking or eating more in between meals? Have you felt driven 
to eat? Have you had eating binges? 
0 None 
1 Loss of appetite but eating without encouragement from others. Food intake about normal 
2 Difficulty eating without urging from others.  Marked reduction of appetite and food intake 
 
13.  Somatic Symptoms General 
 
How has your energy been this past week? 
IF LOW ENERGY: Have you felt tired? (How much of the time? How bad has it been?) 
This week, have you had any aches or pains? (What about backaches, headaches, or muscle 
aches?) 
How much of the time? How bad has it been? 
During the past week, have you had feelings of being weighted down, like you had lead 
weights on your arms and legs? How many days? How much of the time? Do these 
symptoms interfere with your day-to-day activities? 
 
0 None 
1 Heaviness in limbs, back or head. Backaches, headache, muscle ache. Loss of energy and 
fatigability 
2 Any clear-cut symptom 
 
14. Genital Symptoms 
 
Sometimes, along with depression or anxiety, people might lose interest in sex. This 
week, how has your interest in sex been? (I’m not asking about actual sexual activity, but 
about your interest in sex.) 
 
Is sex something you've thought about this week? 
Has there been any change in your interest in sex (from when you were feeling OK)? 
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IF YES: Is this unusual for you, compared to when you feel well? (Is it a little less or a lot less?) 
 
0 Absent 
1 Mild 
2 Severe 
 
15. Hypochondriasis 
 
In the last week, how much have your thoughts been focused on your physical health 
or how your body is working (compared to your normal thinking)?  
 
(Have you worried a lot about being or becoming physically ill? 
Have you really been preoccupied with this?) 
Do you complain much about how you feel physically? 
Have you found yourself asking for help with things you could really do yourself? 
IF YES: Like what, for example? How often has that happened? 
 
0 Non-present 
1 Self-absorption (bodily) 
2 Preoccupation with health 
3 Frequent complaints, requests for help etc. 
4 Hypochondriacal delusions 
 
16. Loss of Weight 
 
Have you lost any weight since this (DEPRESSION) began? IF YES: Did you lose any 
weight this last week? 
(Was it because of feeling depressed or down?) How much did you lose? 
IF NOT SURE: Do you think your clothes are any looser on you? 
How much has your weight changed in the past 2 weeks? 
AT FOLLOW-UP: Have you gained any of the weight back? 
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0 No weight loss 
1 Probably weight loss associated with present illness/situation 
2 Definite (according to patient) weight loss 
3 Not assessed 
17. Insight 
 
Rating based on observation during interview  
 
0 Acknowledges being depressed and ill 
1 Acknowledges illness but attributes cause to bad food, climate, overwork, virus, need  for 
rest etc. 
2 Denies being ill at all 
 
18. Diurnal Variation 
 
Did you feel worse in the morning or the afternoon/evening?.  Would you consider your 
mood/feelings during this time mild or severe compared to other times? 
 
A. Note whether symptoms are worse in the morning or evening. If NO diurnal 
variation,   mark none. 
0 No variation 
1 Worse in AM 
2 Worse in PM 
B. When present, mark the severity of the variation. Mark “none” if NO variation 
 
0 None 
1 Mild 
2 Severe 
 
19. Depersonalization and Derealization (Such as feelings of unreality, 
nihilistic/meaningless ideas) 
 
Rating based on observation during interview  
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0 Absent 
1 Mild 
2 Moderate 
3 Severe 
4 Incapacitating 
 
20. Paranoid Symptoms 
  
Rating based on observation during interview  
 
  
0 None 
1 Suspicious 
2 Ideas of reference 
3 Delusions of reference and persecution 
 
21. Obsessional and compulsive symptoms 
 
Rating based on observation during interview  
 
 
0 Absent 
1 Mild 
2 Severe 
 
Total Score  
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Appendix 18 
Leeds Sleep Evaluation Questionnaire 
 
How would you compare getting to sleep last night with getting to sleep normally? 
 
   
Easier than usual  Harder than usual 
Quicker than usual  Slower than usual 
Felt more drowsy 
than usual 
 Felt less drowsy than usual 
   
 
How would you compare the quality of last night’s sleep with your usual sleep? 
 
Less restful than 
usual 
 More restful than usual 
 
Fewer periods of 
wakefulness than 
usual 
  
More periods of wakefulness than 
usual  
   
 
 
How was your awakening today compared with your usual pattern of awakening? 
 
Easier than usual  Harder than usual 
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Took shorter than 
usual 
  
Took longer than 
usual  
 
 
 
How do you feel on waking today when compared to your usual awakening? 
 
Alert   Tired  
 
 
How was your sense of balance and co-ordination upon getting up? 
 
Less clumsy than 
usual  
 More clumsy than 
usual 
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Appendix 19 
Liebowitz Social Anxiety Scale 
 
Fear of Anxiety  Avoidance 
0 = None  0 = Never 
1 = Mild  1 = Occasional 
2 = Moderate  2 = Often 
3 = Severe  3 = Usually 
 
 FEAR / ANXIETY 
0 -> 3 
 AVOID 
0 -> 3 
1. Telephoning in public.    
2. Participating in small groups.    
3. Eating in public places.    
4. Drinking with others in public places.    
5. Talking to people in authority.    
6. Acting, performing or giving a talk in front of an audience.    
7. Going to a party.    
8. Working while being observed.    
9. Writing while being observed.    
10.Calling someone you don’t know very well.    
11.Talking with people you don’t know very well.    
12.Meeting strangers.    
13.Urinating in public bathroom.    
14.Entering a room when others are already seated.    
15.Being the center of attention.    
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16.Speaking up at a meeting.    
17.Taking an exam.    
18.Expressing a disagreement or disapproval to people you 
don’t know very well. 
   
19.Looking at people you don’t know very well in the eyes.    
20.Giving a report to a group.    
21.Trying to chat someone up.    
22.Returning goods to a shop.    
23.Giving a party.    
24.Resisting a high pressure sales person.    
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Appendix 20 
“Reading the Mind” Questionnaire” 
 
P  jealous  panicked  arrogant  hateful 
1  playful  comforting  irritated  bored 
2  terrified  upset  arrogant annoyed 
3  joking  flustered  desire  convinced 
4  joking  insisting  amused  relaxed 
5  irritated  sarcastic  worried  friendly 
6  aghast  fantasizing  impatient  alarmed 
7  apologetic  friendly  uneasy  dispirited 
8  despondent  relieved  shy  excited 
9  annoyed  hostile  horrified  preoccupied 
10  cautious  insisting  bored  aghast 
11  terrified  amused  regretful  flirtatious 
12  indifferent  embarrassed  sceptical  dispirited 
13  decisive anticipating  threatening  shy 
14  irritated  disappointed  depressed  accusing 
15  contemplative  flustered encouraging  amused 
16  irritated  thoughtful  encouraging  sympathetic 
17  doubtful  affectionate  playful  aghast 
18  decisive  amused  aghast  bored 
19  arrogant  grateful  sarcastic  tentative 
20  dominant  friendly  guilty  horrified 
21  embarrassed  fantasizing  confused  panicked 
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22  preoccupied  grateful  insisting  imploring 
23  contented  apologetic  defiant  curious 
24  pensive  irritated  excited  hostile 
25  panicked  incredulous  despondent  interested 
26  alarmed  shy  hostile  anxious 
27  joking  cautious  arrogant  reassuring 
28  interested  joking  affectionate  contented 
29  impatient  aghast  irritated  reflective 
30  grateful  flirtatious  hostile  disappointed 
31  ashamed  confident  joking  dispirited 
32  serious  ashamed  bewildered  alarmed 
33  embarrassed  guilty  fantasizing  concerned 
34  aghast  baffled  distrustful  terrified 
35  puzzled  nervous  insisting  contemplative 
36  ashamed  nervous  suspicious  indecisive 
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Appendix 21 
WHOQOL-BREF 
The following questions ask how you feel about your quality of life, health, or 
other areas of your life. Please choose the answer that appears most 
appropriate. If you are unsure about which response to give to a question, the 
first response you think of is often the best one.  
Please keep in mind your standards, hopes, pleasures and concerns. We ask that 
you think about your life in the last four weeks. 
 
Very Poor Poor  
Neither poor 
nor good  
Good  Very good  
1 How would you rate your 
quality of life?  
1  2  3  4  5  
 
Very 
dissatisfied  
Dissatisfied  
Neither 
satisfied nor 
dissatisfied  
Satisfied  
Very 
satisfied  
2 How satisfied are you 
with your health?  
1  2  3  4  5  
 
The following questions ask about how much you have experienced certain 
things in the last four weeks 
 Not at all  A little  
A moderate 
amount  
Very much  
An extreme 
amount  
3 To what extent do you feel 
that physical pain prevents 
you from doing what you 
need to do?  
5  4  3  2  1  
4 How much do you need any 
medical treatment to function 
in your daily life?  
5  4  3  2  1  
5 How much do you enjoy life?  1  2  3  4  5  
6 To what extent do you feel 
your life to be meaningful?  
1  2  3  4  5  
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7 How well are you able to 
concentrate?  
 
1 2 3 4 5 
8 How safe do you feel in your 
daily life?  
 
1 2 3 4 5 
9 How healthy is your physical 
environment?  
1 2 3 4 5 
 
The following questions ask about how completely you experience or were able 
to do certain things in the last four weeks. 
Not at all  A little  Moderately  Mostly  Completely  
10 Do you have enough energy 
for everyday life?  
1  2  3  4  5  
11 Are you able to accept your 
bodily appearance?  
1  2  3  4  5  
12 Have you enough money to 
meet your needs?  
1  2  3  4  5  
13 How available to you is the 
information that you need in 
your day-to-day life?  
1  2  3  4  5  
14 To what extent do you have 
the opportunity for leisure 
activities?  
1  2  3  4  5  
15 How well are you able to get 
around?  
1  2  3  4  5  
16 How satisfied are you with 
your sleep?  
1  2  3  4  5  
17 How satisfied are you with 
your ability to perform your 
daily living activities?  
1  2  3  4  5  
18 How satisfied are you with 
your capacity for work?  
1  2  3  4  5  
19 How satisfied are you with 
yourself?  
1  2  3  4  5  
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20.  How satisfied are you with 
your personal relationships?  
1  2  3  4  5  
21 How satisfied are you with 
your sex life?  
1  2  3  4  5  
22 How satisfied are you with 
the support you get from 
your friends?  
1  2  3  4  5  
23 How satisfied are you with 
the conditions of your living 
place?  
1  2  3  4  5  
24 How satisfied are you with 
your access to health 
services?  
1  2  3  4  5  
25 How satisfied are you with 
your transport?  
1  2  3  4  5  
 
The following question refers to how often you have felt or experienced certain 
things in the last four weeks. 
Never  Seldom  Quite often  Very often  Always  
26 How often do you have 
negative feelings such as 
blue mood, despair, 
anxiety, depression?  
5  4  3  2  1  
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Appendix 22 
Labels for bottles 
 
Content of the labelling 
The proposed study is a randomised double blind placebo controlled trial of oxytocin 
(Syntocinon) efficacy in treating detoxified opioid dependent individuals. Some 
subjects will be given Syntocinon and some placebo (double blind). 
SYNTOCINON -  Spray 40 IU/ml, 5 ml to be used in the study is licenced and 
produced by Novartis in Switzerland (Swiss Medic Admissions number 25644). The 
IMP will be imported and QP released by Mawdsley-Brooks & Co Ltd, Quest Park, 
Silk Road, Off Wheatley Road, Doncaster, DN2 4LT, who hold an MIA(IMP), 
Authorisation number 741, for the required activities.  The labelling and dispensing 
of the IMP into a bottle and assembly with the pump and fitting with the actuator will 
be done by Surrey and Borders Partnership NHS Foundation Trust Pharmacy, under 
the instructions given Surrey CRC to ensure blinding of the study. 
PLACEBO – Saline Spray manufactured by Mini-Plasco brand from B Braun PL 
03551/0076. Labelling and dispensing of placebo into the bottle and assembly with 
the pump and the actuator fitted will be done by Surrey and Borders Partnership 
NHS Foundation Trust Pharmacy, under instructions given by Surrey CRC to ensure 
blinding of the study. 
Labelling of both Syntocinon and placebo will be carried out according to annex 13 
of  EU Guidelines to Good Manufacturing Practice detailed below: 
The following information should be included on labels, unless its absence can be 
justified, e.g. use of a centralised electronic randomisation system: 
(a) name, address and telephone number of the sponsor, contract research 
organisation or investigator (the main contact for information on the product, 
clinical trial and emergency unblinding); 
(b) pharmaceutical dosage form, route of administration, quantity of dosage units, 
and in the case of open trials, the name/identifier and strength/potency; 
(c) the batch and/or code number to identify the contents and packaging operation; 
(d) a trial reference code allowing identification of the trial, site, investigator and 
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sponsor if not given elsewhere; 
(e) the trial subject identification number/treatment number and where relevant, 
the visit number; 
(f) the name of the investigator (if not included in (a) or (d)); 
(g) directions for use (reference may be made to a leaflet or other explanatory 
document intended for the trial subject or person administering the product); 
(h) “For clinical trial use only” or similar wording; 
(i) the storage conditions; 
(j) period of use (use-by date, expiry date or re-test date as applicable), in 
month/year format and in a manner that avoids any ambiguity. 
See example below on what will be included on the label: 
 
 
Investigator: Dr Fiona Robinson  
Surrey & Borders Partnership NHS Foundation Trust, Abraham Cowley Unit, 
Chertsey, UK 
01932722096  
  
Clinical Study Protocol No.: CRC341 
Sponsor: University of Surrey  
  
Dosage Form: Nasal spray  
   
Total quantity: 5 ml  
Randomisation No.:XXX  
Batch Number: XXX 
Expiry Date: XX/20XX 
  
For clinical trial use only.  Can be stored below 25°C for no more than 3 days. 
Long storage 2-8°C 
Subject#/ Inits ________ / _________  
Date Dispensed ____________ 
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Appendix 23 
Research Protocol 
 
A RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED PILOT TRIAL OF OXYTOCIN 
EFFICACY IN TREATING DETOXIFIED OPIOID DEPENDENT INDIVIDUALS 
 
Protocol Number: CRC 341   
Version Number:  10 
Date:  23 May 2017    
EudraCT Number: 2014-002708-26    
 
Confidentiality Statement 
The information contained in this document is the property of the University of 
Surrey Clinical Research Centre (Surrey CRC) and is provided to you in confidence as 
an investigator, potential investigator, sponsor, or consultant, for review by you, 
your staff and an applicable Ethics Committee (EC). It is understood that this 
information will not be disclosed to others without written authorisation from the 
Surrey CRC, except to the extent necessary to obtain written informed consent from 
those persons to whom the drug may be administered. 
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CLINICAL TRIAL PROTOCOL AGREEMENT FORM 
Authorisation of final version 
 
A RANDOMISED DOUBLE BLIND PLACEBO CONTROLLED PILOT TRIAL OF OXYTOCIN 
EFFICACY IN TREATING DETOXIFIED OPIOID DEPENDENT INDIVIDUALS  
 
On behalf of the Sponsor (University of Surrey):  
Name:  Mr Ali Alshukry (Research, Integrity & Governance Officer) 
 
Principal Investigator Agreement  
I agree to conduct this trial according to this protocol and to comply with its 
requirements, subject to ethical principles that have their origins in the Declaration 
of Helsinki, safety considerations and the applicable laws and regulations, I agree to 
conduct the trial in accordance with local regulations and the International 
Conference on Harmonisation Topic E6: Guideline for Good Clinical Practice (ICH 
GCP). 
I will promptly submit the protocol to applicable ethical review board(s). I agree not 
to make any changes to the protocol without agreement from the sponsor and prior 
review and written approval from the local Ethics Committee, except where 
necessary to halt an immediate threat to subject safety, or for administrative study 
details when such actions are permitted by local regulations. 
I understand fully the appropriate use of oxytocin (Syntocinon) Spray as described 
in this protocol, and any other relevant material made available by the sponsor.  
I will make certain that all personnel assisting with the study will be adequately 
informed about the Investigational Medicinal Product (IMP) and their study-related 
duties as described in the protocol. 
I understand that, should the decision be made by the Sponsor to terminate 
prematurely or suspend the trial, at any time and for whatever reason, such 
decision will be communicated to me in writing. Conversely, should I decide to 
withdraw from execution of the trial, I will communicate immediately in writing to 
the Sponsor or their representatives. 
Principal Investigator  
 
 
Name:  Fiona Robinson, M.B.Ch.B  
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 LIST OF ABBREVIATIONS AND DEFINITIONS 
 
AE Adverse Event 
ANOVA Analysis of Variance  
BP Blood Pressure 
CA Competent Authority 
CBT Cognitive Behaviour Therapy 
COWS Clinical opiate withdrawal scale questionnaire 
CRC Clinical Research Centre 
CRF Case Report Form 
DSM Diagnostic and Statistical Manual of Mental Disorders  
ELISA Enzyme-linked Immunosorbent Assay 
EU European Union 
FHMS Faculty of Health and Medical Sciences 
GCP Good Clinical Practice 
GP General Practitioner 
HARS Hamilton Psychiatric Scale of Anxiety 
HDRS Hamilton Psychiatric Scale of Depression 
HR Heart Rate 
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee 
IMP Investigational Medicinal Product 
IRB Institutional Review Board 
IU International Units 
LSEQ Leeds Sleep Evaluation Questionnaire 
MedDRA  Medical Dictionary for Regulatory Activities 
MHQ  Medical History Questionnaire 
MHRA Medicines and Healthcare products Regulatory Agency 
NA Non Applicable 
NIMP Non Investigational Medicinal Product 
NMR Nucleic Magnetic Resonance 
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OTC Over The Counter 
OT Oxytocin 
PI Principal Investigator 
RCT Randomised Controlled Trial 
RSI Reference Safety Information 
SAE Serious Adverse Event 
SAS Statistical Analysis System 
SmPC Summary of Product Characteristics 
SOPs Standard Operating Procedures 
SOWS Subjective Opiate Withdrawal Scale 
Surrey CRC Surrey Clinical Research Centre 
SUSAR Suspected Unexpected Serious Adverse Reactions 
UK United Kingdom 
WHOQOL-BREF World Health Organisation Quality of Life Questionnaire Short 
Version 
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Surrey, UK  
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PROTOCOL SYNOPSIS 
 
Title A randomised double blind placebo controlled pilot trial of oxytocin efficacy 
in treating detoxified opioid dependent individuals  
Sponsor University of Surrey  
Principal Investigator  
Trial Location Fiona Robinson. M.B.Ch.B  
Drug & Alcohol Services 
Surrey & Borders Partnership NHS Foundation Trust 
Windmill House  
Abraham Cowley Unit 
St Peter's Hospital 
Holloway Hill 
Chertsey 
Surrey 
KT16 0AE 
Project Phase Pilot study 
Indication Interventional/treatment  
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Study Objectives 
Primary: The primary objective will be to investigate the efficacy of oxytocin 
(Syntocinon) in retaining post-detoxification opioid dependent individuals in 
inpatient rehabilitation programme and in preventing relapse to opioid use. 
Secondary: The secondary objective will be to investigate the efficacy of oxytocin 
(Syntocinon) in reducing opioid craving, anxiety, depression, social anxiety, sleep 
disturbances and in enhancing social cognition and quality of life in post-
detoxification opioid dependent individuals. 
Study Design Double-blind, placebo controlled pilot efficacy study 
Population Post-detoxified opioid dependent individuals participating in Windmill 
house inpatient rehabilitation programme 
Main Selection Criteria 30 subjects (15 in each treatment arm), males and 
non-lactating, non-pregnant females, aged 18-65 years with primary diagnosis of 
opioid dependence according to DSMIV criteria   
Investigational Medicinal Products: 
Formulations 
Route of Administration 
Dose regimen Drug: intranasal oxytocin spray (Other Name: Syntocinon Spray) 
6 insufflations (24 International Units –IU- of oxytocin total) given twice daily for up 
to 14 days (self-administered). The spray will be administered at least 3 days after 
the last dose of opioid detoxification treatment 
Concurrent Controls Placebo control Normal saline intransal spray (5ml Sodium 
Chloride 0.9% for Injection) manufactured by Mini-Plasco brand from B Braun 
:Treatment consists of 6 insufflations (0.1metered dose/insufflation) twice daily for 
up to 14 days (self-administered). The spray will be administered at least 3 days 
after the last dose of opioid detoxification treatment (e.g. methadone/lofexidine)   
Study Endpoints  
Primary: Retention rates in rehabilitation programme at approximately 2 weeks 
from the first dose of Syntocinon/placebo treatment. 
Rates of subjects relapsing to drug use (e.g. urine positives for opioid/illicit drug 
metabolites, self-reporting) at specific time points from the first dose of 
Syntocinon/placebo administration (e.g. approximately 2 and 6 weeks).   
Secondary: Measures of withdrawal symptoms severity, opioid craving, anxiety, 
depression, social anxiety, social cognition, sleep disturbances at the start 
(treatment day 2) and the end (treatment day 14) of the 2 week 
placebo/Syntocinon treatment period and 1 month after the end of the last dose of 
placebo/Syntocinon treatment. Measures of quality of life (wellbeing) at baseline 
and 1 month after the last dose of placebo/Syntocinon treatment. Activity/sleep 
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profile before (i.e. from screening), during and after placebo/Syntocinon treatment 
(up to 1 month after the end of the treatment). 
 
Parameters of Efficacy Rate of retention in rehabilitation programme at 
approximately 2 weeks from the start of Syntocinon/placebo treatment period. 
Relapse rate as measured by urinalysis and/or self-reporting at specific time points 
from the first dose of Syntocinon/placebo administration (e.g. 2 and 6 weeks).    
Measures of withdrawal severity, opioid craving, anxiety, depression, social anxiety, 
social cognition, sleep disturbances at the beginning (treatment day 2) and the end 
of the 2 week placebo/Syntocinon treatment period (treatment day 14) and 1 
month after the last dose of placebo/oxytocin treatment. Measures of quality of life 
(wellbeing) 1 month after the end of the last placebo/Syntocinon study treatment. 
Sleep time activity profile during placebo/Syntocinon treatment up to 1 month post 
treatment.  
Main Parameters of Safety nausea, dizziness, headache, water intoxication 
(adverse events) 
Assessment Schedule Visit 1: Screening visit 
This will take place following admission to Windmill House during the first 2 weeks 
of opioid detoxification to check for eligibility. Demographic data, medical and 
psychiatric history, vital signs, urine screening of illicit drugs and assessment of any 
concomitant medication among others will be acquired.  
Visit 2: Baseline visit 
Prior to the placebo/Syntocinon treatment trial (i.e. at least 2 days after the last 
dose of opioid detoxification), baseline measures of opioid withdrawal symptoms: 
craving, social anxiety, depression, anxiety, social cognition, quality of life and sleep 
will be obtained.  . 
The questionnaires/psychometric tests will include: 
• Clinical opiate withdrawal scale questionnaire (COWS) / Subjective Opiate 
Withdrawal Scale (SOWS) 
• Hamilton Psychiatric Scale of Depression (HDRS) 
• Hamilton Psychiatric Scale of Anxiety (HARS) 
• Liebowitz Social Anxiety Test 
• The Reading the Mind in the Eyes Test- Revised Version 
• The World Health Organisation Quality of Life Questionnaire, WHOQOL-BREF 
• Leeds Sleep Evaluation or Karolinska sleep Questionnaire 
Treatment period 
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Twice daily Syntocinon/oxytocin or placebo treatments (between 9-11 am and 
16.00-18.00 pm) self-administered by subjects for up to 2 weeks.  
Visit 3: Treatment day 1 
Subject will take their first intranasal dose of Syntocinon or placebo 1-3 days after 
baseline day. 
Visit 4: Treatment day 2 
Subjects will administer intranasal dose of Syntocinon/oxytocin or placebo and 50 
minutes later a battery of well-validated tests/questionnaires to quantify anxiety 
(including social anxiety), depression, social cognition, opioids craving, sleep 
disturbances and severity of clinical opioid withdrawal symptoms will be carried out 
as described in visit 2. 
Visit 5: Treatment day 14 
The exact same protocol as described above (visit 4) will be carried out on the last 
day of the treatment protocol (day 14 of placebo/Syntocinon administration)  
The subjects will be randomly tested twice a week for illicit drugs and alcohol by 
urine screening testing and breathalizing test respectively during the 2 weeks of 
placebo/Syntocinon treatment. Self-reporting of drugs or alcohol use will be 
confirmed.  
Visit 6: Post treatment visit 
The post placebo/Syntocinon treatment assessment will take place 30-35 days after 
the end of the treatment protocol around 30-35 days after the subjects have 
completed the rehabilitation programme and have been discharged from the 
rehabilitation unit. Subjects will be asked to return to one of the Surrey & Borders 
rehabilitation centers, and a battery of well-validated scales/questionnaires to 
quantify anxiety (including social anxiety), depression, social cognition, opioids 
craving, severity of withdrawal symptoms, sleep disturbance and quality of life will 
be used (see tests to be used above, visit 2). The subjects will be screened for illicit 
drugs upon this visit. 
 
Throughout the study duration (i.e. from the time they sign consent form, during 
placebo/Syntocinon treatment and up to 1 month following treatment) subjects will 
be asked to keep a diary (ideally electronic in the form of App, currently under 
development) reporting daily  on their drug intake (including illicit drugs, alcohol 
and prescription medication), timing of period (for females to monitor pregnancy 
possibility) and their cravings, withdrawal symptoms severity, sleep quality, 
alertness, calmness, hostility, anxiety, happiness, sadness, sociability with the use of 
special scales. 
Data Analysis 30 subjects (n=15 in each arm) will be used for this pilot study. 
This is considered to be an appropriate sample size for a pilot study in order to 
calculate the variability in response to treatment which will be used to determine 
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subject numbers required to adequately statistically power a comparative large 
study.  
Descriptive statistics will be used to analyse retention in post-detoxification 
treatment and relapse rates between the two treatment groups. A Kaplan–Meier 
survival analysis showing the rate of subjects dropping out 2 weeks from baseline 
(i.e. during Syntocinon/placebo treatment) as well the rate of those relapsing to 
drug use (urine positives for opioid metabolites and/or self-reporting) at specific 
time points from baseline (e.g. 2 and 6 weeks) will also be carried out in both 
groups.  Comparison of changes in number of days until opioid/illicit drug use (self-
reporting or positive urine sample) from the first dose of Syntocinon/placebo 
administration between placebo and Syntocinon group at specific time points (e.g. 2 
and 6 weeks from baseline) will be analysed by t-test. 
Subjective questionnaire measures will be analysed using repeated measures 
analysis of co-variance with group (Syntocinon/placebo) as between group factors 
and testing day as the within subject factor, controlling for baseline ratings.  
Changes in depression, anxiety, craving severity, social cognition, social anxiety, 
quality of life scores between the two treatment groups over time will be compared 
using analysis of variance (ANOVA) repeated measures (within subjects) design, 
controlling baseline ratings. 
All adverse events (AEs) will be appropriately tabulated but no formal statistical 
analysis will be performed  
Duration of Study Period (per subject) The expected duration of a subject’s 
participation from consent to follow up visit is a maximum of 46 days. (duration 
from consent to baseline minimum 1 day, 1 day duration for baseline, 14 days of 
Syntocinon/placebo treatment, follow up visit 30 days after the last dose of 
Syntocinon/placebo treatment). 
 
STUDY FLOW CHARTS 
Study Flow Chart 
Procedures Pre-treatment Treatment period 
Post –treatment follow-up  
 Screening (following admission during the 2 weeks of opioid detoxification) 
 Baseline  Placebo 
Syntocinon 30-35 days after the last dose of  placebo/ 
Syntocinon administration 
Visit number 1 2 3, 4, 5  6 
No. of days 1 1 14  1 
Study day number 1 2  3-16 46 
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Written informed consent x      
Demographic data x      
Medical History Questionnaire (MHQ) x      
Assessment of inclusion/exclusion criteria x     
Medical & psychiatric history x    x 
Alcohol breath test  Twice weekly random testing   x (if 
possible) 
Urine pregnancy b  x   x (if possible) 
Assign subject to randomisation sequence x     
Drug administration         x   
Urinalysis to detect opioids and other drugs of abuse   Twice weekly 
random testing   x 
Questionnaire assessments/psychometric tests  x  x x 
Visual analogue scales or electronic diary (ideally App)  Daily throughout 
the duration of study    
Recording of adverse events  continuous    
Recording concomitant medication  continuous    
Actiwatch measurements  continuous    
Serology, haematology, biochemistryc,d      
Vital sign e x x  x x 
Telephone contactf     x  
 
a n/a 
b Female subjects only. Another pregnancy test will be done upon admission. 
Including the pregnancy test done at baseline, we would be able to safely and 
accurately test for pregnancy. Ideally we would like to test for pregnancy 1 month 
after the treatment period as well. 
c,d Biochemistry tests include TSH, B12, Follate, Na, K+, urea, creatine, Calcium, P, 
total protein, albumin, bilirubin, alkaline phosphatase, All tests are done on 
admission. They will be carried out on subjects only in the event of adverse events 
or if necessary (e.g. infection) 
e Heart rate, blood pressure and oral temperature will be routinely carried out upon 
admission. 
f We will aim to see patients and conduct the questionnaire tests in person but if 
that is not possible then we will resort in telephone contact.  
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Visual Scheme of Flow Chart 
 
  
SUMMARY OF STUDY DESIGN AND RATIONALE 
Introduction 
Oxytocin (OT) is a neurohypophysial hormone which is produced by the 
hypothalamus and stored and secreted by the posterior pituitary gland. Oxytocin 
has important peripheral effects and also acts primarily as a neuromodulator in the 
brain. 
Oxytocin plays an important role in the neuroanatomy of intimacy, specifically in 
sexual reproduction and particularly during and after childbirth. It is released in 
large amounts after distension of the cervix and uterus during labour, facilitating 
birth and maternal bonding, also after stimulation of the nipples for lactation. Both 
childbirth and milk ejection are results of positive feedback mechanisms.  
 
In addition to peripheral effects, oxytocin also acts as a neurotransmitter in the 
brain influencing many aspects of social behaviour (Landgraf and Neumann, 2004; 
Neumann and Landgraf, 2012). The last two decades have witnessed a surge in 
research investigating the application of oxytocin as a method of enhancing 
psychological function in humans. Research involving healthy adults has linked 
intranasal oxytocin with a range of effects such as reducing levels of social anxiety 
(Heinrichs et al, 2003), and increasing levels of trust (Kosfeld et al, 2005), gaze into 
the eyes (Guastella et al, 2008), and accurate emotional processing (Di Simplicio et 
al, 2009). The vast majority of studies investigating oxytocin and social behaviour in 
humans has utilised nasal delivery as the administration method (Macdonald and 
Macdonald, 2010). This has triggered a growing number of clinical trials 
investigating the efficacy of intranasal OT in treating psychiatric conditions 
characterised by symptoms associated with increased anxiety and social 
withdrawal, such as autism and schizophrenia (Carter, 2007; Heinrichs et al, 2007).   
Oxytocin (OT) has also been,  shown to decrease social anxiety in autistic individuals 
(Anagnostou et al, 2012), fragile X syndrome individuals (Hall et al, 2012) , and 
healthy people (Di Simplicio et al, 2009) when administered intranasaly. In addition, 
oxytocin has been shown to reduce depression scores (Baumgartner et al, 2008; Di 
Simplicio et al, 2009) and improve social cognition and quality of life in autistic 
spectrum disorder individuals (Anagnostou et al, 2012) and block alcohol craving 
and withdrawal (including mood, anxiety) in alcohol dependent individuals 
undergoing detoxification with lorazepam (Pedersen et al, 2013). Oxytocin is also 
known to modulate neural circuitry for social cognition and fear in humans (Kirsch 
et al, 2005) and it has been suggested to be effective for the treatment of 
psychiatric conditions characterised by symptoms associated with increased anxiety 
and social withdrawal (Carter, 2007; Heinrichs and Gaab, 2007).  OT is currently 
being investigated as a potential treatment of social deficits and paranoia in 
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schizophrenia and autism. With respect to addiction, there is emerging evidence (all 
preclinical) supporting the involvement of OT in the modulation of the effects of a 
number of drugs of abuse (for reviews see Broadbear et al, 2011; McGregor and 
Bowen, 2012; McGregor et al, 2008; Sarnyai, 2011). With respect to opioids, an 
inhibitory effect of OT has been demonstrated on morphine tolerance, on the 
physical symptoms of naloxone-precipitated morphine withdrawal (Kovacs et al, 
1985b; Kovacs et al, 1984) and on heroin self-administration (Kovacs and Van Ree, 
1985a) in rodents. It has been shown in our laboratory, that the central 
oxytocinergic system is dysregulated in mice undergoing protracted opioid 
abstinence (Zanos et al, 2013). Mice have been found to experience profound 
emotional impairment (anxiety, depression and lack of social preference) following 
prolonged morphine withdrawal and this can be reversed by acute administration 
of the oxytocin analogue carbetocin. Carbetocin also prevents stress-induced 
reinstatement of morphine seeking behaviour in mice undergoing extinction from 
morphine conditioned place preference. The results from this study suggest that the 
profound dysregulation of the oxytocinergic system may be a possible mechanism 
linking anxiety, depression and social withdrawal with opioid abstinence. The 
results also support the OT system as a target for the development of novel 
treatments for opioid withdrawal-related emotional impairment and relapse 
prevention (Zanos et al, 2013). One of the mechanisms by which oxytocin or its 
analogues can exert its beneficial effect has been suggested to be through 
modulation of hypothalamic-pituitary-adrenal (HPA) axis (cortisol release). 
 
There is currently no effective way of predicting relapse vulnerability of opioid 
dependent individuals undergoing detoxification. Predicting increased vulnerability 
to relapse would be of assistance to both the individual and their advisors and allow 
increased support. We are proposing in using metabolomics approach in an attempt 
to identify biomarkers of relapse vulnerability. The repertoire of biochemicals (or 
small molecules) present in cells, tissue, and body fluids is known as the 
metabolome. Today, clinicians utilize only a very small part of the information 
contained in the metabolome, as revealed by the quantification of a limited set of 
analytes to gain information on human health. With a focus on comprehensively 
studying the metabolome, the rapidly growing field of metabolomics captures the 
metabolic state of organisms at the global or "-omics" level. Given that the overall 
health status of an individual is captured by his or her metabolic state, which is a 
reflection of what has been encoded by the genome and modified by 
environmental factors, metabolomics has the potential to have a great impact upon 
medical practice by providing a wealth of relevant biochemical data. Metabolomics 
promises to improve current, single metabolites-based clinical assessments by 
identifying metabolic signatures (biomarkers) that embody global biochemical 
changes in disease, predict responses to treatment or medication side effects 
(pharmachometabolomics). 
Summary of Study Design 
A double-blind, placebo controlled pilot oxytocin (Syntocinon) efficacy study in a 
detoxified opioid dependent individuals (18-65 years of age). It will test the effect of 
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intranasal oxytocin (Syntocinon spray) vs. placebo (spray) on relapse prevention and 
retention rates of  opioid dependent individuals after detoxification programme, 
and on withdrawal-associated opioid cravings, withdrawal symptoms, negative 
mood, anxiety and social anxiety, social cognition and on sleep quality. It will also 
test the effect of intranasal oxytocin (Syntocinon spray) vs. placebo (spray) on 
quality of life (wellbeing) aspects after 1 month of leaving the rehabilitation unit.  
 
This is a single centre trial which will be carried out at Windmill House (inpatient 
only) detoxification unit at Surrey & Borders Partnership NHS Foundation Trust. 
 
The primary outcome will be to investigate the efficacy of oxytocin (Syntocinon) in 
retaining post detoxification opioid dependent individuals in inpatient rehabilitation 
programme and in preventing relapse to drug/opioid use. The secondary outcome 
will be to investigate the efficacy of oxytocin in reducing opioid withdrawal 
symptoms, opioid craving, anxiety, depression, hostility, social anxiety, sleep 
disturbances and in enhancing social cognition, and quality of life in post-
detoxification opioid dependent individuals. 
7.2.1 Profile of Study Drugs 
SYNTOCINON Spray 40 IU/ml, 5 ml to be used in the study is licenced and produced 
by Novartis in Switzerland (Swiss Medic Admissions number 25644). The IMP will be 
imported and QP released by Mawdsley-Brooks & Co Ltd, Quest Park, Silk Road, Off 
Wheatley Road, Doncaster, DN2 4LT, who hold an MIA(IMP), Authorisation number 
741, for the required activities.  The labelling and dispensing of the IMP into a bottle 
and assembly with the pump and fitting with the acuator will be done by Surrey and 
Borders Partnership NHS Foundation Trust Pharmacy, under exemption 37 of The 
Medicines for Human Use (Clinical Trials) regulations 2004.  Instructions will be 
given by Surrey CRC to ensure blinding of the study. 
 
PLACEBO – is manufactured by Mini-Palsco brand from B Braun PL 03551/0076.  
The labelling and dispensing of placebo into a bottle and assembly with the pump 
and fitted with the acuator will be done by Surrey and Borders Partnership NHS 
Foundation Trust Pharmacy under the instructions given Surrey CRC to ensure 
blinding of the study.  
 
Potential Risks and Benefits 
We will only be using a nasal formulation of oxytocin administration in this study. 
Comprehensive product information describing the pharmacology and possible side 
effects of intravenous infusion of synthetic oxytocin is accessible from Novartis 
pharmaceuticals http://www.novartis.com.au/PI_PDF/syt.pdf (see SmPC of the drug 
in Appendix). Moreover, safety information regarding adverse reactions is reported 
on regulatory databases worldwide, for example the Foods and Drugs Association in 
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the United States http://www.fda.gov/safety/medwatch/default.htm or the 
Therapeutic Goods Association in Australia http://www.tga.gov.au/adr/aadrb.htm. 
The European Medicines Agency lists all individual European National regulatory 
authorities http://www.ema.europa.eu/ema/index.jsp?.  
 
i.v. Syntocinon is used to induce or augment labour, treat postpartum haemorrhage 
and intranasal spray used to induce breast milk expression in lactating mothers: 
http://db.cbg-mel.nl/IB-teksten/h03716.pdf. Product information from the 
Netherlands: http://db.cbg-mel.nl/IB-teksten/h03716.pdf lists headaches, nausea 
and allergic dermatitis occurring rarely (>1/10,000, <1/1000) and abnormal uterine 
contractions known to occur sometimes (≥1/1000, <1/100). Previous research 
studies investigating the role of intranasal oxytocin in enhancing lactation have 
reported no safety concerns (Huntingford, 1961; Newton and Egli, 1958). However 
there are special warnings for prolonged use of excessive doses together with large 
volumes of fluid as this has been known to cause water intoxication with 
hyponatraemia (Mayer-Hubner, 1996). 
Recent systematic review of 28 randomised controlled trials conducted between 
1990 and 2010 which investigated the central effects of intranasal oxytocin 
(MacDonald et al, 2011) revealed that it (1) produces no reliable side-effects, and 
(2) is not associated with adverse outcomes when delivered in doses of 18–40 IU for 
short term and used in controlled research settings. A recent study conducted in 
early adolescent boys with autism spectrum disorders, whom were administered 
long term nasal oxytocin showed promising results with excellent compliance and 
no side effects (Tachibana et al, 2013). As a result we can conclude based on the 
above that the potential benefits outweigh the risks.  
1.4 Study Rationale 
The purpose of this pilot study is to test whether intranasal administration of the 
neuropeptide oxytocin is effective in assisting post-detoxification opioid dependent 
individuals to maintain abstinence from opioid use; in increasing retention rates in 
post detoxification rehabilitation programme; in lowering their craving for opioids; 
decreasing their anxiety (including social anxiety) and improving mood, social 
cognition and quality of life. This information is important to drive a larger 
adequately powered efficacy study in a larger population of opioid dependent 
individuals.  
The major problem for opioid dependent individuals who are recovering from their 
addiction is the maintenance of a drug-free state as around only 40% of clients will 
maintain abstinence 1 month post detoxification (Broers et al, 2000; Chutuape et al, 
2001)). Opioid dependent individuals undergoing detoxification suffer from 
persistent emotional withdrawal symptoms, (Jaffe, 1990; Martin and Jasinski, 1969; 
Nunes et al, 2004; Peles et al, 2007) which serve as a motivational trigger to re-
administer the drug and to relapse (Le Moal and Koob, 2007). These symptoms 
associated with emotional distress and dysphoria such as anxiety, irritability, stress, 
depression and anhedonia may persist for months in recovering opioid dependent 
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individuals.   Moreover, there is 30%-50% comorbidity of opioid addiction with 
depression and anxiety (Jaffe, 1990; Martin et al, 1969; Nunes et al, 2004; Peles et 
al, 2007).  In addition, the adverse social consequences of drug withdrawal in 
recovering opioid dependent individuals has been recognised, especially in light of 
the significant benefits that psychosocial support has in maintaining abstinence in 
addicts (Veilleux et al, 2010).   
 
As opioid substitution pharmacotherapy, benzodiazepam based anxiolytics and 
antidepressants have limited benefit in term of relapse prevention or can induce 
dependence in their own right, there is a need to develop more effective, safer 
treatment of emotional opioid withdrawal symptoms and relapse prevention.  
Preclinical study from Dr. Bailey’s laboratory showed promising effect of the 
oxytocin analogue carbetocin in attenuating the negative emotional consequences 
of opioid withdrawal and in preventing the stress-induced reinstatement to opioid-
seeking following extinction, in mice (Zanos et al., 2013). The proposed study is a 
translational pilot study which will provide important pilot data on the efficacy of 
oxytocin (Syntocinon) in reducing craving, emotional withdrawal symptoms and in 
preventing relapse in opioid dependent individuals undergoing detoxification. It will 
provide important information about the variability in response to treatment, which 
will be used to determine subject numbers required for an adequate statistical 
power essential in a comparative long study.  If the treatment proves effective, it 
may form the basis for the development of novel pharmacotherapy for the 
treatment of the negative emotional consequences of opioid addiction and relapse 
prevention which will have major health and socioeconomic impact.  
Rationale for Doses 
The route of administration dosage and regime proposed is entirely driven by 
literature where identical or similar protocols of Syntocinon (Oxytocin) 
administration were used in pilot and adequately powered clinical studies in healthy 
volunteers as well as patients suffering from autistic spectrum disorder, 
schizophrenia and fragile X syndrome (Andari et al, 2010; Ditzen et al, 2009; Feifel 
et al, 2010; Guastella et al, 2008; Hall et al, 2012; Hollander et al, 2007; Tachibana 
et al, 2013). 
Intranasal route of administration was selected over intravenous as it is much less 
invasive, can be easily self-administered by the subject with minimum or no 
supervision and it is believed to reach (or stimulate) the brain more readily to 
induce its central effects. The dose of 6 insufflations (24 IU of oxytocin total) given 
twice daily (9-11 am and 16.00-18.00 pm) has been repeatedly used in studies in the 
literature in healthy volunteers and patients (Andari et al, 2010; Ditzen et al, 2009; 
Feifel et al, 2010; Guastella et al, 2008; Hall et al, 2012; Hollander et al, 2007; 
Tachibana et al, 2013). This treatment regime has shown to be safe, as no or very 
minor adverse effects have been reported. Long term administration (weeks-
months) of a similar regime of Syntocinon administration in patients suffering from 
autistic spectrum disorder and schizophrenia showed no adverse effects (Tachibana 
et al, 2013). On the contrary, the dose regiment of Syntocinon proposed in this 
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study has shown repeatedly to exhibit positive effect in reducing anxiety, 
depression and/or enhancing social anxiety in patients suffering from autistic 
spectrum disorder, schizophrenia and fragile X syndrome and in withdrawn 
alcoholics (Andari et al, 2010; Ditzen et al, 2009; Feifel et al, 2010; Guastella et al, 
2008; Hall et al, 2012; Hollander et al, 2007; Pedersen et al, 2013; Tachibana et al, 
2013). 
 
We decided to stick with the doses of Syntocinon used in the literature as (1) no 
adverse or side effects have been reported (MacDonald et al., 2011) 2) beneficial 
effects have been reported as described above and 3) a recent study conducted in 
early adolescent boys with autism spectrum disorders who were administered long 
term nasal oxytocin showed promising results with excellent compliance and no 
side effects (Tachibana et al, 2013). We decided to be cautious and not to increase 
the dose of oxytocin as there is no substantial literature reporting its effect (positive 
or negative). Given that special warnings for prolonged use of excessive doses of i.v. 
oxytocin together with large volumes of fluid has been known to cause water 
intoxication with hyponatraemia (Mayer-Hubner, 1996), we decided to stay on the 
safe side.  In addition recent data in rats showed that higher doses of oxytocin can 
increase rather than decrease anxiety possibly due to its effect on vasopressin 
receptors at that concentration (Peters et al., 2014; in press). 
Rationale for Study Endpoints 
The treatment of opiate dependence presents many challenges; detoxification can 
be achieved for the majority of dependent individuals, however, maintenance of 
abstinence is more difficult as dependent individuals relapse.  Relapse to opiate use 
frequently leads to premature exit from treatment either during the detoxification 
process or shortly afterwards. The most commonly used measure of successful 
treatment is the length of abstinence achieved post-treatment. There are multiple 
studies in the literature using retention in rehabilitation treatment and drug use 
(lapse/relapse) as primary endpoints to study efficacy of pharmacotherapy in heroin 
dependent individuals. As the majority of the opioid dependent individuals   relapse 
within 1 month of detoxification (Broers et al, 2000; Chutuape et al, 2001), we 
decided to study retention in the post-detoxification rehabilitation programme (2 
weeks from baseline) and maintenance of abstinence up to 4 weeks following 
treatment with placebo/Syntocinon.  Moreover, rates of relapse as measured by 
urine screen and/or self-report is a very common method to quantify efficacy of a 
treatment in preventing relapse. Both these measurements will give a good 
preliminary indication on the efficacy of Syntocinon on relapse prevention.  
The secondary endpoints were chosen in order to measure emotional and other 
consequences of opioid abstinence such as opioid craving, anxiety, depression, 
social anxiety, and reduction in social cognition, poor quality of life and sleep 
disturbances which we hypothesize to be modulated by Syntocinon/oxytocin.  As 
quality of life has also become an important indicator in health care evaluation and 
is low in drug dependent individuals (DeMaeyer et al., 2010), we decided to use it as 
an endpoint for testing the efficacy of Syntocinon but only 4 weeks post 
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placebo/Syntocinon treatment. The environment in the rehabilitation unit is 
considered rather safe and protected. As a result, we did not decide to assess the 
effect of Syntocinon on quality of life during treatment in the rehabilitation unit.  
The timeline of the endpoints (i.e. at the start-treatment day 2, the end of the 2 
week oxytocin/placebo treatment period-treatment day14 and 1 month after the 
last dose of Syntocinon/placebo administration) was chosen in order to investigate 
the acute and chronic effect of Syntocinon on those secondary parameters and 
whether this effect is persistent after the end of the treatment.   
STUDY OBJECTIVES AND ENDPOINTS 
Study Objectives 
We hypothesise that: 
a) Post detoxification opioid dependent individuals exposed to intranasal 
oxytocin (Syntocinon) will have decreased rates of relapse and higher retention 
rates in inpatient rehabilitation programme compared to individuals exposed to 
placebo control. 
b) Intranasal oxytocin (Syntocinon) will reduce opioid craving, anxiety, 
depression, social anxiety, sleep disturbances (e.g. sleep efficiency, nocturnal 
awakenings, sleep duration) in post detoxification opioid dependent individuals 
compared to individuals exposed to placebo control. 
c) Intranasal oxytocin (Syntocinon) will have a positive effect on social cognition, 
quality of life in post-detoxification opioid dependent individuals compared to 
individuals exposed to placebo control. 
Primary Objective 
The primary objective will be to investigate the efficacy of oxytocin in retaining post 
detoxification opioid dependent individuals in inpatient rehabilitation programme 
and in preventing relapse to opioid use. 
Secondary Objective 
The secondary objective will be to investigate the efficacy of oxytocin in reducing 
opioid craving, anxiety, depression, social anxiety, sleep disturbances and in 
enhancing social cognition, quality of life in post-detoxification opioid dependent 
individuals 
Study Endpoints 
Primary Endpoint  
Retention rates in rehabilitation programme at approximately 2 weeks from the 
first dose of Syntocinon/placebo treatment.  Rates of subjects relapsing to drug use 
(e.g. urine positives for opioid/illicit drug metabolites, self-reporting) at specific 
time points from the first dose of Syntocinon/placebo administration (e.g. 
approximately 2 and 6 weeks).   
Secondary Endpoints 
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Measures of withdrawal symptoms severity, opioid craving, anxiety, depression, 
social anxiety, social cognition, sleep disturbances at the start (treatment day 2) and 
the end (treatment day 14) of the 2 week placebo/Syntocinon treatment period and 
1 month after the end of the last dose of placebo/Syntocinon treatment. Measures 
of quality of life (wellbeing) at baseline and 1 month after the last dose of 
placebo/Syntocinon treatment. Activity/sleep profile before (i.e. from screening), 
during and after placebo/Syntocinon treatment (up to 1 month after the end of the 
treatment will be acquired). 
SUBJECT SELECTION AND WITHDRAWAL CRITERIA 
Population base 
30 (n=15 in each arm completing the whole study) opioid dependent individuals, 18-
65 of age, male and females, admitted for opioid detoxification toWindmill House 
(inpatient only) detoxification unit at Surrey & Borders Partnership NHS Foundation 
Trust at St Peters Hospital will be used in this study.  This is considered to be an 
appropriate sample size for a pilot study in order to calculate the variability in 
response to treatment which will be used to determine subject numbers required to 
adequately statistically power a comparative large study.  
Inclusion criteria 
1) Primary diagnosis of opioid dependence according to DSMIV criteria   
2) Males and non-lactating, non-pregnant females, aged 18-65 years.   
3) Subjects must be willing and able to give informed consent  
4) Subjects must have understanding of English  
5) Subjects are required to have completed an opiate detoxification programme at 
Windmill House and remain opiate free before the start of the study. These patients 
will continue with a specific opiate free inpatient programme. The programme runs 
6 days a week, with daily groups comprising a mixture of cognitive behaviour 
therapy (CBT), psychodynamic and recovery related groups.  
Exclusion criteria 
1) Severe psychosis, Bipolar Affective Disorder I, severe depression with suicidal 
ideation and intention, brain trauma or other severe neurological disorders (e.g. 
pan-hypopituitarism). 
2) Taking anxiolytics antipsychotics, sedatives, prostaglandins, certain inhalation 
anaesthetics (e.g. cyclopropane, halothane), opioids for pain management during 
post opiate detoxification. 
3) Pregnant females and lactating mothers 
4) History of severe kidney disease  
5) History of cardiovascular disease (heart disease, heart attacks, high blood 
pressure, heart surgery)  
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6) Habitual drinking of large volumes of water  
7) Nasal bleeding  
8) Any other condition that in the judgement of the investigator would preclude 
participation 
 
 
9.4. Discontinuation and Withdrawal of Subjects from the Study 
Any subject may voluntarily discontinue participation in this study at any time. 
The investigator may also, at his or her discretion, discontinue the subject from 
participating in this study at any time, and must do so if any of the following criteria 
are met: 
• Positive urine test for illicit drug and alcohol use or self-report use of illicit 
drugs and alcohol throughout the duration of the study. The rehabilitation unit has 
a clear rule that anybody found with positive urine for illicit drugs and alcohol will 
be discharged. This is of course essential data that will be used for our primary 
outcome (retention in rehabilitation treatment and relapse). 
• Positive pregnancy test at visit. 
• Concomitant use of any medication which may interfere with study outcome 
and IMP throughout the study. 
The reason for termination will be recorded in the case report form (CRF). A subject 
may withdraw (or be withdrawn) from the study prematurely for the following 
reasons: 
• Withdrawal of consent. 
• Adverse event (AE section must be completed). 
• Protocol deviation. 
• Other must be specified 
All participants who withdraw from the study before completion will be replaced. 
CLINICAL TRIAL PROTOCOL 
The study is a randomised controlled pilot trial (Syntocinon vs. placebo). It will be 
conducted in the Windmill House (inpatient only) detoxification unit at Surrey & 
Borders Partnership NHS Foundation Trust at St Peters Hospital and will consist of 4 
phases, screening (visit 1), baseline (visit 2), placebo/Syntocinon treatment (2 visits 
at the beginning: visit 3 and 4/treatment day 1 and 2) and 1 visit at the end of the 
14 day placebo/Syntocinon treatment period (visit 5) and 1 visit 30-35 days after 
the last dose of placebo/Syntocinon treatment (visit 6). 
Study Procedures 
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Pre-study 
Upon admission 
Upon admission to the detoxification centre at Windmill House, patients will have 
routine vital signs measured (blood pressure, heart rate and temperature) and 
blood samples analysed (haematology, serology, and biochemistry). Urine sample 
will be obtained for drug screening (illicit drugs screening) for pregnancy test (only 
females) and patients will be routinely breathalysed for alcohol.  Medical and 
psychiatric history will also be recorded and reviewed. 
10.1.1.1 Screening (Visit 1) 
Prior to admission to the detoxification centre at Windmill House, people on the 
waiting list will be informed about the study so that they can decide if they would 
like to participate in the study. Once admitted to Windmill House (inpatient only) 
detoxification unit at Surrey & Borders Partnership NHS Foundation Trust, patients 
will firstly be approached by a member of their care team or researcher to see if 
they are interested in participating in the research. If a patient wishes to participate 
in the trial, subject informed consent will be obtained by the researcher after the 
admission to the post opiate detoxification program.  The pre-study screening visit 
will take place following admission to the center during the first 2 weeks of 
detoxification. The following procedures will be performed on the subjects to assess 
eligibility: 
• Demographic data. 
• Medical (cardiovascular and kidney disease) and psychiatric history  
• Vital signs: blood pressure, heart rate, oral temperature. 
• Medical History Questionnaire (MHQ) 
• Assessment of amount of drinking water habit 
• Assessment of nasal obstruction, discharge or bleeding 
• Assessment of inclusion/exclusion criteria 
• Assessment of any concomitant medication taken 
Results from clinical laboratory tests (haematology, clinical chemistry, urinalysis and 
microscopy if required) done upon admission as well from pregnancy test (females 
only) will be available in order to assess eligibility. Extra clinical laboratory tests will 
be done only if needed (e.g. infection). 
Random testing for illicit drugs (urine screen) and breathalysing for alcohol will be 
done twice weekly following admission to the unit. In the event of any positive 
urine samples or breathalysing for alcohol, the patients will be discharged from the 
rehabilitation centre immediately and will not be able to participate in the study. 
These data will be available to the researcher.  
Once all tests are completed satisfactorily and the subject has given informed 
consent, subjects will be enrolled onto the study and asked to attend the baseline 
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visit. Subsequent to the screening, the subjects will be assigned to randomization 
sequence to either Syntocinon or placebo. Monitoring of any AEs will be carried out 
from the time that informed consent has been given. The subjects will be given 
access to an electronic diary, ideally in the form of an app that they would be able 
to access from the mobile phones or computer. In that diary they would be able to 
record any daily information on their drug intake including illicit drugs, alcohol and 
prescription medication, timing of period (for females to monitor pregnancy 
possibility), adverse events and record their craving, withdrawal symptoms, sleep 
quality/diary, alertness, calmness, anxiety, happiness, sadness, sleep quality, 
sociability with the use of scoring scale. They would be told to complete this task at 
specific time points (e.g. 50 minutes after Syntocinon/placebo administration one 
AM and one 50 minutes after Syntocinon/placebo administration PM) throughout 
the whole duration of the study (up to 1 month post placebo/Syntocinon 
treatment). If that proves not to be possible the subjects will be given paper 
analogue scales on which subjects circle how much they crave opioids, experience 
sleep disturbances, lethargy, happiness, sadness, withdrawal symptoms between 
not at all (1) to extremely (9) (see Appendix). They will also be given an actiwatch 
(CamNTech to record their activity and sleep patterns (day time and night-time) 
throughout the whole duration of the study until 1 month post treatment. They will 
be required to wear the actiwatch at all times apart from when in the shower or the 
bath.  
10.1.1.2 Baseline Day (Visit 2) 
Prior to the placebo/Syntocinon treatment trial (i.e. at least 2 days after the last 
dose of opioid detoxification), baseline measures of opioid withdrawal symptoms, 
craving, social anxiety, depression, anxiety, social cognition, quality of life and sleep 
will be obtained.   
Subjects will arrive at the investigation room between 9.00-11.00 h or 16.00-18.00 
h. Their medical status, adverse events, prior and/or concomitant medications, will 
be reviewed. For females, the urine pregnancy test will be performed. Results from 
random testing for illicit drugs (urinalysis) and breathalysing for alcohol which are 
done twice weekly will be reviewed. In the event of any positive urine samples or 
breathalysing for alcohol, the subject will be discharged from the rehabilitation 
centre and will not be able to participate in the study. Baseline measures of feelings 
of withdrawal, cravings, sleep, alertness, calmness, hostility, sociability, mood and 
anxiety will be assessed by either asking the subjects to score them electronically 
via the app or by means of completing paper analogue scales and by means of 
keeping a sleep diary. Approximately 50 minutes after arrival to the investigation 
room a battery of well-validated scales/questionnaires to quantify depression, 
anxiety, social cognition, opioids craving, severity of withdrawal symptoms, social 
anxiety, quality of life and sleep will be used in this study. The domains to be 
measured and the instruments that will be used are summarized below. The tests 
will be conducted and rated by the blinded researcher in the order outlined below 
among whom good inter-rater reliability will be established. 
Liebowitz Social anxiety test (5 minutes) 
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Depression will be evaluated by the Hamilton Psychiatric Scale of Depression (HDRS) 
(15 minutes) 
Anxiety (Hamilton Psychiatric Scale of Anxiety/HARS) (15 minutes) 
Social cognition measurements of emotion recognition (Reading the Mind in the 
Eyes Test- Revised Version) (10 minutes) 
Sleep disturbances (Leeds Sleep Evaluation Questionnaire/LSEQ or/and Karolinska 
sleep questionnaire) (15 minutes) 
Withdrawal symptoms questionnaire: clinical opiate withdrawal scale (COWS) 
Subjective Opiate Withdrawal Scale (SOWS) (10 minutes) 
 
WHO Quality of Life Questionnaire-BREF (WHOQOL-BREF) (15 minutes) 
Vital signs will be subsequently measured (blood pressure, heart rate and 
temperature) 
See Appendix for details of the tests. 
Treatment periods 
10.1.2.1 Treatment day 1 (Visit 3) 
There will be an interval of at least 3 days between the methadone/lofexidine dose 
and the first Syntocinon/oxytocin dose. Subjects will take their first intranasal dose 
of the test substance on treatment Day 1 of the study, 1-3 days after baseline day. 
On treatment day 1, subjects will arrive at the investigation room between 09:00-
11:00 or 16:00-18:00 h. Subjects will be given one bottle containing 5 ml of either 
oxytocin (OT, Syntocinon) or placebo by the researcher. This will be expected to last 
for 4 days. The researcher will instruct subjects in the correct intranasal self-
administration technique and will observe the administration.  A second intranasal 
test dose will be taken between 16:00-18:00 h on day 1 of treatment or at 09:00-
11:00 the following day depending on when the first dose of placebo/Syntocinon 
was administered. Thereafter, subjects will administer intranasal doses between 
09:00-11:00 and 16:00-18:00 hours throughout the 2 week duration of the study. 
The researcher or a member of the team will provide the bottle to the subject each 
time and will observe the administration of the placebo or the drug administration. 
After the administration, the bottle will be returned to safe storage out of the reach 
of the subjects, by the research fellow or a member of the team.   Each test dose 
will consist of 6 insufflations of Syntocinon Spray (containing approximately 24 IU of 
OT) or placebo, with each insufflation given 30 seconds apart and alternating 
between nostrils. OT and placebo test doses will be self-administered from blind-
labeled spray vials designed to deliver 0.1 ml metered volume per insufflation. In 
total, subjects will use a maximum of 4, 5 ml test bottles throughout the duration of 
the study. The research fellow will dispense a new bottle every 4 days and the used 
bottle will be weighed to confirm compliance to the protocol, to determine how 
much solution was actually used from the vial and for drug accountability purposes. 
Spray vials will be stored at room temperature or in a fridge if possible and the tip 
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of the spray nozzle will be cleaned with an alcohol wipe after each dose is 
administered. 50 minutes after placebo/Syntocinon administration the subjects will 
be instructed to assess their feelings of withdrawal, cravings, sleep, alertness, 
calmness, hostility, sociability, mood and anxiety by either asking the subjects to 
score them ideally electronically via the app or by means of completing paper 
analogue scales. Vital signs will be subsequently measured (blood pressure, heart 
rate and temperature). 
10.1.2.2 Treatment day 2 (Visit 4) 
Subjects will arrive at the investigation room on treatment day 2 between 09:00-
11:00 or 16:00-18:00 hours .  Their medical status, adverse events, prior and/or 
concomitant medications, will be reviewed and vital signs will be assessed.  
 
Following that, they will be given their bottle containing 5 ml of either OT or 
placebo and will perform 6 insufflations as described above. 
50 minutes later a battery of well-validated tests/questionnaires to quantify anxiety 
(including social anxiety), depression, social cognition, opioids craving, sleep 
disturbances and severity of withdrawal symptoms will be carried out.  
The domains to be measured and the instruments that will be used are summarized 
below. The tests will be rated and conducted by the researcher among whom good 
inter-rater reliability will be established. 
Liebowitz Social anxiety test (5 minutes) 
Depression will be evaluated by the Hamilton Psychiatric Scale of Depression (HDRS) 
(15 minutes) 
Anxiety (Hamilton Psychiatric Scale of Anxiety/HARS) (15 minutes) 
Social cognition measurements of emotion recognition (Reading the Mind in the 
Eyes Test- Revised Version) (10 minutes) 
Sleep disturbances (Leeds Sleep Evaluation Questionnaire (LSEQ) or/and Karolinska 
sleep questionnaire) (15 min) 
Withdrawal symptoms questionnaire: clinical opiate withdrawal scale 
(COWS)/Subjective Opiate Withdrawal Scale (SOWS) (10min) 
Vital signs will be subsequently measured (blood pressure, heart rate and 
temperature) 
Side effects checklist for nausea, dizziness, headache or any other adverse effects 
will be given immediately after completion of the treatment day. Any subject 
experiencing adverse events will be questioned regarding the nature, severity, 
dates of onset and resolution and outcome of the event, and the record added to 
the subject’s CRF.  Any criterion defining the event as serious will be elucidated, and 
if appropriate a Serious Adverse Event (SAE) report will be prepared. 
10.1.2.3 Treatment days 3-13 
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Subjects will be administer placebo or Syntocinon twice a day on treatment days 3-
13  between 09:00-11:00 and 16:00-18:00 hours. This will be done under strict 
supervision of the researcher or member of the care team. 
10.1.2.4 Treatment day 14 (Visit 5) 
The exact same protocol as described above (visit 4) will be carried out on the last 
day of the treatment protocol (max day 14 of placebo/Syntocinon) of the treatment 
protocol. 
Treatment days 1- max 14 
Subjects will be asked to assess their feelings of cravings, sleep, alertness, calmness, 
hostility, sociability, mood and anxiety daily by either scoring them electronically via 
the app or by means of completing paper analogue scales. The subjects will also 
complete a withdrawal symptoms questionnaire (clinical opiate withdrawal scale 
(COWS)/ Subjective Opiate Withdrawal Scale (SOWS). These tasks will be done 50 
minutes after Syntocinon/placebo administration during the morning session (e.g. 
9.50 a.m)  or afternoon session (e.g. 17.50) throughout the 14 day duration of the 
treatment protocol. As mentioned, the subjects will be given a diary where they 
would be able to record any daily information on their drug intake-including illicit 
drugs, alcohol and prescription medication, timing of period (for females to monitor 
pregnancy possibility), adverse events, sleep etc. 
Testing for illicit drugs (urine screen) and breathalysing for alcohol will be done 
twice weekly during the 14 day duration of the treatment.  In the event of any 
positive urine samples or breathalizing for alcohol, the subject will be discharged 
from the rehabilitation centre and will be deemed as having lapsed/relapsed. 
Subjects will also be discharged if they admit self-reported opioid or any other illicit 
drug (or alcohol) use. Where participants missed periods of time in treatment, they 
will be deemed to have discontinued from the study (and dropped out of 
treatment). 
Post treatment assessment (Visit 6) 
The post placebo/Syntocinon treatment assessment will take place 30-35 days after 
the end of the treatment protocol around 30-35 days after the subject have been 
discharged from the rehabilitation unit. Subjects will be asked to return to one of 
the Surrey & Borders rehabilitation centers between 9-11 or 16.00-18.00 depending 
on the time that the other visits took place) and will be met by the researcher in 
person. If this proves impossible then only we will resort to telephone interview.  
Their medical status, adverse events, concomitant medications will be reviewed. 
Measures of feelings of withdrawal, cravings, sleep, alertness, calmness, hostility, 
sociability, mood and anxiety will be assessed by either asking the subjects to score 
them electronically ideally via the app or by means of completing paper analogue 
scales. Following that, a battery of well-validated scales/questionnaires to quantify 
anxiety (including social anxiety), depression, social cognition, opioids craving, and 
severity of withdrawal symptoms, sleep disturbance and quality of life will be used 
in this study. The domains to be measured and the instruments that will be used are 
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summarized below. Tests will be rated and conducted by the researcher in the 
order outlined below among whom good inter-rater reliability will be established. 
Liebowitz Social anxiety test (5 minutes) 
Depression will be evaluated by the Hamilton Psychiatric Scale of Depression (HDRS) 
(15 minutes) 
Anxiety (Hamilton Psychiatric Scale of Anxiety/HARS) (15 minutes) 
Social cognition measurements of emotion recognition (Reading the Mind in the 
Eyes Test- Revised Version) (10 minutes) 
Sleep disturbances (Leeds Sleep Evaluation Questionnaire (LSEQ) or Karolinska sleep 
questionnaire) (15 minutes) 
 
Withdrawal symptoms questionnaire: clinical opiate withdrawal scale 
(COWS)/Subjective Opiate Withdrawal Scale (SOWS) (10min) 
WHO Quality of Life Questionnaire-BREF (WHOQOL-BREF) (15 minutes) 
Vital signs will be subsequently measured (blood pressure, heart rate and 
temperature) 
We intend to obtain urine sample for opioid and other illicit drugs screening but we 
will also resort to self-reporting as a way to monitor lapse or relapse. Urine sample 
will also be collected for pregnancy test  
The subjects will be asked to record information on their drug intake-including illicit 
drugs, alcohol and prescription medication, sleep parameters, timing of period (for 
females to monitor pregnancy possibility), adverse events etc. daily in their diary 
throughout the 30-35 day duration of the post placebo/Syntocinon treatment.  The 
subjects will be instructed to assess their feelings of withdrawal, cravings, sleep, 
alertness, calmness, hostility, sociability, mood and anxiety by either asking the 
subjects to score them electronically ideally via the app or by means of completing 
visual analogue scales daily throughout the 30-35 day period. The subjects will be 
deemed as having relapsed if their urine test is positive or if they self-report drug or 
alcohol use. 
Side effects checklist for nausea, dizziness and headache or any other adverse 
effects will be given. Any subject experiencing adverse events will be questioned 
regarding the nature, severity, dates of onset and resolution and outcome of the 
event, and the record added to the subject’s CRF.  Any criterion defining the event 
as serious will be elucidated, and if appropriate a Serious Adverse Event (SAE) 
report will be prepared. 
After completing this final visit, their participation in the study will be complete. 
Subjects will receive an inconvenience payment in the form of vouchers according 
to the number of visits completed. Subjects completing all visits will receive an 
amount in the form of vouchers. 
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Post- Study Safety Assessment (1-15 days after last Treatment Period or at early 
withdrawal) 
Subjects will undergo a post-study safety assessment after last placebo/Syntocinon 
Treatment Period before they get released from the inpatient post detoxification 
programme. If a subject withdraws from the study or gets discharged between 
study visits, then a separate visit will be scheduled in order to perform post-study 
safety assessments.  
Subjects will be asked about their general health and whether they had experienced 
any adverse events since their last study visit.  Any subject experiencing adverse 
events will be questioned regarding the nature, severity, dates of onset and 
resolution and outcome of the event, and the record added to the subject’s CRF.  
Any criterion defining the event as serious will be elucidated, and if appropriate a 
Serious Adverse Event (SAE) report will be prepared. 
 
 Assessments will include: 
• Physical examination and psychiatric questionnaire 
• Vital signs (BP, HR, and oral temperature). 
• Clinical laboratory if required (haematology, clinical chemistry, urinalysis and 
microscopy if required). 
Subjects whose results are not considered abnormal clinically from those at 
screening/admission will be considered to have completed the trial. Subjects with 
clinically significant abnormal results will be followed up until results return to 
normal. 
Duration of Study Participation 
The minimum expected duration of subject participation from consent to follow up 
visit is a maximum of 46 days (consent to baseline minimum 1day, 1 day baseline, 
14 days Syntocinon/placebo treatment, minimum: 30 days post treatment follow 
up). 
Study Restrictions 
There will be no dietary or activity restrictions. Subjects will be required to comply 
with the alcohol restriction for the duration of the study: 
Subjects must refrain from drinking alcohol throughout the duration of the 
inpatient detoxification programme (2 weeks of opioid detox+ 4 weeks of post 
detox) and will undergo random alcohol breath test twice to ensure compliance.  In 
the event of positive breathalysing test, the subject will be discharged from the 
rehabilitation centre and will be deemed as having lapsed/relapsed. Alcohol 
consumption is also one of the items that subjects will be asked to monitor in the 
diaries throughout the 46 day duration of the study. 
Prohibited Medications and Non-Drug Therapies 
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Subjects will be taking relevant pharmacotherapy (e.g. diazepam, methadone, 
subotex,buprenorphine, lofexidine, loperamide, ibuprofen/paracetamol, zopiclone, 
buscopan) during the 2 weeks of opioid detoxification.  
Following that, detoxification period (post detoxification period), subjects will be 
prohibited from taking other medications during the course of the study except for 
oral contraceptives, prescribed antidepressants and the occasional use of 
paracetamol and ibuprofen.  There will be an interval of at least 3 days between the 
methadone/lofexidine dose and the first placebo/oxytocin dose. 
If subjects are prescribed any new medications (including creams, ointments, 
inhalers) or if they purchase any medications ‘over the counter’ (including herbal 
remedies), for example from the pharmacy, supermarket or health food shop, they 
must report the name of the drug(s)/herbal preparation(s), the dose and the dates, 
duration of treatment at their next visit and reason for use which will subsequently 
be recorded in the source document and CRF. Patients will be questioned at each 
assessment visit about the use of concomitant medication in the period since the 
last assessment visit. If a subject takes any diazepam, methadone, subotex, 
buprenorphine, lofexidine, loperamide, zopiclone, buscopan or anxiolytics during 
the 2 weeks of Syntocinon or placebo treatment they will be withdrawn from the 
study. 
Participans will be advised to refrain from concomitant use of any other medication, 
either prescription or Over The Counter (OTC) products, which may interfere with 
study outcomes and/or interfere with Syntocinon within the 14 day duration of 
Syntocinon/placebo treatment, during the 30-35 day period after the end of the 
treatment and at least 2 days prior to Syntocinon/placebo treatment.   
Any medication taken from 1 month prior to and throughout the study period must 
be recorded on the source document and case report form with the name of the 
drug, dosage, date(s) of administration and reason for use. 
TRIAL MEDICATION 
Treatment Plan 
Drug: intranasal oxytocin spray (Other Name: Syntocinon Spray), 40 IU/ml, 5 ml 
produced by Novartis in Switzerland (Swiss Medic Admissions number 25644). The 
IMP will be imported and QP released by Mawdsley-Brooks & Co Ltd, Quest Park, 
Silk Road, Off Wheatley Road, Doncaster, DN2 4LT, who hold an MIA(IMP) 
[authorisation number 741] for the required activities.  The labelling and dispensing 
of the IMP into a bottle and assembly with the pump and fitting with the atcuator 
will be done by Surrey and Borders Partnership NHS Foundation Trust Pharmacy, 
under the instructions given  by Surrey CRC to ensure blinding of the study. 
6 insufflations (24 IU Oxytocin total) given twice daily (between 9-11 am and 16-18 
pm) for up to 14 days (self-administered).  The spray will be administered at least 3 
after the last dose of opioid detoxification treatment. 
Placebo control:Normal saline (5ml Sodium Chloride 0.9% for Injection) 
manufactured by Mini-Plasco brand from B Braun The labelling and dispensing of 
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the placebo into a bottle and assembly with the pump and fitting with the acuator 
will be done by Surrey and Borders Partnership NHS Foundation Trust Pharmacy, 
under the instructions given Surrey CRC to ensure blinding of the study.   
6 insufflations (0.1 metered dose/insulfflation) given twice daily (between 9-11 am 
and 16-18 pm) for up to 14 days (self-administered).  The spray will be administered 
at least 3 after the last dose of opioid detoxification treatment. 
Rationale for Doses 
Please see 7.4.2 
Preparation, Administration and Dosage of IMP/NIMP 
Preparation Instructions 
The spray (5 ml Syntocinon spray containing 40 IU/ml oxytocin) or placebo 
(containing 5ml Sodium Chloride 0.9%) should be used in a sitting position. The cap 
should be removed, then, on the first time of use, the pump should be primed by 
depressing the actuator until the spray is release (about three times). Holding the 
bottle upright, the nozzle needs to be inserted into on nostril and to be actuated 
while gently inhaling through the nose. The nasal spray should be stored in a 
refrigerator, at least for long term storage. 
Route of administration 
Intranasal route of administration was selected over intravenous as its much less 
invasive than intravenous, can be easily self-administered by the patient with 
minimum or no supervision and it is believed to reach (or stimulate) the brain more 
readily to induce its central effects. 
11.2.3. Dose and Dosing Schedule  
The doses used 6 insufflations (24 IU of oxytocin total) given twice daily (between 9-
11 am and 16:00-18:00) has been repeatedly used in clinical studies in the literature 
in healthy volunteers and patients (Andari et al, 2010; Ditzen et al, 2009; Feifel et al, 
2010; Guastella et al, 2008; Hall et al, 2012; Hollander et al, 2007; Tachibana et al, 
2013). This treatment regime has shown to be safe as no or very minor adverse 
effects have been reported. Long term administration (weeks-months) of a similar 
regime of syntocinon administration in patients suffering from autistic spectrum 
disorder and schizophrenia showed no adverse effects (Tachibana et al, 2013). On 
the contrary, the dose regiment of syntocinon proposed in this study has shown 
repeatedly to exhibit positive effect in reducing anxiety, depression and/or 
enhancing social anxiety in patients suffering from autistic spectrum disorder, 
schizophrenia and fragile X syndrome and in withdrawn alcoholics (Andari et al, 
2010; Ditzen et al, 2009; Feifel et al, 2010; Guastella et al, 2008; Hall et al, 2012; 
Hollander et al, 2007; Pedersen et al, 2013; Tachibana et al, 2013). 
Each test dose will consist of 6 insufflations of Syntocinon Spray or placebo with 
each insufflation given 30 seconds apart and alternating between nostrils. The 
insufflations will be administered when the subject is in a sitting position. 
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The researcher will dispense a new bottle every 4 days and the used bottle will be 
weighed to confirm compliance to the protocol, to determine how much solution 
was actually ejected from the vial and for drug accountability purposes. The 
researcher or a member of staff will supervise the daily administration of the spray. 
Following each dose administration, the tip of the spray nozzle will be cleaned using 
an alcohol swipe and the cap replaced. 
Packaging and Labelling 
 Name Dose Strength and Form 
Primary Study Material oxytocin spray (Other Name: Syntocinon Spray) 
 40 IU/ml, nasal spray solution 
Placebo Placebo, Normal Saline 5ml Sodium Chloride nasal spray solution 
SYNTOCINON Spray 40 IU/ml, 5 ml  is produced by Novartis in Switzerland (Swiss 
Medic Admissions number 25644). The IMP will be imported and QP released by 
Mawdsley-Brooks & Co Ltd, Quest Park, Silk Road, Off Wheatley Road, Doncaster, 
DN2 4LT, who hold an MIA(IMP) for the required activities.  The labelling and 
dispensing of the IMP into a bottle and assembly with the pump and fitting with the 
actuator will be done by Surrey and Borders Partnership NHS Foundation Trust 
Pharmacy, under the instructions given by Surrey CRC to ensure blinding of the 
study. 
PLACEBO – Saline Spray manufactured by Mini-Plasco brand from B Braun PL 
03551/0076. Labelling and dispensing of placebo into the bottle and assembly with 
the pump and the actuator fitted will be done by Surrey and Borders Partnership 
NHS Foundation Trust Pharmacy, under instructions given by Surrey CRC to ensure 
blinding of the study. 
11.3.1 Storage and Accountability of Drug Supplies 
Storage of the drug will be as per SmPC for Syntocinon and no nasal spray will be 
used after expiry date.  
Long term storage will be in a refrigerator (2-8 oC) at Surrey and Borders 
Partnership NHS Foundation Trust Pharmacy.   
Upon opening, labelling and dispensing of the nasal spray by the pharmacy, the 
drug will be stored according to the shelf-life regulations within SmPC.  The nasal 
spray will be used within 1 month and will be stored at Windmill House at 
temperatures below 25 oC. 
The researcher will provide one 5 ml bottle spray to each subject and will supervise 
the insulfations.  Immediately after that, the researcher will store the bottle 
securely and according to the SmPC regulations; below 25 oC. Each subject will use 
a 5ml bottle spay which will last for 4 days. The researcher will dispense a new 
bottle from the pharmacy every 4 days. In total subjects will use 4 sprays over the 
14 days of treatment. The researcher or member of care team at Windmill house 
will be providing the subject with the Syntocinon spray every day, twice a day to 
avoid any issues with compliance to the protocol.  Dispensing records of the sprays 
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used (placebo or Syntocinon) will be kept daily in a Drug dispensing Log by the 
research fellow. Once the spray has been completely used, the vials will be brought 
to the pharmacy for destruction.  Disposal records will be kept.  
Return of Clinical Supplies 
The unused IMP cannot be returned to the manufacturer. Every effort will be made 
to use all the supply of IMP. Any remaining IMP will be returned to pharmacy for 
destruction. Disposal records will be kept. 
Responsibilities 
The researcher and Prof Skene will have the responsibility of securely maintaining 
the IMP, ensuring that an accurate record of IMP issued and returned (log) is 
maintained. Quality issues should be reported to Prof Skene and Dr. Fiona Robinson 
(Chief Investigator).  
 
 
 
 
Compliance 
The researcher or member of staff at Windmill house will be providing the subject 
with the Syntocinon spray every day, twice a day to avoid any issues with 
compliance to the protocol.   
Treatment Assignment Procedures 
Randomisation 
This is a double blind randomised placebo controlled pilot study. Randomised 
controlled trials are the most rigorous way of determining whether a cause-effect 
relation exists between treatment and outcome and for assessing the cost 
effectiveness of a treatment. It is the gold standard to test the efficacy and/or 
effectiveness of an intervention, in this case Syntocinon. The most important 
advantage of proper randomisation is that it minimizes allocation bias, balancing 
both known and unknown prognostic factors, in the assignment of treatments. As 
the prime aim of this pilot trial is to gather pilot data to support an adequately 
powered RCT, it is important that we stick to the randomisation in this trial. The RCT 
design selected is the parallel-group where each participant is randomly assigned to 
a group, and all the participants in the group receive (or do not receive) an 
intervention (in this case Syntocinon). Placebo control is used in the present study 
to control for the possible “psychological” effect by  administering the spray 
content without the active substance. Randomisation lists will be generated by 
Surrey CRC.   
A sealed envelope containing details of the test product administered at each 
treatment phase will be provided for each randomised subject and will be locked in 
a secure location with limited access at Windmill House under the supervision of 
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the Principal Investigator and at the University of Surrey. In the event of an 
emergency, and where clinically indicated, the investigator may determine a 
participant’s treatment through opening the participant’s individual code-break 
envelope. 
Should the treatment sequence be unblinded, the participant must be withdrawn 
from the study and the post-study assessments performed.  If the blind is broken, 
the investigator will document the date, time of day and reason for code breaking in 
the CRF. 
Blinding/Unblinding 
This is a double blind randomised placebo controlled pilot study. Researcher 
conducting the tests, the participants and the outcome assessors will be blind to 
treatment group. Blinding usually reduces differential assessment of outcomes 
(information bias), but can also improve compliance and retention of trial 
participants while reducing biased supplemental care or treatment (sometimes 
called co-intervention). The Syntocinon and placebo will be packaged in such a way 
that there will just be a number on the label and so the researcher taking IMP or 
placebo from the fridge won’t know what each subject is being given. Surrey CRC 
will be instructing Surrey & Borders Partnership NHS Foundation Trust Pharmacy on 
how to label the placebo/Syntocinon bottles to ensure blinding of the experiment. 
 
12. EFFICACY AND SAFETY PARAMETERS 
12.1. Psychometric Parameters 
12.1.1 Electronic Assessments 
Test Function 
Liebowitz Social anxiety test Social anxiety 
The Reading the Mind in the Eyes Test-  Emotional/social recognition 
Electronic, ideally App diary and self-assessment of mood, craving, sociability state 
(if that not possible then paper version will be used) Drug craving, withdrawal 
symptoms, alertness, calm, hostility, anxiety, happiness, sadness and side effects 
checklist for nausea, dizziness and headache, sleep. In that diary subjects would be 
able to record any daily information on their drug intake-including illicit drugs, 
alcohol and prescription medication, timing of period (for females to monitor 
pregnancy possibility), adverse events and sleep. 
12.1.2 Paper Based Assessment 
Test Function 
Visual Analogue Scale (VAS) 
Paper diary a Drug craving, withdrawal symptoms, alertness, calm, hostility, 
anxiety, happiness, sadness and side effects checklist for nausea, dizziness and 
headache, sleep. Participants mark a series of visual analogue scales ranging from 1 
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to 9, indicating the direction and magnitude of any changes in behavioural state 
they experience following administration of the drug. In that diary subjects would 
be able to record any daily information on their drug intake-including illicit drugs, 
alcohol and prescription medication, timing of period (for females to monitor 
pregnancy possibility), adverse events and sleep. 
Clinical Opiate Withdrawal Scale (COWS) / Subjective Opiate Withdrawal Scale 
(SOWS) Opioid Withdrawal Symptoms 
Hamilton Psychiatric Scale of Depression (HDRS) Depression 
Hamilton Psychiatric Scale of Anxiety (HARS) Anxiety 
The World Health Organisation Quality of life-BREF (WHPQOL-BREF) Quality of life 
Leeds Sleep Evaluation Questionnaire (LSEQ) or Karolinska Sleep Questionnaire
 Subjective effects of a psychoactive compound on an individual’s quality of 
sleep and related behaviour. 
a Visual analogue scale will be used only if electronic assessment, ideally app diary 
is not possible 
Subjects will be given actiwatches which they will wear continuously to monitor 
activity/inactivity/sleep profiles from screening (visit 1) till post treatment (visit 6). 
See Appendix for details of psychometric parameters  
12.2.  Safety Parameters 
Physical examinations, laboratory safety tests (blood chemistry, haematology, and 
urinalysis) will be performed on admission and at scheduled time points throughout 
the study only if deemed necessary. These procedures may also be performed at 
unscheduled time points if considered clinically necessary by the investigator. The 
detailed outline of the study procedures can be found in the study flowchart. 
12.2.1 Vital signs 
Vital signs include: diastolic and systolic blood pressure measurement following five 
minutes in the sitting position, heart rate and oral temperature. They will be 
obtained upon admission to the unit, at the screening visit, baseline visit (visit 2), 
following Syntocinon/placebo treatment visit on treatment days 2 (visit 4) and 14 
(visit 5) and at the follow-up visit (if possible). 
12.2.2 Clinical laboratory assessments 
Blood will be collected upon admission to the rehabilitation unit for laboratory 
analysis of: 
• Haematology: haemoglobin, hematocrit, white blood cells and platelets 
• Blood chemistry: TSH, B12, Follate, Na, K+, urea, creatine, Calcium, P, total 
protein, albumin, bilirubin, ALT, alkaline phosphatase. 
Additionally,  
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Urine sample upon admission, baseline (before placebo/Syntocinon administration) 
and if possible 30 days following last placebo/Syntocinon treatment will be 
collected for pregnancy test in female subjects. 
Urine drug screen for opioids, cocaine, benzodiazepines, barbiturates, 
amphetamines, and cannabinoids, and alcohol breath tests will be performed 
randomly twice a week throughout the whole duration of stay at the rehabilitation 
unit and 30-35 days post placebo/Syntocinon treatment (if possible). The result 
must be negative to allow subject to continue in the study. Positive urine screen or 
breath test will cause immediate discharge of the patient and would be deemed as 
relapsed. 
13 SAFETY MONITORING 
All subjects will receive an information card indicating participation in the study 
with the name, address, and telephone number of a Clinician at Windmill House for 
information in the event of an emergency. 
Adverse Events (AEs) 
It is unlikely that the intervention will cause any adverse events. However, if this 
happens, the researcher who is running the study will document it.  The researcher 
will be trained and ask subjects about their general health and well-being at each 
visit, and record any AEs or SAEs in the CRF. Any such events will be reported 
immediately to Dr. Robinson who is the Windmill Team consultant as well as to Prof 
Skene, and Dr. Kouimtsidis.   
Specification of Safety Parameter 
Laboratory and Other Safety Assessment Abnormalities Reported as AEs and SAEs 
Any abnormal laboratory test results (haematology, clinical chemistry or urinalysis) 
or other safety assessments (e.g. vital signs measurements), including those that 
worsen from baseline, and felt to be clinically significant in the medical and 
scientific judgement of the investigator, are to be recorded as AEs or SAEs. 
However, any clinically significant safety assessments that are associated with the 
underlying disease, unless judged by the investigator to be more severe than 
expected for the subject’s condition, are not to be reported as AEs or SAEs. 
Pregnancy 
It is also the policy of the University of Surrey that any pregnancy in a clinical trial 
subject or the partner of a clinical trial subject must be reported in the same way as 
SAEs.  
Pregnancy complications and elective terminations for medical reasons will also be 
reported as an AE or SAE.  Spontaneous abortions will be reported as an SAE. 
Any pregnancy that occurs during study participation will be reported using a 
clinical trial pregnancy form. The participant will be withdrawn from the study.  To 
ensure subject safety, each pregnancy will be reported to the sponsor within 24 
hours. The PI must assess whether the subject should be withdrawn from the study.  
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The pregnancy must be followed up to determine outcome (including premature 
termination) and status of mother and child.   
Any SAE occurring in association with a pregnancy brought to the investigator’s 
attention after the subject has completed the study and considered by the 
investigator as possibly related to the IMP, will be promptly reported to the 
sponsor. 
Definition of an AE 
Any untoward medical occurrence in a patient or clinical trial subject, to whom a 
medicinal product has been administered and which does not necessarily have a 
causal relationship with this treatment is considered to be an AE. 
Note: An AE can therefore be any unfavourable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of an investigational medicinal product whether or not 
related to the investigational medicinal product. For marketed medicinal products, 
this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or 
misuse. 
Events meeting the definition of an AE include: 
• Exacerbation of a chronic or intermittent pre-existing condition including 
either an increase in frequency and/or intensity of the condition 
• New conditions detected or diagnosed after IMP administration even though 
it may have been present prior to the start of the study 
• Signs, symptoms, or the clinical sequelae of a suspected interaction 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either 
IMP or a concomitant medication (overdose per se will not be reported as an 
AE/SAE). 
Events that do not meet the definition of an AE include: 
• Medical or surgical procedure (e.g. endoscopy, appendectomy); the condition 
that leads to the procedure is an AE. 
• Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen. 
• The disease/disorder being studied or expected progression, signs, or 
symptoms of the disease/disorder being studied, unless more severe than expected 
for the subject’s condition. 
Definition of a SAE 
A serious adverse event is any untoward medical occurrence that, at any dose: 
• Results in death. 
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In general, death should not be reported as an event.  Death is viewed as an 
outcome of an event, rather than an event itself.  In cases where the cause of death 
is unknown, death may be reported as an event initially.  However, every attempt 
should be made to submit a follow-up report identifying the probable cause of 
death when sufficient data are available. A death occurring during the study or 
which comes to the attention of the investigator within 4 weeks after stopping the 
IMP, whether considered due to the IMP or not, must be reported. 
• Is life-threatening. 
NOTE:  The term 'life-threatening' in the definition of 'serious' refers to an event in 
which the subject was at risk of death at the time of the event.  It does not refer to 
an event, which hypothetically might have caused death, if it were more severe. 
• Requires hospitalisation or prolongation of existing hospitalisation. 
NOTE:  In general, hospitalisation signifies that the subject has been detained 
(usually involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the 
physician’s office or out patient setting.  Complications that occur during 
hospitalisation are AEs.  If a complication prolongs hospitalisation or fulfils any 
other serious criteria, the event is serious.  When in doubt as to whether 
“hospitalisation” occurred or was necessary, the AE should be considered serious.  
Hospitalisation for elective treatment of a pre-existing condition that did not 
worsen from baseline is not considered an AE. 
• Results in persistent or significant disability/incapacity. 
NOTE:  The term disability means a substantial disruption of a person’s ability to 
conduct normal life functions. This definition is not intended to include experiences 
of relatively minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhoea, influenza, or accidental trauma (e.g. sprained ankle) which may 
interfere or prevent everyday life functions but do not constitute a substantial 
disruption. 
• Is a congenital anomaly/birth defect. 
• Medical or scientific judgment should be exercised in deciding whether 
reporting is appropriate in other situations, such as important medical events that 
may not be immediately life-threatening or result in death or hospitalisation but 
may jeopardise the subject or may require medical or surgical intervention to 
prevent one or the other outcomes listed in the above definition.  These should also 
be considered serious.  Examples of such events are invasive or malignant cancers, 
intensive treatment in an emergency room or at home for allergic bronchospasm, 
blood dyscrasias or convulsions that do not result in hospitalisation, or development 
of drug dependency or drug abuse. 
Evaluating and Recording Adverse Events 
The investigator or designee is responsible for detecting, documenting and 
reporting events that meet the definition of an AE or SAE. These must be recorded 
in the source adverse event form and/or CRF. 
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For all adverse events, the following must be assessed and recorded on the adverse 
events page of the CRF:  
a) Description of AE 
b) Start date and time 
c) End date and time 
d) Severity i.e. mild, moderate, severe (see below) 
e) Relationship to IMP(s) – completed by study physician 
f) Action taken with study medication 
g) Action / Treatment required, e.g. paracetamol 
h) Outcome 
i) Seriousness (see section on Serious Adverse Events)  
SAEs and AEs will be collected from the time of the first dose of study medication is 
given until the follow up contact.  However any SAEs assessed as related to study 
participation (e.g. IMP, protocol-mandated procedures, invasive tests, or change in 
existing therapy) will be recorded from the time a subject consents to participate in 
the study up to and including any follow-up contact. All SAEs will be reported to 
sponsor within 24 hours. A safety management (pharmacovigilance plan) will be 
drawn up before the start of the trial.  That will include contact details for PV 
reporting Surrey CRC will be acting on behalf of the Sponsor and will take care of 
the reporting to the regulatory authorities 
Intensity of Event 
The intensity of an adverse event is defined as follows: 
Mild Transient symptoms, requiring no treatment, no interference with subject’s 
daily activities, easily tolerated. 
Moderate  Marked symptoms, moderate interference with the subject’s daily 
activities, usually ameliorated by simple therapeutic measures.  
Severe Considerable interference with the subject’s daily activities, requires 
intensive therapeutic intervention, incapacitating.  
The term severe is a measure of intensity: thus a SAE is not necessarily serious. For 
example, nausea of several hours duration may be rated as severe, but may not be 
clinically serious. 
Relationship to study product 
The relationship of each adverse event to the IMP must be recorded as one of the 
following scale: 
Definite: Causal relationship is certain 
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The temporal relationship between drug exposure and the adverse event 
onset/course is reasonable, there is a clinically compatible response to dechallenge 
[a rechallenge procedure may be used, if necessary], other causes have been 
eliminated, and the event is definitive pharmacologically or phenomenologically. 
Probable: High degree of certainty for causal relationship 
The temporal relationship between drug exposure and the adverse event 
onset/course is reasonable, there is a clinically compatible response to dechallenge 
[rechallenge is not required], and other causes have been eliminated or are unlikely. 
Possible: Causal relationship is uncertain 
The temporal relationship between drug exposure and the adverse event 
onset/course is reasonable or unknown, dechallenge/rechallenge information is 
either unknown or equivocal, and while other potential causes may or may not 
exist, a causal relationship to the study drug does not appear probable. 
Unlikely: Not reasonably related 
While the temporal relationship between drug exposure and the adverse event 
onset/course does not preclude causality, there is a clear alternate cause that is 
more likely than the study drug to have caused the adverse event). 
Not Related: No possible relationship 
The temporal relationship between drug exposure and the adverse event 
onset/course is unreasonable or incompatible, or a causal relationship to study drug 
is implausible.  
Expectedness of SAEs 
For this study, an adverse reaction is ‘unexpected’.Recent systematic review of 28 
randomised controlled trials conducted between 1990 and 2010 that investigated 
the central effects of intranasal oxytocin (MacDonald et al, 2011) revealed that it (1) 
produces no reliable side-effects, and (2) is not associated with adverse outcomes 
when delivered in doses of 18–40 IU for short term use in controlled research  
settings. A recent study conducted in early adolescent boys with autism spectrum 
disorders who were administered long term nasal oxytocin showed promising 
results with excellent compliance and no side effects (Tachibana et al, 2013). As a 
result we can conclude that based on the above that adverse reactions are clearly 
unexpected. The reference safety information (RSI) for  be found in the SmPC (see 
Appendix).  
Prompt Reporting of Serious Adverse Events, and Other Events to Sponsor 
SAEs and pregnancies will be reported promptly to the sponsor as described in the 
following table, once the investigator determines that the event meets the protocol 
definition for that event. 
Initial Reports Follow-up Information on a Previous Report 
Type of Event Time Frame Documents Time Frame Documents 
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All SAEs 24 hours “SAE” form 24 hours Updated 
“SAE” form  
Pregnancy 24 hours Pregnancy Notification Form 24 hours Pregnancy Follow-
up Form 
SAEs which come to the attention of the investigator within 28 days if the first dose 
of the IMP, whether considered due to any of the IMPs or not, must be reported 
within the above timelines. 
Treatment and Follow-up of Adverse Events 
All adverse events must be documented and followed up until the event is either 
resolved or adequately explained, even after the subject has completed his/her trial 
treatment. 
In the case of any SAE, the subject must be followed up until clinical recovery is 
complete and laboratory results have returned to normal or until progression has 
been stabilised. This may mean that follow-up will continue after the subject has 
completed the clinical trial and that additional investigations may be requested by 
the sponsor. 
SAEs that are spontaneously reported by a subject to the investigator after study 
completion and considered by the investigator to be caused by the IMP with a 
reasonable possibility should be handled in the same manner as for SAEs reported 
during the study.  
In the event of unexplained clinically abnormal laboratory test values, the tests 
should be repeated immediately and followed up until the results have returned to 
within the range of normal and/or an adequate explanation of the abnormality is 
given. 
If a clear explanation is established, it should be recorded on the CRF. 
Breaking the double blind code 
A sealed envelope containing details of the IMP/NIMP administered at each 
treatment phase will be provided for each randomised subject and will be locked in 
a secure location with limited access at Windmill House under the supervision of 
the Principal Investigator and at the University of Surrey. In the event of an 
emergency, and where clinically indicated, the investigator may determine a 
subject’s treatment through opening the subject’s individual code-break envelope. 
Should the treatment sequence be unblinded, the subject must be withdrawn from 
the study and the post-study assessments performed.  If the blind is broken, the 
investigator will document the date, time of day and reason for code breaking in the 
CRF. 
 Overdose of Investigational Medicinal Product 
Definition of an Overdose for This Protocol 
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If the subject has taken, accidentally or intentionally, any IMP/NIMP administered 
as part of the protocol, and exceeded the dose prescribed by the protocol, the 
investigator or the reporting physician is to decide whether a dose is to be 
considered an overdose, but sponsor has the authority to upgrade the 
determination, if deemed appropriate. Before upgrading a report, it is necessary for 
sponsor to communicate with the investigator and reach a consensus. Overdose is 
highly unlikely as all administration of placebo/Syntocinon will be supervised by the 
researcher or a member of the Windmill team.  
 Management of Overdose 
Overdose of IMP/NIMP in the context of this clinical study may be managed without 
recourse to unblinding the study.   
General symptomatic and supportive measures should be used.   
Further details may be found in the SmPCs for Syntocinon (see Appendix). 
Regulatory reporting requirements for SAE’s 
Prompt notification of SAE’s by the investigator to the Sponsor is essential so that 
legal obligations and ethical responsibilities towards the safety of subjects are met. 
 
The Sponsor has a legal responsibility to notify the Competent Authority (CA) about 
the safety of a product under clinical investigation.   
The Sponsor is responsible for ensuring that all suspected unexpected serious 
adverse reactions (SUSARs) that are fatal or life-threatening are recorded and 
reported as soon as possible to the CA, to the EC and to Norvartis, Switzerland, and 
in any case no later than 7 calendar days after knowledge of such an event by the 
Sponsor, and that the relevant follow-up information is subsequently 
communicated within an additional 8 days. Non-fatal and non-life-threatening 
SUSARs must be reported within 15 days of Sponsor notification.  This includes 
serious adverse events (SAEs) that are known and listed in the protocol or 
investigator’s brochure. 
The Sponsor will be responsible for reporting SAEs to the Regulatory Authorities and 
Ethics Committees according to the latest regulatory requirements. 
Investigator safety reports are prepared for SUSARs according to regulatory 
requirements and Surrey CRC Standard Operating Procedures (SOPs) and are 
forwarded to investigators as necessary. 
STATISTICAL CONSIDERATIONS AND ANALYTICAL PLAN 
Responsibility for Analysis 
The statistical analysis of the data obtained from this study will be the responsibility 
of  Prof Skene and Surrey CRC. 
Justification of Sample Size 
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30 (n=15 in each arm) patients will be used for this pilot study. This is not based on 
power calculations as there is no previous data available investigating the effect of 
oxytocin on relapse prevention and emotional symptoms of withdrawal in post 
detoxified opioid dependent individuals. Nonetheless, this is considered to be an 
appropriate sample size for a pilot study in order to calculate the variability in 
response to treatment which will be used to determine subject numbers required to 
adequately statistically power future comparative large study.  
Level of Significance 
The level of significance to be used is p < .05, two tailed. 
Procedures for Handling Missing, Spurious or Unused Data 
Where missing data occur for a data set being analysed, the resultant data set will 
be analysed as unbalanced without imputation being employed. All missing, 
spurious, or unused data will be listed by subject. Procedures for missing data will 
be outlined in the SAP. 
Definition of Study Completion 
Study completion is defined as the date the subject completes the final visit in the 
study.   
As the primary endpoint of the study is retention/relapsing to drug use, subjects not 
remaining in rehabilitation unit and/or relapsing back to drug use will meet with the 
primary endpoint and not be replaced by other participants.  This data will be used 
for analysis. 
Definition of Criteria for Termination of the Study 
Study termination is defined as a permanent discontinuation of the study due to 
unanticipated concerns of safety to the study subjects or availability of other new 
data (pharmacokinetic, pharmacodynamic, efficacy, biologic etc.) arising from 
clinical or preclinical studies with this study drug.  A study may be paused during 
review of newly available preclinical/clinical safety, pharmacokinetic, 
pharmacodynamic, efficacy, or biologic data, or other issues of interest or potential 
concern prior to a final decision for continuation or termination of the study. 
Analysis 
Subject disposition 
 The number of subjects completing each assessment visit, together with a 
summary of the number of days between visits, will be tabulated.  The number of 
subjects withdrawn during the course of the study will be tabulated by reason for 
withdrawal. The number of subjects discharged due to positive urine (relapsed) as 
well as the number of subjects not completing the rehabilitation programme will be 
tabulated (primary outcome). 
Population description 
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Demographic characteristics (age, sex, weight, height, ethicity) recorded at 
screening will be tabulated. Descriptive statistics will include n, mean, standard 
deviation, median, minimum and maximum.  
All demographic data, screening evaluations, medical history and medication, 
previous and concomitant, will be listed by subject. 
Efficacy Analysis 
Analysis will be prepared   by the researcher. The Statistical Analysis Plan will 
contain in detail the information outlined below. 
Analysis will be performed unblinded, although determination of the population to 
be analysed will take place prior to breaking the blind. All subjects, who meet the 
inclusion/exclusion criteria and complete the study, will be included in the analysis 
of the efficacy parameters. 
14.7.3.1 Primary 
Between groups characteristics will be assessed by t-tests and chi-squared tests. 
Descriptive statistics will be used to analyse retention in post-detoxification 
treatment and relapse rates between the two treatment groups. A Kaplan–Meier 
survival analysis showing the rate of subjects dropping out at 4 weeks of post 
detoxification rehabilitation as well the rate of those relapsing to drug use at 4 
weeks of post-detoxification programme and 1 month after the last dose of 
placebo/oxytocin administration will also be carried out in both groups.  
Comparison of changes in number of days until opioid use from baseline (self-
reporting or positive urine sample) between placebo and oxytocin group at 4 weeks 
of post-detoxification programme and 1 month after the end of placebo/oxytocin 
treatment will be analysed by t-test. 
14.7.3.2 Secondary 
Subjective questionnaire measures will be analyzed using repeated measures 
analysis of co-variance with group (Syntocinon/placebo) as between group factors 
and testing day as the within subject factor, controlling baseline ratings.  
Changes in depression, anxiety, craving severity, social cognition, social anxiety, 
quality of life scores between the two treatment groups over time will be compared 
using analysis of variance (ANOVA) repeated measures (within subjects) design, 
controlling baseline ratings. 
Safety Analysis 
  All subjects who receive at least one dose of study medication will be          
included. 
All AEs will be coded using MedDRA prior to database lock.  Adverse events will be 
analysed, irrespective of their causal relationship, by treatment group.  The terms 
mentioned in the tabulations will be the WHO organ system and preferred terms. 
Tabulations will provide by treatment group, the number of subjects exposed the 
number of subjects with at least one adverse event, the number of subjects with at 
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least one adverse event by organ system and preferred term.  These tabulations will 
be repeated for all adverse events recorded as having a causal relationship to 
treatment.   Separate tables will be provided, if relevant, for AEs and SAEs leading to 
withdrawal from study. 
All AEs will be listed by treatment and subject and will give the following details: 
description of event, the code, date of onset, duration, severity, relationship to 
treatment, whether serious, outcome and corrective treatment if any. 
No formal statistical analysis will be performed. 
Subgroup Analyses 
There were no subgroups in this study. 
Interim Analysis 
No interim analysis is planned. 
Deviations from the statistical plan 
Any deviation(s) from this plan will be described and justified in a protocol 
amendment and/ or in the final statistical report, as appropriate. 
Data processing and statistical analysis 
 
The data processing and statistical analysis of the results will be performed by the 
research fellow under the supervision of Prof Skene and Surrey CRC staff. 
The statistical analysis will be conducted using SAS v8.4 or a later version. 
15. STUDY DOCUMENTATION ADMINISTRATION 
15.1. Source documents and CRF/ eCRF 
All evaluations that are reported in the CRF must be supported by appropriately 
signed identified source documentation related but not limited to: 
Subject identification, last participation in the trial, medical history, AEs, vital signs. 
CRFs are provided for each subject, and all data related to the study will be 
recorded in these CRFs.  The CRFs are to be completed at the time of the subject’s 
visit so that they always reflect the latest observations on the subjects.  
The Investigator must verify that all data entries in the CRFs are accurate and 
correct by signing the relevant pages. If certain information is not available, not 
applicable, not done or unknown, the clinical staff or Investigator will enter the 
relevant abbreviation, i.e. NA to confirm that the data field has not been 
overlooked. 
This also applies to subjects who fail to complete the study. If a subject withdraws 
from the study, the reason must be noted on the CRF. If a subject is withdrawn from 
the study because of a treatment-limiting adverse event, thorough efforts should be 
made clearly to document the outcome. 
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All forms should be typed or filled out using a black ball-point pen, and must be 
legible. All entries, corrections and alterations are to be made by the responsible 
Investigator or her/his designee. With the exception of obvious mistakes, the 
corrections need to be commented. Corrections should be made in such a way that 
the original entry is not obscured. The corrected data should be entered, dated, and 
initialled by the Investigator or his designee. 
The MHQ completed at screening will be kept in a separate file, not part of the CRF. 
This confidential file will also contain details of the subject’s identity and will be 
kept separately from the CRF in a secure place. 
15.2 Monitoring 
In accordance with applicable regulations and standards of GCP, monitors will 
contact the site prior to the start of the study to review with the site staff the 
protocol, study requirements and their responsibilities to satisfy regulatory and 
ethical requirements.  When reviewing data collection procedures, the discussion 
will include identification, agreement and documentation of data items for which 
the CRF will serve as the source document. 
The monitor will review the CRFs, evaluate them for accuracy (including source data 
verification) and completeness, and return all forms with missing information 
and/or errors to the clinical staff or investigator for correction. 
 
The monitor will supervise the study to ensure that the: 
• Data are authentic, accurate, and complete 
• Safety and rights of subjects are being protected 
• Study is conducted in accordance with the currently approved protocol and 
any other study agreements, GCP and all applicable regulatory requirements 
The investigator agrees to allow the monitor direct access to all relevant 
documents. 
15.3 Access to Source Data Documents 
The investigator will permit trial –related monitoring, audits, IRB/IEC review, and 
regulatory inspections by providing direct access to source data/documents. 
Suitably trained staff working directly on the study will also have access to source 
data documents. 
15.4 Data Handling and Record Retention 
The investigator must maintain adequate records to enable the conduct of the 
study to be fully documented.  The investigator should arrange for retention of the 
essential documents in the investigator’s Trial Master File for at least five years 
after the final study report has been signed. No study-related documents will be 
destroyed until receipt of written permission from the Sponsor. 
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Any difficulty in storing original documents should be discussed with the monitor 
pror to initiation of the study. 
15.5. Subject Confidentiality and Data Protection 
The investigator must ensure that subject’s anonymity will be maintained.  On CRFs 
or other documents, subjects should not be identified by their names, but by a 
screening number.  The investigator should keep a separate enrolment log showing 
screening number, names and addresses.  Documents such as subjects’ separate 
written consent forms should be maintained by the investigator in strict confidence. 
 16 QUALITY CONTROL AND QUALITY ASSURANCE 
To ensure compliance with GCP and all applicable regulatory requirements, the 
sponsor may conduct a quality assurance audit of the site records, and the 
regulatory agencies may conduct a regulatory inspection at any time during or after 
completion of the study. In the event of an audit or inspection, the investigator (and 
institution) must agree to grant the auditor(s) and inspector(s) direct access to all 
relevant documents and to allocate their time and the time of their staff to discuss 
any findings/relevant issues. 
A study monitor (Surrey CRC) appointed by the Sponsor is responsible for visiting 
the institution at regular intervals throughout the study to verify adherence to the 
protocol; completeness, accuracy, and consistency of the data; and adherence to 
ICH GCP and local regulations on the conduct of clinical research. The monitor is 
responsible for inspecting the CRFs and ensuring completeness of the study 
essential documents. The monitor will have access to subject medical records and 
other study-related records needed to verify the entries on the CRFs. The monitor 
will communicate deviations from the protocol, SOPs, GCP and applicable 
regulations to the investigator and will ensure that appropriate action designed to 
prevent recurrence of the detected deviations is taken and documented. The 
investigator agrees to co-.operate with the monitor to ensure that any problems 
detected in the course of these monitoring visits are addressed and documented.  
17. CLINICAL TRIAL PROTOCOL DEVIATIONS AND AMENDMENTS 
Any ‘substantial’ protocol amendment(s) (meaning that it could have a significant 
impact on the safety or physical or mental integrity of the subjects, the scientific 
value of the trial, the conduct or management of the trial, the quality or the safety 
of any IMP used in the trial) will be submitted to the Independent Ethics Committee 
(IEC) and Competent Authority (CA) (e.g. MHRA in the UK) prior to its 
implementation. 
For non-substantial changes that do not affect the safety or validity e.g. an 
administrative change, the EU Directive does not require the IEC or CA to be 
notified.  However, for Surrey CRC, the amendment will be forwarded to the IEC for 
their information, and the changes implemented immediately, unless otherwise 
instructed by the sponsor or IEC. 
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In the case of changes consisting of urgent safety measures to protect the trial 
subjects, the sponsor should inform the IEC and CA as soon as possible after these 
measures have been implemented. 
 18. CONDITIONS FOR TERMINATING THE STUDY 
Study completion is defined as the date the last subject completes the final visit in 
the study.  Study termination is defined as a permanent discontinuation of the 
study due to unanticipated concerns of safety to the study subjects or availability of 
other new data (pharmacokinetic, pharmacodynamic, efficacy, biologic etc.) arising 
from clinical or preclinical studies with this study drug. We expect some subjects 
not to complete all visits as some of them will relapse or will not maintain in the 
rehabilitation unit. 
If, in the opinion of the investigator, the clinical observations or pharmacokinetic 
profiles in the study suggest that it may be unwise to continue, the investigator may 
terminate part of, or the entire study, after consultation with the sponsor, or the 
sponsor may terminate part of, or the entire study, for safety or administrative 
reasons. A written statement fully documenting the reasons for such termination 
will be provided to the IEC. 
19. ETHICAL AND REGULATORY REQUIREMENTS 
The study will be conducted in accordance with: 
• The protocol, 
• EU Directive 2001/20/EC governing clinical trials and the associated UK 
Statutory Instruments 2004/1031, 2006/1928, and 2006/2984 and 2008/941 (and 
any updates), 
• EU Directive 2005/28/EC governing GCP which has its origins in ICH Guideline 
E6, 
• The UK Data Protection Act, 1998, and  
• The guiding principles of the Declaration of Helsinki. 
19.1 Informed Consent 
It is the responsibility of the investigator to obtain written informed consent from 
each subject participating in this study, after adequate explanation of the aims, 
methods, anticipated benefits, and potential hazards of the study.  This includes 
obtaining the appropriate signatures and dates on the informed consent document 
prior to the performance of any study specific procedures. Subjects will be given 
written information outlining the study details given approval by the IEC. Any 
changes to the approved version of the information sheet/consent form must be 
approved by the IEC prior to its implementation, unless it is for urgent safety 
measures. A copy of the signed consent form will need to be given to the subject. 
The investigator, or person under his responsibility, must also explain that the 
subject is completely free to refuse to enter the study or to withdraw from it at any 
time.  The CRF for this study contains a section for documenting informed consent, 
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and the investigator, or person under his responsibility, must complete it 
appropriately. 
19.2 Independent Ethics Committee (IEC) 
This protocol and any accompanying material provided to the subjects (such as the 
information sheet or description of the study used to obtain informed consent) will 
be submitted by the investigator, or person under his responsibility, to the 
appropriate IEC.  Approval from the committee must be obtained in writing before 
starting the study and the approval letter must reference which documents were 
reviewd and approved. 
Any required changes will be forwarded to the IEC for their approval. Written 
approval of the revised documents should also be obtained from the IEC. 
Depending upon the exact changes, written approval of the revised documents may 
not be required prior to the commencement of the screening process. 
The IEC must provide a copy of their membership list, and a list of names of those 
members present at the meeting when the study was reviewed. The IEC must also 
have provided a copy of their constitution, and a signed statement indicating that it 
complies with GCP, that will be kept on file at Surrey CRC. 
19.3 Annual/Final Reports 
In accordance with the EU Clinical Trial Directive the sponsor company will notify 
the IEC and CA within 90 days of the end of the study. If the study is terminated 
prematurely, this reporting timeframe will be reduced to 15 days from the 
termination of the study. 
The study report will be provided to the IEC and CA within one year of completion 
of the study, as defined in Section 18 of this protocol. 
The Sponsor will be responsible for submitting annual reports to the IEC and CA. 
 20. FINANCE AND INSURANCE 
Prior to starting the study, the Sponsor will secure funding for the conduct of this 
study, and will enter into a Clinical Trial Agreement with each funder. Each of these 
agreements will include the financial information agreed upon by the parties. 
 Reimbursement, indemnity and insurance shall also be addressed in the Clinical 
Trial Agreement. 
21.  PUBLICATIONS 
The sponsor has an unrestricted right and responsibility to ensure that the results of 
scientific interest arising from the Clinical Trial are appropriately published and 
disseminated. The Sponsor and its employees are permitted to present at symposia, 
national or regional professional meetings, and to publish in journals, thesis or 
dissertations, or otherwise of their own choosing, methods and results of the 
Clinical Trial. 
 439 
 
Authorship of any publications resulting from this study will be determined on the 
basis of the Uniform Requirement for Manuscripts Submitted to Biomedical 
Journals (International Committee of Medical Journal Editors, 2004), which states: 
Authorship credit should be based on (1) substantial contributions to conception 
and design, acquisition of data, or analysis and interpretation of data; (2) drafting 
the article or revising it critically for important intellectual content; (3) final 
approval of the version to be published.  Authors should meet conditions 1, 2, and 
3. 
• Acquisition of funding, collection of data, or general supervision of the 
research group, alone, does not justify authorship. 
• All persons designated as authors should qualify for authorship, and all those 
who qualify should be listed. 
• Each author should have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content. 
Upon completion of the clinical study report, the sponsor will ensure public 
disclosure of the clinical trial research results via the clinicaltrials.gov 
(http://clinicaltrials.gov/) website. The investigator is encouraged to share the 
summary results with the study subjects, as appropriate. 
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Appendix 24 
Graphical Representation of Pilot Trial Data : Scores and Commentary 
Depression and Mood  
At baseline participant 001 was categorised as very severely depressed (HAM-
D score: 29). At day 2, following two treatment visits, participant 001 scored HAM-
D: 19, a difference of 10, and a reduction in depressive symptoms and improved 
mood (see Table 7.1). 
Question 2 of SA measured mood and at baseline participant 001 scored 30, 
indicating low mood. At day 2, following two treatment visits, participant 001 
scored 24, a decrease of 6 points, a reduction in depressive symptoms and an 
indication of improved mood (see Table 3.4).   
 
Table 7.1  Depression and Mood scores for participant 001 
 
Depression and Mood scores for participant 001 as measured by HAM-D 
and SA Qu2. Both measures indicate a reduction in depressive symptoms and 
improved mood  between baseline and day 2, following two treatments of 
oxytocin nasal spray.   
Abbreviations: HAM-D: Hamilton Rating Scale for Depression. SA Q2: The self-
assessment of mood and sociability state :Mood 
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At baseline participant 002 was categorised as moderately depressed (HAM-D 
score: 16). At day 2, following two treatment visits, participant 002 scored HAD-D: 
16, with no difference in depression symptoms.  
Question 2 of SA measured mood and at baseline participant 002 scored 14, a 
score of normal mood.  At day 2, following two treatment visits, participant scored 
15, an increase of 1, indicating that the mood had remained stable with very little 
increase in depressive symptoms (see Table 7.2) 
 
Table 7.2.  Depression and Mood scores for participant 002 
 
Depression and Mood scores for participant 002 as measured by HAM-D 
and SA Qu2. 
HAM-D indicated no change in mood and depressive symptoms between 
baseline and day 2. SA Q2 indicated a slight decrease in mood with a slight 
increase in depressive symptoms.  
Abbreviations: HAM-D: Hamilton Rating Scale for Depression. SA Q2: The  self-
assessment of mood and sociability state : Mood. 
 
Anxiety and state of mind  
At baseline participant 001 was categorised as severely anxious (HAM-A score: 
27).  At day 2, following two treatment visits, participant 001 scored HAM-A: 17, a 
difference of 10 and a reduction in symptoms of anxiety (see Table 3.6).  
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Question 1 of SA measured state of mind and anxiety and at baseline 
participant 001 scored 41, indicating high anxiety.  At day 2, following two 
treatment visits, this had reduced to 34, a reduction 7 and a reduction in symptoms 
of anxiety (see Table 3.6). 
Leibowitz Social Anxiety (LSA), measured anxiety and avoidance, an indication 
of social anxiety.  At baseline participant 001 scored 79, an indication of Social 
Anxiety Disorder.  At day 2, following two treatment visits, participant 002 scored 
78 a reduction in the likelihood of Social Anxiety Disorder (see Table 7.3).  
Table 
7.3 
Anxiety 
and 
State of 
Mind 
scores 
for 
particip
ant 001 
 
 
 
 
 
 
 
Anxiety and State of Mind scores for participant 001 as measured by HAM-A, 
SA Qu1 and LSA.  
All measurements indicated reduced anxiety between baseline and day 2. 
Abbreviations: HAM-A: Hamilton Rating Scale for Anxiety; SA Q1: The self- 
assessment of mood and sociability state  :State of Mind; LSA: Liebowitz Social  
Anxiety Scale 
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At baseline participant 002 was categorised as mildly anxious (HAM-A score: 
17). At day 2, following two treatment visits, participant 002 scored HAM-A: 13, a 
reduction of 4 and a reduction in symptoms of anxiety (see Table 3.7).  
Question 1 of SA measured state of mind and anxiety and at baseline 
participant 002 scored 27, indicating high anxiety.  At day 2, following two 
treatment visits, this had reduced to 20, a reduction of 7 and reduction in the 
symptoms of anxiety (see Table 7.4).  
Leibowitz Social Anxiety (LSA), measured anxiety and avoidance, an indication 
of anxiety.  At baseline participant 002 scored 8, an indication that Social Anxiety 
Disorder is unlikely.  At day 2, following two treatment visits, participant 002 scored 
7, a reduction in the likelihood of Social Anxiety Disorder (see Table 3.7)  
 
Table 7.4 Anxiety and State of Mind scores for participant 002 
 
 
 
 
 
 
 
 
Anxiety and State of Mind scores for participant 002 as measured by HAM-A, 
SA Qu1 and LSA. 
All measurements indicated reduced anxiety between baseline and day 2 . 
Abbreviations: HAM-A: Hamilton Rating Scale for Anxiety; SA Q1: The self- 
assessment of mood and sociability state  :State of Mind; LSA: Liebowitz Social  
Anxiety Scale 
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Participant 001 showed reduced likelihood of Social Anxiety Disorder (Table 
3.6).  Part 2 of LSA measured social avoidance and at baseline Participant 001 
scored 38 and indication of high social avoidance.  At day 2, following two 
treatment visits, participant 001 scored 37, a reduction in the likelihood of social 
avoidance (see Table 3.8) 
Question 3 of SA measured trustworthiness and participants were asked to 
rate how much they could trust other people in their lives, an emotion and 
behaviour which forms part of complex social behaviours.  At baseline participant 
001 measured 5, an indication that there was some trustworthiness felt towards 
others.  At day 2, following two treatment visits, participant 001 scored 1, an 
increase of trustworthiness towards other people (see Table 3.8). 
Question 4 of SA measured hostility, an emotion often directed at others and 
an antisocial behaviour.  At baseline participant 001 measured 6, indicating 
increased hostility.  At day 2, participant 001 measured 5, an indication of reduced 
hostility (see Table 7.5). 
Question 5 of SA rated feelings of socializing and at baseline participant 001 
scored 8 at baseline, indicating feeling very antisocial.  At day 2 participant 001 
scored 9, an increase of 1 and an indication of feeling very antisocial (see Table 3.8).  
Question 6 of SA measured feelings about participating in small group 
activities.  At baseline participant 001 scored 2, indicating feeling comfortable about 
participating in small group activities.  At day 2, following two treatment visits, 
participant 001 scored 1, indicating feeling less discomfort in participating in group 
activities (see Table 3.8).  
 Reading the Mind in the Eyes is a measure of the ability to attribute mental 
states to another person and an indication of social intelligence and social 
perception (see section 3.3.4.7). At baseline participant 001 scored 30, above the 
average score of 26 and an indication of social intelligence and social perception.  At 
day 2 participant 001 scored 31, an indication of an increase in social intelligence 
and social perception (see Table 7.5).  
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Table 7.5 Measures of Sociability for Participant 001 
 
Sociability measures and scores for participant 001 as measured by LSA pt 2, 
SA Qu2, SA Qu3, SA Qu4, SA Qu5 and RtM, between baseline and day 2 . 
Measurements showed that participant 001 had reduced social avoidance, increased 
trustworthiness towards others, reduced hostility, increased feelings of antisocial, 
less discomfort in working in small group and increased social intelligence and social 
perception.  
Abbreviations: LSA pt 2: Liebowitz Social Anxiety measurement Part 2 Social 
Avoidance; SA Q3: The  self-assessment of mood and sociability state: Question 3: 
Trustworthiness;  SA Q4: The self-assessment of mood and sociability state : Question 
4: Hostility; SA Q5: The  self-assessment of mood and sociability state: Question 5: 
Socialising; SA Q6: The  self-assessment of mood and sociability state: Question 6: 
Small Group Activities.  
 
 
Participant 002 showed reduced likelihood of Social Anxiety Disorder (see 
Table 3.7).  Part 2 of LSA measured social avoidance and at baseline Participant 002 
scored 3 and indication of unlikely social avoidance.  At day 2, participant 002 
scored 1, a reduction in the likelihood of social avoidance (see Table 3.9).  
Question 3 of SA measured trustworthiness and participants were asked to 
rate how much they could trust other people in their lives, an emotion and 
behaviour which forms part of complex social behaviours.   At baseline participant 
002 measured 9, an indication that there was very little trustworthiness felt 
towards others.  At day 2, participant 002 scored 7, an increase in trustworthiness 
towards other people (see Table 7.6).  
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Question 4 of SA measured hostility, an emotion often directed at others and 
an antisocial behaviour.  At baseline participant 002 measured 4, indicating mild 
hostility.  At day 2, participant 002 measured 6, an indication of increased hostility 
(see Table 7.6).  
Question 5 of SA rated feelings of socializing and at baseline participant 002 
scored 1 at baseline, indicating feeling very social.  At day 2 participant 002 scored 
6, an increase of 5 and an indication of increased feelings of antisocial (see Table 
3.9).  
Question 6 of SA measured feelings about participating in small group 
activities.  At baseline participant 002 scored 9, indicating feeling very 
uncomfortable about participating in small group activities.  At day 2, participant 
002 scored 4, indicating less discomfort in participating in group activities (see Table 
3.9). 
Reading the Mind in the Eyes as a measure of the ability to attribute mental 
states to another person and an indication of social intelligence and social 
perception (see section 3.2.3.6). At baseline participant 002 scored 26, the average 
score for social intelligence and social perception.  At day 2, participant 002 scored 
29, above average score and an indication of an increase in social intelligence and 
social perception (see Table 7.6). 
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Table 7.6 Measures of Sociability for Participant 002 
 
Sociability measures and scores for participant 002 as measured by LSA pt 2, 
SA Qu2, SA Qu3, SA Qu4, SA Qu5 and RtM.  Measurements showed that participant 
002 had reduced social avoidance, increased trustworthiness towards others, 
increased hostility, increased feelings of antisocial, increased comfort in working in 
small group and increased social intelligence and social  perception.  
Abbreviations: LSA pt 2: Liebowitz Social Anxiety measurement Part 2 Social 
Avoidance; SA Q3: The  self-assessment of mood and sociability state: Question 3: 
Trustworthiness;  SA Q4: The self-assessment of mood and sociability state : Question 
4: Hostility; SA Q5: The  self-assessment of mood and sociability state: Question 5: 
Socialising; SA Q6: The  self-assessment of mood and sociability state: Question 6: 
Small Group Activities  
 
Subjective Opioid Withdrawal Symptoms.  
At baseline participant 001 scored 30 on the SOWS, an indication of moderate 
subjective opioid withdrawal symptoms.  At day 2, participant 001 scored 14, a 
reduction in more than half of the previous scores and indicating little opioid 
withdrawal symptoms (see Table 4.0).  
At baseline participant 001 scored 13 on SA withdrawal symptoms, an 
indication of moderate withdrawal symptoms.  At day 2, this score was 12, 
indicating a consistent subjective rating of moderate opioid withdrawal symptoms 
(see Table 7.7).  
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Table 7.7. Measures of Subjective Opioid Withdrawal Symptoms for participant 
001 
 
 
Subjective Opioid Withdrawal Symptoms for participant 001,  as measured by SOWS 
and SA W/D.  Both measurements indicated reduced opioid withdrawal symptoms 
between baseline and day 2.    
Abbreviations: SOWS: Subjective Opioid Withdrawal Scale; SA W/D: The self- 
assessment of withdrawal symptoms.  
 
At baseline participant 002 scored 33 on the SOWS, an indication of moderate 
subjective opioid withdrawal symptoms.  At day 2 participant 002 scored 39, an 
increase in subjective opioid withdrawal symptoms (see Table 7.8).  
At baseline participant 002 scored 8 on SA withdrawal symptoms, an 
indication of low withdrawal symptoms.   At day 2 this score was 12, indicating an 
increase to moderate opioid withdrawal symptoms (see Table 7.8).  
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Table 7.8. Measures of Subjective Opioid Withdrawal Symptoms for participant 
002 
 
 
Subjective Opioid Withdrawal Symptoms for participant 002,  as measured by SOWS 
and SA W/D.  Both measurements indicated increased opioid withdrawal symptoms 
between baseline and day 2.   
Abbreviations: SOWS: Subjective Opioid Withdrawal Scale; SA W/D: The self-
assessment of withdrawal symptoms  
 
Sleep Behaviour 
 The Leeds Sleep Evaluation Questionnaire (LSQ) showed that subjective sleep 
behaviour varied over time for participant 001.  Getting to Sleep (GTS) felt easier 
over time.  At day -1, the baseline measurements for LSQ sleep measurements, the 
score for getting to sleep was 37.  After one day, the score was 28 indicating an 
improvement in getting to sleep.    Quality of sleep (QOS) improved over time with a 
-1 day score of 101 and after one day participant 001 scored 72.    Ease of waking 
(EOW) scores indicated that participant 001 found waking more difficult over time, 
day -1 score was 9 and after one treatment of oxytocin participant 001 scored 61. 
Sleep awakening behaviour also deteriorated between day -1 with a score of 76 and 
after one day participant 001 scored 145. 
 The Sleep Diary entries for baseline recorded by the participant 001 state that 
bedtime was at 00h30 and attempted sleep at 01h30.  Participant 001 woke once in 
night at 04h45 and remained awake until getting up at 08h30.  This calculates 
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03h15 sleep.  Participant 001 rated this as not a typical night, could have slept 
longer if permitted and rated the sleep as more likely the worst ever.    
Following one treatment day, participant 001 records in the Sleep Diary that 
bedtime was earlier, 22h45 and slept immediately.  Participant 001 records waking 
once, at 05:00 remained awake until getting up at 06:00.  This calculates 6 hours 15 
mins of sleep and improved sleep. Again participant 001 rated this as not a typical 
night, could have slept longer if permitted and rated the sleep as more likely the 
worst ever. 
The atigraphy data (see Figure 7.1) shows objective sleep behaviour readings 
for participant 001 for baseline readings (red) and a similar pattern as recorded in 
the Sleep Diary.  These show that participant 001 had high levels of activity between 
00h00 and a little after 03h00 with some stillness at about 02h00.  There is little to 
no activity between 03h00 and about 05h30.  The atigraphy data readings for 
participant 001, following one treatment visit, (green) reflect a similar pattern as 
recorded in the Sleep Diary. Following 22h00 there was little to no activity until a 
little before 06h00 the next morning. The atigraphy data reading for participant 001 
following a second treatment visit (yellow) records inactivity, however this is not as 
continuous as recorded the previous night.  Inactivity is seen a little after 22h30 
until 00h00 followed a little inactivity at 12h30 until a little after 01h00.  There is 
inactivity again between about 01h45 and a little after 03h00 after which 
participant 001 was very active.  At about 6h00 participant self-discharged from 
WMH and left the building, leaving the actigraphy unit with staff. The Sleep Diary 
was not completed that morning and participant 001 no longer took part in the 
trial. 
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Fig 7.1. Participant 001 actigraphy readings, recorded by an actigraphy unit (watch) with hourly 
intervals.  Periods of inactivity during the night time are noted. 
Red indicates baseline behaviour. There was excessive movement during the period  
of 0h00 and a little after 03h00 followed by inactivity until about 05h30.    
Green indicates behaviour, following one treatment visit.  There were fewer 
periods of activity compared to baseline and inactivity from 23h00 until 06h00.   
Yellow indicates behaviour, following second treatment visit.  This indicated more activity and 
movement compared to the previous night particularly between 22h30 and 0h00 and again  
between 01h45 and 0300.  Participant 001 self-discharged around 06h00 and no longer took 
part in the trial.     
 
 Participant 002 did not complete the Leeds Sleep Questionnaire at day -1 and 
so there are no baseline measurements.  After one day participant 002 recorded 
that Getting to Sleep (GTS) felt easier than normally getting to sleep.  Quality of 
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Sleep (QoS) was recorded as better than usual.   Ease of waking (EoW) was also 
recorded as better than normal and sleep awakening behaviour was recorded as 
feeling better than normal.   
 The Sleep Diary entries for baseline recorded by participant 002 state that 
bedtime was at 00h00 and sleep followed minutes later. Participant 002 recorded 
waking at 05:37 and got up at 06:00. This calculates 05h37 sleep.  Participant 002 
rated this as not a typical night, could have slept longer and rated the sleep as 
almost best ever.  
 Following one treatment visit, participant 002 records in the Sleep Diary that 
bedtime was earlier, at 22h45 and sleep immediately. Participant awoke once in the 
night at 04h00 and remained awake until getting up at 05h00.  Participant 002 
describes this as a typical night, could have slept longer if permitted and rated the 
sleep as the worst ever.  
 Following second treatment visit, participant records in the Sleep Diary that 
bedtime was later, at 00h00 and sleep was immediate.  Participant records waking 
once at 04h10 but sleeping immediately afterwards.  Wake up time was recorded at 
05:20 and getting up at 06h00.  Participant 002 recorded this as a better night and 
rated the sleep as best ever.  
 Participant 002 was discharged following breach of contract and non-
attendance to group therapy more than twice.  No further sleep data was collected.  
 Participant 002 failed to wear the actigraphy unit and and no measurable data 
was available.  
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4.3                      CTA submission (if on file at Surrey CRC) 
4.4                      EudraCT Number 
4.5                      Interim, Annual and/or Final End of Study Report  
4.6                      Correspondence 
5 5.1                      Blank Information Sheet & Consent Form 
5.2                      Study Dates 
5.3                      Advertisements 
5.4                      General Practitioner (GP) letter template 
5.5                      Menu/ Food Facts Form 
5.6                      Subject Identification (ID) card 
5.7                      Other study specific documents 
5.8                      Correspondence 
6 6.1  
                     
Safety Related Information: 
Serious Adverse Event Notifications to Sponsor 
6.2                      Serious Adverse Event Notifications from Sponsor to Regulatory Authorities 
6.3                      Serious Adverse Event Notifications from Sponsor for ISF 
6.4                      Adverse Event Updates 
6.5                      Correspondence 
7 7.1                      Recruitment Documentation 
7.2                      Subject Telephone Screening Log  
7.3                      Subject Screening Log 
7.4                      Subject Enrolment/Randomisation Log and/or Subject ID log 
7.5                      Signed Informed Consent Documents  
7.6                      Completed Source Documents   
7.7                      Completed and signed CRFs 
7.8                      Nurse Handover Documents and Completed Source AE Sheets  
7.9                      Data Queries  
 7.10                      Correspondence 
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TMF 
Section 
Documents Filed  
(tick when filed) 
Y                           N/A 
Study Documents 
8 8.1  
                     
Investigational Medicinal Product (IMP): 
Shipping Records 
8.2                      Sample Labelling 
8.3                      Handling instructions 
8.4                      Accountability Logs and/or dispensing log 
8.5                      Certificate of Analysis – if available, not essential re: ICH GCP section 8.2.16 
8.6                      Unblinding procedure (if applicable) 
8.7                      Code Break Envelopes (if applicable) 
8.8                      Master Randomisation List– if available, not essential re: ICH GCP section 8.2.18 
8.9                      Certificate of Destruction 
8.10                      Qualified Person (QP) release 
8.11                      Release of IMP to Site Checklist 
8.12                      Correspondence 
9 9.1                      Laboratory Normal Ranges 
9.2                      Laboratory Accreditation 
9.3                      Record of Retained Samples 
9.4                      PK Logs & Shipping Documents 
9.5                      Correspondence 
10 10.1                      Contacts 
10.2                      Organogram 
10.3                      Signature Log / Delegation of Duties 
10.4                      CVs 
10.5                      Study Specific Instructions/ Study Procedures Manual/Training Procedures and 
Checklist 
10.6                      Meeting Minutes 
10.7                      Pre-Study Monitoring Report  
10.8                      Trial Initiation Monitoring Report  
10.9                      Close Out Meeting 
10.10                      Monitoring Log 
10.11                      Monitoring Schedule 
10.12                      Nurse/Study Schedule (workbook) 
10.13                      Psychometric Test Battery (GTB2004)/ Other Electronic Tests Details (if applicable) 
10.14                      Details of additional SOPs 
10.15                      Correspondence 
11 11.1                      Secrecy/Confidentiality Agreement 
11.2                      Signed contracts 
11.3                      Investigator Agreements/Financial Disclosures 
11.4                      Completed 1572 (if applicable) 
11.5                      Insurance 
11.6                      Association of the British Pharmaceutical Industry (ABPI) Indemnity 
11.7                      Audit Certificate (if available) 
11.8                      Statistical Analysis Plan (SAP) (if available) 
11.9                      Archive Facilities 
11.10                      Risk Management Plan 
11.11                      Risk Communication Documentation 
11.12                      Correspondence 
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12 12.1                      Blank CRF 
12.2                      Blank Source Documents/workbooks 
12.3                      Correspondence 
13 
     
13.1                      Completed Clinical Study Report 
13.2                      Correspondence 
14 14.1                      Publications 
14.2                      Correspondence 
15 15.1                      Receipt of non-IMP documentation/ supplies 
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Appendix 26 
Mawdsleys SOP form for services offered 
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Appendix 27 
Windmill House – Group and Therapy programme 
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
9:30-10:00 
Ward Meeting 
Lounge 
  09:00-09:45 
1:1 with 
Doctors 
 
   
10:30-11:45 
Solution 
Focused 
 
Oak room 
10:00-12:00 
Recovery 
Through 
Occupation 
Oak Room 
10:00 – 11:30 
Life Mapping 
 
Dining Room 
10:00 – 11:30 
Emotional 
Awareness 
 
Oak Room 
10:00 – 11:15 
Discussion 
 
Oak Room 
10:00 – 11:15 
Review of 
Your Week 
 
Oak Room 
 
12:30 – 2:00 
1:1 with Doctors 
 
  11:00 – 12:00 
Wellbeing 
Management 
Dining room 
   
LUNCH TIME (12-2pm Self-directed time: no electronic devices in communal areas) 
2:15-3:30 
Communication 
Skills 
 
Oak Room 
2:15-3:30 
Relapse 
Prevention 
 
Oak Room 
2:15-3:30 
Self Esteem 
 
Oak Room 
12:00- 7:00 
Recovery 
Planning 
 
A minimum of 
2 hours self- 
directed time 
1:45-3:15 
Recovery 
Planning 
 
Lounge 
  
4:00-4:45 
Information 
Group 
 
Oak Room 
 4:00-4:45 
Relaxation and/or 
Acupuncture 
Oak Room 
 3:30-4:15 
Relaxation 
and/or 
Acupuncture 
Oak Room 
  
  4:00-5:00 
Fitness and 
Wellbeing 
Session at ACU 
Once detox is 
completed 
    
EVENING ACTIVITIES 
7:30-8:30 
Narcotics Anon  
7:45-9:15 
Alcoholics 
Anon 
At ACU 
 
7:30-8:30 
Alcoholics Anon 
7:30-8:30 
Narcotics 
Anon 
 7:30-8:30 
Alcoholics 
Anon 
7:30-8:30 
Support 
Group 
Escorted walks are available throughout the week depending on staff discretion and availability 
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